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Abstract 
Introduction: Alzheimer’s disease (AD) is the most common neurodegenerative disease 
and has a high prevalence worldwide. Neuroinflammation has long been known to play a 
role in AD. However, the findings that several genes associated with inflammation were 
identified as hits in AD GWAS studies brought closer attention to neuroinflammatory 
mechanisms in AD. TREM2 was identified as a genetic risk factor for late onset AD with a 
similar odds ratio to that of APOE4. TREM2 is expressed on microglia, and has been shown 
to be upregulated on the microglia surrounding amyloid plaques both in human post mortem 
tissue and AD mouse models. In this thesis, the AD pathology, microglial phenotype, genetic 
inflammatory profile and proteomic profile of six TREM2 variant cases (5 R47H and 1 D87N 
variant) were investigated and compared to sporadic AD (SAD), familial AD (FAD) and 
neurologically normal control cases with the hypothesis that the TREM2 variant cases will 
differ from both SAD and FAD cases.  
Materials and Methods: Immunohistochemistry was performed on the frontal cortex, 
temporal cortex, hippocampus, putamen and cerebellum of SAD (n=19), FAD (n=11), 
TREM2 variant SAD (n=3), TREM2 variant controls (no AD pathology, n=2) and 
neurologically normal controls (n=6) using antibodies against Aβ, tau (AT8) and microglia 
(Iba1, CD68, CR3-43 and P2RY12). Microglial load/area, circularity and perimeter scores 
were calculated for all microglial markers. The frontal cortex was homogenised from a subset 
of each group and RNA and protein extracted. Nanostring’s Human Inflammation panel with 
their nCounter Technology was used to determine the genetic profile. The proteomic profile 
was assessed using label-free quantitative mass spectrometry. The pathological and 
proteomic profile of the presubiculum was investigated using immunohistochemistry, matrix-
assisted laser desorption ionisation mass spectrometry, laser-capture microdissection and 
further label free quantitative mass spectrometry and compared to the neighbouring area, 
the entorhinal cortex to assess whether it has protective properties against 
neurodegeneration. 
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Results: TREM2 variant AD cases differed from other SAD and FAD cases with a 
significantly increased CD68 load, more circular Iba1, CR3-43 and CD68 microglial positivity 
suggesting the microglia were in a phenotype more consistent with phagocytosis. 
Furthermore, these cases showed an increased upregulation of neuroinflammatory 
processes and neurodegenerative processes at the genetic and proteomic level than SAD 
cases. TREM2 variant controls however, showed large levels of downregulation in these 
processes compared to all groups. APOE genotyping identified the TREM2 variant cases 
correlated with the presence of the ApoE4 isoform. Investigation of the presubiculum area 
identified a large non-fibrillar Aβ deposit that contained significantly less NFT’s, activated 
microglia and N-terminally truncated Aβ peptides than in the entorhinal cortex and had an 
altered proteomic profile more comparable to the TREM2 variant controls than any other AD 
cases. 
Conclusions: Overall, this thesis has shown that TREM2 variant cases posess differences 
in microglial phenotype, genetic and proteomic expression compared to either sporadic or 
familial AD cases. TREM2 variant controls show altered pathology and genetic profiles 
compared to TREM2 variant SAD cases and it can be hypothesised that these cases may 
use similar mechanisms to the neuroprotection observed in the presubiuclum of AD cases. 
TREM2’s link to APOE and the fact that the APOE genotype lacks an ApoE4 allele in 
TREM2 variant controls, indicates that APOE may be exerting this change between TREM2 
variants, leading us to question whether the TREM2 R47H variant is acting independently. 
Further investigations into these pathways and the differences between TREM2 variants that 
develop disease and those that don’t may lead us to the mechanisms that can be targeted 
for treatments. 
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PSP Progressive Supranuclear Palsy 
PURA Transcriptional activator protein Pur-alpha 
PUT Putamen 
PXN Paxillin 
qPCR Quantitative polymerase chain reaction 
QToF Quadrupole time of flight 
RAB21 Ras-related protein Rab-21 
RB1CC1 RB1-inducible coiled-coil protein 1 
RhoA Ras homolog gene family, member A 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RT-PCR Real-time Polymerase Chain Reaction 
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SAD Sporadic Alzheimer's disease 
SCFD1 Sec1 family domain-containing protein 1 
SEM Standard error of mean 
SERPINA3 Alpha-1-antichymotrypsin 
SFTPC Pulmonary surfactant-associated protein C 
SNCA Alpha-synuclein 
SNP Single nucleotide polymorphism 
SNX6 Sorting nexin-6 
SORL1 Sortilin-related receptor 
SQSTM1 Sequestosome-1 
sTREM2  Soluble triggering receptor expressed on myeloid cells 2 
Sub Subiculum 
SYNPO Synaptopodin 
TBS Tris buffered saline 
TCTX Temporal cortex 
TE Tris-EDTA 
TFA TriFluroacetic Acid  
TGFB1 Transforming growth factor beta-1 
TGFB2 Transforming growth factor beta-2 
TLR Toll-like receptor 
TNF Tumour necrosis factor 
TNFα Tumour necrosis factor alpha 
TREM2 Triggering receptor expressed on myeloid cells 2 
TSA Tyramide signal amplification 
TUSC5 Tumor suppressor candidate 5 
TYROBP TYRO protein tyrosine kinase-binding protein 
VGF Neurosecretory protein VGF 
WM White matter 
XPO1 Exportin-1 
XRCC5 X-ray repair cross-complementing protein 5 
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1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common neurodegenerative disease and has a high 
prevalence worldwide. Over 50 million people have dementia worldwide and as life 
expectancy increases, this number is predicted to rise to 152 million by 2050 (World Health 
Organisation, Dementia fact sheet, 2017). With such large numbers, the cost to the economy 
will be huge and there is therefore a need for research to establish what causes the disease.  
Symptoms vary between individuals, however, common symptoms include; memory loss, 
confusion, decreased visual perception and spatial awareness, changes in mood and 
problems finding the correct words.  
A number of risk factors have been identified for sporadic AD, the largest of these being age 
with a significantly increased risk after the age 65 (Lane et al., 2017). Others include; 
smoking, alcohol, obesity, high cholesterol and blood pressure and those with Down 
syndrome are more at risk (Yaghmoor et al., 2014). In addition, having variants in the allelic 
ε4 expression in the APOE gene or variants in the TREM2 gene can lead to an increased 
risk of late onset AD (Guerreiro et al., 2013a; Strittmatter et al., 1993a). 
1.1.1 Pathology 
Alzheimer’s disease is characterized by its pathological hallmarks, Aβ plaques, neurofibrillary 
tau tangles (NFTs), and severe neuronal loss. A three-tiered grading system has been set 
out by the National Institute of Aging, Alzheimer Association guidelines to classify and 
confirm AD in post-mortem human brain. Firstly, the distribution of Aβ plaques are given an 
0-5 score, as Thal staging, where the presence of Aβ deposits are assessed in the 
neocortex, allocortex and basal ganglia before later affecting the brain stem and cerebellum 
(Thal et al., 2002). Secondly, a Braak and Braak score of 0-6 is given for the distribution of 
tau pathology, where the NFT pathology is assessed according to the spread throughout the 
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brain reported by Braak and Braak, (1991). Lastly the frequency of neuritic plaques are 
staged with a score of none to frequent, called the CERAD score. The three different scores 









The underlying disease pathogenesis is still not fully understood. The amyloid cascade  
The underlying disease pathogenesis is still not fully understood. The amyloid cascade 
hypothesis suggests that Aβ is the causative seed of disease while others suggest it is tau 
(Hardy and Higgins, 1992). Some believe that it is the Aβ that initiates the tau pathology and 
that once seeded, neurodegeneration occurs. Recent evidence in which human pathological 
tau was injected into an AD mouse model and tau pathology indicative of AD such as NFT’s, 
neuritic threads (NT) and dystrophic neurites surrounding the amyloid plaques accumulated,  
supports this hypothesis as the amyloid pathology already present seems to have induced 
the tau aggregation (He et al., 2018). Several pathogenic mutations for familial AD (FAD) are 
in genes involved with Aβ processing, giving strength to the argument of Aβ involvement in 
disease pathogenesis. Aβ can be detected in the CSF up to 10 years before dementia is 
observed in mild cognitive impairment (MCI) cases indicating that the protein accumulates 
over a long period of time (Buchhave et al., 2012; Zetterberg and Mattsson, 2014). Aβ 
pathology is also observed in cerebral amyloid angiopathy (CAA), in which the peptide 
Figure 1.1: Table outlining criteria for National Institute of Aging, Alzheimer 
Association classification system to diagnose stage of AD in any particular case 
(modified from Montine et. al 2011) 
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accumulates along the vessel walls. CAA is observed in 80-90% of AD cases. (Bergeron et 
al., 1987; Ellis et al., 1996; Nicoll et al., 2004; Yamada, 2000, 2002; Yamada et al., 1987). 
These findings provide evidence that Aβ accumulation has a detrimental effect in AD. 
However, another view is that the oligomeric, more soluble species of Aβ are more 
detrimental to the brain and the Aβ plaques accumulate as a protective mechanism (Glabe, 
2006; Paranjape et al., 2012; Sengupta et al., 2016).   
Tau forms aggregates in a number of neurodegenerative diseases named tauopathies. As 
tau pathology is present in several dementias such as progressive supranuclear palsy (PSP) 
and corticobasal degeneration (CBD), others believe that tau is the causative pathology in 
AD. Some believe tau to propagate in a prion-like manner and this has been the subject of 
investigation recently. Ahmed et al., (2014), created a model in P301S transgenic tau mice 
that shows spread of tau via synaptic connections. Furthermore, Vasconcelos et al., (2016) 
demonstrated that aggregated Aβ seeded tau pathology and aggregation using a tau 
aggregation assay. NFTs consist of hyperphosphorylated tau and have a different pattern of 
progression throughout the brain compared to Aβ plaques suggesting that the two proteins 
act through different mechanisms (Zetterberg and Mattsson, 2014). However, as the 
distribution of NFT’s can be shown to relate to the clinical stages of the disease, first 
appearing in the entorhinal cortex, tau could be the protein that is closely linked to disease 
progression (Gentier and van Leeuwen, 2015; Zetterberg and Mattsson, 2014). Moreover, as 
tau can accumulate many years before AD symptoms are observed, tau could potentially be 
protective. However, as both Aβ and Tau accumulate in different areas of the brain before 
the onset of symptoms, this could indicate that a third mechanism is needed to start the 
cognitive decline, for cells to begin to die and that the presence of just Aβ and tau are not 
enough alone. Some argue that this third mechanism is linked to inflammation (Zetterberg 
and Mattsson, 2014). The presence of both Aβ and tau in pathological aging cases in which 
no clinical signs of dementia are seen suggests that this could be true (Murray and Dickson, 
2014).  
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1.1.2 Amyloid processing 
The Amyloid Precursor Protein (APP) is expressed in the brain and is a transmembrane 
protein that plays a role in functions such as brain development and plasticity (Zetterberg 
and Mattsson, 2014). The protein is sequentially cleaved with multiple secretases, creating 
different length peptide fragments as a result (Figure 1.2). It can be processed with alpha-
secretase cleaving the Aβ domain nearest the N-terminus before a gamma-secretase 
complex consisting of presenilin-1 and 2, nicastrin and anterior pharynx defective 1 (APH-1), 
then cleaves the C-terminal part of the domain (Camargo et al., 2015; Zhang et al., 2014b). 
The segment of the protein is therefore released out of the cell and creates a non-
amyloidogenic peptide. Secondly, the first cleavage at the N-terminal end is carried out by 
beta-secretase (BACE1) and produces a number of different length amyloidogenic peptides 
(Aβ) instead. These amyloidogenic Aβ peptides have normal roles in synaptic plasticity, 
alongside the presenilins that cleave them (Abramov et al., 2009; Zhang et al., 2009). 
However, during AD, the ratio of non-amyloidogenic peptides to amyloidogenic peptides is 
altered resulting in greater numbers of Aβ peptides which are more prone to aggregation 
than the non-amyloidogenic forms and they start to form amyloid plaques in the extracellular 
space. Gamma secretase cleaves in both the non-amyloidogenic pathway and the 
amyloidogenic pathway but helps to create different lengths of amyloid peptide. It can cleave 
after 40 amino acids or 42 amino acids. The Aβ42 peptide is more prone to aggregation and 
higher levels of the Aβ42 can be seen in AD (Masters and Selkoe, 2012).  
Figure 1.2: Proteolytic cleavage of Amyloid Precursor Protein. Sequential cleavage by α or 
β-secretase followed by γ- secretase at amino acid 40 or 42 (adapted from Mohktar et. al, 
2013) 
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The amyloid cascade hypothesis formulated in 1992 suggested that other pathology all 
results from Aβ peptide aggregation (Hardy and Higgins, 1992). This led to the hypothesis 
that the formation of NFTs and cell loss occurs because of an imbalance between Aβ 
production and its clearance (Hardy and Selkoe, 2002).  
1.1.3 Aβ clearance pathways 
A number of mechanisms are involved in the clearance of Aβ. Examples include 
phagocytosis, enzymatic degradation and receptor-mediated efflux out of the brain, 
highlighted in Figure 1.3 (Tanzi et al., 2004). Intracellular Aβ is degraded via the Ubiquitin-
proteosome system (UPS) or by the autophagy/ lysosomal system (ALS), whereas 
extracellular Aβ is cleared from the brain via different mechanisms (Xin et al., 2018). Aβ can 
be degraded by particular enzymes, such as neprilysin and insulin-degrading enzyme (Bohm 
et al., 2015; Hickman et al., 2008). Alternatively Aβ can be removed via phagocytosis by 
microglial cells. Microglia are known to accumulate around amyloid plaques and are thought 
to contribute to clearance mechanisms in this way (Hickman et al., 2008). However, the 
fastest route of Aβ efflux from the brain is thought to occur via the perivascular drainage 
pathway. In this pathway, Aβ is transported across the BBB into the vascular basement 
membrane and travels from the interstitial fluid into the blood away from the brain (Bohm et 
al., 2015; Xin et al., 2018). More recently, the concept of glyphatic drainage in addition to 
perivascular drainage has come to attention as an alternative route in which Aβ is drained 
into the CSF (Xin et al., 2018).  
Many of these clearance systems have been shown to have reduced efficiency during AD 
pathogenesis. Inhibitors of Aβ clearance include antibodies against LDL- receptor related 
protein 1 (LRP1) and α2-macroglobulin (Shibata et al., 2000). Clearance is thought to be 
inhibited if the triggering receptor expressed on myeloid cells 2 (TREM2) is impaired (Zhao 
and Lukiw, 2015). There have been a number of drug trials that have tried to increase the 
amount of Aβ clearance; however these have been largely unsuccessful (Karran and Hardy, 
2014).  
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Familial forms of AD have been found to have mutations in the APP gene, presenilin 1 
(PSEN1) and presenilin 2 (PSEN2) genes (Bertram and Tanzi, 2012; Bohm et al., 2015). 
Mutations in the APP gene affect the cleavage sites for the different secretases. For 
example, the Swedish mutation, K670N + M671L, changes the conformation of the protein 
so that a beta-secretase (BACE1) can bind more easily, therefore meaning a higher ratio of 
amyloidogenic peptides (Mullan et al., 1992; Zetterberg and Mattsson, 2014). However, it 
has been found that mutation A673T, has the opposite effect, decreasing the binding affinity 
Figure 1.3: Clearance pathways present within the brain. UPS, Ubiquitin proteasome 
system; ALS, Autophagic/lysosomal system; ISF, Institial fluid; CSF, Cerebrospinal fluid; 
BCSFB, Blood-CSF- Barrier (adapted from Xin et. al, 2018) 
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of BACE1 therefore producing less amyloidogenic peptides and having a decreased risk of 
AD (Jonsson et al., 2012a; Zetterberg and Mattsson, 2014).  
The presenilin complex is involved in regulating the cleavage of a number of proteins. As it is 
part of the gamma-secretase complex, it is involved in APP processing. Mutations in the 
PSEN1 gene are the most common form of familial AD (Russo et al., 2000). Missense, splice 
site and duplication mutations have been found in the presenilin genes and this also has an 
effect on the production of Aβ (Bohm et al., 2015). The increased production of Aβ in these 
familial forms of the disease cause early onset and a greater severity of symptoms. miRNA’s 
have been shown to have a role in regulating APP processing by providing post-
transcriptional regulation of the secretases. For example miR-339-5p downregulates BACE1 
expression (Long et al., 2014). Alterations in the expression of these genes may highlight how 
sporadic AD can work along the same mechanisms as familial forms. 
A variety of genome wide association studies have been performed in different populations 
of AD. The first large hit discovered was the APOE gene. It was discovered that having two 
ApoE4 alleles in this gene increases susceptibility to late onset AD with a high odds ratio 
(Strittmatter et al., 1993a). Multiple lines of evidence in studies since this result have shown 
that ApoE has roles in Aβ clearance, metabolism and aggregation and can affect 
synaptogenesis (Huang and Mahley; Puglielli et al., 2003; Zetterberg and Mattsson, 2014).  
More recently, GWAS studies have identified over 20 loci of common variants with small risk 
(Humphries and Kohli, 2014; Rosenthal and Kamboh, 2014). The majority of these hits 
identified genes involved in one of three different functions:  inflammatory response (TREM2, 
CR1 and CFH) (Tanzi et al., 2004); endosome vesicle recycling (BIN1, PICALM, and 
SORL1); and cholesterol management (ABCA7, ABCA1, CLU and CYP46A1), (Camargo et 
al., 2015; Rosenthal and Kamboh, 2014; Zetterberg and Mattsson, 2014). Interestingly, 
some of these genes are also linked to APP processing and Aβ clearance showing that the 
mechanisms of AD may include defects in a number of different pathways (Camargo et al., 
2015).  
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TREM2 was the largest of these hits and variants in this gene were found to be a risk factor 
for late onset AD with a similar odds ratio to APOE (Guerreiro et al., 2013a).  Variants were 
found to be a risk factor for AD, Frontotemporal dementia (FTD), Amyotrophic lateral 
sclerosis (ALS) and Parkinson’s disease (PD) (Jiao et al., 2014; Jin et al., 2015; Jonsson et 
al., 2012b; Kober et al., 2014; Lu et al., 2015).  
1.2 TREM2 
1.2.1 Genetic variants 
A number of GWAS studies have reported variants in TREM2 as a significant hit in the risk 
for neurodegenerative diseases (Jiao et al., 2014; Jin et al., 2015; Jonsson et al., 2012b; 
Kober et al., 2014; Lu et al., 2015). A number of different variants in the gene were 
discovered with only a few of these inferring risks of disease. The most common finding is 
the R47H variant which infers a risk for late onset AD in European populations with studies 
also showing significant association in Icelandic and African American populations, 
(Abduljaleel et al., 2014; Hooli et al., 2014; Korvatska O et al., 2015; Malkki, 2015; Ortega-
Cubero et al., 2015; Rosenthal et al., 2015; Slattery et al., 2014). However, the variant did 
not reach significance in Iranian, Chinese or East Asian populations. Some also reported 
associations of risk for FTD with this variant but others found no association (Borroni et al., 
2014; Thelen et al., 2014). Thelen et al., (2014) proposes that an FTD association is seen 
when underlying AD pathology is observed. Slattery et al., (2014) reported that people with 
the R47H variant often have earlier symptom onset but otherwise they are reported to have a 
similar disease course to those that have sporadic AD without a variant. Luis et al., (2014) 
also show the R47H variant carriers have a greater degree of grey matter loss, as measured 
by MRI volumetric analysis, suggesting that although they follow the same disease course 
clinically as the sporadic cases without a variant, they may get the disease earlier.  
Twelve other TREM2 variants were identified as outlined in Table 1.1 from Guerreiro et al., 
(2013a). Twenty-two variant alleles were found in 1092 AD cases and 5 variant alleles were 
found in 1107 control cases. They have been associated mainly with FTD and late onset AD 
with different odds ratios that do not associate as strongly as R47H.  
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1.2.2 Nasu-Hakola 
Homozygous mutations in the TREM2 gene result in a disease called Nasu-Hakola disease 
(Neumann and Daly, 2013). The TREM2 variants Q33X, Y38C and T66M are responsible for 
the inherited form of this disease (Guerreiro et al., 2013a; Neumann and Daly, 2013).  
However, variants in the TYROBP/DAP12 gene can also be responsible (Neumann and 
Daly, 2013; Solje et al., 2014). TYROBP/DAP12 is an adaptor molecule that binds to TREM2 
and signals a downstream cascade of events (Dempsey, 2015; Jones et al., 2014; Lue et al., 
2015; Neumann and Daly, 2013). This pathway is clearly indicated in the pathogenesis of 
this disease and the fact that some of these variants have been associated with risk for 
LOAD suggests that both diseases could share some common mechanisms (Neumann and 
Daly, 2013).  
Nasu-Hakola, also known as polycystic lipomembranous osteodysplasia with sclerosing 
leukoencephalopathy, is a rare disease in which patients have a frontal-like dementia and 
multiple bone cysts at an early age (Neumann and Daly, 2013; Sasaki et al., 2015). These 
patients have a loss of myelin and white matter gliosis occurring in both the frontal and 
temporal lobes (Satoh et al., 2014). The glycosylation status of TREM2 is disrupted with 
some of these variants, impairing the ability for the cell to traffic TREM2 to the plasma 
membrane for further cleaving/shedding (Park et al., 2015a). A study using 
immunohistochemistry look at the microglia in this disease alongside protein analysis to 
correlate with DAP12 expression show that Nasu-Hakola patients have variable microglial 
expression of DAP12 (Sasaki et al., 2015). Satoh et al., (2011) report that whilst 
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Table 1.1: Coding Variants Found in TREM2 through DNA Sequencing in Patients with Alzheimer’s (adapted from Guerriero et. al, 2013a) 
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DAP12 can be detected on ramified microglia in controls, there is an absence of DAP12 
expressing microglia in Nasu-Hakola patients. The microglia in the demyelinated lesions do 
however express CD33 (Satoh et al., 2015). CD33 has also been indicated to play a role in 
AD, thus adding further to the evidence that these two diseases share some common 
mechanisms (Rosenthal and Kamboh, 2014).   
1.2.3 TREM2 structure and function 
TREM2 (triggering receptor expressed on myeloid cells 2) is a 40kD, 230 amino acid 
transmembrane protein belonging to the immunoglobulin family that is expressed on the 
plasma membrane of a number of different dendritic cells, including microglia (Jones et al., 
2014; Kober et al., 2014; Neumann and Daly, 2013; Paradowska-Gorycka and Jurkowska, 
2013). TREM2 is mapped on human chromosome 6p21 and consists of an extracellular 
domain, a transmembrane domain and a cytoplasmic tail as shown in Figure 1.4 (Allcock et 
al., 2003; Paradowska-Gorycka and Jurkowska, 2013). The extracellular domain has three 
N-glycosylation sites (Paradowska-Gorycka and Jurkowska, 2013). It is part of a cluster of 
genes also including TREM1, TREM4, TREM5, TREML1, and TREML2. TREM3 is also 
found in mice (Klesney-Tait et al., 2006; Whittaker et al., 2010). It is a highly conserved 
Figure 1.4: Structure of TREM2 and DAP12 across cell membrane (Paradowska-
Gorycka et. al, 2013) 
Chapter 1 - Introduction 
Page | 38  
 
protein and is thought to be a hub or highly connected gene for microglia in a number of 
different brain regions, including regions that are affected in AD such as the hippocampus 
where the gene is highly connected (Forabosco et al., 2013; Matarin et al., 2015).  
TREM2 is thought to function through two different pathways, one that suppresses 
inflammation and one that aids phagocytosis of any debris in or around the neurons (Frank 
et al., 2008; Guerreiro et al., 2013a; Park et al., 2015b; Rohn, 2013). It has been shown that 
TREM2 induces phagocytosis of apoptotic/injured neurons, Aβ plaques, damaged myelin 
and any cell debris (Jiang et al., 2013). Multiple studies have shown that when TREM2 is 
downregulated there is less microglial activation, impaired phagocytosis of injured 
neurons/Aβ plaques and an increase in levels of Tumor Necrosis Factor (TNF) and nitric 
oxygen species whereas when TREM2 is overexpressed there is increased phagocytosis 
and a decrease in pro-inflammatory signals (Jones et al., 2014; Takahashi et al., 2005). 
TREM2 is thought to suppress the inflammatory response through reducing any by-standing 
damage from inflammation, specifically inhibiting release and secretion of microglial 
cytokines and releasing TNF to promote survival (Jiang et al., 2013).  
Multiple studies suggest that TREM2 plays an important role in AD through the clearance of 
Aβ plaques (Guerreiro et al., 2013a; Jones et al., 2014; Lue et al., 2015). In those with 
TREM2 variants, microglia are less able to phagocytose the plaques and are therefore more 
at risk of disease (Jones et al., 2014). For example, TREM2 expression correlates with β-
secretase expression and the level of cortical Aβ (Guerreiro et al., 2013a; Martiskainen et al., 
2015). TREM2 induces phagocytosis of Aβ peptides in culture and has been shown to be 
localized and upregulated in microglia that surround plaques in mice models. However, this 
is not the case when the mice are TREM2 deficient (Lue et al., 2015). It is also reported that 
as AD progresses TREM2 is downregulated, Aβ42 is less efficiently cleared and the pro-
inflammatory response increases (Hickman and El Khoury, 2014; Jones et al., 2014; Zhao et 
al., 2013).  
One way that TREM2 performs these functions is by being able to recognise and bind to 
anionic lipids, lipopolysaccharides and zwitterions such as dextran sulphate, 
phosphatidylserine, sulfatides and sphingomyelin, both exposed in damaged neurons and in 
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bacteria (Dempsey, 2015; Neumann and Daly, 2013; Poliani et al., 2015; Wang et al., 2015). 
When fibrillar Aβ accumulates, it is thought to associate with lipids in lipid membranes and 
some bacteria (Grösgen et al., 2010; Zinser et al., 2007). When TREM2 recognises this, 
phagocytosis starts and plaques are cleared. It has been shown that when the R47H TREM2 
variant causes a change in the structure of the protein, it makes it more tightly folded and 
less able to bind to lipids (Abduljaleel et al., 2014; Wang et al., 2015). Therefore, it is 
hypothesized that this is the reason people with the TREM2 R47H variant are less able to 
clear plaques and are therefore at a higher risk of developing AD later in life.  
TREM2 undergoes proteolytic processing at the plasma membrane in which γ-secretase 
cleaves the ectodomain creating both a C-terminal fragment and a secreted/soluble fragment 
that is released extracellularly called sTREM2, with sTREM2 binding to other nearby cells 
(Kleinberger et al., 2014; Wunderlich et al., 2013). Once cleaved, the Srk kinases are 
triggered to start their signalling cascade and when the tyrosine residues in the DAP12 
protein (also known as TYROBP) are phosphorylated, the two bind and start the signal 
cascade that promotes phagocytosis and suppresses pro-inflammatory cytokine release 
from microglia (Colonna, 2003; Lue et al., 2015; Neumann and Daly, 2013). Several ligands 
for TREM2 have been identified, such as lipid ions and heat shock 60 protein that are 
reported to initiate the signalling cascade (Lue et al., 2015). Interestingly, both Bailey et al., 
(2015) and Atagi et al., (2015) provide evidence that APOE can bind to TREM2, suggesting 
that the two AD mechanisms are linked.  
DAP12 is a transmembrane adaptor protein that contains ITAMS (immunoreceptor tyrosine-
based activation motifs) and can also couple with Killer cell activating receptors on the 
surface of Natural Killer cells for antigen presentation (Aoki et al., 2003; Ma et al., 2014; 
Satoh et al., 2011). It is reported that DAP12 can also bind to the C-terminal fragment that is 
cleaved from the full-length protein therefore providing competition to the binding of DAP12 
to full-length TREM2 and initiating the downstream signalling cascade (Ma et al., 2014; 
Wunderlich et al., 2013; Zhong et al., 2015). Over-expression of either the full-length protein 
or the C-terminal fragment show a decrease in inflammatory response so Zhong et al., 
(2015) suggest that DAP12 stabilises the concentration of TREM2 providing protection 
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against increased inflammatory responses. Satoh et al., (2015) also report that this type of 
ITAM signalling is controlled by ITIM (immunoreceptor tyrosine-based inhibitory motif) 
signalling.  
1.3 Microglia 
Microglia are immune cells of the central nervous system and derived from the myeloid 
lineage (Town et al., 2005). Originally it was thought that microglia had three different forms; 
amoeboid, ramified and intermediates and that when not in these forms they were resting 
microglia (Lynch, 2009). However, they are constantly scanning their environment looking for 
potential damage or debris, even when they are not activated. These resting microglia were 
thought to have a ramified appearance and cover all areas between neurons without any 
contact with one another (Altman, 1994).  It was then believed that once they became 
activated they would become more amoeboid and migrate to the area affected (Altman, 
1994). 
Some believed that microglia had different phenotypes and activation states that determine 
what function and morphology they take on. Different markers were used to determine each 
of these phenotypes. It was thought that there were M1 (classical activation) and M2 
(alternate activation) types of activated microglia with the M1 phenotype being pro-
inflammatory and the M2 type being anti-inflammatory. The M2 subtypes were further 
classified into M2a and M2b phenotypes (Boche et al., 2013; Tang and Le, 2015). Although 
markers can be seen for the different functions of the microglia, either pro-inflammatory or 
anti-inflammatory, this classification of microglia being a certain phenotype was tentative.  
There is now a consensus that microglia are actually in a state of continuum in which they 
can change phenotype/morphology depending on the environment around them, meaning a 
microglial cell can become any one of the phenotypes previously discussed (Lynch, 2009; 
Town et al., 2005). Microglia from the choroid plexus or perivascular microglia have a 
different origin so are thought to be in a more constantly activated state whereas the 
microglia from the parenchyma are found in a wider number of states (Altman, 1994). 
Environmental cues give signals to the microglia to determine what state they take. A 
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number of molecules found on microglia, such as TREM2, CD200 and CX3CR1, regulate the 
transition of microglia from one type to the next (Kierdorf and Prinz, 2013). This change can 
be seen within a few hours of any change in environment with the cells becoming more 
antigen presenting, more amoeboid, and starting to surround neurons (Altman, 1994).  
Microglia become activated when there is a change in the environment surrounding it. For 
example, if there are foreign bodies in the space, if a neuron is dying or if the tissue is 
damaged, ATP can be released which also activates the microglia (Altman, 1994). A number 
of receptors are expressed on the cells once activated. IFN stimulates the microglia to 
present MHC antigens whereas Fc receptors are expressed when TNF/IL-1 are detected 
(Altman, 1994). When microglia are activated they release a number of molecules. One 
branch of these molecules are the complement proteins (Thameem Dheen et al., 2007). 
Other molecules released include CSF-1, IL-1, reactive oxygen species, nitric oxide, TNFα, 
PGE2 (Jones et al., 2014). 
Wu et al., (2014) report that in mice the microglia can be transformed into a more protective 
phenotype when neural stem cells are in the environment. The presence of neural stem cells 
increases protective markers such as CX3CR1, IGF-1 and TREM2 and they are thought to 
activate the TLR9/ERK1/2 pathway. TGF and IL10 are also released by this type of microglia 
and are responsible for regulating tissue repair and suppressing reactive oxygen species 
(Chakrabarty et al., 2015).  
Microglial priming is thought to increase the inflammatory response in aging individuals 
(Norden and Godbout, 2013; Perry and Holmes, 2014). By primed, it is meant that the 
microglia increase the amount of pro-inflammatory cytokines released and the number of 
receptors expressed on their surfaces meaning that when the immune system is challenged, 
the microglia are in a hyper-active state intensifying the inflammatory reaction (Perry and 
Holmes, 2014).  
When microglia are in a pro-inflammatory phenotype, their actions can also be detrimental to 
the local environment as the molecules that they release can be cytotoxic (McGeer and 
McGeer, 1995). For example, cytokines, complement proteins and reactive oxygen species 
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(Shih et al., 2006; Thameem Dheen et al., 2007). When this occurs in neurodegenerative 
diseases such as AD, this can worsen the symptoms of the disease. As the majority of these 
diseases occur in the older population, brains are already primed due to aging, meaning the 
inflammatory aspect of the disease will have a larger effect.  
Inflammation in AD therefore plays two roles in the disease. The pro-inflammatory reaction 
causes more neuronal damage, meaning that symptoms worsen (Wang et al., 2015). 
However, the anti-inflammatory reaction may help to clear the amyloid plaques and 
neurofibrillary tangles in the brain. The role that is most prominent in AD pathogenesis and 
neurodegeneration is still unclear.  
There is a great deal of evidence showing that microglia are responsible for clearing amyloid 
plaques from the extracellular space (Lee et al., 2013; Rogers and Lue, 2001; Rogers et al., 
2002). Dense plaques are surrounded by microglia that have thick cell processes and 
cytoplasmic swelling whereas more diffuse plaques have a more ramified microglial 
phenotype (Mattiace et al., 1990a). It is believed that after surrounding the plaques, the 
microglia phagocytose them by internalizing microaggregates of Aβ peptides (Paresce et al., 
1997). Tuppo and Arias, (2005) reports that Aβ is pro-inflammatory itself as it can activate 
other inflammatory components. The anti-inflammatory microglia also try and suppress the 
pro-inflammation occurring by releasing CSF-1 which has been shown by Gomez-Nicola et 
al., (2013) to slow neuronal damage and progression. Increased amounts of MHC II 
molecules have also been observed in patients with AD and a number of different 
complement proteins are found to be in the plaques (Eikelenboom and Gool, 2004; 
Emmerling et al., 2000; Ishii and Haga, 1984; Kolev et al., 2009; Veerhuis et al., 1995).  
1.4 Aims 
This thesis aims to further elucidate the role that TREM2 is playing in AD and what this infers 
for other neurodegenerative diseases. By looking at human post-mortem brain tissue 
carrying TREM2 variants and comparing these to sporadic AD cases (SAD), familial AD 
cases (FAD) and neurologically normal controls, it is hoped the impact that TREM2 variants 
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have can be determined. This can be then used to evaluate what role the TREM2 protein 
plays normally and will potentially help us to further understand the pathogenesis of 
Alzheimer’s disease and other neurodegenerative diseases. 
To achieve this cases will be used to:  
1. Investigate the pathological hallmarks of Aβ plaques and NFT’s by performing 
immunohistochemistry to assess load of both pathologies and type of amyloid 
plaque across Thal phases 
2. Investigate the microglial phenotype that is present by performing 
immunohistochemistry with multiple microglial markers and assessing the load, 
shape and perimeter of the cells stained with each marker 
3. Investigate the human inflammatory genetic profile using nanostring 
4. Investigate the proteomic profile using label-free quantitative mass spectrometry 
techniques and comparing to genetic profile data 
5. Investigate the presubiculum, an area protected from AD pathology, using 
immunohistochemistry and biochemical techniques.  
1.5 Hypothesis 
The TREM2 variant cases will differ in their pathological, genetic and proteomic profiles 
when compared to SAD and FAD. TREM2 variant AD cases will have increased Aβ loads 
and a different composition of amyloid plaques determined by immunohistochemistry. In 
addition, they will have an altered tau load. Microglia will not surround the amyloid plaques in 
the TREM2 variant cases to the same extent as other AD cases and will therefore be less 
activated and in a more ramified, homeostatic phenotype. As TREM2 is an inflammatory 
marker, the TREM2 variant cases will have an altered inflammatory profile both genetically 
and proteomically. The presubiculum will be an area that is protected from 
neurodegeneration and will have an altered proteomic profile to the neighbouring entorhinal 
cortex region.
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2 Materials and Methods 
2.1 Case demographics and ethics 
2.1.1 Case selection 
All cases were provided by the collection at Queen Square Brain Bank for Neurological 
Disorders, London, United Kingdom. Cases were fully consented and have full ethical 
approval for use in this study. The six cases that have previously been identified as having a 
TREM2 variant by Guerreiro et al., (2013a) using exome or full genome sequencing were 
used in this study . Two of these are pathologically diagnosed as healthy controls with three 
having a neuropathologically confirmed diagnosis of sporadic Alzheimer’s disease (SAD) 
and one having a diagnosis of familial Alzheimer’s disease (FAD) due to a PSEN1 mutation. 
Five of the cases have the R47H variant with one AD case having the D87N variant (Table 
2.3). Nineteen SAD cases (Table 2.3) were selected to match the TREM2 variant cases in 
sex, age, post-mortem delay and disease stage (Table 2.2). A third group of eleven FAD 
cases were selected (Table 2.3); eight PSEN1 variants and three APP variants. However, 
due to the early onset of FAD cases these did not match the other cases in age of onset or 
death but do match for post-mortem delay and disease duration (Table 2.2). A control group 
of pathological aging cases were used to determine if any differences seen were due to AD 
or pathological aging (Table 2.3). Other GWAS hits related to AD were not investigated in 
these cases.  
2.1.2 Staging of cases 
A neuropathological diagnosis was determined by neuropathologists at Queen Square Brain 
Bank. Cases were assessed using the three-tiered grading system set out by the National 
Institute of Aging, Alzheimer’s Association guidelines. Firstly, the distribution of Aβ plaques 
were given a Thal phase 0-5 score, where the presence of Aβ deposits are assessed in the 
neocortex, allocortex and basal ganglia before later affecting the brain stem and cerebellum 
(Thal et al., 2002). Secondly, a Braak and Braak score of 0-6 was given for the distribution of 
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tau pathology, where the NFT pathology is assessed according to its suggested spread 
throughout the brain (Braak and Braak, 1991). Lastly the frequencies of neuritic plaques 
were staged with a score of none to frequent, called the CERAD score. The three different 
scores are then used to determine how severe the AD is using the criteria shown in Table 
2.1 (Montine et al., 2011). The detailed pathological staging of the cases is outlined in Table 
2.3. 
A Thal phase for Aβ plaques B Braak and Braak NFT stage C CERAD neuritic plaque score
0 0 0 none 0 none
1 1 or 2 1 I or II 1 sparse
2 3 2 III or IV 2 moderate
3 4 or 5 3 V or VI 3 frequent  
Table 2.1: National Institute of Aging, Alzheimer’s Association staging criteria for 
determining severity of Alzheimer’s disease. Table modified from (Montine et al., 2011). 
 
Age at onset p=0.0016 **
SAD vs. FAD p=0.0011 **
SAD vs. TREM2 p=0.6769 ns
FAD vs. TREM2 p=0.7215 ns
Age at death p=0.0002 ***
SAD vs. FAD p=0.0199 *
SAD vs. TREM2 p>0.9999 ns
SAD vs. Control p=0.1448 ns
FAD vs. TREM2 p=0.4102 ns
FAD vs. Control p=0.0001 ***
TREM2 vs. Control p=0.1873 ns
Disease duration p=0.9971 ns
SAD vs. FAD p>0.9999 ns
SAD vs. TREM2 p>0.9999 ns
FAD vs. TREM2 p>0.9999 ns
Post-mortem delay p=0.2705 ns
SAD vs. FAD p>0.9999 ns
SAD vs. TREM2 p>0.9999 ns
SAD vs. Control p=0.4607 ns
FAD vs. TREM2 p>0.9999 ns
FAD vs. Control p>0.9999 ns
TREM2 vs. Control p>0.9999 ns
Table 2.2: Statistics comparing disease groups. Kruskal-Wallis one way ANOVA with 
Dunn’s multiple comparisons was performed on age of onset, age at death, disease duration 
and post-mortem delay. * for p<0.05, ** for p<0.005, *** for p<0.0005, ****p<0.0001, ns for 
non-significant. 
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Thal CERAD ABC 
TREM2 Variant cases 
1 M 55 64 9 35:40:00 R47H E3/E4 CBS SAD 6 5 Frequent A3B3C3 
2 F 56 66 15 51:20:00 R47H E4/E4 SAD SAD 6 5 Frequent A3B3C3 
3 M - 76 - 60:35:00 R47H E2/E2 Control Control 0 0 None A0B0C0 
4 M - 82 - 25:30:00 R47H E3/E3 Control Control 0 0 None A0B0C0 
5 M 60 71 11 52:30:00 D87N E3/E4 FTD SAD 6 5 Frequent A3B3C3 
6 F 36 41 5 64:15:00 
R47H 
E3/E3 SAD FAD 6 5 Frequent A3B3C3 Pre 200 
PS1 
Sporadic Alzheimer's disease cases (SAD) 
7 M 63 73 10 31:10:00 - - SAD SAD 6 5 Frequent A3B3C3 
8 F 51 63 12 16:00:00 - E3/E4 SAD SAD 6 5 Frequent A3B3C3 
9 F 51 62 11 62:55:00 - E3/E4 SAD SAD 6 5 Frequent A3B3C3 
10 F 65 70 5 46:58:00 - E3/E3 SAD SAD 5 5 Moderate A3B3C3 
11 M 64 77 13 90:05:00 - E4/E4 SAD SAD 6 5 Frequent A3B3C3 
12 F 49 62 13 76:40:00 - E3/E3 SAD SAD 6 5 Frequent A3B3C3 
13 M 72 88 16 85:35:00 - E3/E4 SAD SAD 6 5 Frequent A3B3C3 
14 M 52 69 17 35:04:00 - E3/E3 SAD SAD 6 5 Frequent A3B3C3 
15 M 65 72 7 38:55:00 - E3/E4 SAD SAD 5 5 Moderate A3B3C3 
16 F 76 85 9 90:20:00 - E3/E4 SAD SAD 6 5 Frequent A3B3C3 
17 M 55 64 9 76:45:00 - E3/E4 SAD SAD 6 5 Frequent A3B3C3 
18 F 69 74 5 93:40:00 - - SAD SAD 6 5 Frequent A3B3C3 
19 M 80 85 5 129:15:00 - - SAD SAD 5 5 Moderate A3B3C3 
20 F 46 52 6 51:55:00 - - LBD SAD 6 5 Frequent A3B3C3 
21 F 49 55 6 47:50:00 - E3/E3 SAD SAD 6 5 Frequent A3B3C3 
Chapter 2 – Materials and Methods 
























Thal CERAD ABC 
22 M 67 72 5 91:10:00 - E2/E4 bvFTD SAD 6 5 Frequent A3B3C3 
23 F 65 79 14 22:30:00 - E3/E4 SAD SAD 6 5 Frequent A3B3C3 
24 M 52 68 16 35:20:00 - E3/E4 FTD/Picks SAD 6 5 Frequent A3B3C3 
25 M 58 68 10 52:05:00 - E3/E4 SAD SAD 6 5 Frequent A3B3C3 
Familial Alzheimer's disease cases (FAD) 
26 F 48 59 11 26:15:00 
PSEN1 
202F 
E4/E4 FAD FAD 6 5 Frequent A3B3C3 
27 F 35 52 17 32:30:00 
PSEN1 
Intron 4 
E4/E4 FAD FAD 6 5 Frequent A3B3C3 
28 M 61 70 9 161:15:00 
PSEN1 
S132A 
E3/E4 FAD FAD 5 5 Frequent A3B3C3 
29 M 42 51 9 43:10:00 
PSEN1 
mutation 
E3/E3 FAD FAD 6 5 Frequent A3B3C3 
30 F 48 59 11 89:42:00 V717L APP  E3/E3 FAD FAD 6 5 Frequent A3B3C3 
31 M 60 66 6 68:05:00 V717L APP  E3/E3 FAD FAD 6 5 Frequent A3B3C3 




E3/E3 MSA FAD 5 5 Frequent A3B3C3 
33 F 46 66 20 31:55:00 R278I E3/E4 FAD FAD 6 5 Frequent A3B3C3 




E3/E3 FAD FAD 6 5 Frequent A3B3C3  
35 F 44 56 12 16:25:00 APP V717I E3/E3 FAD FAD 6 5 Frequent A3B3C3 
36 F 39 47 8 - 
PSEN1 
Intron 4 
E3/E3 FAD FAD 6 5 Frequent A3B3C3 
Control cases 




2 3 Moderate A2B1C2 
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Thal CERAD ABC 




2 1 Sparse A1B1C0 
39 F - 73 - 24:00:00 - E3/E4 Normal 
Pathological 
aging 
2 2 Sparse A1B1C2 
40 M - 88 - 16:15:00 - E3/E3 Normal 
Pathological 
aging 
2 2 Moderate A1B1C2 




0 2 None A0B1C0 




3 1 Moderate A1B2C2 
Averages 
TREM2 2F:4M 52 67 10 50:35:00 - - - - 4 3 - A2B2C2 
SAD 9F:10M 60 70 10 61:48:00 - - - - 6 5 - A3B3C3 
FAD 7F:4M 45 55 10 53:44:12 - - - - 6 5 - A3B3C3 
Control  3F:3M - 84 - 37:50:00 - - - - 2 2 - A1B1C1 
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2.2 APOE status 
2.2.1 DNA extraction 
100mg of frozen cerebellum was chipped from a selection of cases (cases 1-5, 8-17, 21-25, 
37-42) where ApoE status was not already determined (cases 6, 26-36) and where frozen 
tissue was available (cases 7, 18-20). Tissue was homogenised in extraction buffer (0.1M 
NaCl, 20mM Trizma base, 25mM EDTA disodium, 0.5% SDS), proteinase-K solution 
(10mg/ml) added, the samples inverted and incubated at 55ᵒC for three days to digest the 
tissue. A 1:1:1 mix of phenol, chloroform and IAA (Invitrogen) was added, samples vortexed 
and centrifuged for five minutes at 12,000rpm. The top aqueous layer was removed into a 
clean Eppendorf tube and 3M NaAC pH5.3 added to it. Samples were vortexed and 100% 
ethanol was added to enable the DNA to precipitate. Samples were kept at -20ᵒC for twenty-
four hours to allow further precipitation to occur before being spun for twenty minutes at 
12,000rpm at 4ᵒC. The aqueous supernatant was removed by aspiration and 70% ethanol 
was used to wash the pellets containing the DNA. Samples were kept at 4oC for twenty 
minutes before being spun again for five minutes at 12,000rpm. Ethanol wash was removed 
by aspiration. The pellet was left to dry at room temperature before being resuspended in TE 
(Tris-EDTA) solution and stored at 4ᵒC.  
2.2.2 Genotyping 
The Qiagen PCR Mix–GC Rich kit was used to create a PCR master mix including Q 
solution, dNTPs, Taq, a forward primer, a reverse primer and a buffer containing 15mM 
MgCl2 and H2O. The primers used to determine the ApoE status were previously reported 
and detailed in Table 2.4 (Emi et al., 1988). The master mix was added to DNA from each 
sample and a PCR run with the following settings: 94ᵒC for five minutes, 30x (94ᵒC for thirty 
seconds, 60ᵒC for thirty seconds, 72ᵒC for thirty seconds), 72ᵒC for five minutes before being 
left at 4ᵒC. The PCR end products were digested using the Hhal kit (Promega). The buffer 
with Hhal was added to samples, vortexed and spun before being incubated at 37ᵒC for two 
hours. A metaphor agarose gel was prepared with 3% metaphor agarose and 2% normal 
agarose with GelRed dye added. Thermo Scientific O’Range Ruller 10bp DNA ladder was 
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added to one well and the digested PCR end product for each sample added to the other 
wells. The gel was run for one hour thirty minutes at 80V before being visualised in a DNR 
Bio-Imaging Systems MiniBIS Pro. 
 
2.3 Tissue processing 
Post-mortem brain tissue donated to Queen Square Brain Bank arrives fresh and is hemi-
dissected. The right half is coronally sectioned and is flash frozen at -80ᵒC. The left half is 
immersed in 10% buffered formalin solution for three weeks before being examined and cut 
into five mm coronal slices. Small blocks are then taken and are processed to ensure 
preservation of the material. They are processed on a six-day cycle through graded alcohols 
and chloroform as outlined in Table 2.5. They are then embedded into paraffin wax and eight 
µm sections are taken for immunohistochemistry.  
 
1 70% Alcohol 12.00hrs
2 90% Alcohol 12.00hrs
3 90% Alcohol 12.00hrs
4 Absolute alcohol 12.00hrs
5 Absolute alcohol 12.00hrs
6 Absolute alcohol 12.00hrs






Step Reagent Time spent (6 day cycle)
Table 2.5: Steps of 6 day tissue processing cycle 
F4 primer: ACAGAATTCGCCCCGGCCTGGTACAC
F6 primer: TAAGCTTGGCACGGCTGTCCAAGGA
Table 2.4: Primers used for APOE genotyping. Reported in (Emi et al. 1988). 
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2.4 Immunohistochemistry 
2.4.1 Formalin fixed paraffin embedded (FFPE) sections 
Eight µm thick sections were cut from formalin-fixed, paraffin-embedded tissue from frontal 
cortex, temporal cortex, hippocampus, putamen and cerebellum of all cases. Slides were 
dried overnight at 37ᵒC before being adhered at 60ᵒC. The paraffin was removed using 
xylene and slides were rehydrated with absolute alcohol.  Endogenous peroxide activity was 
blocked using a methanol/H202 (0.3%) solution. Sections were pre-treated according to 
subsequent antibody use shown in Table 2.6. Additionally, some sections were treated with 
98% formic acid for ten minutes at room temperature before being washed in H2O. All slides 
were placed in citrate buffer (0.45g citric acid, 5.8g tri-sodium citrate, 2 litres deionised H2O, 
pH6) and heated in a pressure cooker for ten minutes. Slides were incubated in 10% non-fat 
milk solution/ TBS for thirty minutes at room temperature, to block unspecific antibody 
binding. Primary antibodies were applied for one hour at room temperature, the 
concentration of each antibody used is shown in Table 2.6. Antibodies are commercially 
available and the majority are used in routine practice for neuropathological diagnosis. 
Those antibodies that are not used routinely in diagnostic practice underwent a round of 
quality control, incubating with a range of dilutions to see if the signal was specific. The 
slides were washed in TBS-Tween solution (Thermo Scientific) before being placed in the 
respective biotinylated secondary antibodies (rabbit anti-mouse, 1:200, Dako, swine anti-
rabbit, 1:200, Dako) for thirty minutes. After a second round of washing in TBS-Tween, 
Avidin-Biotin Complex solution (Vector) was applied for thirty minutes. Slides were washed 
before 3,3′-di-aminobenzidine-TBS-H202 solution (1ml 5% DAB in 100ml TBS-Tween, 32µl 
H2O2) was used as the chromogen and slides were counterstained in Mayer’s haematoxylin 
(1g haematoxylin, 50g potassium or aluminium alum, 0.2g sodium iodate, 50g chloral 
hydrate). Slides were dehydrated through 70% alcohol, 90% alcohol, absolute alcohol and 
xylene, then mounted using DPX mounting medium (Thermo Scientific). Slides were then 
viewed under the Nikon Eclipse Ni microscope and photographs were taken for illustrative 
purposes at several magnifications. For quantitative analysis slides were scanned at 40x 
magnification using a Leica SCN400F slide scanner. 
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2.4.2 Frozen sections 
Frozen sections from SAD cases and control cases were cut at 10µm on a cryostat (Bright, 
OTF5000) and mounted onto superfrost slides (Solmedia), then stored at -800C until 
required. Sections were air dried for ten minutes before either being fixed in 4% PFA or ice-
cold acetone for thirty minutes depending on the downstream immunohistochemical 
analysis. Slides were washed for five minutes, three times in TBS-Tween before being 
incubated in 10% non-fat milk for thirty minutes. The rest of the immunohistochemical 
protocol followed the methods in section 2.4.1. 
2.4.3   Immunoflourescence 
Double immunohistochemistry was performed with several antibodies to check if staining 
was specific to certain cell types. Frozen sections were used and treated with the same 
protocol detailed in section 2.4.2. After the avidin-biotin complex was applied, TSA red 
(Perkin Elmer) was applied for fifteen minutes at room temperature before the second 
primary antibody was added onto the sections and left to incubate overnight at 4ᵒC. The 
sections were washed in TBS-Tween for five minutes, three times, the relevant secondary 
antibody and avidin-biotin complex applied as previously described before the sections were 
incubated in TSA green (Perkin Elmer). Slides were washed in TBS-Tween before the 
sections were mounted using mounting medium with DAPI (Vector Labs). These slides were 
then observed on Leica DM5500B microscope and fluorescent images taken from z stacks 
with both stains and overlaid to investigate co-localisation. 
Chapter 2 – Materials and Methods 









































rabbit pAb 1:100 








goat pAb 1:;40 








rabbit pAb 1:100/1:200 


























































































Table 2.6: Details of primary antibodies used 
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2.4.4 Thioflavin S staining 
Thioflavin-S staining was performed to visualise Aβ in an amyloid conformational state. 
Immunofluorescence with an Aβ antibody was performed with methods outlined in section 
2.4.3 in the red channel. Sections were then incubated in 0.1% aqueous Thioflavin-S 
solution (Sigma) for seven minutes at room temperature. 70% ethanol was used to 
dehydrate the sections and wash the excess Thioflavin-S off the sections. Sections were 
then mounted with Vector mounting medium with DAPI and coverslipped. These slides were 
then observed on Leica DM5500B microscope and fluorescent images taken from z stacks 
with both stains.  
2.5 Pathology analysis 
2.5.1 Regions analysed 
To analyse the amount of Aβ plaques, tau and microglial loads throughout the AD brains, the 
Thal staging regions were analysed, as these regions are an indicator of pathology 
progression throughout the brain. This included the frontal cortex, temporal cortex, 
hippocampus, putamen and cerebellum regions (Thal et al., 2000). The substantia nigra is 
also a Thal staging region. However, as the neuromelanin in the dopaminergic neurons is 
also brown they were sometimes hard to distinguish from the DAB staining meaning it was 
difficult to decipher the pathology being invesigated (Aβ plaques, NFT’s or microglia). 
Therefore, this area was not used in final analysis. P2RY12 microglial analysis was 
undertaken later than other microglial analysis, as it was only recently discovered to be a 
marker of homeostatic microglia (Hickman and El Khoury, 2014). Therefore, due to time 
constraints only the frontal cortex, temporal cortex and hippocampal areas were analysed 
with this antibody.  
2.5.2 Region selection 
All sections were scanned using a Leica slide scanner at 40x magnification and a digital 
image was then stored. Aperio Imagescope (v12.3.0.5056) was used to view the images and 
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extract the area of interest decreasing the file size. The extracted images were loaded into 
ImageJ (https://imagej.nih.gov/ij/) and a macro used, developed by a collaborator (Yau Lim, 
Kings College London), to analyse the areal fraction of the immunohistochemistry, the 
number of microglia and the circularity of the microglial staining. The macro allowed a region 
of interest to be selected on the image. Image J measured the coordinates of the region of 
interest. The coordinates were added to a Python script which generated coordinates of 
random squares. The random squares from the region of interest were then analysed (Figure 
2.1). Random squares were selected at 1000x1000 pixels square which represented 
500µm2. Bland-Altman plots with linear regression were utilised to determine the number of 
squares needed for reproducibility of results (Appendix Figure 1).  
2.5.3 Manual counting 
The macro could not be used to distinguish the type of plaque or the number of NFT’s alone 
due to all DAB staining being counted in the analysis. The analysis would therefore count all 
plaque types together and pathological tau including NFTs, neurites and dystrophic neurites. 
Therefore, a manual counting method was utilised for this type of analysis. After random 
squares had been generated using the Python script for each area in each case, NFT’s and 
different plaque types (diffuse or dense-core) were manually counted to determine how 
many NFTs or plaques were in the representative sample. Whole NFTs were systematically 
counted with any partial NFT’s on the edge of images excluded. NFTs were identified as 
large, globose masses in the neuron cytoplasm  (Probst et al., 1991a). Dense core plaques 
were only counted when a dense core could be seen (Figure 2.2a), otherwise they were 
counted as diffuse plaques (Figure 2.2b). Only whole plaques were counted as to not 
exclude any dense cores. The number for each random square was taken before a mean 
was calculated for each case in each region and Wilcoxon-paired rank tests were performed 
to determine any significant differences between each region at a level of p<0.05. 
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Figure 2.1: A flow diagram showing process of analysing the immunohistochemical staining using Imagescope, Python and ImageJ software 
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2.5.4 Density/Areal fraction 
After random squares were generated using a Python script as detailed above, the macro 
developed by Yau Lim (unpublished method) was used to determine the area of the square 
that was immunohistochemically stained with 3,3′-di-aminobenzidine by each antibody. A 
threshold was set between sixty-eighty saturation to select all the brown chromogen (Figure 
2.1). Areal fractions were calculated for each square and means were then taken for each 
case, each region and each antibody. Kruskal-Wallis one way ANOVA tests with Dunn’s 
multiple comparisons were performed to determine any significant differences at a level of 
p<0.05.  
2.5.5 Circularity and size 
For all microglial antibodies, the shape and size of the microglia were assessed using the 
same macro. Each single microglia was given a measure on how round it was using the hull 
and circle function in ImageJ, with 1 being a perfect circle and 0 being an imperfect shape. A 
rounder score closer to one indicates the microglia more amoeboid in shape whereas a 
score closer to zero indicates the microglia were more ramified. This was done to assess the 
phenotype within the microglia observed. The perimeter of each microglia was also 
measured to determine the size of the microglia. An average perimeter and circularity value 
was taken for each square and a mean of the squares were taken for each case, region and 
stain. Kruskal-Wallis one way ANOVA tests with Dunn’s multiple comparisons were 
performed to determine any significant differences at a level of p<0.05.  
Figure 2.2: Distinguishing between dense-core (a) and diffuse (b) Aβ plaques. Dense 
core highlighted by white arrow 
a b 
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2.6 Genetic expression 
2.6.1 RNA extraction 
RNA extraction was performed using the Qiagen RNeasy kit and protocol. 100mg of frozen 
frontal cortex tissue from each case was sampled and placed into Qiazol lysis buffer. A 
Qiagen TissueRuptor was used to homogenise the tissue. Chloroform was added and the 
samples were vortexed before being spun at 12,000g at 4ᵒC for fifteen minutes. The samples  
separated into three layers, with the top layer being aqueous RNA. The top layer was 
removed and one and a half times 100% ethanol was added. The solution was put into a 
Qiagen RNeasy Mini Spin Column and spun at 10,000 rpm for one minute. The flow-through 
was discarded and buffer RW1 was added. Samples were spun again at 10,000rpm for 
fifteen seconds and flow through discarded. Qiagen DNase I incubation mix was added to 
the samples and left to degrade any genomic DNA for fifteen minutes. Buffer RW1 was 
added subsequently and columns were spun at 10,000 rpm for fifteen seconds. Samples 
were washed three times with Buffer RPE being spun twice at 10,000rpm for one minute and 
lastly for two minutes to dry out the columns. RNase free water was added, left to stand for a 
couple of minutes and then eluted into a new tube by being spun at 10,000rpm for three 
minutes. The eluent was then re-added to the column and the same was repeated to get 
maximum RNA elution.   
2.6.2 Nanostring 
The RNA concentration and purity was measured using an Eppendorf spectrophotometer. 
The concentration, the A260/A280 ratio and the A260/A230 ratio were measured (Appendix 
Table 1). All samples were diluted to 50ng/ul and were analysed at NanoString Technologies 
Seattle. The samples were analysed on the Human Inflammation panel containing two 
hundred and fifty-six genes and thirty extra genes were also added that were relevant to AD 
(Appendix Table 2). As shown in Figure 2.3, the probes for each gene consist of a reporter 
probes are hybridised into solution. Excess probes are removed and probe/target complexes 
aligned and immobilised in the nCounter cartridges. The digital analyser then read and 
quantitated all the individual barcodes. This technique allowed for direct analysis of gene 
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expression within a sample without the need for conversion to cDNA and additional rounds 
of amplification. The nSolver software was used to analyse the raw data (Geiss et al., 2008). 
Negative controls that did not contain probes were used to detect any background and 
averages of these were subtracted from the counts. The results were then normalised using 
positive controls and five housekeeping genes (CLTC, GAPDH, GUSB, PGK1, TUBB). All 
pairwise ratios between groups were made from the normalised data and two-tailed t-tests 
were performed to establish any significance at p<0.05. In order to correct for false discovery 
rate (FDR) the Benjamini-Yekutieli method was used to exclude any false positive results. 
Figure 2.3: Diagram showing the nanostring method. Hybridising probes to the targets 
within the sample, purifying and immobilising the sample by washing away excess probes 
and aligning them to the cartridge before a digital analyser counts how many of each 
barcode. (diagram adapted from www.nanostring.com) 
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Frozen hippocampal sections were cut at 10μm thick as above for the cases selected. 
Sections were mounted onto PEN-membrane slides that are coated with polyethylene 
naphthalate (Leica). Slides were treated with the normal immunohistochemistry protocol 
above and left to dry overnight. Using the Leica DM6000B laser capture microdissection 
microscope the individual cells of a certain type /area of interest were drawn around, cut out 
with a laser and collected in the lids of separate 0.2ml Eppendorf tubes. Samples were then 
kept at -20ᵒC until needed.  
2.7.2 Protein extraction 
Frozen frontal cortex or LCM samples as prepared above were homogenised in 50mM 
Ambic buffer with 2% ASB-14 using the Precellys 24 homogenizer (Bertin Instruments) in the 
CK-14 tubes with a cycle of speed 6500 for two x twenty seconds with a five second gap in 
between. An Eppendorf spectrophotometer was then used to determine the protein 
concentration of each sample and the amount needed to reach the optimal protein 
concentration was calculated. Due to time and money limitations a pool of each disease 
group was created that had equal protein concentration from each case in order to get the 
maximum depth possible. Samples were spun at maximum speed for ten minutes at 4ᵒC and 
the supernatant was removed and kept in a different tube. The remaining pellet was 
resuspended in ice cold acetone, vortexed and left at -20ᵒC for at least an hour. They were 
then vortexed again, spun at 14000rpm for ten minutes at 4ᵒC and the supernatant 
containing the metabolites was removed and kept for future analysis. The pellets were 
allowed to air-dry before being suspended in 70% formic acid and vortexed. They were then 
left shaking overnight before being dried in a speed-vac. The original supernatants had ice-
cold acetone added and left at -20ᵒC overnight. The next day they were vortexed and spun at 
14000rpm for ten minutes at 4ᵒC. The supernatant containing the metabolites was removed 
and added to the metabolites from the pellet for future analysis. The remaining pellet was 
dried in the freeze dryer.  
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2.7.3 Protein digestion 
Dried supernatants and pellets were reconstituted in 100mM Tris 8M Urea 2% ASB-14 
pH7.79, vortexed and left shaking for one hour to resolubilise the proteins. Dithioerythritol 
(Sigma) was then added, vortexed and left shaking for a further hour as a reducing agent. To 
stop the peptides forming disulphide bonds Iodoacetamide (Sigma) was added to alkylate 
the proteins and act as a peptidase inhibitor. The samples were vortexed and left for thirty 
minutes. Trypsin-LysC enzyme (Promega Trypsin/Lys-C Mix, Mass Spec Grade cat no. 
V5073) was added to digest the proteins and was left for three-four hours at 37ᵒC before H2O 
was added and the samples were left overnight at 37ᵒC. 
2.7.4 C18 peptide clean up 
The digested samples were diluted 1:1 in 0.2% TriFluroacetic Acid (TFA) and 5pmol of 
Waters MassPREP enolase digestion standard (part no. 186002325) was added to the 
digest. The Agilent C18 Bond Elut 96 well plates (Part no. A496011C) were used to clean 
the peptides. The wells were primed with 50% acetonitrile (ACN) 0.1%TFA and then washed 
twice with 0.1% TFA. The diluted digest samples were added to the wells and allowed to drip 
through. The flow-through was collected and re-applied. The residual salts were washed 
away by adding 2 x 3% ACN 0.1% TFA and the peptides were eluted using 2 x 50% ACN 
0.1% TFA into a new 96-well plate. Samples were transferred to eppendorfs and dried using 
a speed vac.  
2.7.5 Quantitative label free mass spectrometry 
The digested cleaned peptides were reconstituted in 3% ACN 0.1% TFA and transferred to a 
QToF Trueview vial. A pool of all samples was created to be a quality control. Label-free 
mass spectrometry was performed with a SYNAPT G2-Si High Definition machine with 2D 
fractionation. There were four fractions run for each sample and 0.5µg of protein were 
injected per fraction per run. The order of samples was randomised to avoid technical bias. 
The raw data was loaded into Progenesis for proteomics software and automatically 
processed with the following settings: low energy threshold set to two hundred and fifity 
counts; elevated energy threshold set to seventy-five counts; intensity threshold set to seven 
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hundred and fifty counts; elution start at ten minutes and elution end at fifty minutes. The 
alignment was reviewed and if less than 80%, the alignment was manually corrected. The 
results were filtered to exclude any charges above ten. Healthy controls were compared to 
diseased groups. Peptides were identified with an MSe search with the following parameters: 
missed cleavages, max one; max protein mass, 800000 kDa; modifications of 
carbamidomethyl C, oxidation M, deamidation N and Q. The ion matching requirements were 
set as follows: three fragments/peptide, five fragments/protein, one peptide/protein. The 
identifications were refined by deleting any with a sequence length less than five. The fold 
change for each protein was then exported before further downstream analysis was 
performed on it.  Proteins that had been identified with only one unique peptide were 
excluded from the analysis. 
2.7.6 Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry 
Collected whole presubiculum and amyloid plaques from the entorhinal cortex samples were 
sent off for mass spectrometry analysis in Prof Henrik Zetterberg’s lab in Sweden. The 
samples were aspirated with 70% formic acid ten times, centrifuged and aspirated again. 
Samples were vortexed and dried before being resuspended in 5 µl 0.1% FA 20 % ACN. To 
prepare the matrix, 0.5µl of the seed-layer (20 g/L α cyano (CHCA) in 90% acetone, 10 % 
methanol with 0.005 % TFA) was added to the probe and 1ul of sample, 1µl sample matrix 
(15 g/L α cyano (CHCA) in ACN (CH3CN) and 0.1 % TFA (1:1)) were mixed before being 
placed on the probe. Aβ was extracted using this method. The number of Aβ peptides in 
each sample was determined using matrix-assisted laser desorption ionization time-of-flight 
mass spectrometry as outlined in (Portelius et al., 2015). 
2.8 Bioinformatics 
As a label-free approach was taken, all genes or proteins that met the threshold set (p<0.05 
for nanostring, >2-fold change in expression for proteomics) were put into publicly available 
databases to assess the relationships between them and the biological processes, molecular 
functions and cell components that were enriched in the different disease groups. To assess 
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the enriched gene ontology terms Webgestalt (Zhang et al., 2005) was used. GOview was 
used to compare terms that were over-represented between regions or disease group.  
Ingenuity Pathway Analysis software was used to perform in depth canonical pathway 
analysis and determine any bio functions altered in the datasets.  Ingenuity Pathway 
Analysis is a tool that uses the database, Ingenuity Knowledge base to identify canonical 
pathways that are represented within the data.  The Ingenuity Knowledge base is created by 
manually curating the literature as well as combining other publically available resources, 
listed in Figure 2.4.  The pathways that are represented are each given a z-score, which is a 
predictor of whether the pathway is activated or inhibited in the dataset being analysed. This 
prediction is based upon the upregulation or downregulation of the individual genes/proteins 
that are represented from each pathway. Understanding which pathways are the most 
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Figure 2.4: Diagram to show design of Ingenuity Knowledge Base. Adapted from www.qiagenbioinfomatics.com.  
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3 Neurodegenerative pathology in TREM2 variant 
cases 
3.1 Abstract 
Introduction: TREM2 was identified as a genetic risk factor for late onset AD with a similar 
odds ratio to that of APOE4. Numerous studies have looked at different models to identify 
what role TREM2 variants have on the underlying pathomechanisms of AD and whether this 
influences the pathological hallmarks; Aβ plaques and neurofibrillary tangles. In this study, 
the AD pathology of six TREM2 variant cases (5 R47H and 1 D87N variant) were assessed 
and compared to sporadic and familial AD cases. 
Methods and materials: All cases (TREM2 n=6; SAD n=19; FAD n=11) underwent a 
pathological assessment using the current diagnostic criteria (Montine et al., 2011). A 
detailed pathological analysis was undertaken to assess the pathological hallmarks 
including; Aβ load, plaque type (diffuse or dense-cored) and tau load. Load was assessed in 
the Thal phase regions: frontal cortex, temporal cortex, hippocampus, putamen and 
cerebellum. Random areas were taken for analysis using Python and ImageJ analysis 
software. APOE genotypes were determined in all cases and the affect of each genotype on 
load was assessed.  
Results: TREM2 variant AD cases were identified to have varying levels of cortical and 
hippocampal atrophy. They had amyloid and tau pathology as well as additional alpha-
synuclein pathology present in some cases. All but one TREM2 variant case had additional 
CAA and APOE genotypes identified no ApoE2 isoforms within the TREM2 variant AD 
cases. There were significantly different loads of Aβ and AT8 between brain regions and 
FAD cases had significant differences to SAD and TREM2 variants in both pathologies. The 
frontal cortex, temporal cortex and putamen regions had significantly greater diffuse plaques 
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than dense-core plaques in both SAD and FAD cases. However, there were no significant 
differences in the hippocampus.  
Conclusions: TREM2 variant cases that had an ApoE4 allele have similar pathology to 
those of sporadic AD cases whereas TREM2 variant cases without an ApoE4 allele were 
diagnosed as normal controls and do not have Aβ plaques or NFT’s. APOE risk and TREM2 
risk may be linked as they could share similar mechanisms through being binding partners. 
TREM2 variants may be involved in reduced elimination of Aβ and therefore result in 
increased risk of AD. However, these results do not indicate any change in pathology 
between SAD and TREM2 variants. Further investigation into what other mechanisms 
TREM2 utilises is needed to understand its role in more depth.  
3.2 Introduction 
3.2.1 TREM2 as a genetic risk factor 
As previously discussed in 1.2.1, TREM2 was discovered in 2012 as a genetic risk factor for 
late onset AD with a similar odds ratio to that of APOE4 (Guerreiro et al., 2013a; Jonsson et 
al., 2012b). Subsequently, a number of TREM2 variants were found to have links to not only 
AD but also Frontotemporal dementia (FTD), Amyotrophic lateral sclerosis (ALS) and 
Parkinson’s disease (PD) (Borroni et al., 2014; Cady et al., 2014; Ghani et al., 2016; Giraldo 
et al., 2013; Guerreiro et al., 2013b; Lill et al., 2015; Rayaprolu et al., 2013; Thelen et al., 
2014).  The variants that were identified to be risk variants for AD were R47H, Q33X, Y38C, 
T66M, D87D, R98W, H157Y, R62H, T96K, L211P, W191X and D87N. However, the variant 
with the highest frequency and the one that has been validated by many groups is R47H.  
The R47H variant has been reported to be a risk variant in several cohorts with the range of 
1.6-fold to 3.4-fold effect size being described between groups (Guerreiro et al., 2013a; Hooli 
et al., 2014; Rosenthal et al., 2015; Slattery et al., 2014). Several groups have investigated 
the R47H TREM2 variant using imaging, pathology and structural studies to try and establish 
what effect this mutation has on the biological function of TREM2. Many believe that the 
R47H mutation leads to a loss-of-function of TREM2 due to the protein’s secondary structure 
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becoming distorted and therefore no longer being able to bind anionic lipids or alternative 
ligands (Abduljaleel et al., 2014; Wang et al., 2015).  
Additionally, it has been suggested that the R47H variant leads to a more severe form of AD 
than those without a TREM2 variant. Notably, R47H carriers have been observed to have 
either earlier age of onset or shorter disease duration (Korvatska O et al., 2015; Slattery et 
al., 2014). Imaging studies have shown R47H carriers (n=16 and n=12 respectively) to have 
increased frontal atrophy, particularly in the orbitofrontal cortex, increased temporal atrophy 
and relative sparing of the hippocampus (Luis et al., 2014; Slattery et al., 2014). Pathological 
observations from a series of cases show that R47H variants have a greater amount of AD 
pathology such as amyloid plaques and neurofibrillary tangles as well as some reports of 
greater alpha-synuclein pathology being present (Korvatska O et al., 2015; Roussos et al., 
2015). In addition to this, the R47H variant has been associated with increased levels of both 
sTREM2 levels, tau and hyper-phosphorylated tau in CSF (Cruchaga et al., 2013; Piccio et 
al., 2016).  
The D87N variant has not been as widely reported and is not as frequent as the R47H 
Figure 3.1: TREM2 ectodomain structure. Disease-associated residues are highlighted 
with sticks. Adapted from Kober et. al 2016.  
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variant as it is more frequently associated with Nasu-Hakola disease than AD (Ghani et al., 
2016; Guerreiro et al., 2013a). Both R47H and D87N variants are located on the extracellular 
domain of the TREM2 protein, however the position of the mutations have been reported to 
have different effects on TREM2 function (Ghani et al., 2016). Soluble TREM2 levels in the 
CSF of D87N carriers is reduced whereas in R47H carriers it was increased (Ghani et al., 
2016; Piccio et al., 2016). The D87N variant is situated on the inside of the protein whereas 
the R47H variant is located on the outside and is therefore accessible to ligand binding as 
illustrated in Figure 3.1 (Kober et al., 2016). The R47H variant has been shown to have less 
maturation, secretion and phagocytosis than wildtype TREM2 in HEK293 cells indicating that 
the variant impairs the normal processing of the protein (Kleinberger et al., 2014).  
3.2.2 Pathological observations for TREM2 variants 
As TREM2 was identified as a risk factor for AD, it led to the hypothesis that the TREM2 
protein may have a role in the pathogenesis of AD. The role of TREM2 in AD was 
investigated in several animal models known to have typical amyloid or tau pathology. 
TREM2 was found to be upregulated or positively correlated in the presence of amyloid 
plaques and phosphorylated tau or tau deposition (Chan et al., 2015; Frank et al., 2008; 
Guerreiro et al., 2013a; Jiang et al., 2015; Lue et al., 2014; Martiskainen et al., 2015; Matarin 
et al., 2015; Melchior et al., 2010; Varvel et al., 2015). However, Lue et al., (2014) showed 
no correlation between TREM2 levels and amyloid plaque burden but did confirm the 
correlation with tau pathology in human post-mortem temporal cortices from AD cases.  
TREM2 is not thought to directly increase the load of AD pathology. However, when TREM2 
is upregulated it has been hypothesised that the number of microglia surrounding plaques 
increases or the activation of inflammatory pathways is triggered via activation of tau 
kinases, leading to greater levels of phosphorylated tau. (Jay et al., 2017; Jiang et al., 
2016a; Melchior et al., 2010; Yuan et al., 2016). Jiang et al., (2014) indicate that the TREM2 
upregulation could be down to compensating for increased Aβ1-42 levels.  
Numerous studies demonstrate that TREM2 is responsible for the phagocytosis of Aβ by 
causing activation or proliferation of microglia around the amyloid plaques. However, Yuan et 
al., (2016) propose that it is in fact a microglia barrier expressing TREM2 that helps to keep 
Chapter 3 – Neurodegenerative pathology in TREM2 variant cases 
Page | 71  
 
amyloid plaques compact and protected from neuritic damage in neurons. They have shown 
that the amyloid plaques in TREM2 deficient mice are more diffuse and less compact than 
those of wildtype mice. 
1.5.1 Effects of TREM2 expression on pathology in experimental models 
To establish what effect a variant in TREM2 may have, TREM2 deficient and TREM2 
overexpression models were studied with varying results. Jay et al., (2015) demonstrated 
that in an APPPS1-21;TREM2-/- model at 4 months of age there was reduced Aβ in the 
hippocampus but no change in the cortical load compared to APPPS1-21; TREM2+/+ mice  
and at 8 months of age there was no difference in amyloid load measured in the 
hippocampus (Jay et al., 2017).  On the other hand, 4 months of age 5xFAD; TREM-/- mice 
showed no change in the hippocampal Aβ deposition but 8.5 month old mice showed no 
effect on the Aβ cortical load, but had an increase in hippocampal Aβ deposition (Wang et 
al., 2015, 2016). This indicates that TREM2 function changes during disease progression.  
Further evidence for this can be seen in TREM2 overexpression models. TREM2 
overexpression in APPPS1 mice at 7 months shows a reduction in the number of amyloid 
plaques and increased Aβ phagocytosis, therefore, rescuing the neurons from injury, 
whereas the same strain at 18 months did not rescue neuronal or synaptic loss (Jiang et al., 
2014, 2016b). In addition, when TREM2 was overexpressed in primary microglia from the 
same mice at 7 months and 18 months, there was increased Aβ phagocytosis or no 
response from the microglia, respectively (Jiang et al., 2016b). However, the 18-month-old 
microglia were less able to phagocytose Aβ than the 7-month-old microglia in normal 
conditions. More importantly, TREM2 haploinsufficiency has no effect on amyloid plaque 
burden in 3 or 7 month APPPS1 mice which correlates with the heterozygous variants in 
TREM2 that cause the risk of AD (Ulrich et al., 2014).  
While this is the case with TREM2 and its effect on amyloid function, a similar instance can 
be observed for tau deposition. Increased tau pathology and phosphorylation is observed 
when TREM2 is silenced in P301S mice whereas overexpression of TREM2 at 7 months 
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rescued this effect by decreased phosphorylation and reduced neuronal and synaptic loss in 
the hippocampus (Jiang et al., 2015, 2016a).  
3.2.3 TREM2 and APOE 
APOE was identified as a genetic risk factor for AD, with different allelic compositions 
determining the level of risk (Allen D. Roses, 1996). The ApoE4 allele confers the greatest 
risk, followed by ApoE3 and then ApoE2. ApoE2 has been shown to have protective 
properties in AD (Corder et al., 1993). 
The main function of APOE is to transport lipids across different cells and tissues although it  
plays a role in other functions too, such as APP processing, tissue repair, immunoregulation 
and remodelling (Herz and Bock, 2002; Huang and Mahley, 2014; Mahley, 1988; Mahley 
and Huang, 1999; Mahley and Ji, 1999; Weisgraber et al., 1994). The mechanism by which 
APOE transports lipids across different cells and tissues is by binding to lipoproteins and 
heparan sulphate proteoglycans (HSPG’s). The different APOE isoforms have different 
affinities for lipoproteins due to their different structural conformations so have different 
effects on this function (Huang and Mahley; Weisgraber et al., 1994). 
APOE appears to be required for amyloid plaque production in mice and there have been 
several studies that have reported APOE to be associated with amyloid plaque pathology 
(Bales et al., 1999; Namba et al., 1991; Strittmatter et al., 1993b; Wisniewski and Frangione, 
1992). Further to this Cho et al., (2001) reported that APOE is responsible for amyloid 
plaques increasing in size. It is thought that APOE effects Aβ metabolism through 
interaction with several other molecules such as lipoproteins and HSPGs and suggests that 
this allows for the plaques to increase in size (Verghese et al., 2013).  
The ApoE4 isoform has been shown to increase the amount of amyloid pathology compared 
to other isoforms by forming complexes with Aβ more rapidly and effectively (Bogdanovic et 
al., 2002; Cho et al., 2001; Strittmatter et al., 1993a). On the other hand, ApoE4 has been 
shown to decrease Aβ clearance in mice compared to ApoE3 and causes neuronal and 
behavioural deficits even in mice that have no Aβ deposition (Castellano et al., 2011; Huang 
and Mahley, 2014). These findings indicate that increased amyloid production and 
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decreased clearance in carriers of the ApoE4 isoform leads to the increased susceptibility 
identified for AD. 
Furthermore, ApoE4 has been identified to be more susceptible to proteolytic cleavage than 
ApoE3 and therefore produces carboxyl terminal truncated fragments at a greater rate. 
These fragments have been linked to amyloid plaques and neurofibrillary tangles in AD 
brains and they are thought to disrupt the cytoskeletal structure of both tau and 
neurofilament (Brecht et al., 2004; Harris et al., 2003; Huang, 2011; Huang et al., 2001; 
Jones et al., 2011). In addition, ApoE4 transgenic mice were demonstrated to have 
increased levels of phosphorylated tau and APOE was identified as being genetically 
associated with CSF tau and phosphorylated tau (Brecht et al., 2004; Cruchaga et al., 2013; 
Harris et al., 2003).  
As both APOE and TREM2 have been identified as genetic risk factors for AD, and TREM2 
has been shown to also bind anionic lipids, it has been hypothesised that TREM2 may 
function along similar mechanisms as APOE (Daws et al., 2003; Wang et al., 2015). 
Subsequently, APOE was identified to be an agonist to TREM2 (Atagi et al., 2015; Bailey et 
al., 2015; Jendresen et al., 2017). Nevertheless, no difference was observed in the binding 
affinities for the different APOE isoforms to TREM2 (Atagi et al., 2015; Yeh et al., 2016).  
APOE has previously been identified to have two binding sites; a receptor binding site and a 
lipid binding site (Cho et al., 2001; Jendresen et al., 2017). Jendresen et al., (2017) 
identified that TREM2 binds to the receptor binding site on APOE. Heparan sulphate and Aβ 
have both been shown to bind to both or either of the binding sites and both heparan 
sulphate and APOE have been reported within amyloid plaques (Jendresen et al., 2017; 
Strittmatter et al., 1993b; Winkler et al., 1999). Therefore, if Aβ is associated with 
lipoproteins via APOE, using its lipid binding region, then TREM2 could scavenge Aβ 
attached to lipoproteins and stimulate a TREM2/APOE signalling pathway that leads to 
increased Aβ clearance (LaDu et al., 2012; Liao et al., 2014; Verghese et al., 2013).  
Interestingly, TREM2 variants associated with AD have been revealed to have less 
activation by lipids or partial loss of binding of lipids when compared to wildtype TREM2, in 
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particular to lipoproteins including APOE (Atagi et al., 2015; Bailey et al., 2015; Wang et al., 
2015; Yeh et al., 2016). Conversely, APOE genotype has not been shown to influence 
TREM2 binding. ApoE4 carriers do have less TREM2 expression than ApoE3 carriers but 
there is no significant difference in ApoE4 carriers to non-carriers in sTREM2 CSF levels 
(Gispert et al., 2016; Heslegrave et al., 2016; Li et al., 2015; Suarez-Calvet et al., 2016). 
3.2.4 Aims 
At Queen Square Brain Bank, TREM2 variants have been identified in six cases. These 
include R47H variants with (n=3) and without AD (n=2) at time of death and a D87N variant 
with AD (n=1). Here, the pathological features of these brains were compared to sporadic 
AD, familial AD and controls.  
In addition to this, a detailed quantitative pathological analysis of plaque burden and plaque 
type together with tau load was undertaken to look at the pathological loads in these cases 
by determining the load in Thal phase regions of the brain.  
The APOE genotype was determined on these cases and the effects of these genotypes on 
all pathological analysis were explored.  
3.3 Materials and Methods 
3.3.1 Case demographics 
All cases from Table 2.3 were used for pathological analysis of Aβ and hyperphosphorylated 
tau load (see table for detailed case demographics). The macroscopic observations reported 
in the coronal slices were available from all six TREM2 cases using detailed reports from 
Queen Square Brain Bank. A summary of these findings is listed in Table 3.2. Macroscopic 
images were only available for the D87N TREM2 variant case (case 5, Table 3.1).  
3.3.2 APOE genotyping 
APOE genotyping was performed for cases where frozen tissue was available (TREM2 
(n=5), SAD (n=15)) as described in the methods in 2.2. This included all cases excluding 
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cases 1, 12, 13 and 14 from Table 2.3. APOE genotype for other cases were already known 
from a previous study.  
3.3.3 Pathology analysis 
Immunohistochemistry with Aβ or AT8 antibodies was performed as described in 2.4 on 
sections from each of the cases (SAD (n=19), FAD (n=11), TREM2 SAD (n=3)) in the Thal 
phase regions (frontal cortex, temporal cortex, hippocampus, putamen and cerebellum). 
Antibody supplier, concentrations and species are listed in Table 2.6.  
Analysis for Aβ or Tau load was calculated using methods described in 2.5. The type of 
plaque was determined by manual counting as described in 2.5.3.   
3.3.4 Statistics 
Kruskal-Wallis one way ANOVA with Dunn’s multiple comparisons was performed on load 
analysis. Wilcoxon paired ranks test was performed on plaque type analysis. Significance is 
shown as * for p<0.05, ** for p<0.005, *** for p<0.0005, ****p<0.0001. GraphPad Prism v7 
was used to complete this analysis.  
3.4 Results 
3.4.1 Pathological observations 
All cases with a TREM2 variant underwent routine macroscopic and microscopic inspection 
by a neuropathologist to confirm diagnosis. Table 3.1 outlines the primary and differential 
diagnoses for each of the TREM2 variant cases. Four of the cases had a confirmed 
diagnosis of AD and two cases were confirmed to be neurologically normal controls. 
Macroscopic images were only available for the D87N variant case (case 5, Table 3.1) as 
illustrated in Figure 3.2. External appearances showed there was a degree of atrophy in the 
frontal and temporal cortices, whereas the parietal, occipital and cerebellum showed no 
macroscopic abnormalities (Figure 3.2a). Examination of the coronal slices confirmed the 
reduction in height of the frontal cortex with an enlargement of the lateral ventricle (Figure 
3.2b), whilst the hippocampus was a relatively normal size (Figure 3.2c and Figure 3.2d).  
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Alzheimer's disease (NIA Reagan high likelihood of dementia)
·Amygdala predominant Lewy body pathology
·Cerebral amyloid angiopathy (mild)
Alzheimer's disease (NIA Reagan high likelihood of dementia) 
·Moderate/severe cerebral amyloid angiopathy
·TDP-43 pathology in the amygdala and Entorhinal cortex
3 1327g Cerebral amyloid angiopathy (moderate) 0 0
Cerebrovascular disease
·White matter infarcts
Alzheimer’s disease (NIA Reagan high likelihood of dementia)
·Cerebral amyloid angiopathy (moderate)
·Neocortical Lewy body disease (intermediate likelihood of DLB as cause of dementia)
Alzheimer’s disease (NIA Reagan high likelihood of dementia)
         ·Moderate cerebral amyloid angiopathy
1 1252g 6 5
2 811g 6 5
6 1108g 6 5
4 1350g 0 0
5 1029g 6 5
 
Table 3.1 Neuropathologically confirmed primary and differential diagnoses for TREM2 variant cases. Details tabulated from histology reports at 
Queen Square Brain Bank. 
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Severe dilatation Normal Normal Severe dilatation Mild dilatation 
Frontal Moderate atrophy Severe atrophy Normal Normal Severe atrophy 
Moderate 
atrophy 




Occipital Normal Severe atrophy Normal Normal Normal Normal 
Parietal Mild atrophy Severe atrophy Normal Normal Normal Mild atrophy 
Deep white 
matter 
Reduced Reduced Normal Normal Reduced Reduced 
Hippocampus Mild atrophy Severe atrophy Normal Normal Normal Mild atrophy 
Amygdala Normal Severe atrophy Normal Normal Mildly reduced Normal 
Thalamus Moderate atrophy Mild atrophy Normal Normal Normal Normal 










Putamen Normal Mild reduction Normal Normal Normal Normal 
Globus pallidus Normal Mild reduction Normal Normal Normal Normal 
Substania Nigra Mild Pallor Mild Pallor Normal Normal Mild Pallor Marked pallor 
Locus Coeruleus Mild Pallor Mild Pallor Normal Normal Mild Pallor Marked pallor 
Medulla Normal Normal Normal Normal Normal Normal 
Pons Normal Normal Normal Normal Normal Normal 
Cerebellum WM Normal Normal Normal Normal Normal Normal 
Dentate nucleus Normal Normal Normal Normal Normal Normal 
Table 3.2 Macroscopic observations for all TREM2 variant cases. These observations were made by an experienced neuropathologist at Queen Square 
Brain Bank. 
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The caudate nucleus showed slight flattening whilst the bulk of the putamen was normal.  
The subthalamic nucleus was unremarkable, whilst the thalamus was significantly reduced in 
bulk.  All macroscopic observations for all six TREM2 variant cases are outlined in Table 3.2. 
TREM2 variant AD cases had varying patterns of atrophy in different brain regions whereas 
both TREM2 variant controls showed no macroscopic abnormalities.  
Routine immunohistochemistry was performed on each case to determine the final 
diagnosis. Microscopic observations showed similar patterns for all four AD confirmed 
TREM2 variant cases (Table 2.2, cases 1, 2, 5, 6). There were frequent neuritic amyloid 
plaques throughout the cortical layers in the frontal cortex (Figure 3.3a) made up of diffuse 
amyloid plaques and mature dense core amyloid plaques (Figure 3.3b).  These four cases 
fulfilled level 5 of Thal phase for amyloid pathology where Aβ deposition was seen in the 
cortex (Figure 3.3a and Figure 3.3b), the CA1 region of the hippocampus (Figure 3.3d), the 
striatum (Figure 3.3e), the substantia nigra (Figure 3.3f) and the cerebellum (Figure 3.3g).  
Braak and Braak stage 6 was fulfilled as the cases showed tau pathology in the presence of 
neurofibrillary tangles (NFT’s) in the cortex (Figure 3.3h) and occipital cortex (Figure 3.3i). 
Two cases (case 1 and case 5) also had additional alpha-synuclein pathology with Lewy 
bodies being observed in the amygdala (Figure 3.3j) and substantia nigra (Figure 3.3k). The 
two controls (Table 3.1, case 3 and 4) had a Thal phase of zero for Aβ pathology, therefore 
no Aβ plaque pathology was found in any brain region examined and both cases had a 
Braak and Braak score of zero (Figure 3.3l, case 3) indicating no tau pathology. 
Figure 3.2 Macroscopic photographs of Case 5 from Table 2.1. (a) External 
appearances, (b) Coronal section of frontal cortex, (c), Coronal section displaying the 
hippocampus (d) Coronal section from a neurologically confirmed healthy control case 
displaying the hippocampus. 
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Figure 3.3 Microscopic observations of TREM2 variant cases. Case 1 with R47H 
TREM2 variant diagnosed with AD (a-k). (a) Aβ pathology in frontal cortex showing the 
density of the plaques; (b) Aβ pathology in frontal cortex showing both diffuse and dense-
core plaques; (c) Aβ in  parenchymal  blood vessel of frontal cortex demonstrating CAA as 
highlighted with arrow; (d) Aβ staining in CA1 region of hippocampus; (e) Aβ staining in 
striatum; (f) Aβ staining in substantia nigra surrounding the dopaminergic neurons; (g) Aβ 
staining in cerebellum; (h) AT8 staining in the CA1 subregion of the hippocampus; (i) AT8 
staining in the occipital cortex; (j) alpha-synuclein staining in the amygdala; (k) alpha-
synuclein staining in substantia nigra. Case 3 (l-n) with R47H TREM2 variant with 
neurologically normal diagnosis. (l) AT8 staining in the hippocampus (m) Aβ staining in blood 
vessels of hippocampus; (n) Aβ staining in blood vessels of frontal cortex. (a-k)  
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3.4.2 CAA in TREM2 variant cases 
Five out of six of the TREM2 variant cases were observed to have cerebral amyloid 
angiopathy (CAA) in the neuropathogist reports (Table 3.1). This includes one of the cases 
that was diagnosed to be a neurologically normal control as CAA is not included in the 
diagnostic criteria for AD. Case one had occasional leptomingeal vessels showing patchy Aβ 
deposition so mild CAA, case two had moderate leptomingeal CAA with patchy and 
circumferential Aβ deposition along with a small number of cortical vessels having Aβ 
deposition. Case three had a moderate number of leptomingeal and superficial cortical 
vessels with patchy or circumferential Aβ deposition (Figure 3.3c, Figure 3.3m and Figure 
3.3n). Case five had occasional leptomingeal arterioles with circumferential Aβ deposition 
leading to moderate CAA. Case 4 did not have CAA and was a neurologically normal control 
and was reported to have cerebrovascular disease as white matter infarcts were found 
(Table 3.1). A new criteria for scoring CAA cases was determined in 2016 (Skrobot et. al, 
2016). However as these cases were achived cases the new criteria has not been used to 
score these cases.  
To observe whether there were any differences in the amyloid plaque pathology between 
SAD, FAD and TREM2 variant AD cases, the Aβ load was determined for each case in each 
disease group across the Thal staging regions (Figure 3.5a). There was a significant 
difference in Aβ load between regions (p=0.0028) but not disease groups (p=0.6667). The 
frontal cortex had the bulk of Aβ load whereas the hippocampus and putamen had markedly 
less Aβ. The FAD cases in both the hippocampus and putamen were an exception to this 
having significantly more Aβ than both SAD (hippocampus p=0.0411, putamen p=0.0330) 
and TREM2 variant AD cases (putamen p=0.0283). The TREM2 variant AD cases followed a 
close pattern to the SAD cases across all regions except for a decrease in Aβ in the 
temporal cortex but this was not significant.  
Using software analysis to assess the Aβ load does not allow the different plaque 
morphologies to be distinguished. To investigate whether different plaque types were more 
prominent in the TREM2 cases, a semi-quantitative assessment was undertaken in all brain 
regions studied for Aβ load. Dense-core amyloid plaques (Figure 3.4a) and diffuse amyloid 
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plaques (Figure 3.4b) were manually counted as described in 2.5.3. There was no significant 
difference in plaque types between the disease groups (TREM2, SAD and FAD) for all 
regions: frontal cortex (Figure 3.6a, p=0.8); temporal cortex (Figure 3.6b, p=0.9333); 
hippocampus (Figure 3.6c, p=0.6667); and putamen (Figure 3.6d, p=0.6667).  
Dunn’s multiple comparisons post-hoc analysis also showed that in the frontal cortex, 
temporal cortex and putamen both SAD and FAD cases had significantly more diffuse 
plaques than dense-core plaques (frontal cortex, SAD p=0.002, FAD p=0.0156, TREM2 
variant AD p=0.125; temporal cortex, SAD p=0.001, FAD p=0.0156, TREM2 variant AD 
p=0.25; putamen, SAD p=0.002, FAD p=0.0156, TREM2 variant AD p=0.125). TREM2 
variant AD cases did not reach significance but this could be due to the small number of 
cases in this group as the trend followed suit. In the hippocampus, no significant differences 
were observed between plaque types (SAD, p=0.0938; FAD, p=0.125; TREM2 variant AD, 
p=0.25). 
 
Figure 3.4 Example of amyloid plaque and neurofibrillary tangle pathology. (a) a 
mature dense core amyloid plaque; (b) diffuse amyloid plaques; (c) AT8 staining with NFT’s 
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Figure 3.5: Quantitative analysis of Aβ load. In frontal cortex (FCTX), temporal cortex 
(TCTX), hippocampus (HIPPO) and putamen (PUT) brain regions. (a) Aβ load of SAD, FAD 
and TREM2 variant cases. SAD in blue; FAD in red; TREM2 variant cases in green. (b) Aβ 
load of different APOE genotypes: 2/4 in light purple; 3/3 in light pink; 3/4 in dark purple; and 
4/4 in dark pink. (a-b) Load measured as mean % area stained. Kruskal-Wallis one way 
ANOVA was performed for each region or APOE genotype with Dunn’s multiple 
comparisons. Significance is shown as * for p<0.05, ** for p<0.005, *** for p<0.0005, 
****p<0.0001. Error bars represent SEM. 
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3.4.3 Neurofibrillary tangles in TREM2 variant cases 
To assess the level of tau that had accumulated in the TREM2 variant AD cases compared 
to SAD and FAD cases, the AT8 load was quantified (Figure 3.7) in the frontal and temporal 
cortices, hippocampus, putamen and cerebellum. An example of tau pathology is shown in 
Figure 3.4c. There was a significant difference of AT8 load between brain regions 
(p<0.0003) but not between disease groups (p=0.8068). There is a significant increase in 
AT8 load in the frontal cortex of FAD cases to TREM2 variant AD cases (p=0.0248) and 
Figure 3.6: Semi-quantitative analysis of plaque type; diffuse or dense-core 
plaques in SAD, FAD, and TREM2 variant cases. Measured across (a) frontal cortex, 
(b) temporal cortex, (c) hippocampus, and (d) putamen brain regions. Diffuse plaques in 
blue; dense core plaques in red. Kruskal-Wallis one way ANOVA was performed to 
determine statistical differences between disease groups. Wilcoxon-paired ranks test 
was performed to determine statistical differences between types of plaques for each 
disease group in each region. Significance is shown as * for p<0.05, ** for p<0.005, *** 
for p<0.0005, ****p<0.0001. Error bars represent SEM. 
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Figure 3.7: Quantitative analysis of tau load using AT8 staining. In frontal cortex 
(FCTX), temporal cortex (TCTX), hippocampus (HIPPO), putamen (PUT) and cerebellum 
(CBM) brain regions. (a) AT8 load of SAD, FAD and TREM2 variant cases. SAD in blue; 
FAD in red; TREM2 variant cases in green. (b) AT8 load of different APOE genotypes: 2/4 in 
light purple; 3/3 in light pink; 3/4 in dark purple; and 4/4 in dark pink. (a-b) Load measured as 
mean % area stained.  Kruskal-Wallis one way ANOVA was performed for each region or 
APOE genotype with Dunn’s multiple comparisons. Significance is shown as * for p<0.05, ** 
for p<0.005, *** for p<0.0005, ****p<0.0001. Error bars represent SEM. 
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similarly this was observed in the putamen (p=0.0476). Additionally, the FAD cases had a 
significantly higher AT8 load compared to SAD cases (p=0.0016). All other comparisons 
were non-significant (Figure 3.7). The TREM2 variant AD cases differ from region to region 
and appear to have a different pattern of AT8 load compared to SAD and FAD cases. Extra 
power with additional TREM2 variant cases would identify if these differences were worth 
investigating further.  
3.4.4 APOE genotypes in TREM2 variant cases 
As APOE genotypes have been identified as a strong genetic risk factor with an increased 
risk of up to 10-fold, the APOE genotypes of cases used in this study were identified where 
possible as shown in Table 2.3. Each cases’ APOE genotype was identified by bands on a 
metaphor agarose gel (Figure 3.8). There are six combinations of APOE genotype possible 
with the ɛ2 allele reported to be protective against AD and the ɛ4 allele reported to be 
detrimental to the risk of AD. Table 3.3 shows the distribution of APOE alleles for all types of 
disease group studied. As expected there were predominantly more ɛ3 and ɛ4 alleles 
present throughout the cases. When looking at the TREM2 variant cases in detail, the cases 
that were pathologically confirmed as controls did not include any ɛ4 alleles. However, those 
TREM2 variant cases that were confirmed to have AD, all had at least one ɛ4 allele.  
APOE genotype had no influence on Aβ load between the different disease groups 
(p=0.5867) but was significantly different between regions (p=0.0001, Figure 3.5b). However, 
this may just be an effect seen across all cases as the pathology spreads throughout the 
brain in agreement with the Thal phases. 
The same was true of APOE genotype effect on AT8 load (Figure 3.7b). There was a 
significant difference between regions (p=0.0012) but no significant difference between 
disease groups (p=0.9794). 
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Disease group 2/2 2/3 2/4 3/3 3/4 4/4
Control Y Y Y
SAD Y Y Y Y
FAD Y Y Y
TREM2 control Y Y




Table 3.3 APOE genotypes found within each disease group 
 
3.5 Discussion 
In this study, each TREM2 variant case has been assessed for the classic AD pathology and 
the amount of amyloid and tau pathology in each of these cases has been identified and 
compared to sporadic and familial forms of the disease.  
As described previously by Guerreiro et al., (2013a) all of the cases that were pathologically 
confirmed to have AD, fulfilled the criteria of Braak stage 6 and Thal phase 5. Further to this, 
two of the cases had additional alpha-synuclein Lewy-body pathology, some of which was 
identified in the substantia nigra, which is a pathological hallmark of Parkinson’s disease. 
TREM2 variants have been previously suggested to be a susceptibility factor in Parkinson’s 
Figure 3.8: Representative image of gel indicating APOE genotypes in different cases. 
The three arrows point to the bands we are interested in to determine the genotype. The 
labels at the top state what APOE genotype is shown in each corresponding lane. 
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disease, however, there has been some debate on how true this association is (Lill et al., 
2015; Mengel et al., 2016; Rayaprolu et al., 2013; Tan et al., 2016). If true, having PD 
pathology may not be a surprise and Korvatska O et al., (2015) showed that R47H carriers 
are more likely to have additional alpha-synuclein pathologies than non-carriers. Luis et al., 
(2014) also showed that R47H carriers with AD, present with significantly more parkinsonian 
signs than AD cases that are non-R47H carriers. As both an R47H variant case (case1) and 
a D87N variant case (case 5) showed alpha-synuclein pathology, it suggests that alpha-
synuclein pathology is not specific to a certain TREM2 variant.  
Imaging studies have shown R47H variants to have increased frontal and temporal atrophy 
and minimal change in the hippocampus (Luis et al., 2014; Slattery et al., 2014). Here, we 
observe moderate to severe frontal atrophy, mild to severe temporal atrophy and normal to 
severe hippocampal atrophy in the pathologically confirmed AD TREM2 cases. Although 
certain changes have been observed in imaging studies, pathological observations of 
TREM2 variant cases with AD do not show the same differences from case to case as they 
range from mild to severe atrophy in different brain regions. A comparison with more TREM2 
variant AD cases together would indicate whether a pattern does emerge. 
Interestingly, five out of the six TREM2 variant cases had CAA including one of the cases 
that was clinically normal and pathologically confirmed as a neurologically normal control. 
This presence of CAA is not an uncommon finding as 80-90% of AD cases have a form of 
CAA and up to 35% of elderly patients without AD are reported to have CAA although not as 
severe as in AD cases. However, only three of the SAD cases and two of the FAD cases in 
this cohort had CAA (Ellis et al., 1996; Nicoll et al., 2004; Yamada, 2000, 2002; Yamada et 
al., 1987). Further investigation should be done to determine the incidence of TREM2 variant 
cases having CAA. Having a TREM2 variant may lead to a higher incidence of CAA may 
hinder the clearance of Aβ along the intramural periarterial drainage pathway. This may lead 
to an increase in the levels of soluble Aβ in the parenchyma, increase amyloid pathology and 
lead to an increased risk of AD. Evidence for this is shown by the fact that many CAA cases 
have increased neuritic plaques and NFT’s present to those without CAA (Brenowitz et al., 
2015; Pfeifer et al., 2002).  
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APOE genotypes have been shown to have increased risk on the severity of CAA that 
occurs in a similar manner to AD (Alonzo et al., 1998; Pfeifer et al., 2002). ApoE4 giving the 
greatest risk, followed by ApoE3 but unlike in AD where ApoE2 confers a protection rather 
than a risk, ApoE2 instead is known to cause vascular changes that may lead to vessel 
rupture within the brain (Yu et al., 2015). As APOE has been reported to be a ligand for 
TREM2, it is therefore interesting that the APOE genotypes of the TREM2 variant cases that 
have been confirmed to have SAD all lack an ApoE2 allele and contain an ApoE4 allele. This 
was also the case in three other studies, amounting to twenty-six cases in total (Korvatska O 
et al., 2015; Krasemann et al., 2017; Yuan et al., 2016).  This indicates that the risk that 
TREM2 variants confer (R47H in particular) may be linked to the risk that the APOE 
genotype confers either by acting through similar mechanisms or by having similar effects 
(Murray et al. 2018). As they bind to each other however, it is more likely to be the former. 
TREM2 variants have been shown to have a reduced affinity to bind lipids and lipoproteins 
such as APOE so perhaps TREM2 normally binds to an APOE-Aβ complex and stops it from 
crossing over the vessel wall but instead when TREM2 is impaired, APOE is free to complex 
with Aβ and cross the blood vessel wall (Abduljaleel et al., 2014; Wang et al., 2015). This 
may result in the IPAD pathway being utilised to clear Aβ from the brain but the increased 
load in Aβ in the vessels may cause modifications in HSPG’s and therefore greater CAA.  
LRP1, a low-density lipoprotein receptor is known to bind to APOE and Aβ and can be found 
in both senile plaques and in amyloid deposits in vessel walls (Bu, 2009; Kim et al., 2009; 
Rebeck et al., 1995). It has been reported that ApoE4 blocks the receptor mediated 
endocytosis employed by LRP1 which is part of a lipid transport pathway and therefore 
reduces the elimination of Aβ and causes increased Aβ in the vessel walls (Deane et al., 
2008; Huynh et al., 2017).  LRP1 can also bind to HSPG’s and similarly these are found in 
senile plaques and CAA as well as also binding to APOE and Aβ (Cooper, 1997; Cotman et 
al., 2000; van Horssen et al., 2001; Mahley and Ji, 1999; Van Gool et al., 1993; Zhang et al., 
2014a). CAA is reported to worsen as the basement membrane of the vessels thickens and 
one cause for this is increased levels of HSPG’s in the basement membrane (Hawkes et al., 
2013; Qi and Ma, 2017).  
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It has been hypothesised that TREM2 variants cause a loss in ability of the microglia to 
phagocytose Aβ (Boche et al., 2013; Guerreiro et al., 2013a; Jonsson et al., 2012b). As 
APOE is a ligand for TREM2, it has been suggested that through binding to APOE 
sequestered in amyloid plaques, it triggers the phagocytic mechanism (Atagi et al., 2015; 
Jendresen et al., 2017). As TREM2 variants are less able to bind APOE this phagocytosis is 
not triggered and greater accumulation of Aβ ensues. As having an ApoE4 genotype causes 
increased Aβ deposition and decreased Aβ clearance, TREM2 variant cases that additionally 
have an ApoE4 variant, as most commonly do, would be at increased risk for Aβ 
accumulation and therefore increased risk of AD (Castellano et al., 2011). Although the 
results here show that Aβ load does not significantly differ between SAD and TREM2 variant 
cases, the mechanism in which the Aβ plaques accumulate may differ. TREM2’s link to 
APOE may highlight the mechanism that confers cases with a TREM2 variant to be at a 
higher risk of accumulating AD pathology. 
Conversely, Yuan et al., (2016) suggest that the microglia that surround amyloid plaques 
form a barrier and that TREM2 helps to form this barrier keeping the plaques compact. They 
have shown that this barrier is reduced in TREM2 R47H carriers and that in this instance the 
plaques are more diffuse and less neuritic in nature. However, here it is observed that all AD 
cases have significantly more diffuse plaques than dense-core plaques (compact plaques) in 
all regions tested but there is no significant difference in the levels of diffuse plaques 
between disease groups.  A limitation to this study was that the diffuse or dense-core 
plaques were counted manually which may be a less reliable method due to capacity for 
human error and a reason for inconsistent results with Yuan et al. On the other hand, neither 
the microglia surrounding the amyloid plaques nor the size of the amyloid plaques were 
assessed, so further assessment of the microglia surrounding the plaques in these TREM2 
variant cases may determine why these discrepancies between results exist. Then again, 
Yuan et al. only quantified amyloid plaques within the middle frontal gyrus whereas here 
multiple regions have been shown to have varying results. Neither this study nor Yuan et al’s 
study determined what cortical layer the plaques analysed were from. Further investigations 
into whether cortical layers have different pathological characteristics may give further insight 
into the discrepancies observed within the two sets of results.  
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The affect that TREM2 has on Aβ load has been debated in the literature. TREM2 deficiency 
mouse models showed differences between the cortical load and hippocampal load 
depending on the age of mice tested (Jay et al., 2015, 2017, Wang et al., 2015, 2016). 
Additionally, this was observed in TREM2 overexpression models (Jiang et al., 2014, 
2016b). Nevertheless, TREM2 haploinsufficient models showed no difference in Aβ load 
compared to wildtypes (Ulrich et al., 2014). Here we see significant differences between 
regions with a marked increase in Aβ load in the cortical areas compared to the 
hippocampus and we see this across all three AD subtypes. There is also a significant 
difference in Aβ load between disease groups but this is mainly due to the FAD cases having 
significantly more Aβ in the later Thal stages than SAD or TREM2 variant cases. Thus, the 
results here show the most similarity to the haploinsufficient models, indicating a modest 
effect if any. That aside, TREM2 variant cases follow the levels of Aβ in SAD cases more 
closely than FAD levels indicating that the TREM2 variants may cause risk through 
mechanisms operating in sporadic cases. There was no significant difference in Aβ load 
according to APOE genotype which differs from the literature in which ApoE4 is reported to 
cause greater Aβ deposition (Bogdanovic et al., 2002; Cho et al., 2001; Strittmatter et al., 
1993a). Therefore, the way that Aβ is deposited between cortical layers may be more 
important here rather than how much of the protein is present.  
In comparison, tau pathology is described to increase in TREM2 deficient models and 
decrease in TREM2 overexpression models (Jiang et al., 2015, 2016a). Here we identify that 
although there are significant differences in the amount of tau across the Thal phase regions, 
these are seen in all three AD subgroups. Again, the FAD cases have significantly more 
hyperphosphorylated tau in the frontal cortex and putamen than the TREM2 variant cases 
and this trend follows in the hippocampus. However, no differences can be observed in the 
comparison between TREM2 variant and SAD cases indicating again that TREM2 variant 
cases could act in the same manner as SAD cases or have mechanisms that reach the 
same conclusion. It is likely that as TREM2 variants are heterozygous, that the effect seen 
by TREM2 deficient mice is more extreme than the one we see here when comparing to 
SAD cases as the wildtype.  
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3.5.1 Conclusions 
To summarise, TREM2 variant cases with AD display all the pathological characteristics of 
sporadic AD and although the amount of Aβ or hyperphosphorylated tau does not differ 
significantly from the sporadic form of AD, CAA was present in all but one TREM2 variant 
case. Both SAD and TREM2 variant cases may differ from FAD cases though, indicating that 
further elucidation of the different mechanisms involved throughout sporadic and familial 
disease should be investigated to understand the full pathogenesis of this disease.  
The TREM2 cases investigated in this study that had a pathological diagnosis of AD all had 
an ApoE4 genotype whereas the TREM2 variant cases that were diagnosed as normal 
controls did not carry an ApoE4 allele. This brings into question the known link between 
TREM2 and APOE and whether the risk associated with TREM2 is independent of ApoE4. 
They both are thought to have a role in the processing of amyloid deposits and through 
interaction with APOE, TREM2 may play a role in Aβ elimination either through Aβ 
phagocytosis or by other mechanisms that still need exploring. In this case, TREM2 variants 
have reduced APOE binding, and therefore reduced Aβ elimination from the brain. Perhaps 
this is why increased risk of AD is observed in these cases. However, the lack of difference 
between Aβ load in SAD and TREM2 variant AD cases suggest that TREM2 may be playing 
an alternative role than that of Aβ elimination. 
TREM2 variants were identified to have other pathologies such as alpha-synuclein pathology 
which is indicative of it having an effect in other neurodegenerative disease such as 
Parkinson’s disease. If TREM2 influences Aβ elimination, it may also influence clearance of 
other insoluble deposits that form within the brain such as Lewy bodies in Parkinson’s 
disease, TDP-43 inclusions in frontotemporal dementias and more. Investigating this 
clearance mechanism further will help us to elucidate the role that TREM2 is playing and 
identify whether this is how TREM2 variants are at greater risk of these diseases. 
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4 Microglial phenotype of TREM2 variant cases   
4.1 Abstract 
Introduction: It is now accepted that microglia have a continuum of activation states and 
that any one microglia can be in any given state at any one time. Amoeboid shaped 
microglia are linked to an activated, phagocytic phenotype whereas ramified shaped 
microglia are more indicative of a homeostatic or surveillant phenotype. Activated microglia 
have been shown to surround neuritic plaques, but not diffuse plaques, and are thought to 
play a role in Aβ deposition as well as Aβ clearance. TREM2 was identified as a genetic risk 
factor for late onset AD with similar odds ratio to APOE. TREM2 is expressed on microglia, 
and has been shown to be upregulated on the microglia surrounding amyloid plaques both in 
human post mortem tissue and in AD mouse models. TREM2 deficient animal models show 
a decrease in phagocytosis and increased AD pathology compared to wildtype. Therefore, 
the microglial phenotype of TREM2 variant cases were investigated in post-mortem human 
brains and compared to the microglial phenotypes in SAD, FAD and controls.  
Materials and methods: Immunohistochemistry was performed with the following microglial 
markers; Iba1, CD68, CR3-43 (HLA-DR) and P2RY12 on a variety of disease groups; SAD 
(n=19), FAD (n=11), TREM2 variant AD cases (n=4), TREM2 variant controls (n=2) and 
controls (n=6) in the following areas; frontal cortex, temporal cortex, hippocampus, putamen 
and cerebellum. Random squares were selected and microglial load, circularity and 
perimeter were assessed using ImageJ software and Python scripts. Seven commercially 
available TREM2 antibodies were used to investigate whether TREM2 could be identified in 
post-mortem human brain tissue. 
Results: Microglia in TREM2 variant AD cases have an increased CD68 load, more circular 
Iba1, CR3-43 and CD68 positivity. They also exhibit smaller size Iba1 and CR3-43 microglia 
indicating that these cases have a more amoeboid microglial phenotype than all other 
disease groups including TREM2 variant controls, which suggests that more phagocytosis 
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occurs in these cases. ApoE2/2 has a ramified microglial phenotype whereas ApoE4/4 cases 
have an amoeboid microglial phenotype, matching that of TREM2 variant AD cases.  
Conclusions: TREM2 variant AD cases have a more morphologically activated microglial 
phenotype compared to SAD and FAD cases. This data therefore shows that the different 
disease groups have altered microglial phenotypes with a microglial phenotype less 
consistent with activation seen in other AD subgroups. This could indicate that different 
microglial responses occur in different AD subgroups. APOE could influence the effects of 
these responses. Further understanding of these responses and the different mechanisms 
that are needed to make them occur will allow us to understand why TREM2 variant AD 
cases are at an increased risk of AD.  
4.2 Introduction 
4.2.1 Microglia in AD 
It has long been thought that inflammation, and in particular, microglia, play a role in the 
pathogenesis of AD. However, exactly what that role is, is still being debated and the 
evidence from previous studies points to them having multiple functions within the 
progression of AD. Some reports point to microglia being neuroprotective while others 
suggest they further exacerbate the disease.  
Microglia have been shown to be in close proximity to amyloid plaques with studies 
indicating that microglia appear to be activated when early amyloid plaques appear although 
these studies do have their limitations due to limited antibodies being available at the time to 
detect microglial morphology (Arends et al., 2000; Frautschy et al., 1998; Gahtan and 
Overmier, 1999; Gentleman, 2013; Mann et al., 1995; Martin et al., 1994; Rogers et al., 
1988; Wegiel and Wisniewski, 1990; Wegiel et al., 2000). Further studies by Wegiel’s group 
show that microglia form an amyloid star morphology, consisting of five or six microglial cells 
surrounding an amyloid core (Wegiel and Wisniewski, 1990; Wegiel et al., 2000). This 
hypothesis was confirmed by Yuan and colleagues, (2016) who show a microglial barrier 
forming around amyloid plaques. However in transgenic mice models of AD, the plaques are 
formed by recruiting new microglia to the plaque (Wegiel et al., 2000). Aβ is thought to be  
Chapter 4 – Microglial phenotype of TREM2 variant cases 




produced mainly by neurons but has also been shown to be produced by microglia since 
they also express APP (Banati et al., 1993; Frackowiak et al., 1992; Lassmann et al., 1993; 
Pappolla et al., 1991; Probst et al., 1991b; Wegiel and Wisniewski, 1990; Wegiel et al., 2000; 
Wisniewski et al., 1989, 1996, 1998). Whilst it has been demonstrated that microglia could 
contribute to the formation of amyloid plaques, studies show that removing the microglia 
does not affect plaque load, suggesting that the microglia cannot be solely responsible 
(Grathwohl et al., 2009). Bolmont et al., (2008) suggest that instead the microglia are rapidly 
recruited to the amyloid plaque and that they have a role in maintaining the amyloid plaque.  
There are two types of plaques in the AD brain, with different compositions, morphology and 
toxicity. Neuritic plaques are amyloid plaques that are also surrounded by dystrophic 
neurites and are thought to be more toxic than diffuse amyloid plaques that do not contain 
the dystrophic neurites (Serrano-Pozo et al., 2011). Microglial density has been shown to be 
correlated with the levels of neuritic plaque but not diffuse plaques (Arends et al., 2000; 
Giulian, 1999; Mattiace et al., 1990a; Paresce et al., 1997; Rogers et al., 1988; Wegiel and 
Wisniewski, 1990; Wisniewski et al., 1989). Microglia display an amoeboid morphology in the 
presence of dense core or neuritic plaques, whereas a more ramified morphology when in 
Figure 4.1: Different morphologies and activation states of microglial cells. The 
spectrum from ramified homeostatic microglia to activated and amoeboid microglia. The 
circularity score is indicated by the number between 0 and 1 as shown. 
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the vicinity of diffuse plaques (Figure 4.1). Bisht et al., (2016) even suggest that the microglia 
that surround amyloid plaques have a different underlying structure that becomes apparent 
during disease or under chronic stress and identified them as dark microglia. Greater 
numbers of microglia have been shown to co-localise to Aβ40 than to Aβ42  and it has been 
suggested that the areas of an amyloid plaque that are uncovered by microglia contain the 
Aβ42 fibrils (Mann et al., 1995). These uncovered Aβ42 fibrils become toxic to nearby 
neurons and recruit phagocytic activated microglia by initiating an inflammatory response 
(Wegiel et al., 2000). This inflammatory response, a combination of TNFα, IL-1β and IFN-γ, 
can be toxic to neurons and stimulate an increase in Aβ production in neurons, thereby 
creating a vicious circle (Blasko et al., 2004; Goldgaber et al., 1989).  
Microglia are also thought to be responsible for Aβ clearance via phagocytic mechanisms.  
Aβ has been shown to cause activation of microglia and induce a chemotactic and 
phagocytic response, partly due to release of IL-1β and complement proteins (Barger and 
Harmon, 1997; Boche et al., 2013; Gahtan and Overmier, 1999; Gentleman, 2013; Giulian et 
al., 1996; Griffin et al., 1989, 1995; Itagaki et al., 1989; Meda et al., 1995, 1995; Rogers and 
Lue, 2001; Rogers et al., 1992a, 1992b; Sheng et al., 1998; Yin et al., 2017). Both Aβ in 
plaques and dystrophic neurites become targets for phagocytosis (Gahtan and Overmier, 
1999). Microglia have been shown to be capable of phagocytosing Aβ in several studies but 
there are also reports that the Aβ resides in microglial phagosomes for long periods of time 
making this a non-efficient mechanism of clearance (Frackowiak et al., 1992; Gahtan and 
Overmier, 1999; Paresce et al., 1997; Shaffer et al., 1995; Weldon et al., 1998). However, at 
end stage disease activated microglial number no longer correlates with disease progression  
and there is a reduction of dense-core plaques and greater numbers of diffuse plaques 
suggesting that mechanisms of Aβ clearance start to outweigh mechanisms of Aβ deposition 
as the disease progresses (Hyman et al., 1993; Thal et al., 1998; Wegiel et al., 2000).  
Although the number of amyloid plaques decreases at the end stage of disease, the levels of 
NFT’s continue to increase and microglia have been shown to correlate strongly with NFT 
levels throughout all stages of disease (DiPatre and Gelman, 1997; Kitazawa et al., 2004). 
Sanchez-Mejias et al., (2016) showed that there were reduced levels of microglia in the 
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hippocampus compared to cortical areas and that this was due to soluble phosphorylated tau 
being toxic towards the microglia and making them apoptotic. They suggest that this then 
causes a decreased inflammatory response which leads to exacerbated disease. 
Alternatively, microglia may drive tau pathology via the fratalkine receptor as demonstrated 
in a hTau mouse model deficient for CX3CR1 in which these mice exhibited increased levels 
of phosphorylation and aggregation at an earlier age compared to wildtypes (Bhaskar et al., 
2010; Maphis et al., 2015). 
4.2.2 Microglial markers 
As discussed previously in 1.3, there are conflicting views in the literature reporting microglial 
phenotypes correlating with different functions they undertake. It is now viewed that there are 
many different functional phenotypic states of microglia (Figure 4.1) and that one microglia 
may be transitioning between states at any one given time (Boche et al., 2013; Korzhevskii 
and Kirik, 2016). This makes it difficult to determine the role microglia are playing in different 
diseases. To investigate microglial activation in post-mortem human brain tissue multiple 
markers (Iba1, CD68, CR3/43 and P2RY12) were used that identify different aspects of the 





Activation state Morphology 
Iba1 motility 
 homeostatic and activated 
microglia 
Mostly ramified 





ramified with shorter 
processes 
P2RY12 motility homeostatic ramified   
Table 4.1: Range of microglial markers and different properties of each. Markers used 
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4.2.2.1 Iba1 
Ionized calcium binding adapter molecule 1 (Iba1), was identified to be a pan microglial 
marker that detects ramified and amoeboid forms of microglia (Boche et al., 2013; Streit et 
al., 2009). It is a member of the calcium binding group of proteins and is thought to play a 
role in reorganising the cytoskeleton in the microglial processes through binding to actin 
(Sasaki et al., 2001). It is a 17kDa protein consisting of 147 amino acids and is encoded in 
the major histocompatibility complex class (MHC) III region (Boche et al., 2013; Imai et al., 
1996; Yamada et al., 2006). Some groups have reported Iba1 to be present in both microglia 
and macrophages whereas others have only found it exclusively in microglia (Boche et al., 
2013; Imai et al., 1996; Ito et al., 1998). Regardless of the differing reports on which 
microglia are stained, Iba1 is used widely as a standard marker as it is found in both the 
cytoplasm and ramified processes of microglia (Korzhevskii and Kirik, 2016).  
4.2.2.2 CD68 
CD68 is used as a phagocytic marker for microglia as it is a lysosomal protein found within 
microglia, monocytes and macrophages (Boche et al., 2013; Fadini et al., 2013; Holness and 
Simmons, 1993; Korzhevskii and Kirik, 2016; Shikuma et al., 2014; Smith et al., 2013; 
Zotova et al., 2011). It is a transmembrane protein that belongs to the lysosome-associated 
membrane family (LAMP) and is involved in the process of microglia binding to low density 
lipoproteins (Song et al., 2011). It detects activated microglia, with amoeboid microglia being 
detected more readily than microglial processes on ramified forms although this could be 
due to CD68 around the nucleus being detected more readily than CD68+ve lysosomes in 
the processes (Albright et al., 2000; Andjelkovic et al., 1998; de Groot et al., 2001; Hulette et 
al., 1992; Korzhevskii and Kirik, 2016; Lue et al., 1996; Nagai et al., 2001; Roggendorf et al., 
1996; Ulvestad et al., 1994).  
4.2.2.3 HLA-DR (CR3-43) 
HLA-DR is a marker that is used to identify reactive/activated microglia. It is a glycoprotein 
that is part of the major histocompatibility complex class II (MHC II) subgroup (Dandrea et 
Chapter 4 – Microglial phenotype of TREM2 variant cases 
Page | 99  
 
al., 2001; Esiri et al., 1991; Guillemin and Brew, 2004; Hassan et al., 1991; Korzhevskii and 
Kirik, 2016; Lee et al., 2002; Mattiace et al., 1990b; McGeer et al., 1988; Nagai et al., 2001; 
Rogers et al., 1988; Sasaki and Nakazato, 1992; Streit et al., 2004; Styren et al., 1990; 
Zotova et al., 2011). It stains the plasma membrane of microglia cells or brain macrophages 
but does not stain other cells such as astrocytes, oligodendrocytes or neurons (McGeer et 
al., 1988; Styren et al., 1990). It has been shown to be upregulated in several 
neurodegenerative diseases, including AD, PD, Pick’s disease and ALS (Carpenter et al., 
1993; DiPatre and Gelman, 1997; Itagaki et al., 1989; McGeer et al., 1988, 1993). 
4.2.2.4 P2RY12 
All markers described so far stain both microglia and macrophages. Hickman et al., (2013) 
and Butovsky et al., (2013) identified a set of genes that are specific to microglia, which 
would allow the differentiation between microglia and macrophages in the brain tissue. 
P2RY12 has been shown to be involved in the early microglial response to injury and is 
involved in the motility of the processes and a chemotactic response to ATP released from 
injured neurons or astrocytes (Sipe et al., 2016; Swiatkowski et al., 2016). P2RY12 stains 
predominantly ramified microglia. As this receptor is expressed as part of the microglia’s 
homeostatic signature, the signal is lost as the cells become activated and move away from 
their homeostatic state.  
4.2.3  TREM2 and microglia  
Since TREM2 was discovered as a genetic risk factor for late onset AD, research into the 
role of TREM2 has greatly increased. However, as it stands, much of the literature is 
conflicting, especially in terms of the precise role TREM2 has on Aβ clearance and whether 
its activation is linked to pro- or anti-inflammatory mechanisms. 
4.2.3.1 TREM2 cellular location and aged studies 
TREM2 was identified as a receptor on myeloid cells before it was identified to be a risk 
factor for late-onset AD and its role in microglia has therefore been extensively studied. 
TREM2 has been shown to be expressed by myeloid cells throughout the CNS. 
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Immunofluorescence was used to identify that TREM2 is variably expressed in multiple brain 
regions such as the cortex, hippocampus, putamen and spinal cord (Hsieh et al., 2009). 
However, the quality of TREM2 antibodies is questionable, making the expression of TREM2 
complex to determine. Further to this variability between regions, microglia expressing 
TREM2 were counted using the number of silver grains exposed to a TREM2 riboprobe and 
revealed that TREM2 expression also varies within regions as not all microglia in any one 
region express TREM2 (Schmid et al., 2002).  
There has been some debate on whether TREM2 is specifically expressed on microglia or 
whether TREM2 is also expressed on peripheral macrophages and circulating monocytes 
(Chertoff et al., 2013; Jay et al., 2015). Poor reagents that are not well characterised have 
led to confusion over the reliability of TREM2 antibodies in human tissue. Some believe they 
are only staining the circulating monocytes and not microglia, however, this could be an 
antibody sensitivity or specificity issue (Fahrenhold et al., 2017; Satoh et al., 2013). Jay et al 
suggested that it was in fact TREM2-expressing peripheral macrophages that were 
surrounding amyloid plaques and not microglia due to the fact they were CD45+ve and 
P2RY12-ve, with CD45 being believed to be a marker of macrophages and P2RY12 of 
resident microglia. Other studies also reported that there was no change in TREM2 
expression between microglia and peripheral macrophages (Frank et al., 2008; Jay et al., 
2015; Prokop et al., 2015; Ulrich et al., 2014). However, since that discovery, it has become 
clear that the P2RY12 marker of resident microglia marks a more ramified homeostatic form 
of microglia and not an activated amoeboid form that is typical of phagocytosis. Different 
markers can be up or down regulated in different activation states. This may be where the 
discrepancy lies. Subsequently, it was found that TREM2 is a gene that is highly enriched in 
microglia compared to macrophages in using direct RNA- sequencing and qPCR (Hickman 
et al., 2013).  
Long-term aging studies have shown that the amount of microglia in wild type mice does not 
differ significantly from mice that are TREM2 knockouts until they are 2 years of age (Poliani 
et al., 2015). However, in primary microglia in vitro models the number of microglia decrease 
when TREM2 levels decrease and TREM2 knockout primary microglia showed reduced 
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proliferation suggesting that TREM2 may play a role in microglial proliferation in certain 
conditions (Cantoni et al., 2015; Zheng et al., 2016, 2017). 
4.2.3.2 TREM2 and inflammation 
TREM2 is thought to have a role in determining homeostatic control within microglia with 
high levels promoting phagocytosis and low levels promoting a pro-inflammatory state 
(Boche et al., 2013; Guerreiro et al., 2013a; Jonsson et al., 2012b; Wu et al., 2014). 
Increases in TREM2 expression leads to increased phagocytosis and decreased TREM2 
expression leads to decreased phagocytosis. TREM2 is thought to induce phagocytosis 
through NF-κB independent mechanisms. However, NF-κB sensitive miRNA-34a has been 
shown to affect TREM2 expression levels, indicating that NF-κB may still have an indirect 
effect on TREM2 activity (Bouchon et al., 2001; Jones et al., 2014; Takahashi et al., 2005). 
Alternative activation of phagocytosis works through toll-like receptors and activates NF-κB 
and inflammatory cytokine levels (Blander and Medzhitov, 2004; Frank et al., 2008; 
Guerreiro et al., 2013a; Jonsson et al., 2012b; Takahashi et al., 2005). TREM2 expression is 
also affected by other pro-inflammatory molecules such as TNFα, IFNγ and LPS (Hickman et 
al., 2013; Satoh et al., 2013; Zhao and Lukiw, 2013; Zheng et al., 2016). When TREM2 is 
knocked down in primary microglia, an increase in inflammatory responses through toll-like 
receptors is observed, suggesting that when TREM2 is deficient, an alternative method of 
inflammation and phagocytosis is triggered (Takahashi et al., 2005). However, this method 
causes higher levels of cytokines, such as TNFα, nitric oxide synthase-2 and IL-1β, and 
therefore has a more detrimental effect on the brain (Frank et al., 2008; Guerreiro et al., 
2013a; Jonsson et al., 2012b; Piccio et al., 2007; Takahashi et al., 2005). This is validated by 
TREM2 knockout models which display increased levels of age-related neuroinflammation 
compared to wildtypes (Jiang et al., 2014). Further to this, TREM2 ablation causes reduced 
motility of microglia towards chemo-attractants and gene expression levels in these models 
show a signature that is more closely associated with homeostatic microglia (Mazaheri et al., 
2017).  
TREM2 is not expressed by neurons and is not known to be expressed by other cell types 
but TREM2 ligands are thought to be expressed on apoptotic neurons, providing signals to 
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microglia for phagocytosis (Hsieh et al., 2009). Further evidence for this is that TREM2 
expression increases when there is injury induced cell death and TREM2 deficient models 
show impaired clearance of apoptotic neurons (Frank et al., 2008; Hsieh et al., 2009; Satoh 
et al., 2013; Sieber et al., 2013; Takahashi et al., 2005). This leads to increased levels of 
necrotic debris and neuroinflammation which can exacerbate disease (Hsieh et al., 2009; 
Thrash et al., 2009). 
4.2.3.3 Evidence of factors that can influence TREM2 expression  
Levels of TREM2 expression have been shown to differ between brain regions in post-
mortem human brain. However, regardless of region they are increased in microglia that 
surround amyloid plaques in both human brain and AD mice models (APP23, 5xFAD) (Frank 
et al., 2008; Jay et al., 2015; Perez et al., 2017; Satoh et al., 2013). They are not detected on 
P2RY12+ve parenchymal microglia (Jay et al., 2015). Oligomeric Aβ is thought to have the 
same effect on TREM2 expression as lipopolysaccharide (LPS), causing a decrease in 
expression (Zheng et al., 2016). LPS is found in the outer membrane of Gram-negative 
bacteria and it is commonly used in experiments to stimulate an inflammatory response.  
This decreased expression of TREM2 is thought to reduce the levels of phagocytosis and 
exacerbate the disease. There is a reduced ability for the microglia to respond to Aβ and 
phagocytose Aβ42 peptides in TREM2 deficient models compared to wildtypes, with 
additional reduction of phagocytosis of apoptotic neurons in these models (Jay et al., 2015; 
Jones et al., 2014; Kleinberger et al., 2014; Satoh et al., 2013; Ulrich and Holtzman, 2016; 
Wang et al., 2015; Zhao and Lukiw, 2013). Overall, TREM2 deficient models have reduced 
inflammation and increased amyloid and tau pathology (Colonna and Wang, 2016; Jay et al., 
2015; Painter et al., 2015; Ulrich and Holtzman, 2016). TREM2 deficiency in a 5xFAD mouse 
model showed reduced microgliosis with the microglia around amyloid plaques not fully 
enclosing them (Wang et al., 2015, 2016; Yuan et al., 2016). In a TREM2 haploinsufficient 
mouse model (TREM2+/-/APPPS1-21) there were also less microglia found around the 
amyloid plaques (Ulrich and Holtzman, 2016; Ulrich et al., 2014).  
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TREM2 is able to bind to APOE and APOE has been reported to be upregulated in microglia 
that surround amyloid plaques. The microglia that surround the neuritic plaques in AD were 
found to have a distinct phenotype to other microglial cells and have been termed ‘dark 
microglia’, disease-associated microglia (DAM) or microglia of neurodegeneration (MGnD) 
by different groups using both electron microscopy and transcriptomic profiling techniques 
(Bisht et al., 2016; Keren-Shaul et al., 2017; Krasemann et al., 2017). These microglia have 
been found to act differently to other activated microglia and this is thought to occur through 
the upregulation of several genes that stimulate the TREM2 pathway, including APOE 
(Keren-Shaul et al., 2017). Recently, Krasemann et al., (2017) have identified that APOE 
triggers the differentiation of microglia from a homeostatic state to that of this new disease-
associated phenotype found in AD via activation of TREM2 (Keren-Shaul et al., 2017).  
4.2.4 Aims 
In this chapter, the microglial phenotype in the brains identified with a TREM2 variant were 
investigated and compared to sporadic AD cases, familial AD cases and controls. 
Differences between the TREM2 variants that had pathologically confirmed AD and those 
that were pathologically confirmed as neurologically normal controls at time of death were 
also compared.  
To identify the microglial phenotype in these cases three factors were measured: 1), 
microglial load; to assess the abundance of microglia; 2) the circularity; to assess whether 
the microglia were in an amoeboid, more phagocytic shape or whether they were ramified; 
and 3) the perimeter; to assess the size of the microglia. These factors were measured in the 
frontal cortex, temporal cortex, hippocampus, putamen and cerebellum. Four different 
microglial markers were investigated; Iba1, CD68, CR3-43 and P2RY12.  
To assess whether APOE genotype influenced the microglial phenotype in these cases, an 
analysis based on APOE genotype for all measures was undertaken.  
As TREM2 antibodies have been unreliable and unspecific in the past, seven commercially 
available TREM2 antibodies were optimised using several conditions to try and determine a 
good antibody to measure TREM2 distribution within AD post-mortem brain tissue.  
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4.3 Materials and Methods 
4.3.1 Case demographics and selection 
All case demographics are detailed in Table 2.3. All cases were used for pathological 
analysis of microglia using the antibodies, Iba1, CD68 and CR3-43, whereas only cases 1-9, 
12, 14-15, 17, 26-27, 29-35, 37-42 were used for P2RY12 analysis. Case 25 was used for 
TREM2 antibody optimisation.  
4.3.2 Immunohistochemistry 
Immunohistochemistry with Iba1, CD68, CR3-43 and P2RY12 antibodies was performed as 
described in 2.4 (SAD (n=19), FAD (n=11), TREM2 AD (n=4), TREM2 controls (n=2), 
controls (n=6). Representative brain regions from the five Thal phases were investigated 
(frontal cortex, temporal cortex, hippocampus, putamen and cerebellum). Only frontal cortex, 
temporal cortex and hippocampus were assessed with the P2RY12 antibody. Details of the 
antibodies used in this study are listed in Table 2.6.  
Seven TREM2 antibodies listed in Table 2.6 were tested with different conditions using the 
methods of immunohistochemistry on formalin fixed paraffin embedded sections and frozen 
sections from flash frozen tissue, which are both outlined in 2.4.1 and 2.4.2. Each antibody 
was tested with different pre-treatments which included pressure cooking in citrate buffer 
(0.45g citric acid, 5.8g tri-sodium citrate, two litres deionised H2O, pH6) for ten minutes with 
or without prior immersion in 100% formic acid for ten minutes. Frozen cryostat sections 
were subjected to 4% paraformaldehyde solution for thirty minutes or ice-cold acetone for 
thirty minutes. Sections were visualised under a microscope (Nikon Eclipse Ni) and pictures 
taken for each condition at 40x magnification. 
4.3.3 Pathology analysis 
Analysis for Iba1, CD68, CR3-43 and P2RY12 load was calculated using methods described 
in 2.5. The circularity and perimeter were calculated using the hull and circle macro 
described in 2.5.5.   
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4.3.4 Statistics 
Kruskal-Wallis one way ANOVA tests with Dunn’s multiple comparison analysis were 
performed on each region for each antibody and each microglial analysis (load, circularity, 
and perimeter) with a 0.05 significance level. Significance is shown as * for p<0.05, ** for 
p<0.005, *** for p<0.0005, ****p<0.0001. GraphPad Prism v7 was used to complete this 
analysis. 
4.4 Results 
4.4.1 Microglial load in TREM2 variant cases compared to Alzheimer’s disease 
To assess the percentage of the grey matter, across all six cortical layers, that was occupied 
by microglia, the microglial load was assessed and compared between SAD, FAD, TREM2 
variant AD cases, TREM2 variant controls and controls across brain regions that represent 
the five Thal phases. Load was expressed as a percentage of the area stained by the 
antibody. The highest microglial load was observed with the P2RY12 marker (Figure 4.2d 
and l), followed by Iba1 (Figure 4.2a and i) then CD68 (Figure 4.2b and k) and CR3-43 
(Figure 4.2c and j). 
TREM2 variant AD cases had a significantly higher CD68 load in the frontal cortex compared 
to the FAD cases (p=0.0127) and the TREM2 variant controls (p=0.0147, Figure 4.2k). 
Representative CD68 images from SAD, FAD, TREM2 variant AD and TREM2 variant 
control cases can be seen to show these differences (Figure 4.2e-h). There was also a 
significant increase in the TREM2 variant AD cases compared to the controls in the 
cerebellum (p=0.0444). This trend follows suit throughout all regions whereas all other 
disease groups appear to be at similar levels throughout all regions.   
There were no significant differences that could be seen when assessing Iba1 load. 
However, TREM2 variant AD cases appeared to have a markedly increased Iba1 load in the 
frontal cortex compared to other groups but was markedly decreased in the temporal cortex, 
putamen and cerebellum (Figure 4.2i). TREM2 variant controls followed an opposite pattern 
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to the TREM2 variant AD cases in the frontal cortex, temporal cortex and putamen. SAD and 
FAD cases had consistent loads across regions.  
No significant differences were seen between disease groups when assessing CR3-43 load 
(Figure 4.2j). The levels of CR3-43 load were observed across all regions in each disease 
group with the highest levels being observed in the frontal cortex.  TREM2 variant AD cases 
appear to follow the same trend as SAD cases when comparing to other disease groups.  
SAD, FAD, TREM2 variant controls and controls had similar levels of P2RY12 load in both 
the frontal and temporal cortices with a greater level of variation between disease groups 
observed in the hippocampus (Figure 4.2l). 
The microglial load with each marker was correlated to both the Aβ load and the tau load 
and linear regression analysis performed to determine if the line significantly deviated from 
zero (Figure 4.3 and Figure 4.4). There was a significant correlation between Iba1 and Aβ in 
the TREM2 variant cases frontal cortex (p=0.0003), FAD hippocampus (p=0.0071), SAD 
putamen (p=0.0383) and FAD putamen (p=0.0046). However, the TREM2 variant cases 
were negatively correlated whereas the SAD and FAD cases were positively correlated. 
CD68 and Aβ were also significantly correlated in SAD putamen (p=0.0497). 
CR3-43 and tau are significantly correlated in SAD temporal cortex (p=0.0365), TREM2 
variant temporal cortex (p=0.0310) and SAD putamen (p=0.0424) with the TREM2 variant 
cases showing negative correlation and the others positive as with the Aβ. CD68 and tau are 
also significantly correlated in TREM2 variant temporal cortex in the same direction 
(p=0.0382) 
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Figure 4.2: Microglial load in TREM2 variant cases compared to AD and controls. 
Measured using different microglial markers in frontal cortex (FCTX), temporal cortex 
(TCTX), hippocampus (HIPPO), putamen (PUT) and cerebellum (CBM) and compared in 
disease groups; SAD, FAD, TREM2 AD, TREM2 Control and Control. Load measured as 
mean percentage of squares stained. Representative images of microglial 
immunohistochemistry for Iba1 (a), CD68 (b), CR3-43 (c) and P2RY12 (d) on case 7. 
Representative images of CD68 staining in the frontal cortex of SAD (e, case 13), FAD (f, 
case 27), TREM2 AD (g, case 2) and TREM2 control (h, case 3). Iba1 load (i), CD68 load 
(k), CR3-43 load (j), and P2RY12 load (l). Key is shown to show colour for each disease 
group. Black arrows highlight CD68+ve microglia. Scale bar represents 50µm.  Kruskal-
Wallis one way ANOVA was performed with Dunn’s multiple comparison to assess 
significance. Significance is shown as * for p<0.05, ** for p<0.005, *** for p<0.0005, 
****p<0.0001. Error bars represent SEM. 
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Figure 4.3: Correlations between Aβ load and microglial load. Each graph highlights the 
correlations between Aβ load and each microglial marker as indicated by colour in the key 
shown. Each graph is individual for disease group and region. Linear regression analysis 
was performed and any significant deviations of the line from zero are indicated with their p 
value with significance p<0.05.  
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Representative CD68 images from SAD, FAD, TREM2 variant AD and TREM2 variant  
 
 
Figure 4.4: Correlations between tau load and microglial load. Each graph highlights the 
correlations between AT8 load and each microglial marker as indicated by colour in the key 
shown. Each graph is individual for disease group and region. Linear regression analysis 
was performed and any significant deviations of the line from zero are indicated with their p 
value with significance p<0.05. 
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4.4.2 Microglial circularity in TREM2 variant cases compared to Alzheimer’s disease 
As microglia have a spectrum of different morphological phenotypes, ranging from a 
ramified, surveillance phenotype to a more amoeboid phagocytic phenotype the shape of the 
microglia was also investigated across the different disease groups to determine whether 
one phenotype was more prominent in any of the disease groups. This was measured as an 
index of circularity in which a perfect circle would score 1 and an imperfect shape would be 
0. Ramified microglia would have a score closer to 0 whereas amoeboid microglia would 
have a score closer to 1 (Figure 4.2a-d).  
TREM2 variant AD cases had significantly more circular Iba1 microglia than controls in the 
temporal cortex (p=0.0248) and more circular microglia in both the SAD (p=0.0342) and FAD 
groups (p=0.0302) in the cerebellum (Figure 4.5e). This trend followed suit in the frontal 
cortex and putamen. However, the hippocampus appeared to have more circular microglia in 
the controls compared to other regions. 
TREM2 variant AD cases also have significantly more circular CR3-43 microglia than the 
SAD cases (p=0.0128) in the frontal cortex and more circular microglia than the controls 
(p=0.0064) in the temporal cortex (Figure 4.5f).  
Furthermore, TREM2 variant AD cases had significantly more circular CD68 microglia than 
the controls in the frontal cortex (p=0.0296, Figure 4.5g). A similar trend to this can be seen 
in the putamen.   
As expected P2RY12 microglia generally had a circularity score closer to 0 than Iba1, CD68 
and CR3-43 microglia (Figure 4.5h). No major differences were observed between disease 
groups for P2RY12 circularity scores either with all groups scoring a small amount above or 
below 0.3. 
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Figure 4.5: Microglial circularity in TREM2 variant cases compared to AD and controls. 
Measured using different microglial markers in frontal cortex (FCTX), temporal cortex (TCTX), 
hippocampus (HIPPO), putamen (PUT) and cerebellum (CBM) and compared in disease groups; 
SAD, FAD, TREM2 AD, TREM2 Control and Control. A score of 1 is a perfect circle whereas a 
score of 0 is an imperfect shape. Mean values were taken from each case in a disease group. 
Two representative randomly selected squares are shown for case 2 (a) and case 14 (c). The 
corresponding circularity scores for these squares are shown (b, d). Iba1 circularity (e), CD68 
circularity (g), CR3-43 circularity (f), and P2RY12 circularity (h). Key is shown to show colour for 
each disease group. Scale bar represents 50um. Kruskal-Wallis one way ANOVA was performed 
with Dunn’s multiple comparison to assess significance. Significance is shown as * for p<0.05, ** 
for p<0.005, *** for p<0.0005, ****p<0.0001. Error bars represent SEM. 
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4.4.3 Microglial perimeter in TREM2 variant cases 
The load and shape of the microglia have been investigated; with the macro developed by 
Yau Lim, the size of the individual microglia could also be investigated. The perimeters of the 
microglia were assessed to determine if the size changed according to disease group 
(Figure 4.6a-d). The overall perimeter of the microglia across the different markers does not 
differ drastically; with only CD68 having smaller perimeters than the rest of the markers 
(Figure 4.3g) and this was most likely due to the lack of processes on these microglia. 
However, as CD68 and Iba1 are markers in which their target antigen is not on the plasma 
membrane, the stain may not take into account the whole size of the cell.  
TREM2 variant AD cases have significantly reduced perimeter of Iba1 microglia in the 
temporal cortex compared to SAD cases (p=0.0293), with this trend following suit in the 
putamen (Figure 4.6e). The TREM2 variant AD cases have significantly reduced perimeter of 
CR3-43 microglia compared to SAD cases in the frontal cortex (p=0.0054) and controls in 
the temporal cortex (p=0.0293, Figure 4.6f). No significant differences in the perimeter of 
CD68 microglia were found (Figure 4.6g). As CD68 microglia are predominantly amoeboid in 
shape, the size of the microglia may not differ greatly. Similarly, no significant differences in 
perimeter were detected in P2RY12 microglia (Figure 4.6h). 
The SAD and FAD cases have the same size perimeter throughout all of the markers and all 
regions excluding the frontal cortex of CR3-43 microglia suggesting that although they may 
have differences in load and shape between the different AD subtypes, the size of the 
microglia does not differ greatly.  
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Figure 4.6: Microglial perimeter in TREM2 variant cases compared to AD and 
controls. Measured using different microglial markers in frontal cortex (FCTX), temporal 
cortex (TCTX), hippocampus (HIPPO), putamen (PUT) and cerebellum (CBM) and 
compared in disease groups; SAD, FAD, TREM2 AD, TREM2 Control and Control. Mean 
values were taken from each case in a disease group. Two representative randomly 
selected squares are shown for case 13 (a) and case 33 (c). The corresponding perimeters 
for these squares are shown (b, d). Iba1 perimeter (e), CD68 perimeter (g), CR3-43 
perimeter (f), and P2RY12 perimeter (h). Key is shown to show colour for each disease 
group. Scale bar represents 50µm. Kruskal-Wallis one way ANOVA was performed with 
Dunn’s multiple comparison to assess significance. Significance is shown as * for p<0.05, ** 
for p<0.005, *** for p<0.0005, ****p<0.0001. Error bars represent SEM. 
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4.4.4 APOE genotype effect on microglia 
As discussed in Chapter 3, TREM2 variant AD cases all were found to have at least one 
ApoE4 allele, whereas the TREM2 variant controls had no ApoE4 alleles. It was therefore 
hypothesised that there is a potential link between TREM2 variants and APOE genotype. To 
investigate this link further, the microglial load, shape and size was investigated according to 
APOE genotype as illustrated in Figure 4.4, Figure 4.8, and Figure 4.6.  
No significant differences in microglial load were observed for any of the microglial markers. 
However, Iba1 load appeared to be increased in the ApoE3/4 group in the frontal cortex and 
hippocampus (Figure 4.7a). CR3-43 load appears to have showed decreased load in the 
ApoE2/2 group compared to other groups and a pattern in ApoE2/2< ApoE2/4< ApoE3/3< 
ApoE3/4< ApoE4/4 in the hippocampus, putamen and cerebellum (Figure 4.7b). CD68 load 
also showed a pattern of increasing load as less ApoE2 and more ApoE4 was present 
(Figure 4.7c). This pattern followed throughout all the regions for CD68. However, the 
ApoE4/4 group does have large error bars which may account for this difference. There was 
no marked difference in the P2RY12 load in frontal cortex but the load in the temporal cortex 
followed the pattern ApoE2/2> ApoE3/3> ApoE3/4> ApoE4/4, whereas the hippocampus 
showed a decrease in the ApoE2/2 load compared to other groups (Figure 4.7d). Therefore, 
the activated microglial markers (CD68 and CR3-43) showed a decrease in ApoE2/2 in 
cortical areas aside from P2RY12 in which ApoE2/2 has the highest load in the temporal 
cortex. This suggests that the P2RY12+ve resting microglia are more abundant in ApoE2/2 
cases than other APOE genotypes.  
Microglial circularity comparisons between APOE genotypes also showed no significant 
differences. Nevertheless, Iba1 microglia do appear to be more circular in shape in the 
ApoE4/4 group compared to other groups in the frontal cortex and temporal cortex (Figure 
4.8a). Although the hippocampus shows the opposite with ApoE2/2 being more circular in 
that region. CR3-43 microglia on the other hand, show more circular microglia in the 
ApoE2/2 group in the frontal cortex and putamen (Figure 4.8b), though the ApoE2/4 
microglia appear to be less circular in the putamen. Similarly to Iba1 load, ApoE2/2 CD68 
microglia were less circular than other groups in the frontal cortex (Figure 4.5c). P2RY12 
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microglia are consistent in microglial load throughout regions (Figure 4.8d). 
Further to this, there were no significant differences found in the Iba1 or P2RY12 microglial 
perimeter. The perimeter of the Iba1 microglia appeared to be decreased in the ApoE4/4 
group in the frontal cortex but increased compared to the ApoE2/2 group in the hippocampus 
(Figure 4.6a). CR3-43 and CD68 microglia with ApoE2/2 microglia were significantly 
decreased in perimeter in the frontal cortex compared to the ApoE2/4 group (CR3-43 
p=0.0298, Figure 4.6b, CD68 p=0.0249, Figure 4.6c). P2RY12 microglia had slightly 
elevated perimeter in ApoE2/2 cases in the temporal cortex, whereas a decrease was seen 
in this group in the hippocampus (Figure 4.6d).  
 
Figure 4.7: Microglial load compared between APOE genotypes. Measured using 
different microglial markers in frontal cortex (FCTX), temporal cortex (TCTX), hippocampus 
(HIPPO), putamen (PUT) and cerebellum (CBM). APOE genotypes were 2/2, 2/4, 3/3, 3/4 
and 4/4. Load is measured as mean percentage of squares stained. (a) Iba1 load, (b) CD68 
load, (c) CR3-43 load, (d) P2RY12 load. Key is shown to show colour for each APOE 
genotype. Kruskal-Wallis one way ANOVA was performed with Dunn’s multiple comparison 
to assess significance. Significance is shown as * for p<0.05, ** for p<0.005, *** for 
p<0.0005, ****p<0.0001. Error bars represent SEM. 
 
a 
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4.4.5 TREM2 antibody optimisation 
The aim of this optimisation was to identify a reliable commercially available TREM2 
antibody to investigate the TREM2 distribution levels across the different regions of the brain 
and compare this between TREM2 variant cases and other sporadic and familial AD cases. 
Reports from the literature using TREM2 antibodies show the antibodies work well in mouse 
brain tissue but in human formalin fixed tissue the results are variable and are therefore not 
reliable. In this study six TREM2 antibodies were available and were tested to determine 
which antibody would be most optimal. The TREM2 antibodies (Table 4.4.2) were optimised 
in both formalin-fixed paraffin embedded and frozen tissue and liver sections were used as a 
positive control. Table 4.1 shows the details of each antibody in detail, including the epitope 
that they target. A summary of the findings with each antibody can be seen in Table 4.2. 
Figure 4.8: Microglial circularity compared between APOE genotypes. Measured using 
different microglial markers in frontal cortex (FCTX), temporal cortex (TCTX), hippocampus 
(HIPPO), putamen (PUT) and cerebellum (CBM). APOE genotypes were 2/2, 2/4, 3/3, 3/4 
and 4/4. A score of 1 is a perfect circle whereas a score of 0 is an imperfect shape. Mean 
values were taken from each case in a disease group. (a) Iba1 circularity, (b) CD68 
circularity, (c) CR3-43 circularity, (d) P2RY12 circularity. Key is shown to show colour for 
each APOE genotype. Kruskal-Wallis one way ANOVA was performed with Dunn’s multiple 
comparison to assess significance. Significance is shown as * for p<0.05, ** for p<0.005, *** 
for p<0.0005, ****p<0.0001. Error bars represent SEM. 
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Table 4.4.2: Features of TREM2 antibodies tested 
 
Antibody Company Epitope length Epitope Species Clonality
TREM2 Proteintech (13483-1-AP) 200 22-222 rabbit pAb
TREM2 R&D (AF1828) 155 19-174 goat pAb
TREM2 Sigma (HPA012571) 112 33-144 rabbit pAb
TREM2 Sigma (HPA010917) 35 196-230 rabbit pAb
TREM2 SantaCruz (sc-373828) 160 1-160 mouse mAb
TREM2 Abgent (AP5469a) 28 22-50 rabbit pAb
TREM2 Abcam (ab117645) 168 1-168 goat pAb
Figure 4.9: Microglial perimeter compared between APOE genotypes. Measured using 
different microglial markers in frontal cortex (FCTX), temporal cortex (TCTX), hippocampus 
(HIPPO), putamen (PUT) and cerebellum (CBM). APOE genotypes were 2/2, 2/4, 3/3, 3/4 
and 4/4. Mean values were taken from each case in a disease group. (a) Iba1 perimeter, (b) 
CD68 perimet r, (c) CR3-43 perimeter, ( ) P2RY12 perimeter. Key is shown to show colour 
for each APOE genotype. Kruskal-Wallis one way ANOVA was performed with Dunn’s 
multiple comparison to assess significance. Significance is shown as * for p<0.05, ** for 
p<0.005, *** for p<0.0005, ****p<0.0001. Error bars represent SEM. 
Table 4.2: Features of TREM2 antibodies 
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The Abcam antibody showed a small amount of staining in the control liver section (Figure 
4.11a). Positive staining in the grey matter showed neuronal cells but the white matter 
remained negative (Figure 4.11). Staining worked better in the frozen tissue than the paraffin 
tissue. Acetone and PFA fixations gave rise to different staining patterns.  
Figure 4.10: TREM2 antibody optimisation – Abgent (AP5469a). Sections were tested 
under the following conditions: (a) Liver; (b) paraffin, grey matter; (c) frozen acetone, grey 
matter; (d) frozen PFA, grey matter; (e) frozen acetone, white matter; (f) frozen PFA, white 
matter. (b) 1:200 dilution, (a, c-f) 1:50 dilution. Images at 40x magnification. 
Figure 4.11: TREM2 antibody optimisation – Abcam (ab117645). Sections were tested 
under the following conditions: (a) Liver; (b) paraffin, grey matter; (c) frozen acetone, grey 
matter; (d) frozen PFA, grey matter; (e) frozen acetone, white matter; (f) frozen PFA, white 
matter. (b) 1:100 dilution, (a, c-f) 1:50 dilution. Images at 40x magnification. 
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The Abgent antibody showed no clear staining in the liver section possibly indicating that the 
staining seen in the brain is non-specific (Figure 4.10a). The staining resembled neurons, 
however in the white matter it looked as if there was some glial nuclei staining (Figure 4.10). 
Better staining was seen in the frozen tissue with the acetone and PFA fixations giving 
different results.  
 
Figure 4.12: TREM2 antibody optimisation – SantaCruz (sc-373838). Sections were 
tested under the following conditions: (a) Liver; (b) paraffin, grey matter; (c) frozen acetone, 
grey matter; (d) frozen PFA, grey matter; (e) frozen acetone, white matter; (f) frozen PFA, 
white matter. All sections were stained with a 1:50 dilution. Images at 40x magnification. 
 
The SantaCruz antibody showed staining that was neuronal in nature (Figure 4.12). Different 
pre-treatments did not work, with the PFA fixation in the frozen tissue white matter, the only 
image to show any real staining. Therefore, this antibody is not reliable. 
The HPA010917 antibody showed no real staining in the liver section (Figure 4.14a). It had 
stronger staining in the white matter compared to the grey matter and very little staining was 
evident in the paraffin sections (Figure 4.14). In the PFA fixed frozen tissue, the staining 
resembled cellular processes, however, in the acetone fixed section the staining was more 
compact and perhaps would include the nuclei as well as some processes. 
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Staining of the HPA012571 antibody showed more promising results. The liver control 
section showed staining that looked more specific to the Kupffer cells that we would expect 
to stain with TREM2 (Figure 4.13a). Paraffin sections had a large amount of background 
staining but no specific staining. However, in the frozen sections, staining that resembled 
Figure 4.14: TREM2 antibody optimisation – HPA010917. Sections were tested under the 
following conditions: (a) Liver; (b) paraffin, grey matter; (c) frozen acetone, grey matter; (d) 
frozen PFA, grey matter; (e) frozen acetone, white matter; (f) frozen PFA, white matter. All 
sections were stained with a 1:100 dilution. Images at 40x magnification. 
Figure 4.13: TREM2 antibody optimisation – HPA012571. Sections were tested under the 
following conditions: (a) Liver; (b) paraffin, grey matter; (c) frozen acetone, grey matter; (d) 
frozen PFA, grey matter; (e) frozen acetone, white matter; (f) frozen PFA, white matter. (b) 
1:200 dilution, (a, c-f) 1:100 dilution. Images at 40x magnification. 
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microglia was observed. The section that had been fixed in PFA looked to be the correct 
morphology (Figure 4.13).  
The R&D antibody control liver section appears to show specific staining of the Kupffer cells 
(Figure 4.15a). Unlike with the other antibodies, the paraffin sections look to have staining 
that could be specific as do the frozen sections (Figure 4.15). However, some of the staining 
does look neuronal whereas other parts look similar to glial pathology. Some of the glial-
looking staining looks to be potentially more of an astrocyte morphology than the microglial 
pathology.  
The Proteintech antibody staining does not show any specific staining in the liver control 
section (Figure 4.16a). Conversely, in the brain tissue sections staining can be observed 
(Figure 4.16). Whether it is specific or not remains to be answered but the paraffin with 
pressure cooking treatment only and the frozen sections, both PFA and acetone fixed, would 
suggest that there could be. The morphology seen could be indicative of a more activated 
form of microglia.  
 
 
Figure 4.15: TREM2 antibody optimisation – R&D (AF1828). Sections were tested under 
the following conditions: (a) Liver, PC; (b) paraffin, grey matter, PC; (c) paraffin, white matter, 
PC; (d) paraffin, grey matter, PC+FA; (e) paraffin, white matter, PC+FA; (f) frozen PFA, white 
matter. All sections stained at 1:40 dilution. Images at 40x magnification. PC, pressure 
cooked in citrate buffer; FA, formic acid pretreatment. 
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Figure 4.16: TREM2 antibody optimisation – Proteintech (13483-1-AP). Sections were 
tested under the following conditions: (a) Liver, PC; (b) paraffin, white matter, PC; (c) 
paraffin, white matter, PC+FA; (d) frozen PFA, white matter; (e, f) frozen acetone, white 
matter. (a-e) 1:100 dilution, (f) 1:200 dilution. Images at 40x magnification. PC, pressure 
cooked in citrate buffer; FA, formic acid pretreatment. 
Table 4.3: Summary of TREM2 antibody optimisation 
 
4.5 Discussion 
4.5.1 Microglial phenotype in TREM2 variant cases 
In this study, the microglial phenotype of the TREM2 variant AD cases was investigated 
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of APOE genotype on the microglial phenotype was also investigated and seven TREM2 
antibodies were analysed for their potential in staining microglial cells.  
The microglial phenotype of the TREM2 variant AD cases have an increased amoeboid 
morphology, suggesting that the microglia are activated in these cases to higher levels than 
other AD groups and controls. This is due to increased loads of CD68 across all regions 
tested, a general increase in circularity across microglial markers and a decrease in the 
perimeter of microglia, indicative of smaller amoeboid shaped microglial cells. Additionally, 
decreased P2RY12 levels in the temporal cortex are indicative of less ramified parenchymal 
microglia. CD68 is a lysosomal marker and is well established to be a marker of phagocytic 
microglia (Boche et al., 2013; Fadini et al., 2013; Holness and Simmons, 1993; Korzhevskii 
and Kirik, 2016; Shikuma et al., 2014; Smith et al., 2013; Zotova et al., 2011). The microglia 
in TREM2 variant AD cases are more capable of phagocytosis as the microglia are more 
circular and have a smaller perimeter. TREM2 is thought to act through both loss and gain of 
function. Many TREM2 deficient models have highlighted that deficiencies in TREM2 
decrease the levels of phagocytosis and that overexpression of TREM2 can increase 
phagocytosis levels, this may suggest that TREM2 variant models do not have a loss of 
function but instead a gain of function (Jay et al., 2015, 2017; Jiang et al., 2014, 2016b; 
Wang et al., 2015, 2016).  
However, previous studies investigating the R47H or D87N variant have suggested that 
these TREM2 variants are indeed loss of function mutations. It has been shown that the 
R47H variant alters the structure of the TREM2 protein so that it can no longer bind to 
anionic lipids or alternative ligands (Abduljaleel et al., 2014; Wang et al., 2015). R47H 
variants have also been shown to have an increased load of AD pathology, suggesting that 
clearance mechanisms may be inefficient or that Aβ is deposited at a quicker rate in these 
cases (Korvatska O et al., 2015; Roussos et al., 2015). However, our data show a higher 
number of activated microglia, indicating increased phagocytosis and therefore clearance of 
Aβ would be more efficient. Reasons for this could be due to the lack of cases that have 
been tested. Replication of this study in a wider sample cohort would determine if this is the 
case. Furthermore, other clinical features of AD such as seizures in individual cases could 
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affect the level of microglial activation and influence the results. Further clinic-pathological 
correlation on a case to case basis would need to be done to rule this out. If the R47H 
variant does have a loss of function, perhaps the variant causes the process of phagocytosis 
and clearance to slow down and become less efficient and as a compensatory mechanism, 
more microglia are recruited and activated into an amoeboid morphology to try and increase 
the clearance of Aβ. If this was the case, the pathology would increase as clearance slows 
down and disease would be exacerbated, putting the TREM2 variant carriers at risk. TREM2 
deficiency would then have the same effect as there would be lower levels of phagocytosis in 
both cases.  
Interestingly, the TREM2 variant cases that were neurologically normal at time of death and 
did not have any underlying AD pathology, had a different phenotype to that observed in 
TREM2 variant AD cases. Although not many changes were seen in the microglia size or 
shape in these cases, they did have a different level of abundance than the TREM2 variant 
AD cases. They appear to have an opposite pattern of Iba1 load due to the fact that if 
TREM2 variant AD cases had an increased load then the TREM2 variant controls had a 
decreased load and vice versa throughout several regions. They also appear to have a more 
inactivated form of microglia, especially lacking antigen presenting cells (those represented 
by CR3-43 staining) and increased levels of P2RY12 microglia compared to TREM2 variant 
AD cases. Therefore, having a TREM2 variant can have varying effects in different people 
and there may be other factors involved in the TREM2 pathway that also need to be present 
for the variant to have a pathogenic effect and increase risk. At present, there are no 
published studies that look at carriers of the TREM2 variants that did not develop AD. 
Further investigations into the differences might elucidate the role TREM2 is playing in 
disease.  
Although different APOE genotypes showed no significance between varying microglial 
phenotypes, the ApoE2/2 group appear to have a more inactivated phenotype with a 
decreased load, more ramified shape and a smaller perimeter when observing trend 
patterns. They also appear to have increased P2RY12 load, indicative of more homeostatic 
parenchymal microglia (Butovsky et al., 2013). ApoE4/4 cases look to have a similar 
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microglial phenotype to that of the TREM2 variant AD cases with increased CD68 load 
compared to other groups and are more amoeboid in shape. As the ApoE4/4 is known as a 
risk factor in AD patients and ApoE2/2 is thought to be protective, the fact they have different 
phenotypes may not be unexpected. However, as with the TREM2 variant AD results, we 
see what should be a more activated phenotype typical of phagocytosis in the ApoE4/4 
cases suggesting there should be more clearance of Aβ in these cases. Microglial clearance 
could be enhanced in these cases but other clearance mechanisms could be impaired 
causing a cumulative effect that results in no difference. APOE has been shown to bind to 
LRP1 and also be involved in intramural periarterial drainage (IPAD) and could potentially be 
having an effect on this clearance system (Bu, 2009; Kim et al., 2009; Rebeck et al., 1995). It 
has been reported that ApoE4 blocks the receptor mediated endocytosis employed by LRP1 
which is part of a lipid transport pathway and therefore reduces the elimination of Aβ and 
causes increased Aβ in the vessel walls (Deane et al., 2008; Huynh et al., 2017). 
It has previously been suggested that the ApoE4 allele may cause its pathogenic effect 
through inflammatory mechanisms due to the fact that it does not protect against microglial 
activation as some of the other alleles do (Barger and Harmon, 1997; Gahtan and Overmier, 
1999). Recently, Shi et al., (2017) found that in a P301S tau transgenic AD mouse model, 
ApoE4 mice exhibit greater levels of neuroinflammation. This provides evidence that TREM2 
and APOE are linked in their pathway and that the theory provided by Krasemann et al., 
(2017), which suggests APOE is upregulated which then triggers the TREM2 pathway, may 
be true.  
As well as highlighting decreased levels of phagocytosis in TREM2 deficient models, they 
also showed that in these models, an alternative method of inflammation and phagocytosis 
was used, through toll like receptors (Blander and Medzhitov, 2004; Frank et al., 2008; 
Guerreiro et al., 2013a; Jonsson et al., 2012b; Piccio et al., 2007; Takahashi et al., 2005). 
This method causes higher levels of toxic cytokines such as TNFα, nitric oxide synthase 2 
and IL-1β. Therefore, it could be possible that in the TREM2 variant models, microglia still 
become activated, perhaps through the APOE pathway. However, the classic phagocytic 
mechanism is reduced due to ineffective ligand binding, meaning that this alternative method 
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of phagocytosis is utilised, toxic cytokines are produced, which in turn cause a more toxic 
environment and causes disease to be exacerbated.  
4.5.2 TREM2 antibody characterisation 
There have been reports that show testing of TREM2 antibodies in formalin-fixed, paraffin-
embedded tissue showed a small amount of staining observed with multiple antibodies 
(Satoh et al., 2013). This led to the question of whether TREM2 is widely expressed in the 
brain and if in fact it was more likely expressed on infiltrating peripheral macrophages or on 
monocytes rather than the resident microglia in the brain (Fahrenhold et al., 2017; Jay et al., 
2015). Subsequently, direct RNA sequencing and qPCR analysis deciphering the similarities 
and differences in microglia and peripheral macrophages has taken place and confirmed that 
TREM2 is expressed only on microglia (Hickman et al., 2013).  
The immunohistochemical staining carried out here shows a more comprehensive look at a 
larger range of antibodies. None of the TREM2 antibodies have previously been tested on 
frozen tissue and although the frozen tissue lacks morphology compared to paraffin 
embedded sections, the staining with the anti-TREM2 antibodies appeared more positive. In 
the case of some antibodies, Abcam, HPA010917, HPA012571, R&D and Proteintech, 
staining patterns resembled microglial processes. However, there still remains to be large 
variation in the staining between cases. This could be because the TREM2 protein level is 
only just detectable by the sensitivity of the immunohistochemical methods. Further 
development and validation of TREM2 antibodies needs to occur for this to be addressed. 
This would need to include characterisation using western blots, immunocytochemistry and 
testing with mutants to see if when TREM2 is absent the staining in abolished. Using frozen 
tissue for morphological studies is challenging, so ideally antibodies that could be used in 
paraffin should be developed.  
4.5.3 Conclusions 
In summary, TREM2 variant cases have a different microglial profile to those in SAD or FAD 
cases. TREM2 variant AD cases have more activated microglia, that should lead to more 
phagocytosis and increased clearance but previous literature suggests this is not the case. A 
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complicated inflammatory cascade is occurring in these cases which can cause these 
TREM2 variant cases to be at risk of AD. The reason this is a risk and not inevitable though, 
is due to other factors that stops or slows some of these cases getting AD and alters their 
microglial phenotype. One of these factors could be APOE genotype, because as indicated 
previously, TREM2 and APOE act along the same pathway and TREM2 variant AD cases all 
have an ApoE4 allele. Better TREM2 antibodies will enable us to look at the distribution of 
TREM2 and help to elucidate what is occurring in these TREM2 variant cases and therefore 
what role TREM2 plays in the pathogenesis of SAD or FAD. 
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5 The genetic and proteomic profiles of TREM2 
variant cases 
5.1. Abstract 
Introduction: Neuroinflammation has long been known to play a role in AD. However, the 
findings that several genes associated with inflammation were identified as hits in AD GWAS 
studies brought closer attention to neuroinflammatory mechanisms in AD. The finding that 
TREM2 was a genetic risk factor for late onset AD with a similar odds ratio to APOE4 gave 
further insight that neuroinflammation may be important. TREM2 is expressed on microglia 
and microglia play a large role in the inflammatory cascades in the brain. Previous genetic 
and proteomic studies had identified the immune response to be an altered pathway, but 
whether it was a cause of the disease or consequence was still to be determined. Here the 
genetic profile of neuroinflammation in TREM2 variant cases compared to SAD, FAD and 
normal controls was investigated and then compared to the protein expression in the same 
cases. 
Materials and methods: Frontal cortex was taken from SAD (n=10), FAD PSEN1 (n=7), 
FAD APP (n=3), TREM2 variant SAD (n=3), TREM2 variant FAD (n=1), TREM2 variant 
controls (n=2) and normal controls (n=6). RNA was extracted using the Qiagen RNeasy kit 
and samples were sent for Nanostring nCounter analysis using the Human Inflammation 
panel consisting of 256 genes and an added 30 specific neurodegenerative genes. Data was 
analysed with nSolver software and fold changes compared to controls were calculated. 
Secondly, the protein was extracted, trypsin digested and analysed using 2D nanoUPLC 
coupled to a QTOF mass spectrometer (Synapt G2 Si). Proteins were quantitated and 
identified using label free proteomics (MSe). Data was processed using Progenesis software 
and fold-changes compared to controls were calculated. Both sets of data were analysed 
using Ingenuity Pathway Analysis software to determine the canonical pathways and disease 
functions highly represented in the datasets.  
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Results: The neuroinflammatory signalling pathway was found to be altered in all AD 
subgroups with TREM2 variant SAD cases displaying greater levels of upregulation in genes 
involved than SAD cases. TREM2 variant controls however, showed large levels of 
downregulation in this pathway. Genes involved in the TLR response were increased in the 
TREM2 variant SAD cases. The top pathways changing in the proteomic data were involved 
with cell proliferation, cytoskeletal organisation and amyloid processing. Proteins involved 
with neurodegeneration were upregulated at the highest levels in the TREM2 variant AD 
cases. APOE protein levels differed by 6-fold between TREM2 variant SAD and TREM2 
variant controls.  
Conclusions: Many genes, proteins and pathways are changing throughout the duration of 
AD. Some pathways such as cell proliferation and cytoskeletal organisation appear to be 
affected no matter which AD subtype is present. However, neuroinflammation differs 
between subtypes, with the TREM2 variants displaying the greatest differences. As TREM2 
variant SAD and TREM2 variant controls have such contrasting profiles, another factor must 
be needed in order for AD to take place. The lack of an ApoE4 allele in the TREM2 variant 
controls and the presence of one in the TREM2 variant SAD cases, indicate that APOE 
genotype could be this factor or have its own independent effects. APOE and TREM2 both 
affect the TLR pathway leading to increased pro-inflammatory cytokine release and 
increased cell death. Further investigation into these pathways and mechanisms may help 
elucidate the reasons that TREM2 variants confer a risk to AD.  
5.2. Introduction 
5.2.1. Inflammation in AD 
Inflammation has been shown previously to be involved in the pathogenesis of AD. However, 
it was brought to closer attention when a number of GWAS studies identified several 
inflammatory genes as GWAS hits for AD, indicating that the inflammatory pathway may play 
a prominent role in AD pathogenesis. These hits included TREM2, HLA-DR, INPP5D, 
MEF2C, CR1 and CLU (Zhang et al., 2015).  
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Inflammation in AD has been studied extensively to assess the role that it plays. As both pro-
inflammatory and anti-inflammatory pathways have been shown to be present in AD brains, 
deciphering what is occurring as a cause of AD and what is occurring simply as an effect of 
disease is a complex matter and makes the study of inflammation a challenging one.  
Cytokines such as Il-1, Il-6 and TNF-α have been shown to be involved with Aβ deposition 
via the processing of APP (Akiyama et al., 2000; Buxbaum et al., 1992; Dickson et al., 1993; 
Eikelenboom and Gool, 2004; Goldgaber et al., 1989; Griffin et al., 1989; Huell et al., 1995; 
Vandenabeele and Fiers, 1991). There is also evidence that C1q from the complement 
pathway can aid fibril formation through binding of several Aβ molecules in close proximity to 
each other, therefore promoting fibrillisation (Akiyama et al., 2000; Webster and Rogers, 
1996; Webster et al., 1994, 1995). However, as these pro-inflammatory cytokines are shown 
to be released and the complement pathway activated upon Aβ fibrillisation, a cycle of 
inflammation and Aβ deposition ensue.  
Microglia are thought to be the specialised macrophages of the CNS. It was therefore 
hypothesised that their main role in AD would be involving inflammation. The activation of 
microglia has been shown to occur as one of the earliest changes in AD and numbers of 
activated microglia correlate with disease severity using clinicopathological correlations and 
different model systems to show when microglial pathology appears in line to amyloid plaque 
deposition (Arends et al., 2000; Gentleman, 2013; Giulian, 1999; Martin et al., 1994; 
Mattiace et al., 1990b; Paresce et al., 1997; Rogers et al., 1988; Wegiel and Wisniewski, 
1990; Wisniewski et al., 1989).  
Microglia produce the cytokines Il-1, Il-6 and TNF-α and are shown to cluster around neuritic 
amyloid plaques (Dickson et al., 1993; Eikelenboom and Gool, 2004; Griffin et al., 1989; 
Huell et al., 1995). However, activated microglia do not cluster around diffuse amyloid 
plaques, suggesting that through release of these cytokines, Aβ fibrillisation into neuritic or 
dense core plaques occurs (Arends et al., 2000; Giulian, 1999; Mattiace et al., 1990a; 
Paresce et al., 1997; Rogers et al., 1988; Wegiel and Wisniewski, 1990; Wisniewski et al., 
1989). One study observed that although the cerebellum is affected by AD pathology, no 
cerebellar functions are typically clinically impaired in AD. They linked that the cerebellum 
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has predominantly diffuse plaques rather than neuritic plaques and suggested that 
inflammation is needed, in the form of microglial clustering around the plaques, for neuritic 
plaque formation to occur, initiating a cascade of pro-inflammatory mediators leading to 
neurodegeneration that results in clinical symptoms (Eikelenboom et al., 1998; Joachim et 
al., 1989). Alternatively, the plaques may not have time to mature into neuritic plaques due to 
the cerebellum being the last Thal phase region to accumulate Aβ plaques. 
In addition to cytokines, various other inflammatory mediators have been identified in Aβ 
plaques, such as other cytokines, chemokines, a range of complement factors and many 
acute phase proteins (Akiyama et al., 2000; Eikelenboom and Gool, 2004). Aβ is thought to 
act similarly to bacteria and elicit a strong pro-inflammatory response via these molecules, 
leading to the production of reactive oxygen species, synaptic loss and neurotoxicity. 
Activating and recruiting more microglia to the amyloid plaques (Akiyama et al., 2000; 
Eikelenboom and Gool, 2004; Eikelenboom et al., 1998).  
Not all microglia have a pro-inflammatory role, many have anti-inflammatory properties. As 
the cascade of pro-inflammatory mediators occurs, anti-inflammatory cascades are triggered 
which initially mediate the clearance of Aβ and any neuronal debris (Akiyama et al., 2000). 
This is completed through phagocytic mechanisms in which the Aβ binds to receptors on the 
microglial cells, thereby transforming the cells into a phagocytic phenotype. It is 
hypothesised that this clearance becomes less efficient as the disease progresses, with 
microglia no longer being able to degrade the Aβ at an efficient rate (Paresce et al., 1997).  
Microglia have roles both in forming and clearing amyloid plaques, indicating that the 
inflammation in AD can be both causative as well as an effect. Familial AD cases have 
mutations in the APP, PSEN1 or PSEN2 genes which effect APP processing and this is 
known to cause AD. However, in late onset sporadic AD, the cause of disease is unknown 
with multiple risk factors being discovered. The major risk factor for sporadic AD is age and 
microglia have been shown to become primed as we age (Hoeijmakers et al., 2016; Lane et 
al., 2017). This means that they require fewer stimuli in order to elicit an inflammatory 
response. Holtman et al., (2015) showed that primed microglia have an over-representation 
of genes involved with phagosomes, lysosomes, antigen presentation and AD signalling. It is 
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hypothesised that these primed microglia are stimulated easily and through APP processing 
and plaque formation, microglia help to initiate the pathogenesis of AD using inflammatory 
cascades (Perry and Holmes, 2014).  
Multiple studies have looked at the gene expression and proteomic expression profiles in 
AD. Genetic expression studies using whole homogenate brain samples with microarray 
data or RNA sequencing data highlight pathways involved in: NF-κB signalling, complement 
and integrin, NADPH oxidase complex, phagocytic processes, IFN-γ –related pathways, 
metabolism, protein ubiquitination, vasculature development, synaptic signalling, synaptic 
transmission, synaptic plasticity, protein biosynthesis, protein trafficking, protein turnover and 
mitochondrial energy generation (Berchtold et al., 2014; Bossers et al., 2010; Chen et al., 
2013; Holtman et al., 2015). 
Other studies have isolated the microglia or astrocytes in AD and these studies revealed that 
pathways involved in immune response were unsurprisingly highlighted. Astrocytes showed 
decreased expression in genes involved with neuronal support and neuronal communication, 
whereas microglia showed decreased expression in genes involved with phagocytosis and 
endocytosis (Orre et al., 2014; Sekar et al., 2015). Furthermore, gene expression studies 
showed differences between different models of AD. Cells overexpressing APP highlighted 
changes in pathways in cell cycle, cell proliferation and p53 signalling (Wu et al., 2016). 
Transcriptomics on 5xFAD Tg AD mice showed complement and integrin overexpression, 
NADPH oxidase complex, phagocytic processes and IFN-γ related pathways (Landel et al., 
2014). Similarly, gene expression in the rTg4S10 mouse model overexpressing mutant 
human tau highlighted predominantly inflammatory processes and alterations in neuronal 
network activity (Wes et al., 2014). Overall, there is a large range of processes or pathways 
that seem to be changing at the genetic level in AD, although numerous pathways involved 
in inflammation are present.  
Proteomic studies also show similar pathways to be involved in different data sets in AD. 
Post-mortem brain proteomic studies have highlighted pathways involved in ubiquitin 
signalling and the ubiquitin proteasome system, energy metabolism, glycolysis, oxidative 
stress, apoptosis, signal transduction and synaptic functioning (Gentier and van Leeuwen, 
Chapter 5 – The genetic and proteomic profiles of TREM2 variant cases 
Page | 134  
 
2015; Musunuri et al., 2014). When senile plaques were isolated proteins involved with 
neuronal transport and cytoskeletal components were present in the plaques (Liao et al., 
2004). Similarly, a study looking at the proteomics of LAN5 neuroblastoma cells that had 
been incubated with Aβ42 revealed changes in cytoskeletal dynamics, ribosomal biogenesis 
and spliceosome dysregulation, indicating that the many pathways that are changing in AD, 
may not all be related to the amyloid plaque pathology (Nuzzo et al., 2017). Proteomics in 
the AβPPswe/PS1dE9 mice additionally had genes changing that were involved in 
cytoskeletal structure, energy metabolism, synaptic components and protein degradation, 
much in line with what was observed in the human brain (Fu et al., 2015).  Matarin et al., 
(2015) provided a comprehensive study using a microarray to study gene expression in 
several transgenic AD mouse models that had either mutant human APP, PSEN1, 
APP/PSEN1 or mutant tau and compared these to wildtype mice. They found that in mice 
producing Aβ plaques the immune response correlated with plaque load, whereas the older 
mice that produced neurofibrillary tangles showed an increased immune response but 
additionally had decreased gene expression associated with synaptic function (Matarin et al., 
2015).  
The pathways that are found in genetic expression studies do not always correlate with 
protein expression data, thus making it hard to determine the real changes that are occurring 
to cause AD pathogenesis. As the immune system is adaptive and constantly changing to 
match its environment, it is difficult to predict changes that occur with genetic expression 
data. Although many studies have investigated either the genetic expression or the 
proteomic expression, limited studies have investigated both together to compare the 
differences at the transcriptional level to the translational level. In the cases where multi-
omics has been performed, it has been proven to highlight novel network biology data that 
can be utilised to find biomarkers. A combination of transcriptomics and proteomics revealed 
the MAPK/ERK was reduced in AD and that the clathrin-mediated receptor endocytosis 
pathway was increased (Hallock and Thomas, 2012; Santiago et al., 2017). Similarly, there 
are limited sets of data that have compared the genetic or proteomic expression profiles of 
different AD groups directly to each other. Berchtold et al., (2014) compared MCI to AD 
samples and Conejero-Goldberg et al., (2011) identified differences in gene expression 
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based on APOE genotypes. However, there hasn’t been a comprehensive comparison of 
gene or protein expression between SAD and FAD, other than multiple studies being 
discussed in a review (Lista et al., 2015).  
5.2.2. Inflammation and TREM2 
TREM2 was identified by GWAS studies as a hit for AD and subsequently was identified as a 
genetic risk factor for late onset AD with a similar odds ratio to ApoE4 (Guerreiro et al., 
2013a; Jonsson et al., 2012b). TREM2 is expressed on microglia and is known to have its 
own role in inflammatory processes. It was therefore of interest to examine whether the risk 
associated with TREM2 variants was due to an altered inflammatory profile. 
TREM2 was found to be a regulator of phagocytosis and therefore has a role in the 
clearance of Aβ. TREM2 deficiency models showed reduced phagocytosis compared to 
wildtype (Jay et al., 2015; Jones et al., 2014; Kleinberger et al., 2014; Satoh et al., 2013; 
Ulrich and Holtzman, 2016; Wang et al., 2015; Zhao and Lukiw, 2013). It is therefore 
hypothesised that TREM2 heterozygous variants that have the increased risk of AD, have a 
loss of function and are less able to clear the Aβ. R47H variants have reduced levels of 
ligand binding which is thought to stop the signalling cascade TREM2 performs once bound 
via its signalling partner, TYROBP, to occur (Abduljaleel et al., 2014; Wang et al., 2015).  
The normal signalling cascade stimulates the microglial cell to go into an anti-inflammatory 
phagocytic phenotype, with minimal pro-inflammatory cytokines being produced (Blander 
and Medzhitov, 2004; Frank et al., 2008; Guerreiro et al., 2013a; Jonsson et al., 2012b; 
Takahashi et al., 2005). Reduced TREM2 expression has been shown to cause increased 
TLR activity (Yaghmoor et al., 2014). Furthermore, when TREM2 phagocytic mechanisms do 
not occur, an alternative method of phagocytosis via the TLRs can be initiated which in turn 
leads to increased pro-inflammatory mediators being released (Frank et al., 2008; Guerreiro 
et al., 2013a; Jonsson et al., 2012b; Piccio et al., 2007; Takahashi et al., 2005). This may 
indicate that although clearance is occurring, further Aβ deposition and neuronal death is 
being stimulated. Therefore, it is plausible that TREM2 variants that have a loss of function 
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and can no longer signal via normal mechanisms, would use this alternative pathway, have 
reduced clearance of Aβ and a higher risk of AD.  
An alternative theory to this is that microglia form a barrier around the Aβ plaques, 
encapsulating them, preventing them from causing any damage and that any uncovered 
parts are what cause neuronal toxicity (Yuan et al., 2016). One mechanism that this is 
thought to work is that TREM2 binds to APOE which in turn is part of the plaque. Through 
this interaction a pathway is activated which recruits microglia and forms a barrier. This 
barrier in TREM2 deficient models is markedly reduced, leading to the thoughts that more Aβ 
plaque is uncovered in the variants, meaning further toxicity and a higher risk of AD 
occurring (Condello et al., 2017; Jay et al., 2015; Ulrich et al., 2014; Wang et al., 2015; Yuan 
et al., 2016).  
There hasn’t yet been any evidence to show differing propensities for different APOE alleles 
to bind to TREM2 with different affinities but a study that looked at the transcriptomics of 
ApoE3 compared to ApoE4 identified the pathways responsible for mitochondrial function, 
calcium regulation and cell cycle re-entry to differ between the two groups (Condello et al., 
2017; Conejero-Goldberg et al., 2011). This could indicate that different mechanisms and 
pathways are activated or upregulated according to the APOE genotype present.  
5.2.3. Aims 
In this chapter, the genetic and proteomic expression profiles are compared between SAD, 
FAD and TREM2 variant cases compared to controls. To identify any differences occurring in 
the inflammatory mechanisms, nanostring technology was used to assess 256 inflammatory 
genes and 30 AD specific markers between disease groups. This was then compared to 
label-free mass spectrometry proteomic data to determine if the same changes were 
observed at protein level. A direct comparison between all three groups and across two 
platforms has not been performed before so allows us to take an in-depth look at the 
mechanisms that are involved in each disease subgroup.  
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5.3. Materials and Methods 
5.3.1. Case selection 
All case demographics are detailed in Table 2.3. For nanostring analysis, the following cases 
were used for each group: SAD (cases 7, 9-15, 17-18); FAD (cases 26, 29-35); TREM2 
variant SAD (cases 1, 2, 5); TREM2 variant FAD (case 6); TREM2 variant control (cases 3-
4); and controls (cases 37-42). Label-free mass spectrometry analysis cases were pooled 
into groups before running on the mass spectrometer. Two pools for each disease group 
were created where enough cases were available; otherwise only one pool was used. The 
cases used in each pool are outlined for each group: SAD (pool 1, cases 7,8 and 14; pool 2, 
cases 9, 12, 15, 17); FAD PSEN1 (pool 1, 27, 33-34; pool 2, 26, 29, 32); FAD APP (pool 1, 
30-31, 35); TREM2 variant SAD (pool 1, cases 1, 2, 5); TREM2 variant FAD (pool 1, case 6), 
TREM2 variant control (pool 1, cases 3-4); and Controls (pool 1, cases 37-39; pool 2, cases 
40-42).  
5.3.2. Nanostring 
RNA from chipped frontal cortex of cases stated above were extracted as per protocols 
described in 2.6.1 (SAD (n=10), FAD (n=8), TREM2 SAD (n=3), TREM2 FAD (n=1), TREM2 
control (n=2) and controls (n=6)). RNA was evaluated for quality using an Eppendorf 
spectrometer and only accepted if A260/A280 value was >1.8 and A260/A230 value was 
>1.5. Samples were diluted to 50ng/µl and analysed by Nanostring Technologies, Seattle. 
Full protocol details can be found in 0. Data was analysed using nSolver software provided 
by Nanostring Technologies. Fold changes compared to controls were calculated for each 
AD subgroup. 
5.3.3. Proteomics 
To assess the protein expression in the samples, proteins were extracted from the frontal 
cortex from each case (SAD (n=7), FAD PSEN1 (n=8), FAD APP (n=3), TREM2 SAD (n=3), 
TREM2 FAD (n=6), TREM2 controls (n=2), controls (n=6)) pooled, digested, and analysed 
using a Synapt G2-Si High Definition mass spectrometer using 2D fractionation to perform 
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quantitative label-free mass spectrometry. These methods are described in detail in 2.7.2, 
2.7.3, 2.7.4, 2.7.5. Raw data was processed using Progenesis software, normalised and 
fold-change was calculated compared to controls for each AD subgroup. 
5.3.4. Bioinformatics 
Ingenuity Pathway Analysis (IPA) software was utilised to analyse the pathways and 
functions represented in both datasets. A comparison analysis for each dataset to compare 
AD subgroups was undertaken and a comparison for each subgroup across the different 
methods was done to assess the differences between genetic and proteomic profiles in 
these cases. Pathways and functions were predicted to be activated if they had a positive z-
score and were coloured orange. They were predicted to be inhibited if they had a negative 
z-score and were coloured blue. Red genes represent genes upregulated in the datasets 
and green genes represent downregulated. Further details about the IPA software can be 
found in 2.8. To assess the level of overlap between over-represented biological processes 
in the datasets, Webgestalt was used to identify the GO terms and GOview was used to 
determine those that overlapped.  
Nanostring (p<0.05) SAD FAD TREM2 FAD TREM2 SAD TREM2 Control 
Upregulated 124 91 33 22 10 
Downregulated 2 2 0 0 15 
Table 5.1: Number of significantly changing genes in nanostring dataset. The number 
of genes that were changing with a p value <0.05 are indicated for each disease group and 
split into those that were upregulated or downregulated compared to controls. 
5.4. Results 
5.4.1. Genetic expression in TREM2 variant cases 
The full set of 286 genes both from NanoString Technologies Human Inflammation panel 
and 30 targeted genes more specific to AD were successfully processed and analysed. A full 
table of results are available in the Appendix Table 3, showing the average counts, ratios 
and p-values for all genes.  
A total of 124 genes were upregulated significantly in SAD cases compared to controls at a 
significance level of p<0.05, of which 70 genes at p<0.01 and 24 genes at p<0.001 (Table 
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5.1, Table 5.2). Two genes were downregulated significantly in SAD, MRC1 (macrophage 
mannose receptor 1) and SNCA (alpha-synuclein) (p<0.05). 91 genes were significantly 
upregulated in FAD cases compared to controls at level of p<0.05, 22 genes at p<0.01 and 2 
genes, NFKB1 (nuclear factor NF-kappa-B p105 subunit) and TGFB2 (transforming growth 
factor beta-2) at p<0.001 (Table 5.1, Table 5.3). Two genes were downregulated significantly 
in FAD cases compared to controls, PIK3C2G (Phosphatidylinositol 4-phosphate 3-kinase 
C2 domain-containing subunit gamma) and SNCA (p<0.05). 22 genes were upregulated 
significantly in TREM2 variant SAD cases compared to healthy controls at a level of p<0.05 
(Table 5.1,Table 5.4). 11 genes were upregulated significantly and 14 genes were 
downregulated in TREM2 variant controls to healthy controls (p<0.05). 33 genes were 
upregulated in the TREM2 FAD variant compared to healthy controls (p<0.05). 
Several genes show significantly altered expression in only one group (Table 5.5). For 
example, genes such as APOE (apolipoprotein E) and PEN2 (Gamma-secretase subunit 
PEN-2), were only significantly upregulated in SAD compared to control but were not 
significant in any other groups. Similarly, CD68 (Macrosialin), IL6R (Interleukin-6 receptor 
subunit alpha) and TYROBP (TYRO protein tyrosine kinase-binding protein) were only 
significantly up regulated in FAD compared to control. TREM2 variant cases were the only 
group to have a significant upregulation of GRB2 (Growth factor receptor-bound protein 2).  
On the other hand, there were several genes that were significantly altered across all groups 
Table 5.6). These genes that demonstrated a more than 2-fold change in expression 
compared to controls across all three groups included HSPB2 (Heat shock protein beta-2), 
TGFB1 (Transforming growth factor beta-1), CSF1 (Macrophage colony-stimulating factor 1) 
and CXCR4 (C-X-C chemokine receptor type 4).  
Investigating the data using Ingenuity Pathway Analysis software, the top-scoring pathway 
was the neuroinflammatory signalling pathway. This was expected as the neuroinflammation 
panel was used. However, the pathway was predicted to be activated in SAD, FAD, TREM2 
variant SAD and TREM2 variant FAD but it was predicted to be inhibited in the TREM2 
variant controls when all cases were compared to controls (Figure 5.1). Figure 5.2 shows a 
diagram of this pathway and visualises the differences in gene expression across the  
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CCL2 C-C motif chemokine 2 3.53 0.0478 
IRF7 Interferon regulatory factor 7 3.26 0.0141 
MRC1 Macrophage mannose receptor 1 -3.08 0.0197 
MYL2 
Myosin regulatory light chain 2, ventricular/cardiac 
muscle isoform 
2.88 0.0051 
IRF1 Interferon regulatory factor 1 2.78 0.0292 
TGFB3 Transforming growth factor beta-3 2.77 0.0014 
HSPB1 Heat shock protein beta-1 2.68 0.0044 
NOX4 NADPH oxidase 4 2.58 0.0223 
TNF Tumor necrosis factor 2.57 0.004 
HSPB2 Heat shock protein beta-2 2.51 0.0008 
C4A Complement C4-A 2.47 0.0358 
TGFB1 Transforming growth factor beta-1 2.46 0.0024 
CSF1 Macrophage colony-stimulating factor 1 2.35 0.0053 
CXCR4 C-X-C chemokine receptor type 4 2.29 0.0307 
TNFSF14 Tumor necrosis factor ligand superfamily member 14 2.27 0.0117 
TSPO Translocator protein 2.20 0.0465 
PTGDR2 Prostaglandin D2 receptor 2 2.04 0.053 
TREM2 Triggering receptor expressed on myeloid cells 2 2.03 0.0139 
GFAP Glial fibrillary acidic protein 1.99 0.0132 
ELK1 ETS domain-containing protein Elk-1 1.98 0.0128 
OAS2 2'-5'-oligoadenylate synthase 2 1.96 0.0079 
IL23R Interleukin-23 receptor 1.96 0.0395 
MAPKAPK
2 
MAP kinase-activated protein kinase 2 1.95 0.0019 
RELA Transcription factor p65 1.95 0.0024 
CCL22 C-C motif chemokine 22 1.89 0.0121 
BCL6 B-cell lymphoma 6 protein 1.85 0.0226 
IL10 Interleukin-10 1.83 0.0225 
TRADD 
Tumor necrosis factor receptor type 1-associated 
DEATH domain protein 
1.80 0.0376 
CCL20 C-C motif chemokine 20 1.79 0.004 
CD40LG CD40 ligand 1.78 0.0015 
Table 5.2: Top 30 genes significantly changing in expression in SAD compared to 
control. Top 30 decided on greatest fold change of expression with a significance of p<0.05. 
(-) represents downregulated compared to control. 
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CXCR2 C-X-C chemokine receptor type 2 9.22 0.015 
HSPB1 Heat shock protein beta-1 5.74 0.0041 
CCL2 C-C motif chemokine 2 4.82 0.0288 
MAFF Transcription factor MafF 4.38 0.0059 
TLR8 Toll-like receptor 8 4.32 0.0403 
NOX4 NADPH oxidase 4 3.44 0.0269 
IRF1 Interferon regulatory factor 1 3.43 0.018 
PTGER4 Prostaglandin E2 receptor EP4 subtype 3.23 0.0313 
FOS Proto-oncogene c-Fos 3.17 0.0536 
IL1R1 Interleukin-1 receptor type 1 3.06 0.026 
IL10 Interleukin-10 3.05 0.0387 
TGFB1 Transforming growth factor beta-1 2.88 0.0141 
CSF1 Macrophage colony-stimulating factor 1 2.87 0.0123 
MASP1 Mannan-binding lectin serine protease 1 2.81 0.0363 
IL12A Interleukin-12 subunit alpha 2.72 0.0176 
HSPB2 Heat shock protein beta-2 2.69 0.009 
CXCR4 C-X-C chemokine receptor type 4 2.62 0.0442 
BCL6 B-cell lymphoma 6 protein 2.52 0.0096 
MAPKAPK2 MAP kinase-activated protein kinase 2 2.43 0.0054 
GFAP Glial fibrillary acidic protein 2.34 0.0119 
C4A Complement C4-A 2.32 0.0477 
MYD88 
Myeloid differentiation primary response protein 
MyD88 
2.29 0.021 
CEBPB CCAAT/enhancer-binding protein beta 2.27 0.0122 
SHC1 SHC-transforming protein 1 2.22 0.0073 
TGFB2 Transforming growth factor beta-2 2.20 0.0004 
TREM2 Triggering receptor expressed on myeloid cells 2 2.16 0.0081 
RELA Transcription factor p65 2.12 0.0023 
CCL8 C-C motif chemokine 8 2.09 0.0474 
DDIT3 DNA damage-inducible transcript 3 protein 2.06 0.0085 
NFE2L2 Nuclear factor erythroid 2-related factor 2 2.03 0.0014 
Table 5.3: Top 30 genes significantly changing in expression in FAD compared to 
control. Top 30 decided on greatest fold change of expression with a significance of p<0.05. 
(-) represents downregulated compared to control. 
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KLK6 Kallikrein-6 3.26 0.0496 
MASP2 Mannan-binding lectin serine protease 2 3.01 0.017 
CSF1 Macrophage colony-stimulating factor 1 2.73 0.0213 
TGFB1 Transforming growth factor beta-1 2.67 0.041 
TNFSF14 
Tumor necrosis factor ligand superfamily member 
14 
2.62 0.0145 
HSPB2 Heat shock protein beta-2 2.55 0.0129 
TSPO Translocator protein 2.42 0.0543 
RELA Transcription factor p65 2.39 0.0059 
MAPKAPK2 MAP kinase-activated protein kinase 2 2.34 0.0223 
CXCR4 C-X-C chemokine receptor type 4 2.28 0.0419 
TGFB3 Transforming growth factor beta-3 2.13 0.0317 
BCL6 B-cell lymphoma 6 protein 2.03 0.0542 
NFKB1 Nuclear factor NF-kappa-B p105 subunit 2.02 0.0156 
IL17A Interleukin-17A 1.98 0.0388 
C6 Complement component C6 1.94 0.0205 
KEAP1 Kelch-like ECH-associated protein 1 1.84 0.0173 
STAT3 Signal transducer and activator of transcription 3 1.79 0.0501 
RHOA Transforming protein RhoA 1.78 0.0029 
TRADD 
Tumor necrosis factor receptor type 1-associated 
DEATH domain protein 
1.78 0.0411 
MAFK Transcription factor MafK 1.74 0.0537 
NFE2L2 Nuclear factor erythroid 2-related factor 2 1.70 0.0135 
CTSD Cathepsin D 1.70 0.0162 
IRF3 Interferon regulatory factor 3 1.69 0.018 
IL12B Interleukin-12 subunit beta 1.69 0.0549 
HDAC4 Histone deacetylase 4 1.68 0.0308 
DAXX Death domain-associated protein 6 1.67 0.0147 
CCL20 C-C motif chemokine 20 1.67 0.0272 
SMAD7 Mothers against decapentaplegic homolog 7 1.66 0.0214 
P2RX7 P2X purinoceptor 7 1.64 0.0072 
CD55 Complement decay-accelerating factor 1.64 0.0089 
Table 5.4: Top 30 genes significantly changing in expression in TREM2 variant cases 
compared to controls. Top 30 decided on greatest fold change of expression with a 
significance of p<0.05. (-) represents downregulated compared to control. 
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Only significantly changing in SAD 
  
IRF7 Interferon regulatory factor 7 3.26 0.0141 
IL23R Interleukin-23 receptor 1.96 0.0395 
OAS2 2'-5'-oligoadenylate synthase 2 1.96 0.0079 
CCL22 C-C motif chemokine 22 1.89 0.0121 
C3AR1 C3a anaphylatoxin chemotactic receptor 1.74 0.0472 
APOE Apolipoprotein E 1.72 0.005 
AGER Advanced glycosylation end product-specific receptor 1.70 0.0069 
FASLG Tumor necrosis factor ligand superfamily member 6 1.70 0.0012 
FXYD2 Sodium/potassium-transporting ATPase subunit gamma 1.64 0.0056 
IRF5 Interferon regulatory factor 5 1.63 0.04 
TGFBR1 TGF-beta receptor type-1 1.62 0.0144 
C8A Complement component C8 alpha chain 1.60 0.0008 
PTGS1 Prostaglandin G/H synthase 1 1.59 0.0411 
CRP C-reactive protein 1.57 0.0298 
PTGIR Prostacyclin receptor 1.55 0.0493 
CCL17 C-C motif chemokine 17 1.51 0.0033 
HMGN1 Non-histone chromosomal protein HMG-14 1.39 0.0165 
TCF4 Transcription factor 4 1.35 0.0053 
HIF1A Hypoxia-inducible factor 1-alpha 1.33 0.0421 
PTK2 Focal adhesion kinase 1 1.32 0.0027 
GNAQ Guanine nucleotide-binding protein G(q) subunit alpha 1.30 0.0008 
IL9 Interleukin-9 1.30 0.0474 
PEN2 Gamma-secretase subunit PEN-2 1.30 0.0537 
MAFG Transcription factor MafG 1.26 0.0248 
MAP2K6 Dual specificity mitogen-activated protein kinase kinase 6 1.24 0.0086 
    
Only significantly changing in FAD 
  
HSPB1 Heat shock protein beta-1 5.74 0.0041 
MAFF Transcription factor MafF 4.38 0.0059 
FOS Proto-oncogene c-Fos 3.17 0.0536 
MYD88 Myeloid differentiation primary response protein MyD88 2.29 0.021 
MYC Myc proto-oncogene protein 2.00 0.0414 
CD68 Macrosialin 1.90 0.0182 
TYROBP TYRO protein tyrosine kinase-binding protein 1.87 0.0371 
IL6R Interleukin-6 receptor subunit alpha 1.77 0.0465 
    
Only significantly changing in TREM2 
  
GRB2 Growth factor receptor-bound protein 2 1.35 0.0225 
Table 5.5: Genes only significantly changing in either SAD, FAD or TREM2 variant 
cases compared to controls. 
Chapter 5 – The genetic and proteomic profiles of TREM2 variant cases 


















HSPB2 Heat shock protein beta-2 2.51 0.0008 2.69 0.009 2.55 0.0129 
MAP3K1 Mitogen-activated protein kinase kinase kinase 1 1.40 0.0025 1.70 0.0162 1.54 0.0321 
ADAM10 
Disintegrin and metalloproteinase domain-containing 
protein 10 
1.42 0.0005 1.32 0.0056 1.52 0.0129 
CYSLTR2 Cysteinyl leukotriene receptor 2 1.61 0.0021 1.65 0.0269 1.41 0.0511 
MAX Protein max 1.40 0.0035 1.49 0.0172 1.55 0.0284 
MEF2A Myocyte-specific enhancer factor 2A 1.33 0.0002 1.32 0.0105 1.28 0.0256 
NFATC3 Nuclear factor of activated T-cells, cytoplasmic 3 1.62 0.0005 1.84 0.0018 1.56 0.0172 
RAF1 RAF proto-oncogene serine/threonine-protein kinase 1.42 0.0046 1.60 0.0027 1.63 0.003 
BIRC2 Baculoviral IAP repeat-containing protein 2 1.20 0.0201 1.27 0.0046 1.33 0.0061 
DDIT3 DNA damage-inducible transcript 3 protein 1.32 0.017 2.06 0.0085 1.55 0.0135 
NFKB1 Nuclear factor NF-kappa-B p105 subunit 1.67 0.006 1.84 0.0004 2.02 0.0156 
TGFB3 Transforming growth factor beta-3 2.77 0.0014 1.89 0.0411 2.13 0.0317 
BCL6 B-cell lymphoma 6 protein 1.85 0.0226 2.52 0.0096 2.03 0.0542 
C5 Complement C5 1.66 0.0127 1.58 0.0185 1.46 0.0382 




1.29 0.0434 1.37 0.0078 1.38 0.0444 
CREB1 Cyclic AMP-responsive element-binding protein 1 1.38 0.0072 1.38 0.0236 1.39 0.0192 
CSF1 Macrophage colony-stimulating factor 1 2.35 0.0053 2.87 0.0123 2.73 0.0213 
CXCR4 C-X-C chemokine receptor type 4 2.29 0.0307 2.62 0.0442 2.28 0.0419 
DAXX Death domain-associated protein 6 1.62 0.0008 1.61 0.0205 1.67 0.0147 
HDAC4 Histone deacetylase 4 1.56 0.0095 1.61 0.0541 1.68 0.0308 
HMGB1 High mobility group protein B1 1.21 0.0131 1.16 0.0429 1.29 0.0186 
IRF3 Interferon regulatory factor 3 1.57 0.0093 1.84 0.0092 1.69 0.018 
MAP3K7 Mitogen-activated protein kinase kinase kinase 7 1.19 0.0033 1.21 0.026 1.25 0.0004 
MAPKAPK2 MAP kinase-activated protein kinase 2 1.95 0.0019 2.43 0.0054 2.34 0.0223 
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MAPKAPK5 MAP kinase-activated protein kinase 5 1.50 0.0006 1.40 0.0375 1.45 0.0307 
NFE2L2 Nuclear factor erythroid 2-related factor 2 1.44 0.0257 2.03 0.0014 1.70 0.0135 
PDGFA Platelet-derived growth factor subunit A 1.39 0.0103 1.61 0.0057 1.50 0.0146 
RAC1 Ras-related C3 botulinum toxin substrate 1 1.17 0.0239 1.23 0.0235 1.30 0.0025 
RELA Transcription factor p65 1.95 0.0024 2.12 0.0023 2.39 0.0059 
RIPK1 Receptor-interacting serine/threonine-protein kinase 1 1.46 0.0164 1.53 0.0402 1.57 0.0349 
SMAD7 Mothers against decapentaplegic homolog 7 1.59 0.002 2.01 0.0036 1.66 0.0214 
SNCA Alpha-synuclein -1.18 0.0309 -1.63 0.0262 -1.44 0.0032 
STAT3 Signal transducer and activator of transcription 3 1.54 0.0289 2.02 0.0177 1.79 0.0501 
TGFB1 Transforming growth factor beta-1 2.46 0.0024 2.88 0.0141 2.67 0.041 
TRAF2 TNF receptor-associated factor 2 1.45 0.0146 1.90 0.0197 1.55 0.029 
Table 5.6: Genes that are significantly changing in all disease groups compared to control. (-) represents downregulated compared to control. 
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different disease groups. Both the SAD and TREM2 SAD diagrams show predominant red 
genes, indicating large amounts of upregulation in neuroinflammatory genes, as also 
indicated by the highest changing genes in Table 5.2 (Figure 5.2a and b). The TREM2 
variant control diagram however, shows predominantly green genes, indicating large levels 
of downregulation in neuroinflammatory genes. This pattern also followed suit throughout the 
rest of the canonical pathways visualised in the heatmap (Figure 5.1), indicating that 
although the TREM2 variant controls have the same variant in TREM2, they have an altered 
inflammatory gene expression profile when compared to controls. The APOE genotype in the 
TREM2 variant controls do not include any ApoE4 alleles whereas the TREM2 SAD cases 
all contain an ApoE4 allele. Therefore, this could be one factor explaining this difference.  
The next canonical pathways that scored highest indicate which out of the many 
inflammatory pathways are the most activated or inhibited. These include TREM1-signalling, 
role of pattern recognition receptors (Figure 5.3), NF-κB signalling and p38 MAPK signalling 
pathways (Figure 5.1). The individual pathway gene expression heat maps for these can be 
found in Appendix Figure 2, 3, 4. In all four pathways, TREM2 SAD cases have an increased 
level of upregulation compared to SAD cases when both groups are compared to normal 
controls. This may indicate that TREM2 variant cases have a more severe inflammatory 
phenotype than SAD cases. However, no significant differences between these TREM2 
variant SAD cases and SAD cases in age of onset or disease duration are observed.  
Assessing the most represented bio functions that were scored by IPA analysis revealed that 
the top diseases and functions changing were migration of cells, cell movement, cell 
movement of tumour cell lines, leukocyte migration and cell movement of leukocytes 
indicating that activating the genes involved in the migration of cells may be involved in the 
disease pathogenesis (Figure 5.1b). Again, the TREM2 variant controls had a predicted 
inhibition for all of these functions listed, whereas all other groups were predicted to be 
activated. 
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Figure 5.1: Top pathways and functions represented in nanostring data. (a) List of 
top 30 canonical pathways in nanostring data listed according to the z-score given by 
IPA software. (b) List of top diseases and functions represented in nanostring data 
according to z-score given by IPA software. Orange represents a predicted activation of 
the pathway and blue represents a predicted inhibition of the pathway based on 
expression values found in the data. Intensity of colour relates to how activated or 
inhibited the pathway is predicted to be.  
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Figure 5.2: Diagram depicting neuroinflammation signalling pathways. (a) Gene 
expression for SAD overlaid on pathway, (b) gene expression for TREM2 variant SAD cases 
overlaid on pathway and (c) gene expression for TREM2 variant control cases overlaid on 
pathway. Red genes are upregulated in dataset and green genes are downregulated. 
Intensity of colour shows level of up- or down-regulation with greater intensity meaning 
higher expression changes. Details of the pathway are difficult to see but overall difference 
of up- and downregulation of genes between disease groups is evident.  
 
5.4.2. Proteomic expression in the frontal cortex of TREM2 variant cases 
To determine if the genetic expression changes also occur at the translational level, label-
free mass spectrometry was performed to determine changes in protein expression. A total 
of 6012 proteins were detected in the soluble supernatant fraction and 5571 in the insoluble 
pellet fraction. Proteins were either detected in both the soluble and insoluble fraction (3269 
proteins) or they were unique to the soluble fraction (2743 proteins) or insoluble fraction 
(2302 proteins). Most proteomic studies only look at the soluble fraction. However, assessing 
the proteins that are normally insoluble allows for the detection of proteins that precipate in 
vivo and may be involved in pathological inclusions. Only proteins that were changing >1.5 
fold compared to controls were considered as changing in analysis. Both the up- and down- 
regulation of proteins were observed in every disease group when compared to controls, 
with the TREM2 FAD group  having the highest number of proteins changing in both 
directions and the least changing in the SAD group (Table 5.7).  
The largest changes in protein expression according to fold change are listed for each 
disease group, the highest 20 upregulated, and the 20 most downregulated proteins are 
shown. A full list of all proteins detected can be found on Supplementary CD Table 1.  
Table 5.7: Number of proteins changing in expression in mass spectrometry dataset. 
The number of proteins that were changing with greater than 1.5 fold change compared to 
















Upregulated 195 325 363 651 361 430 
Downregulated 158 349 289 555 235 419 
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a 
Figure continued on next page 
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Figure continued on next page 
Figure continued on next page 
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Figure 5.3: Diagram depicting role of pattern recognition receptor pathways. (a) Gene expression for SAD overlaid on pathway, (b) gene expression for 
TREM2 variant SAD cases overlaid on pathway and (c) gene expression for TREM2 variant control cases overlaid on pathway. Red genes are upregulated in 
dataset and green genes are downregulated. Intensity of colour shows level of up- or down-regulation with greater intensity meaning higher expression 
changes 
c 
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These proteins identified in this study demonstrating the largest changes in expression have 
already been linked to AD in other studies. For SAD (Table 5.8), the highest upregulated 
protein was KRT6A (Keratin, type II cytoskeletal 6A) at a level of 25.3-fold increase in the 
insoluble fraction. KRT6A is a cytoskeletal protein and a number of cytoskeletal proteins 
have been identified previously to be present with Aβ plaques (Liao et al., 2004). DSC1 
(Desmocollin-1) was found to be upregulated 8.5-fold in the insoluble fraction compared to 
controls and is associated with the adrenergic signalling system (Ramos et al., 2006). A 
polymorphism of this gene has been found in AD cases, linking the adrenergic signalling 
pathway to AD (Ramos et al., 2006). COL25A1 (Collagen alpha-1(XXV) chain) was 
upregulated 7.9-fold in the insoluble fraction and has been identified previously to provide 
increased risk of AD in a Swedish population (Forsell et al., 2010). It has also been shown to 
bind to amyloid fibrils and facilitate the formation of plaques by increasing the protease 
resistance of the Aβ (Tong et al., 2010). CRTC1 (CREB-regulated transcription coactivator 1) 
is upregulated 6.1-fold in the insoluble fraction and has been linked to memory function 
transcription in AD, with reports that it is differentially methylated in the AD hippocampus 
(Mendioroz et al., 2016; Parra-Damas et al., 2014; Saura, 2012). C4A (Complement C4-A) is 
upregulated 4.3-fold in the insoluble fraction and has also been observed to increase in other 
blood and brain proteomic studies (Khan et al., 2016). VGF, a neurosecretory protein, is 
downregulated 4.3-fold in the soluble fraction compared to controls and has already been 
identified as a CSF biomarker for AD (Busse et al., 2015; Hendrickson et al., 2015; Spellman 
et al., 2015). Additionally, it has been shown to have decreased levels in AD using 
immunohistochemistry (Cocco et al., 2010). KPNA6 (Importin subunit alpha-7) is 
downregulated 2.5-fold in the insoluble fraction and has also been shown to be decreased in 
another RNA sequencing study on AD (Roy et al., 2017). SYNPO (Synaptopodin) is 
downregulated 2.4-fold in the insoluble fraction and is involved in synaptic transmission. It 
has been shown to be downregulated in Parkinson’s with dementia and Dementia with lewy 
bodies (Datta et al., 2017). PRIM1 (DNA primase small subunit) is downregulated 2.3-fold in 
the insoluble fraction and is involved in proliferation and cell cycle. It has been shown to be 
downregulated in a Down’s syndrome mouse model (Hewitt et al., 2010). 
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compared to control 
KRT6A Keratin, type II cytoskeletal 6A 25.32 
KRT6C Keratin, type II cytoskeletal 6C 8.93 
DSC1 Desmocollin-1 8.47 
COL25A1 Collagen alpha-1(XXV) chain 7.94 
KRT5 Keratin, type II cytoskeletal 5 6.57 
KRT16 Keratin, type I cytoskeletal 16 6.50 
CRTC1 CREB-regulated transcription coactivator 1 6.07 
APOE Apolipoprotein E 6.01 
KRT17 Keratin, type I cytoskeletal 17 5.40 
MAPT Microtubule-associated protein 4.49 
C4A Complement C4-A 4.29 
IRF2BP1 Interferon regulatory factor 2-binding protein 1 3.78 
OBSCN Obscurin 3.37 
QARS Glutamine--tRNA ligase 3.35 
COL9A2 Collagen alpha-2(IX) chain 3.29 
KRT1 Keratin, type II cytoskeletal 1 3.13 
ASAP2 
Arf-GAP with SH3 domain, ANK repeat and PH domain-
containing protein 2 
3.10 
UBN1 Ubinuclein-1 3.08 
ARFGEF1 Brefeldin A-inhibited guanine nucleotide-exchange protein 1 3.03 
DCTN2 Dynactin subunit 2 2.96 





compared to control 
ASAP3 
Arf-GAP with SH3 domain, ANK repeat and PH domain-
containing protein 3 
-7.45 
VGF Neurosecretory protein VGF -4.32 
TBC1D8B TBC1 domain family member 8B -4.16 
SCG2 Secretogranin-2 -3.16 
USP4 Ubiquitin carboxyl-terminal hydrolase 4 -2.91 
VPS51 Vacuolar protein sorting-associated protein 51 homolog -2.80 
HIST1H1E Histone H1.4 -2.55 
KPNA6 Importin subunit alpha-7 -2.52 
TCEAL3 Transcription elongation factor A protein-like 3 -2.48 
TPM2 Tropomyosin beta chain -2.47 
FARSA Phenylalanine--tRNA ligase alpha subunit -2.44 
SYNPO Synaptopodin -2.43 
ALDH3A2 Fatty aldehyde dehydrogenase -2.40 
IRF2BP2 Interferon regulatory factor 2-binding protein 2 -2.38 
TNRC18 Trinucleotide repeat-containing gene 18 protein -2.35 
TAGLN Transgelin -2.31 
PRIM1 DNA primase small subunit -2.30 
KSR1 Kinase suppressor of Ras 1 -2.29 
SENP6 Sentrin-specific protease 6 -2.21 
SLC12A7 Solute carrier family 12 member 7 -2.20 
Table 5.8: Top 20 up- and down- regulated proteins changing in expression in SAD 
compared to controls. Italics represent proteins that were in the insoluble fraction. 
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In FAD (PSEN1 Table 5.9, APP Table 5.10), CTGF (Connective tissue growth factor) is 
upregulated 4-fold in the insoluble fractions in PSEN1 variants. Its levels were shown to 
correlate with neuritic plaques and it is thought to increase Aβ production but increase Aβ 
degradation within glial cells (Yang et al., 2017a; Zhao et al., 2005). GRIA2 (Glutamate 
receptor 2) is upregulated in APP cases 5.3-fold in the insoluble fraction and this protein has 
been shown to differ in expression according to APOE genotype (Conejero-Goldberg et al., 
2011). COL25A1 is upregulated in APP variant cases at 4.8-fold in the insoluble fraction so a 
further increase is seen in SAD cases. CRABP1 (Cellular retinoic acid-binding protein 1) is 
upregulated 4.6-fold in the insoluble fraction in APP cases and this has been shown 
previously to be upregulated in cells with increased Aβ42/Aβ40 ratio (Uhrig et al., 2008). 
C4B (Complement C4-B) is upregulated 3.3-fold in the insoluble fraction in APP cases and 
has previously been identified to increase in an AD CSF proteomic study (Finehout et al., 
2005). CRK, an adaptor molecule, is upregulated 3.2-fold in the insoluble fraction in APP 
cases and is involved in regulating APP processing. BGN (Biglycan) is downregulated in 
PSEN1 cases 2.7-fold in the soluble fraction but was found to be upregulated in FAD 
fibroblasts (Bellucci et al., 2007). It is a proteoglycan that has been found with Aβ plaque 
cores and alters APP splicing (Bjelik et al., 2007). EPC2 (Enhancer of polycomb homolog 2) 
is downregulated in APP cases 3.3-fold in the soluble fraction and is associated with AD 
CSF biomarkers (Kim et al., 2011) GAP43 (Neuromodulin) is downregulated 2.9-fold in the 
insoluble fraction in APP cases and is thought to be involved with the sprouting response 
seen in AD (Masliah et al., 1992). GAP43 levels have been reported to decline as synaptic 
degeneration occurs  (Bogdanovic et al., 2000; de la Monte et al., 1995).  
In TREM2 variant SAD cases (Table 5.11), the highest upregulated protein observed was 
GOLGA8R (Golgin subfamily A member 8R) at a level of 60.8-fold in the insoluble fraction 
and is a part of the golgi apparatus. C4A is also upregulated 6.8-fold in the insoluble fraction 
compared to controls, similarly to SAD cases. ANXA2 (annexin A2) is upregulated 4.4-fold in 
the insoluble fraction and has been found to interact with tau and play a role in inflammation 
(Gauthier-Kemper et al., 2011; Pineda et al., 2012). 
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Fold change compared to 
control 
SEC31A Protein transport protein Sec31A  9.26 
APOE Apolipoprotein E  7.40 
MRPL46 39S ribosomal protein L46, mitochondrial  6.76 
RAB5C Ras-related protein Rab-5C  6.72 
TMC6 Transmembrane channel-like protein 6  6.38 
NDUFA7 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 7  
5.84 
JAKMIP3 Janus kinase and microtubule-interacting protein 3  5.61 
BRAF Serine/threonine-protein kinase B-raf  4.89 
MPI Mannose-6-phosphate isomerase  4.70 
FAF2 FAS-associated factor 2  4.64 
APOL2 Apolipoprotein L2  4.54 
NONO Non-POU domain-containing octamer-binding protein  4.35 
USP15 Ubiquitin carboxyl-terminal hydrolase 15  4.19 
PPEF2 Serine/threonine-protein phosphatase with EF-hands 2  4.16 
RIC8A Synembryn-A  4.15 
CTGF Connective tissue growth factor  3.95 
FAM169A Soluble lamin-associated protein of 75 kDa  3.91 
GMPR GMP reductase 1  3.73 
HIP1 Huntingtin-interacting protein 1  3.67 
DNPEP Aspartyl aminopeptidase 3.57 




Fold change compared to 
control 
ARMC9 LisH domain-containing protein ARMC9  -5.88 
WNK2 Serine/threonine-protein kinase WNK2  -5.32 
SPIRE1 Protein spire homolog 1  -4.94 
SLFN11 Schlafen family member 11  -4.82 
APC2 Adenomatous polyposis coli protein 2  -4.50 
CAMSAP1 Calmodulin-regulated spectrin-associated protein 1  -3.98 
TPM2 Tropomyosin beta chain  -3.78 
ARID4A AT-rich interactive domain-containing protein 4A  -3.31 
SNW1 SNW domain-containing protein 1  -3.16 
GDA Guanine deaminase  -2.99 
CELSR1 Cadherin EGF LAG seven-pass G-type receptor 1  -2.95 
ARHGEF9 Rho guanine nucleotide exchange factor 9  -2.89 
TNIK TRAF2 and NCK-interacting protein kinase  -2.82 
TAGLN Transgelin  -2.81 
CNN1 Calponin-1  -2.74 
LSM14B Protein LSM14 homolog B  -2.73 
BGN Biglycan  -2.72 
MYH13 Myosin-13  -2.71 
CASKIN1 Caskin-1  -2.67 
IGHG2 Ig gamma-2 chain C region  -2.67 
Table 5.9: Top 20 up- and down- regulated proteins changing in expression in FAD 
PSEN1 compared to controls. Italics represent proteins that were in the insoluble fraction. 
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Table 5.10: Top 20 up- and down- regulated proteins changing in expression in FAD 




Fold change compared 
to control 
APOE Apolipoprotein E 6.97 
GRIA2 Glutamate receptor 2 5.28 
COL25A1 Collagen alpha-1(XXV) chain 4.76 
CRABP1 Cellular retinoic acid-binding protein 1 4.56 
MAPT Microtubule-associated protein 4.53 
CTNND1 Catenin delta-1 4.42 
SH3GL1 Endophilin-A2 3.60 
DCTN2 Dynactin subunit 2 3.57 
C4B Complement C4-B 3.28 
RBP1 Retinol-binding protein 1 3.28 
LTN1 E3 ubiquitin-protein ligase listerin 3.20 
CRK Adapter molecule crk 3.15 
SH3GL2 Endophilin-A1 3.13 
DNAH10 Dynein heavy chain 10, axonemal 2.98 
EPN3 Epsin-3 2.86 





GSTM2 Glutathione S-transferase Mu 2 2.82 
PDP1 
[Pyruvate dehydrogenase [acetyl-transferring]]-
phosphatase 1, mitochondrial 
2.81 
GPSM2 G-protein-signaling modulator 2 2.81 




Fold change compared 
to control 
CXXC1 CXXC finger 1 (PHD domain), isoform CRA_c -4.39 
MPDZ Multiple PDZ domain protein -4.22 
ASAP3 
Arf-GAP with SH3 domain, ANK repeat and PH domain-




Calmodulin-regulated spectrin-associated protein 1 -3.80 
DEPDC4 DEP domain-containing protein 4 -3.28 
EPC2 Enhancer of polycomb homolog 2 -3.26 
HSP90AB
2P 
Putative heat shock protein HSP 90-beta 2 -3.25 
SLC17A7 Vesicular glutamate transporter 1 -3.12 
SEC16A Protein transport protein Sec16A -3.11 
AVPR1B Vasopressin V1b receptor -3.06 
FAM71F1 Protein FAM71F1 -2.85 
GAP43 Neuromodulin -2.85 
NKTR NK-tumor recognition protein -2.84 
ARFGEF
3 
Brefeldin A-inhibited guanine nucleotide-exchange protein 
3 
-2.81 
CA1 Carbonic anhydrase 1 -2.73 
PRPH Peripherin -2.72 
SIRPA 





Histone H1.4 -2.59 
CADM3 Cell adhesion molecule 3 -2.58 
EPB42 Erythrocyte membrane protein band 4.2 -2.56 
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This could demonstrate a difference between normal SAD and TREM2 variant SAD. GRIA2 
is upregulated 4.09-fold in the insoluble fraction, similarly to the FAD APP cases and EPC2 
is also downregulated 2.64-fold in the soluble fraction, similar to FAD APP cases. The 
protein which demonstrated the most marked downregulation in these cases was CCNG1 
(Cyclin-G1) at a level of 18.9-fold in the soluble fraction. It may be involved in the inhibition of 
cell proliferation and is associated with DNA damage. PXN (Paxillin) is downregulated 2.7-
fold in the insoluble fraction and has been found to be a hub gene involved in age-related 
networks (Liang et al., 2012).  
The TREM2 variant FAD case (Table 5.12) had a different profile to the TREM2 variant SAD 
cases. The highest upregulated protein is CRYZL1 (Quinone oxidoreductase-like protein 1) 
at 14.5-fold in the soluble fraction but not much is known about this protein at present. AHSG 
(Alpha-2-HS-glycoprotein) is upregulated 7.1-fold in the soluble fraction in this case and has 
been found to have a polymorphism in the gene associated with late onset AD in Italians 
(Geroldi et al., 2005). It has also been found to be downregulated in AD CSF. SERPINA3 
(Alpha-1-antichymotrypsin) is upregulated 5.8-fold in the insoluble fraction and a 
polymorphism in this gene has been shown to effect age of onset and disease duration of 
AD (Kamboh et al., 2006). HBG2 (Haemoglobin subunit gamma-2) is upregulated 5.6-fold in 
the soluble fraction and a SNP association suggests it has a role in AD. Haemoglobin is also 
thought to bind to Aβ (Perry et al., 2008). The highest two downregulated proteins are 
XRCC5 (X-ray repair cross-complementing protein 5) at 99.3-fold in the soluble fraction and 
SCFD1 (Sec1 family domain-containing protein 1) at 27.3-fold in the soluble fraction. XCCR5 
is a DNA repair protein and it has been shown to protect against oxidative stress damage 
associated with copper levels (Du et al., 2011).  As TREM2 variant SAD cases have altered 
CCNG1 that is involved with DNA damage and the TREM2 variant FAD case has altered 
XCCR5, involved with DNA repair, DNA regulation may be important in these variants. 
SCFD1 is involved in the transport of proteins between the endoplasmic reticulum and the 
golgi apparatus and it has been suggested as a risk factor for ALS (van Rheenen et al., 
2016). VGF was found to be downregulated 8.7-fold in the soluble fraction in this case, 
similarly to SAD cases. COL4A1 (Collagen alpha-1(IV) chain) is upregulated 4.9-fold in the 
soluble fraction and is known to provoke an inflammatory reaction (Marchesi, 2016). 
Chapter 5 – The genetic and proteomic profiles of TREM2 variant cases 




Table 5.11: Top 20 up- and down- regulated proteins changing in expression in TREM2 








Fold change compared 
to control 
GOLGA8R Golgin subfamily A member 8R 60.79 
APOE Apolipoprotein E 7.77 
MAPT Microtubule-associated protein 7.74 
ECT2 Protein ECT2 7.14 
IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 7.11 
C4A Complement C4-A 6.83 
FHAD1 Forkhead-associated domain-containing protein 1 6.27 
SPG7 Paraplegin 6.21 
PHF5A PHD finger-like domain-containing protein 5A 5.04 
CPSF7 Cleavage and polyadenylation-specificity factor subunit 7 4.80 
RIC8A Synembryn-A 4.58 
ANXA2 Annexin A2 4.41 
STXBP6 Syntaxin-binding protein 6 4.41 
HIST1H4A Histone H4 4.23 
ZBTB38 Zinc finger and BTB domain-containing protein 38 4.21 
SQSTM1 Sequestosome-1 4.16 
GRIA2 Glutamate receptor 2 4.09 
RBM25 RNA-binding protein 25 3.98 
APP Amyloid beta A4 protein 3.91 
PSMC4 26S protease regulatory subunit 6B 3.85 




Fold change compared 
to control 
CCNG1 Cyclin-G1 -18.89 
ASAP3 
Arf-GAP with SH3 domain, ANK repeat and PH domain-
containing protein 3 
-12.19 
GPATCH2 G patch domain-containing protein 2 -8.72 
KSR1 Kinase suppressor of Ras 1 -4.69 
EPB42 Erythrocyte membrane protein band 4.2 -4.30 
ZEB2 Zinc finger E-box-binding homeobox 2 -4.22 
SRRM2 Serine/arginine repetitive matrix protein 2 -3.66 
FBF1 Fas-binding factor 1 -3.53 
ASNS Asparagine synthetase [glutamine-hydrolyzing] -3.45 
SI Sucrase-isomaltase, intestinal -3.27 
CCDC51 Coiled-coil domain-containing protein 51 -3.10 
TAGLN Transgelin -2.89 
NUCKS1 
Nuclear ubiquitous casein and cyclin-dependent kinase 
substrate 1 
-2.84 
CIRBP Cold-inducible RNA-binding protein -2.76 
HNRNPUL1 Heterogeneous nuclear ribonucleoprotein U-like protein 1 -2.69 
PXN Paxillin -2.67 
C2CD3 C2 domain-containing protein 3 -2.65 
EPC2 Enhancer of polycomb homolog 2 -2.64 
PITPNM3 
Membrane-associated phosphatidylinositol transfer 
protein 3 
-2.60 
WNK2 Serine/threonine-protein kinase WNK2 -2.60 
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CRYZL1 Quinone oxidoreductase-like protein 1 14.54 
PEX19 Peroxisomal biogenesis factor 19 7.14 
AHSG Alpha-2-HS-glycoprotein 7.08 
IRF2BP2 Interferon regulatory factor 2-binding protein 2 6.40 
SERPINA3 Alpha-1-antichymotrypsin 5.79 
ARFGEF1 Brefeldin A-inhibited guanine nucleotide-exchange protein 1 5.66 
HBG2 Hemoglobin subunit gamma-2 5.59 
THAP4 THAP domain-containing protein 4 5.38 
APOE Apolipoprotein E 5.23 
TXNDC17 Thioredoxin domain-containing protein 17 4.91 
SHMT2 Serine hydroxymethyltransferase, mitochondrial 4.87 
COL4A1 Collagen alpha-1(IV) chain 4.85 
RGS3 Regulator of G-protein signaling 3 4.85 
NAAA N-acylethanolamine-hydrolyzing acid amidase 4.79 
CCAR2 Cell cycle and apoptosis regulator protein 2 4.60 
COL9A2 Collagen alpha-2(IX) chain 4.56 
RPS4X 40S ribosomal protein S4, X isoform 4.47 
KCNIP4 Kv channel-interacting protein 4 4.47 
IQSEC2 IQ motif and SEC7 domain-containing protein 2 4.45 
FEZ1 Fasciculation and elongation protein zeta-1 4.35 







XRCC5 X-ray repair cross-complementing protein 5 -99.33 
SCFD1 Sec1 family domain-containing protein 1 -27.33 
HIST1H1E Histone H1.4 -8.71 
ASAP3 
Arf-GAP with SH3 domain, ANK repeat and PH domain-
containing protein 3 
-8.70 
VGF Neurosecretory protein VGF -8.66 
RB1CC1 RB1-inducible coiled-coil protein 1 -8.14 
ADAM11 
Disintegrin and metalloproteinase domain-containing protein 
11 
-7.70 
ZNF852 Zinc finger protein 852 -5.58 
TBC1D8B TBC1 domain family member 8B -5.35 
CORO1A Coronin-1A -4.94 
ADGRB2 Adhesion G protein-coupled receptor B2 -4.86 
PPFIA4 Liprin-alpha-4 -4.63 
HTRA1 Serine protease HTRA1 -4.50 
STXBP1 Syntaxin-binding protein 1 -4.19 
CDH13 Cadherin-13 -4.13 
HDGFRP3 Hepatoma-derived growth factor-related protein 3 -3.97 
WDFY1 WD repeat and FYVE domain-containing protein 1 -3.93 
SLC17A7 Vesicular glutamate transporter 1 -3.85 
NCKIPSD NCK-interacting protein with SH3 domain -3.82 
PPIL2 Peptidyl-prolyl cis-trans isomerase-like 2 -3.76 
Table 5.12: Top 20 up- and down- regulated proteins changing in expression in TREM2 
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KCNIP4 (Kv channel-interacting protein 4) is upregulated 4.8-fold in the soluble fraction and 
is known to cause increased Aβ42 via affecting γ-secretase activity (Massone et al., 2011). 
RB1CC1 (RB1-inducible coiled-coil protein 1) is downregulated 8.1-fold in the soluble 
fraction and is thought to have a role in AD as insufficiency of this protein causes neuronal 
atrophy to occur (Chano et al., 2007). HTRA1, a serine protease, is downregulated 4.5-fold 
in the soluble fraction and is involved with Aβ and tau clearance. It can degrade APP and 
cleave tau, as well as selectively degrading ApoE4 more efficiently than ApoE3 (Chu et al., 
2016; Grau et al., 2005; Tennstaedt et al., 2012). PPIL2 (Peptidyl-prolyl cis-trans isomerase-
like 2) is downregulated 3.8-fold in the soluble fraction in this case and was found to regulate 
BACE-1 activity in a cell-based assay (Beyer et al., 2014).  
TREM2 variant controls (Table 5.13) only share one protein in the highest 20 proteins 
demonstrating changes in expression with the TREM2 SAD group. PXN is downregulated 
6.3-fold in the insoluble fraction compared to normal controls. The highest upregulated 
protein observed in the TREM2 controls is PSMB7 (Proteasome subunit beta type-7) at 13.1-
fold in the soluble fraction. Downregulation of this protein has shown inhibited cell 
proliferation in AD (Wu et al., 2016). An opposite effect here may be an indication of a 
mechanism that is involved in the risk effect of TREM2 variants. On the other hand, NEDD8 
is upregulated 9.6-fold in the soluble fraction in these cases but this protein was observed to 
be in neurofibrillary tangle pathology (Mori et al., 2005). PARP1 (Poly [ADP-ribose] 
polymerase 1) is upregulated 3.3-fold in the insoluble fraction. PARP1 activity is activated by 
oxidative stress and it induces cell death. Aβ has also been shown to induce PARP1 activity 
(Wencel et al., 2017). MAP1B (Microtubule-associated protein 1B) is upregulated 3.1-fold in 
the insoluble fraction and is present in sites where neurofibrillary tangles are deposited in AD 
(Iqbal et al., 2005). The most downregulated protein in these cases was ASAP3, Arf-GAP 
with SH3 domain, ANK repeat and PH domain-containing protein 3, at 54.57-fold difference 
in the insoluble fraction, which promotes cell proliferation (Tian et al., 2017). CDH8 
(cadherin-8) is also highly downregulated in the TREM2 variant controls at 48.1-fold in the 
soluble fraction. It is a cell-adhesion protein and they are thought to have a role in cell sorting 
due to them being able to connect cells together (Suzuki and Takeichi, 2008).  
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Fold change compared 
to control 
PSMB7 Proteasome subunit beta type-7 13.12 
NEDD8 NEDD8 9.55 
WDR19 WD repeat-containing protein 19 9.32 
SLC14A1 Urea transporter 1 5.92 
C2CD3 C2 domain-containing protein 3 5.37 
SHTN1 Shootin-1 4.89 
PGBD5 PiggyBac transposable element-derived protein 5 4.13 
WDR47 WD repeat-containing protein 47 4.05 
IGHA2 Ig alpha-2 chain C region 3.88 
LAMA5 Laminin subunit alpha-5 3.81 
SCYL1 N-terminal kinase-like protein 3.73 
MAP2K1 Dual specificity mitogen-activated protein kinase kinase 1 3.63 
SLC25A5 ADP/ATP translocase 2 3.61 
PSAP Prosaposin 3.50 
NEB Nebulin 3.50 
PARP1 Poly [ADP-ribose] polymerase 1 3.29 
KRT10 Keratin, type I cytoskeletal 10 3.27 
LAMA2 Laminin subunit alpha-2 3.25 
CCDC30 Coiled-coil domain-containing protein 30 3.16 
MAP1B Microtubule-associated protein 1B 3.14 




Fold change compared 
to control 
ASAP3 
Arf-GAP with SH3 domain, ANK repeat and PH domain-
containing protein 3 
-54.57 
CDH8 Cadherin-8 -48.09 
WDFY1 WD repeat and FYVE domain-containing protein 1 -11.28 
COX6A1 Cytochrome c oxidase subunit 6A1, mitochondrial -9.54 
SRRM2 Serine/arginine repetitive matrix protein 2 -8.96 
AGFG1 Arf-GAP domain and FG repeat-containing protein 1 -7.18 
RAB24 Ras-related protein Rab-24 -6.49 
MKRN1 E3 ubiquitin-protein ligase makorin-1 -6.47 
PXN Paxillin -6.28 
PANK4 Pantothenate kinase 4 -6.08 
GC Vitamin D-binding protein -5.48 
H3F3A Histone H3.3 -5.42 
HBB Hemoglobin subunit beta -4.95 
FDFT1 Squalene synthase -4.82 
TECPR1 Tectonin beta-propeller repeat-containing protein 1 -4.75 
CA1 Carbonic anhydrase 1 -4.52 
PTPRE Receptor-type tyrosine-protein phosphatase epsilon -4.50 
CUX2 Homeobox protein cut-like 2 -4.43 
ERO1A ERO1-like protein alpha -4.40 
VARS Valine--tRNA ligase -4.28 
Table 5.13: Top 20 up- and down- regulated proteins changing in expression in TREM2 
controls compared to controls. Italics represent proteins that were in the insoluble fraction. 
  
Chapter 5 – The genetic and proteomic profiles of TREM2 variant cases 
Page | 165  
 
In addition to these proteins changing in the different disease groups, several proteins 
related to AD or neurodegeneration in general were also altered (Table 5.14). APP and 
MAPT are the proteins directly related to AD pathology and in both cases these were 
upregulated in all groups other than the TREM2 variant controls, in which they were 
downregulated when compared to normal controls. For APP, the greatest fold change was 
observed in the TREM2 variant FAD case (4.2-fold, insoluble fraction), followed by the 
TREM2 variant SAD case (3.9-fold, insoluble fraction) in which it was one of the highest 20 
proteins observed to be upregulated (Table 5.11). For MAPT, the greatest fold change 
difference was observed in the TREM2 variant SAD cases (7.7-fold, insoluble fraction) with 
an increase of 3.2-fold above the next highest group. It was in the highest 20 proteins 
upregulated for SAD (Table 5.8), FAD APP (Table 5.10) and TREM2 SAD (Table 5.11). The 
same pattern was observed with the GFAP (Glial fibrillary acidic protein) which is normally 
used as a reactive astrocyte marker. GFAP was upregulated across all groups but the 
greatest level of upregulation was observed in the TREM2 variant SAD group in both the 
soluble and insoluble fractions (3.8-fold soluble, 3.2-fold insoluble). APOE was upregulated 
across all groups in the insoluble fraction, being in the highest 20 proteins upregulated for all 
groups other than TREM2 variant controls. Again, the highest level of upregulation was 
observed in the TREM2 variant SAD cases (7.8-fold, insoluble fraction). SNCA (alpha-
synuclein) was shown to be upregulated in SAD, TREM2 variant SAD and TREM2 variant 
controls but downregulated in all FAD cases for both soluble and insoluble fractions.  
Ingenuity pathway analysis highlighted that the top canonical pathways (predicted to be 
activated or inhibited by the expression of genes represented in them) differ between the 
soluble and insoluble fractions (Figure 5.4). The top pathways in the soluble fraction are 
HIPPO signalling, Melatonin signalling, LXR/RXR activation, amyloid processing, actin 
cytoskeleton signalling and neuroinflammation signalling. HIPPO signalling, amyloid 
processing and neuroinflammation signalling are predicted predominantly to be activated 
across the disease groups, whereas melatonin signalling, LXR/RXR activation and actin 
cytoskeleton signalling are more a mixture of predicted activation and inhibition between 
groups. The TREM2 variant FAD case appears to have a more activated pathway phenotype 
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containing protein 10 
1.36 1.38 1.13 2.15 1.48 - 
ABCA7 
ATP-binding cassette sub-
family A member 8 
- - 1.09 - 1.27 - 
APOE apolipoprotein e 1.05 1.26 1.07 1.64 1.24 1.12 
APP Amyloid beta A4 protein - 1.17 1.24 - 1.06 1.15 
CLU Clusterin 1.33 1.30 1.47 1.75 1.27 1.16 
CTSD Cathepsin D 1.02 1.08 1.05 1.12 1.16 1.08 




1.46 2.86 1.77 2.36 1.04 1.44 
P2RX7 P2X purinoreceptor 7 - 1.05 1.01 1.12 1.31 - 




family A member 7 
1.14 1.96 - 1.13 2.04 2.04 
APOE apolipoprotein e 6.01 7.40 6.97 5.23 7.77 1.16 
APP Amyloid beta A4 protein 2.92 2.88 2.78 4.21 3.91 1.34 
CLU Clusterin 1.32 1.65 1.27 1.70 1.49 1.05 
CTSD Cathepsin D 1.04 1.21 1.27 1.20 1.17 1.55 




4.49 3.00 4.53 3.51 7.74 1.24 
SNCA Alpha-synuclein 1.57 1.10 2.37 2.21 1.41 2.34 
Table 5.14: Protein expression in genes associated with neurodegeneration. Red 
represents upregulation and green represents downregulation compared to controls. Italics 
represent proteins that were in the insoluble fraction. 
  
compared to other disease groups. The top pathways in the insoluble fraction are EIF2 
signalling, RhoA signalling, signalling by Rho family GTPases, ERK5 signalling, glioma 
signalling and ephrin receptor signalling. EIF2 signalling and glioma signalling are 
predominantly predicted to be inhibited across the disease groups with TREM2 variant 
controls having the opposite prediction. RhoA signalling, signalling by Rho family GTPases, 
ERK5 signalling and ephrin receptor signalling have a more activated prediction. The 
TREM2 variant control group has a different pattern showing predominantly predicted 
activation throughout the top canonical pathways, whereas the other groups are more varied 
between activation and inhibition.  
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Bio function analysis on the IPA software had greater similarity between soluble and 
insoluble fractions (Figure 5.5). Top functions represented in the soluble fraction were viral 
infection, infection by RNA virus, infection of cells, cell viability of tumour cell lines and 
infection of tumour cell lines. Whereas in the insoluble fraction they were cell movement, 
migration of cells, infection by RNA virus, infection of epithelial cell line and infection of 
embryonic cell line. Infection was the main function represented from both fractions, with a 
prediction of inhibition across most groups being observed.  This may indicate that a loss of 
infection markers for infection may play a role in AD. However, TREM2 variant control 
groups had activation of this function. The other top function represented was cell migration 
and movement and in contrast this function was predicted to be activated in all groups. 
TREM2 variant groups had a higher amount of functions predicted to be activated than the 
cases without a TREM2 variant, particularly in the soluble fraction. TREM2 variant cases 
especially had an activated profile predicted throughout the top functions listed in the soluble 
fraction. The dementia disease/function was on the list of top diseases and bio functions 
listed for the insoluble fraction. It is predicted to be activated in all groups, although the 
TREM2 variant controls had a lower z-score. This is a good validation of the methods and 
analyses used in this work. 
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Figure 5.4: Canonical pathways represented in proteomic data. (a)Canonical pathways 
found in the soluble fraction according to z-score given by IPA software, (b) canonical 
pathways found in the insoluble fraction according to z-score given by IPA software. Orange 
represents a predicted activation of the pathway and blue represents a predicted inhibition of 
the pathway based on expression values found in the data. Intensity of colour relates to how 
activated or inhibited the pathway is predicted to be.  
 
a b 
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Figure 5.5: Diseases and functions represented in proteomic data. (a)Diseases and 
functions found in the soluble fraction according to z-score given by IPA software, (b) 
diseases and functions found in the insoluble fraction according to z-score given by IPA 
software. Orange represents a predicted activation of the pathway and blue represents a 
predicted inhibition of the pathway based on expression values found in the data. Intensity of 
colour relates to how activated or inhibited the pathway is predicted to be.  
 
a b 
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5.4.3. Comparative analysis 
When comparing the genetic expression data obtained through nanostring methods and the 
protein expression data from the label-free mass spectrometry, it must be performed with 
limitations in mind. As the nanostring data only investigated 256 neuroinflammatory genes 
and 30 genes specific to neurodegeneration, neuroinflammatory pathways are more likely to 
appear as represented when comparing the two data sets. It is therefore, no surprise that 
when the top canonical pathways represented in each disease group and using each 
experiment were compared, the neuroinflammatory signalling pathway was present in all but 
the TREM2 variant control group (Figure 5.7). However, this pathway was one of the top 
canonical pathways represented in the insoluble fraction of the proteomics showing that 
neuroinflammation is still a major factor at the protein level and should be investigated 
thoroughly. The neuroinflammation signalling pathway is predicted to be activated in both the 
nanostring and proteomic data of all groups apart from the proteomics of the FAD group, in 
which it is inhibited.  
The general pattern when comparing the canonical pathways is that the pathways are 
predicted to be activated in the genetic expression data but inhibited in many of the 
proteomic data. The TREM2 variant FAD case is different to this pattern in the fact that it has 
a higher level of activated pathways predicted in the soluble fraction compared to other 
groups. Additionally, the TREM2 variant control group once again has a different profile in 
that the pathways most highly represented in this group are predicted to be inhibited at the 
Figure 5.6: Overlap of over-represented GO biological process terms between disease 
groups when compared to controls between genetic and proteomic analysis. (a) 
nanostring data represented, (b) soluble fraction of proteomics, (c) insoluble fraction of 
proteomics. FAD sections include GO terms for both PSEN1 and APP cases, TREM2 
sections include GO terms for TREM2 SAD, TREM2 FAD and TREM2 controls.  
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genetic level but activated at the protein expression level. This again highlights how different 
the TREM2 variant control group are to not only the other AD groups but the other cases that 
have a TREM2 variant.  
To look at the specific amount of overlap between different disease groups, the genes and 
proteins that had greater than 1.5 fold expression difference were entered into Webgestalt 
and represented GO biological processes were determined. The amount of overlap was then 
decided using the GOview online software. As depicted in Figure 5.6, the nanostring data 
had both a large amount of overlap of terms between groups and terms that were specifically 
over-represented in each disease group. However, when the same analysis was undertaken 
with the proteomic data, a large amount of terms were specifically seen in the TREM2 
variant group with fewer terms in the SAD and FAD groups and very minimal terms being 
overlapped between groups. This was true for both soluble and insoluble fractions and 
highlights that there are many differences in the expression seen at the genetic and 
proteomic levels. 
5.5. Discussion 
In this chapter, both the genetic and proteomic expression profiles have been investigated in 
SAD, FAD, TREM2 SAD, TREM2 FAD and TREM2 controls and have been compared to 
controls before being compared to each other. Both sets of data give us an insight into the 
disease processes occurring in AD. The majority of the findings in this study confirm 
previous genetic or proteomic studies. However, here, the cases could be additionally split 
into cohorts of sporadic and genetically determined AD.  
Using nanostring nCounter technology the gene expression of 256 Human inflammation 
genes and 30 neurodegenerative specific genes were investigated to determine the 
neuroinflammatory profiles of the different AD subgroups. Neuroinflammation was shown to 
be affected in all of the subgroups with TREM2 SAD having a significantly upregulated 
neuroinflammatory profile in comparison to SAD. TREM2 variant controls had the opposite 
profile with largely downregulated genes being observed compared to controls.  
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Figure 5.7: Canonical pathway comparison between nanostring and proteomic data 
sets. (a) comparison of top canonical pathways in SAD, (b) FAD, (c) TREM2 SAD, (d) 
TREM2 FAD and (e) TREM2 controls compared to controls ordered by z-score determine by 
IPA software. First column is nanostring data, second column the soluble fraction of 
proteomics (s) and third the insoluble pellet fraction of proteomics (p). Orange represents a 
predicted activation of the pathway and blue represents a predicted inhibition of the pathway 
based on expression values found in the data. Intensity of colour relates to how activated or 
inhibited the pathway is predicted to be. 
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When looking in closer detail at the canonical pathways represented, we can see many 
pathways that may be implicated in AD pathogenesis. One of these, the role of pattern 
recognition receptors, highlights the role that TLR’s may play between the different AD 
subgroups. TLR1-8 were upregulated in the SAD group but TLR2 and TLR4 were 
upregulated to a higher level in the TREM2 variant SAD group. TREM2 acts via the ITAM 
motif present on its adapter protein DAP12. DAP12 negatively regulates the TLR response 
(Boutajangout and Wisniewski, 2013; Ito and Hamerman, 2012). Consequently, it is 
accepted that TREM2 inhibits the TLR response and therefore suppresses the pro-
inflammatory cytokines produced (Boutajangout and Wisniewski, 2013; Hamerman et al., 
2005). As TREM2 R47H variants are thought to have a loss-of-function mutation and not 
bind to its ligands as effectively, the TLR response is no longer suppressed, further pro-
inflammatory cytokines are released and cell death continues to occur. As an increase is 
seen in the TLR gene expression in TREM2 variant SAD cases compared to SAD cases 
without a TREM2 variant, the TLR response may be exacerbated in these variants, leading 
to more neuroinflammation than normal which may play a role in why TREM2 variants cause 
a risk to late onset AD. However, these TLR’s are downregulated in TREM2 variant controls, 
meaning that another factor must be needed for TLR’s to become upregulated in the 
presence of a TREM2 variant.  
Label-free proteomics was utilised to determine the proteomic profile of any proteins in these 
different cases and determine if the genetic expression data translated to the protein level. 
Neuroinflammation was not found to be the most highly represented canonical pathway at 
the protein level but it was one of the top pathways represented in the insoluble fraction, 
highlighting that neuroinflammatory mechanisms are important in AD pathogenesis. As 
plaques are likely to be in the insoluble fraction, this could indicate that neuroinflammation 
plays a role in amyloid plaque pathology.  
Astrocytes are also thought to play a part in the neuroinflammatory processes observed in 
the brain and in neurodegenerative disease. An upregulation of the GFAP gene, a marker for 
reactive astrocytes, was observed in the SAD and FAD groups as well as an upregulation of 
this protein across all groups. The TREM2 variant SAD group however, had a larger 
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increase than any other group. This would suggest that although TREM2 is found on 
microglia, the downstream signalling cascades that stem from it also affect the 
neuroinflammatory processes that are found within astrocytes.  
As would be expected in AD brain, the proteomic data showed increases in genes 
associated with amyloid and tau pathology, with amyloid processing being one of the top 
canonical pathways represented in both the soluble and insoluble fractions of the 
proteomics. Most of the proteins that were involved with amyloid processing or in Aβ 
fibrillisation (COL25A1, CTGF, CRABP1, CRK, BGN, HBG2, KCNIP4, HTRA1, PPIL2) were 
observed to change in the FAD cases. As the pathogenic mutations in either PSEN1 or APP 
cause an increased production of Aβ, the fact other proteins involved in these processes are 
affected most in these cases is logical. APP had the highest fold change compared to 
controls in TREM2 variant FAD and TREM2 variant SAD, suggesting the production of APP 
alters in these TREM2 variant cases. The same was true for MAPT, with the highest 
upregulation occurring in the TREM2 variant SAD cases. The loss of function of TREM2 
variants may lead to an altered pro-inflammatory microglial phenotype, which then results in 
increased production of APP and MAPT.  
Two proteins commonly found in the presence of neurofibrillary tangles, NEDD8 and MAP1B 
were both found to be upregulated in the TREM2 variant control cases. NEDD8 is a 
ubiquitin-like protein and promotes proteasomal degradation. As these are upregulated in 
TREM2 controls, it may suggest that these cases do still have the potential for neurofibrillary 
tangle pathology to occur but another factor is stopping the process from occurring or 
progressing.  
Cytoskeletal signalling cascades have been identified previously to be affected in AD, with 
both actin and microtubule organisation being affected (Henriques et al., 2015). The results 
here suggest that these pathways are changing the most within AD, at least at the protein 
level. Actin cytoskeleton signalling was in the top five canonical pathways represented in the 
soluble fraction of the proteomic data with a prediction that it was inhibited in most AD 
subgroups. However, the pathways RhoA signalling, signalling by Rho family GTPases and 
ERK5 signalling were all in the top five canonical pathways represented in the insoluble 
Chapter 5 – The genetic and proteomic profiles of TREM2 variant cases 
Page | 175  
 
fraction of the proteomics, with a prediction that they are activated across AD subgroups. 
Breakdown of the cytoskeleton in the neurons, leads to impaired axonal transport, synaptic 
dysfunction and ultimately cell loss (Henriques et al., 2015). Unlike other changes observed, 
these pathways were affected in all AD subgroups in a similar manner. There were no 
differences observed in the TREM2 variant cases. This could indicate that although 
cytoskeletal abnormalities are an important factor for AD pathogenesis, it does not contribute 
to the risk of developing the disease in TREM2 variants carriers.  
Other pathways and proteins that are affected are those involved with cell proliferation. The 
top represented canonical pathway in the soluble fraction of proteomics was HIPPO 
signalling. HIPPO signalling is a pathway involved in controlling cell proliferation as well as 
apoptosis. Inhibition of this pathway has been shown to cause cancer due to increased 
proliferation and decreased cell death (Wang and Wang, 2016). In AD, it has been 
suggested this pathway becomes hyperactivated, acts through binding to APP and causes 
decreased cell proliferation (Wang and Wang, 2016). This study has confirmed that as 
HIPPO signalling is predicted to be activated across all the disease subgroups. As further 
evidence of cell proliferation being affected, the protein ASAP3 was one of the top 
downregulated proteins in all groups other than the FAD PSEN1 group and this protein 
promotes cell proliferation. Also, PSMB7 is upregulated in TREM2 variant controls but 
inhibits cell proliferation. CCNG1, on the other hand, is downregulated in TREM2 variant 
SAD cases but also inhibits cell proliferation. Although differences are not observed between 
disease subgroups, the regulation of cell proliferation is clearly important in AD and needs to 
be investigated further.  
APOE was another protein upregulated compared to controls across all disease subgroups 
in the insoluble fraction.  As APOE can bind to Aβ plaques that would precipitate in the 
insoluble fraction, this may explain the increase. However, the amount of upregulation was 
much higher in all groups compared to the TREM2 variant controls and was highest in the 
TREM2 variant SAD cases. APOE is also a risk factor for late onset AD with similar odds to 
that of TREM2. Therefore, determining what effect is had by APOE genotype and which 
effect by TREM2 risk variants can be difficult to decipher. As individual cases were pooled 
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for proteomic analysis, a separate analysis based on APOE genotype is not possible. 
However, the TREM2 variant controls did not contain any ApoE4 alleles and the TREM2 
variant SAD cases all contain at least one ApoE4 allele. It is therefore interesting that the 
TREM2 variant controls have a markedly different neuroinflammatory profile compared to 
TREM2 variant SAD cases. An ApoE4 allele could be the additional factor that is required for 
the TREM2 variant effect on the pathways discussed above. Age of onset and disease 
duration do not significantly differ between TREM2 variants with an ApoE4 allele and SAD 
cases with an ApoE4 allele. Therefore, it is feasible that these cases are working along 
similar mechanisms.  
TREM2 and APOE have been shown to bind and Krasemann et al., (2017) suggest that 
APOE triggers the TREM2 signalling pathway (Atagi et al., 2015; Bailey et al., 2015; 
Jendresen et al., 2017). These results may support this theory in part. TLR activators have 
been shown to also reduce microglial expression of TREM2 with further reduction seen in 
ApoE4/4 carriers compared to other genotypes (Li et al., 2015). As mentioned previously, 
reduced TREM2 leads to an increased TLR response and release of further pro-
inflammatory cytokines which exacerbate disease. APOE is a lipoprotein and lipoproteins are 
responsible for activating TLR2. TLR2 was found to be upregulated in TREM2 variant SAD 
cases at a greater level to SAD cases. As the TREM2 variant SAD cases all carry one 
ApoE4 allele, a greater reduction of TREM2 expression may be seen, leading to increased 
TLR activation and a pro-inflammatory signalling cascade to ensue. As the TREM2 variant 
controls do not contain an ApoE4 allele, this cascade may not occur in these cases, leading 
to the different profile of TLR activation and neuroinflammation that is observed.  
Comparisons between the nanostring data and the proteomic data highlights multiple 
approaches are needed to decipher the underlying pathological mechanisms in these 
diseases and that we will gain the most accurate information if we continue to complete 
multi-omic datasets and look at network biology. Furthermore, stratifying the cases we 
investigate according to their pathological and genetic background will enable us to visualise 
the whole picture. Large differences between expression at the genetic and proteomic levels 
could be explained as either compensatory mechanisms at the translational level for 
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differences occurring at the transcriptional level or alternative splicing 
regulation/dysregulation. A proteomic study identified that cells exposed to Aβ42 displayed 
spliceosome dysregulation, suggesting that this could be a possibility (Nuzzo et al., 2017). 
Additionally, a number of miRNA’s have been reported to be reduced in AD, such as miR-
339-5p found to regulate expression of BACE1 and miR-132/212 found to regulate tau 
expression (Long et al., 2014; Smith et al., 2015). Further investigation into the different 
isoforms expressed for the proteins changing in the greatest amounts would help us to 
understand these changes in greater detail. 
5.5.1. Conclusions 
In summary, pathways involved in neuroinflammation, cytoskeletal organisation, cell 
proliferation and amyloid processing have been shown to change in AD compared to 
controls at either the genetic or proteomic level across multiple cell types. TREM2 variant 
SAD cases appear to have an altered genetic neuroinflammatory profile compared to SAD 
and FAD cases. Particular changes in TLR gene expression in TREM2 variant SAD groups 
compared to other AD groups lacking a TREM2 variant are apparent and indicate a 
mechanism in which TREM2 variants could confer risk of AD. TREM2 variant controls have a 
strikingly different neuroinflammatory genetic profile and altered proteomic expression of 
proteins associated with AD pathology and reactive astrocytes when compared to normal 
controls. This indicates that changes do occur in these TREM2 variants but they do not have 
the same effect as in TREM2 variant SAD cases. These TREM2 variant controls lack an 
ApoE4 allele and have the opposite effect to TREM2 variant SAD cases with an ApoE4 
allele. APOE genotype could be important to determine which effect a TREM2 variant may 
have. Further investigation to determine if these effects are independent of each other or not 
need to be undertaken for us to fully elucidate the role of TREM2 variants and why they 
confer risk of AD. Whilst this investigation does not decide whether inflammation is causing 
AD or just a consequence, it points towards it having a role in the pathogenesis of TREM2 
variants.   
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6 Could the presubiculum be protected from 
neurodegeneration observed in AD and TREM2 
variant cases? 
6.1 Abstract 
Introduction: One of the most severely affected regions of the brain in AD is the 
hippocampal formation and parahippocampal region. This region can be divided into 
subregions, which include the presubiculum. The presubiculum is medially adjacent to the 
entorhinal cortex and is shown to connect anatomically with both the entorhinal cortex, the 
hippocampus and deeper brain nuclei. Over a decade ago, it was observed that the adjacent 
regions, subiculum and entorhinal cortex, have differing Aβ composition/appearance. Both 
the entorhinal cortex and the subiculum contain Aβ plaques, whereas the presubiculum has 
one large diffuse ‘cloud’ of Aβ. Here some of the variables that influence the formation of the 
Aβ deposits found in the presubiculum were investigated and analysed to determine if there 
was an identifiable factor in this region that made it resistant to further AD pathogenesis. 
Materials and methods: Immunohistochemistry was carried out with Aβ, AT8, Iba1, CD68, 
CR3-43 antibodies on the hippocampus, taken at the level of the lateral geniculate body. 
This level contained both the presubiculum and entorhinal cortex of SAD (n=19), FAD (n=11) 
and TREM2 variant AD (n=3) cases and immunohistochemistry was performed to make 
pathological comparisons between the areas. Fluorescent Aβ immunohistochemistry 
combined with Thioflavin-S histological staining was also performed to visualise the Aβ 
conformational state in both regions. Tau and microglial density were calculated with Image 
J analysis of random squares from both the presubiculum and entorhinal cortex. The number 
of NFT’s were counted manually. The specific Aβ peptides present within the presubiculum 
and entorhinal cortex were determined following laser-capture microdissection (LCM) paired 
with matrix assisted laser desorption ionisation time-of-flight mass spectrometry analysis. 
Immunohistochemistry using antibodies against N-terminally truncated and pyroglutamate 
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modified Aβ peptides was performed to validate results. Label-free quantitative mass 
spectrometry using a Synapt G2-Si High Definition QToF with 2D fractionation was used to 
determine if there were any proteomic differences between the two regions.  
Results: Aβ immunohistochemistry showed a large non-fibrillar Aβ deposit in the 
presubiculum and fibrillar dense core Aβ plaques in the entorhinal cortex of SAD, FAD and 
TREM2 variant cases. Significantly less hyperphosphorylated tau and significantly less 
NFT’s were observed in the presubiculum compared to entorhinal cortex in both SAD and 
FAD cases. Iba1 microglial levels only changed in SAD cases with significantly more 
microglia being observed in the presubiculum and with other disease groups showing no 
difference. Activated microglial markers, CD68 and CR3-43 both show significantly less 
microglial activation in the presubiculum compared to the entorhinal cortex. Aβ peptide 
analysis identified more N-terminally truncated and pyroglutamate modified Aβ peptides 
present in the entorhinal cortex compared to minimal unmodified Aβ peptides present in the 
presubiculum. However, immunohistochemistry with antibodies for varying Aβ peptides was 
detected in both regions. Proteomic analysis revealed many changes in expression between 
the presubiculum and entorhinal cortex. Changes were observed in APP processing, Aβ 
deposition, Aβ clearance, Aβ toxicity, tau accumulation and microglial activation. 
Conclusions: This study demonstrated that the Aβ deposition/composition and the 
microglial response in the presubiculum is morphologically and proteomically diverse from its 
neighbouring region, the entorhinal cortex. The changes observed in the presubiculum result 
in less aggregation of Aβ and tau and reduced microglial activation. Why this area responds 
differently to AD pathogenesis remains unclear. Further biochemical analysis of this area 
and the proteins mentioned here are needed to elucidate what causes this phenomenon and 
its effect. Understanding what factor(s) are the key to this neuroprotective mechanism, could 
lead to therapeutic neuroprotection that can be applied to the whole brain and halt AD 
disease progression.  
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6.2 Introduction 
6.2.1 Parahippocampal anatomy and connections 
One of the most severely affected regions in AD is the hippocampal region (Akiyama et al., 
1990; Wisniewski et al., 1998). The hippocampus is an important region for memory function 
and memory loss is one of the first symptoms of AD. It is also an important area for 
navigation, shown by the discovery that place cells, grid cells and head direction cells 
provide a navigational map (Nassar et al., 2015; O’Keefe and Nadel, 1978; Simonnet et al., 
2017; Tukker et al., 2015). 
The neuroanatomy and connectivity of this region of the brain has been studied in great 
detail and has several sub-regions as depicted in Figure 6.1. The hippocampal formation is 
formed of the dentate gyrus, the CA3/4, CA2, CA1 areas and the subiculum. Directly 
adjacent to this is the parahippocampal region which is connected with the hippocampal 
formation through a pathway known as the perforant pathway (Augustinack et al., 2010; 
Caballero-Bleda and Witter, 1994; van Strien et al., 2009). The parahippocampal region is 
made up of the pre- and para- subiculum, the transsubiculum and the entorhinal cortex 
(Drexel et al., 2013). In rodents, the presubiculum area is further classified into the 
presubiculum and the postsubiculum (Ding, 2013).   
Figure 6.1: Anatomy of the hippocampus and parahippocampal region. Modified from 
Drexel et al. 2013. DG, dentate gyrus; Sub, Subiculum; PrS, Presubiculum; EC, entorhinal 
cortex 
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Originally it was thought that the only connection between the parahippocampus and the 
hippocampal formation were the projections arising from the entorhinal cortex via the 
perforant pathway. However, it is now known that a number of other subregions in the 
parahippocampus send efferent fibres to the hippocampal formation, with the presubiculum 
being one (Caballero-Bleda and Witter, 1994). The presubiculum has several afferent and 
efferent connections both within the hippocampal/parahippocampal area and to further areas 
of the brain (van Groen and Wyss, 1990). There is evidence that the presubiculum sends 
projections to the; dentate gyrus, CA3, CA1, subiculum, parasubiculum, septum, anterior 
thalamic nuclei, retrosplenial cortex and most prominently the entorhinal cortex (Akiyama et 
al., 1990; van Groen and Wyss, 1990; van Strien et al., 2009). For example, Simonnet et al., 
(2017) report that thalamic afferents recruit presubicular principal neurons and Martinotti 
interneurons and that these projections have a role in head direction signals. Reports show 
that these interneurons have a wide variation in their physiological properties (Nassar et al., 
2015; Tukker et al., 2015). The parasubiculum also sends projections to the entorhinal 
cortex, however they are quite distinct in the fact that the parasubiculum sends projection to 
layer II of the entorhinal cortex, whereas the presubiculum sends projections to layer III of 
the entorhinal cortex (Caballero-Bleda and Witter, 1994).  The fact that these layers project 
on to different areas of the hippocampal formation could be important for function (Caballero-
Bleda and Witter, 1994). The presubiculum differs from its neighbouring areas, such as the 
medial entorhinal cortex, due to the fact its superficial layers do not have large amounts of 
excitatory connectivity (Couey et al., 2013; Dhillon and Jones, 2000; Fuchs et al., 2016; 
Pastoll et al., 2013; Peng et al., 2017).  
Furthermore, James Papez noted in 1937 that there was a direct connection between the 
hippocampus and the hypothalamus involving a number of brain regions (Papez JW, 1937). 
This was later proved to be true and referred to as the Papez circuit (Figure 6.2) (Shipley, 
1974). The presubiculum forms part of this circuit with connections arising from the 
supramamillary region onto the anterior thalamic nuclei to the cingulate cortex before the 
presubiculum (Akiyama et al., 1990; van Groen and Wyss, 1990; Shipley, 1974). The 
presubiculum then connects this to the perforant pathway via the entorhinal cortex and is 
often referred to as the “relay centre” (Akiyama et al., 1990; Kalus et al., 1989). 
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6.2.2  Pathological observations in the presubiculum 
Over two decades ago, a few groups observed that the presubiculum showed different 
pathological properties in AD when compared to the other subdivisons of the hippocampal 
formation and the parahippocampal region (Akiyama et al., 1990; Kalus et al., 1989; 
Wisniewski et al., 1998). They observed that this area did not contain Aβ plaques but instead 
had a ‘cloud’ or ‘lake-like’ pattern of diffuse Aβ staining that seemed to fill the presubiculum 
(Kalus et al., 1989).   
Nissl staining was used to identify the presubiculum, as the parvopyramidal layer of the 
presubiculum is formed of small densely packed pyramidal neurons that have large nuclei, 
which are easily identified from the larger, less densely packed neurons of the 
parvopyramidal layer of the parasubiculum (Akiyama et al., 1990; Braak, 1978; Ding, 2013; 
van Groen and Wyss, 1990; Kalus et al., 1989). Acetylcholine esterase staining also 
Figure 6.2: Papez circuit and the connections between the regions involved. Modified 
from Augustinack et. al 2010. PP, perforant pathway; DG, dentate gyrus; genu IC, genu of 
the internal capsule; MMT, mamillothalamic tract; Sub, Subiculum. 
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produced a different pattern between the parasubiculum and the presubiculum, resulting in a 
further method of identification (Ding, 2013; van Groen and Wyss, 1990).  
Comparing the Nissl staining with either Aβ immunohistochemistry or Thioflavin-S and 
Congo-red stains showed that only diffuse amyloid was identified within this area as the 
presubiculum was negative for amyloid in the β-sheet conformation (Akiyama et al., 1990; 
Wisniewski et al., 1998). Additionally, Ji et al., (2015) highlighted that the PiB radioligands, 
used as a PET ligand to detect amyloid, did not bind to the presubiculum in AD, further 
confirming that the Aβ in the presubiculum is not in an amyloid conformational state. 
Wisniewski et al., (1998) however, did note that there may actually be a higher total 
percentage of Aβ load in the presubiculum compared to other hippocampal areas. Only 
sparse NFTs were seen in the presubiculum, considerably lower amounts than that of the 
subiculum or CA1 areas (Akiyama et al., 1990; Kalus et al., 1989; Wisniewski et al., 1998). 
Additionally, no activated glial staining was present in the presubiculum, which led to 
suggestions that the Aβ production/clearance mechanisms may be impaired in this region 
(Akiyama et al., 1990; Wisniewski et al., 1998). No amyloid- associated proteins were 
detected here either; neither proteins that promote amyloid fibrilisation e.g. ApoE, or proteins 
that inhibit amyloid fibrillisation e.g. ApoJ (Wisniewski et al., 1998). In contrast, the entorhinal 
cortex shows severe neuronal loss, dense core amyloid plaques, frequent NFT’s, activated 
microglia and activated astrocytes (Akiyama et al., 1990; Ji et al., 2015; Kalus et al., 1989; 
Wisniewski et al., 1998).  
Imaging studies have shown that both the presubiculum and subiculum areas show 
prominent atrophy from early stages in the disease, namely mild cognitive impairment (MCI) 
stage, which progressively worsens with disease progression (Carlesimo et al., 2015). The 
authors suggest that this may be because of degeneration of the perforant pathway, which 
the presubiculum is a part of. Mizutani and Kasahara, (1997) have shown previously that this 
pathway is degenerated in AD and that this starts in the entorhinal cortex and is spread 
through the subiculum and into the hippocampus. However, they made no mention as to 
whether this affects the presubiculum in this pathway.  
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Further to this, McCuUoch and Dewar, (1991) report that the presubiculum has six times the 
amount of galanin binding sites than the other hippocampal or parahippocampal regions. 
Galanin is thought to inhibit the acetylcholine release in rats (Girotti et al., 1993). As 
acetylcholine release is reduced in AD brains, the presence of more galanin binding sites 
could be one way in which the presubiculum is protected from the effects of AD (Kása et al., 
1997).  
This phenomenon of diffuse amyloid deposits in the presubiculum is not unique to AD. 
However, this has not previously been reported in the literature. The pathological ‘cloud’ 
hallmark is visualised in the presubiculum in other forms of dementia such as Familial British 
Dementia and Familial Danish Dementia as well as some forms of Prion disease (Murray et. 
Al, manuscript in preparation).  
Although the presubiculum was previously overlooked as an important region within the 
parahippocampus, its high connectivity with other important regions, both for memory and 
navigation, suggest otherwise. The different type of pathology in this region compared with 
the traditional pathology seen in the other hippocampal and parahippocampal regions 
indicate that the presubiculum has different properties. Diffuse amyloid deposits are seen 
from early in disease (Thal phases 2 and 3) and do not change through to end stage 
disease, with reports of these large deposits being seen in non-demented aging cases 
(Akiyama et al., 1990; Wisniewski et al., 1998).  
6.2.3 Amyloid plaque composition 
The amyloid plaques that are present in AD are composed of aggregated Aβ protein. Aβ is 
formed when cleavage of the amyloid precursor protein (APP) occurs by the secretases 
(Russo et al., 2002). Aβ peptides of varying length occur due to the secretases cleaving at 
different points at both the N-terminus and the C-terminus (Chávez-Gutiérrez et al., 2012; 
Russo et al., 2002; Szaruga et al., 2015).  
The four most dominant Aβ peptides are Aβ1-42, Aβ1-40, Aβ4-42 and pGluAβ3-42 (Bouter 
et al., 2013; Portelius et al., 2010, 2015; Russo et al., 2002). The full-length Aβ protein is 
formed of residues Aβ1-42 however; the Aβ1-40 peptide is also highly abundant and has 
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been shown to be less prone to aggregation (Pike et al., 1995). The β-sheet formation of the 
fibrils is due in part to pGluAβ3-42 affecting the α-helix structure and in mice it has been 
shown that Aβ4-42 is linked to behavioural memory deficits (Bouter et al., 2013; Goldblatt et 
al., 2015). A range of N-terminally truncated and pyroglutamate-modified Aβ peptides have 
been detected and shown to be more toxic than the full length peptides (Miller et al., 1993; 
Pike et al., 1995; Portelius et al., 2010, 2015; Russo et al., 2002). Russo et al., (2002) 
reports that cleavages at the N-terminus make the peptide more prone to toxicity which 
affects its degradation properties, whereas cleavages at the C-terminus affect the fibril 
morphology.  
Portelius et al., (2015) determined that AD patients have a higher amount of N-terminally 
truncated and pyroglutamate-modified peptides than pathological aging cases (AD pathology 
without cognitive decline). N-terminally truncated peptides have been detected both in 
familial and sporadic forms of AD, however, they appear to be observed earlier in familial 
cases and in Down syndrome cases, with the protein load being linked to disease severity 
(Portelius et al., 2010; Russo et al., 2002).  
6.2.4 Aims 
In this chapter, Aβ immunohistochemistry was used to determine the pathological differences 
that are observed between the presubiculum and the entorhinal cortex. In this study SAD, 
FAD and TREM2 variant AD cases were compared to determine if the presubiculum differs 
between different AD subgroups. Laser-capture microdissection paired with mass 
spectrometry was employed to identify the Aβ peptide species present in the presubiculum 
and entorhinal cortex. Various antibodies for different N-terminally truncated and 
pyroglutamate modified Aβ isoforms were used with immunohistochemistry to determine if 
the composition of Aβ differed between the presubiculum and the entorhinal cortex. 
To understand whether this area is fully protected from AD pathology, the density of hyper-
phosphorylated tau and microglia using multiple microglial markers were determined as well 
as the number of NFT’s counted.  
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To assess which proteins are present in the presubiculum and determine their expression 
levels compared to those in the entorhinal cortex, quantitative label- free mass spectrometry 
was performed. These results were analysed to determine if the presubiculum has specific 
tissue factors or pathways altered in comparison to the neighbouring entorhinal cortex.  
6.3 Materials and Methods 
6.3.1 Case selection 
All case demographics are detailed in Table 2.3. Cases 1, 2, and 5-36 were used for Aβ 
immunohistochemical comparison between the presubiculm and entorhinal cortex (SAD 
(n=19), FAD (n=11), TREM2 SAD (n=3)). Case 25 was used for fluorescent 
immunohistochemistry and histological Thioflavin-S staining. All cases were used for 
pathological analysis of tau and microglia using the antibodies, AT8, Iba1, CD68 and CR3-
43. Cases 1, 5, 9, 25, 27 and 30 were used to determine the type of Aβ peptide present 
(SAD (n=2), FAD (n=2), TREM2 SAD (n=2)). Case 29 was used for immunohistochemistry 
with a range of N-terminally truncated and pyroglutamate modified Aβ isoforms. Cases 1, 5, 
9, 13, 14, 16, 33 and 34 were used for quantitative label-free mass spectrometry (SAD (n=4), 
FAD (n=2), TREM2 SAD (n=2)).  
6.3.2 Immunohistochemistry 
Immunohistochemistry with Aβ, AT8, Iba1, CD68, CR3-43, 1-57 (N-terminal AβpE3), 2-48 
(N-terminal AβpE3) and pE (pyroglutamate) antibodies was performed, as described in 2.4, 
on the parahippocampus region.  Details of the antibodies used in this study are listed in 
Table 2.6. Sequential sections of the same region were taken for each antibody. The Aβ 
immunohistochemistry was used to determine where the presubiculum was, the large diffuse 
area of staining, and this was used to select the same area on the other sequential sections.  
Thioflavin-S staining was performed, as described in 2.4.4, alongside fluorescent Aβ 
immunohistochemistry.  
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6.3.3 Pathological analysis 
Density analysis for AT8, Iba1, CD68, and CR3-43 was calculated using methods described 
in 2.5. The number of NFT’s were then manually counted after cases were blinded.  
6.3.4 LCM 
Laser-capture microdissection was used as described in 2.7.1 to capture the presubiculum 
and three-hundred amyloid plaques from the entorhinal cortex for each case analysed. 
Individual plaques were used here as we were directly comparing the Aβ species distributed 
in the regions. Secondly, the presubiculum and an area of the entorhinal cortex of the same 
size were captured and used for quantitative label- free mass spectrometry. Here the whole 
region was captured as we were looking for any proteomic changes. 
6.3.5 Proteomics 
To assess the type of Aβ peptides present in the presubiculum and entorhinal cortex, laser-
captured samples were taken and sent to Prof. Henrik Zetterberg’s lab for matrix assisted 
laser desorption ionisation time-of-flight mass spectrometry analysis using the methods 
described in 2.7.6.  
To assess which proteins were present and their expression in both the presubiculum and 
entorhinal cortex, laser-captured samples were protein extracted, digested, and run on a 
Synapt G2-Si High Definition machine with 2D fractionation to perform quantitative label-free 
mass spectrometry. These methods are described in more detail in 2.7.2, 2.7.3, 2.7.4, 2.7.5. 
Fold change was calculated by dividing one region by the other for each protein.  
6.3.6 Statistics 
Wilcoxon paired rank tests were used to determine significance between the presubiculum 
and entorhinal cortex for each disease group with the AT8, Iba1, CD68 and CR3-43 
antibodies. GraphPad Prism v7 was used to complete this analysis. 
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6.4.1 Amyloid pathology in the presubiculum 
Aβ immunohistochemistry identified that the morphology of the Aβ deposits in the 
presubiculum is different to the Aβ morphology in the neighbouring regions, the subiculum 
and the entorhinal cortex in AD. The presubiculum contained a ‘lake-like’ diffuse Aβ deposit 
Figure 6.3: Pathological analysis of the presubiculum in familial (FAD, case 33, a-c), 
sporadic (SAD, case 8, d-f), and TREM2 variant (case 1, g-i) Alzheimer’s disease. Aβ 
immunohistochemistry demonstrated the presence of a large diffuse deposit in the 
presubiculum (a, d, g, black arrow) and can be seen at higher magnification (b, e, h). The 
adjacent entorhinal cortex showed mature Aβ plaques (c, f, i) Bar in a, d and g represents 
1000 µm and it represents 50 µm in all remaining images. 
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and the entorhinal cortex contained mature Aβ plaques. This large diffuse area of staining in 
the presubiculum was observed in all SAD, FAD and TREM2 variant AD cases (Figure 6.3) 
and did not differ when comparing different disease durations or stages of pathology.  
To show that the Aβ being deposited in the presubiculum is diffuse in nature, and not in an 
amyloid conformational state, fluorescent Aβ immunohistochemistry alongside Thioflavin 
staining was performed. The large deposit found in the presubiculum was identifiable with 
fluorescent Aβ immunohistochemistry (Figure 6.4b, white arrow) but was Thioflavin-S 
negative (Figure 6.4d), indicating that the Aβ in this region is in a pre-amyloid conformational 
state.  The Aβ plaques in the entorhinal cortex, however, were Aβ-positive and Thioflavin-S 
positive (Figure 6.4c and e), demonstrating that they have the β-pleated structure required 
for an amyloid conformation. 
6.4.2 Tau pathology in the presubiculum 
To determine if a similar pattern could be observed for both AD pathological hallmarks, the 
amounts of phosphorylated tau in the presubiculum and entorhinal cortex were determined 
using AT8 immunohistochemistry. AT8 staining includes NFT’s, neuropil threads and 
neurites. When determining the density of the tau immunohistochemistry there was 
significantly less AT8 staining in the presubiculum than in the entorhinal cortex (Figure 6.5) 
in both SAD (p<0.0001) and FAD (p=0.001) groups, with the same trend being observed in 
the TREM2 variant AD cases (Figure 6.6a). Further to this, the number of NFT’s were 
quantified with significantly less NFT’s being observed in the presubiculum compared to the 
entorhinal cortex in SAD (p<0.0001) and FAD (p=0.001), with the TREM2 variant AD cases 
also following the same trend. 
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Figure 6.4: Pathological comparisons of the presubiculum and entorhinal 
cortex in Alzheimer’s disease. Aβ immunohistochemistry in an AD case where 
the presubiculum area is highlighted with yellow and the entorhinal cortex green 
(a, case 25). Higher magnification images can be seen of the presubiculum (f) 
and the entorhinal cortex (g). Fluorescent Aβ immunohistochemistry highlights 
the contrast between the diffuse nature of the presubiculum (b, white arrow) and 
the entorhinal cortex (c) which is confirmed by negative Thioflavin staining of the 
presubiculum (d) and positive staining in the entorhinal cortex (e). Bar in (a) 
represents 1000µm in a; 100µm in b, c, d, and e; 50µm in f and g. 
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Figure 6.5: Tau and microglial comparisons between the presubiculum and entorhinal 
cortex in Alzheimer’s disease. Tau immunohistochemistry shows the difference between 
the density of neuropil threads and neurofibrillary tangles in the presubiculum and entorhinal 
cortex. The microglial marker, Iba1, shows the number of microglia being similar between 
the two regions, whereas CD68 and CR3-43 highlight the increase in the number of 
activated microglia in the entorhinal cortex compared to the presubiculum. 
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Figure 6.6: Quantification of tau immunohistochemistry in the presubiculum and 
entorhinal cortex. The density of the tau immunohistochemistry observed in the entorhinal 
cortex and presubiculum was quantitated (a). The overall density included NFTs and 
neuropil threads were significantly higher in the entorhinal cortex compared to the 
presubiculum in SAD and FAD. The number of NFTs was also significantly higher in the 
entorhinal cortex compared to the presubiculum in SAD and FAD (b). Presubiculum is shown 
by blue circles and entorhinal cortex by red squares. FAD; Familial Alzheimer’s disease: 
SAD; Sporadic Alzheimer’s disease: TREM2; TREM2 variant AD cases. Significance was 
identified by Wilcoxon paired ranks test and is shown as * for p<0.05, ** for p<0.005, *** for 
p<0.0005, ****p<0.0001. Bars represent median with 95% confidence intervals.  
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6.4.3 Microglial pathology in the presubiculum 
To assess the level of microglial activation in the presubiculum deposit, three different 
microglial markers were used to determine the amount of microglia and their activation 
states between the two regions. Iba1 was used to assess the number of microglia as it is a 
pan microglial marker that recognises both surveillant microglia and activated microglia. 
CD68 and CR3-43 were used to assess the level of microglial activation as they recognise 
phagocytic microglia and antigen presenting cells respectively. Immunohistochemistry 
showed that levels of Iba1 positive microglia were largely unchanged between the two areas 
except for the SAD group in which there were significantly more microglia in the 
presubiculum than the entorhinal cortex in the sporadic AD group (Figure 6.7a, p=0.0323). 
Conversely, the activated microglial stains CD68 and CR3-43 were decreased in the 
presubiculum compared to the entorhinal cortex in SAD (CD68 p<0.0001, CR3-43 p=0.0003) 
and FAD groups (CD68 p=0.0195, CR3-43 p=0.0195). TREM2 variant AD cases showed no 
difference (Figure 6.7b and c).  
Although TREM2 variant AD cases did not show any significant changes throughout any of 
the immunohistochemical stains, there is a reduced number of Iba1 positive microglia in both 
the presubiculum and entorhinal cortex compared to sporadic and familial cases (Figure 
6.7a). This may indicate that there are less microglia overall in the TREM2 variant cases, 
and may mean that the effect of different pathology in the presubiculum could be less 
prominent in these cases when compared to SAD or FAD cases.  
6.4.4 Amyloid peptides in the presubiculum 
To identify the biochemical profile of Aβ peptides in the presubiculum compared to the 
entorhinal cortex, a combination of laser-capture microdissection and matrix-assisted laser 
desorption ionisation time-of-flight mass spectrometry (MALDI-MS) was used to identify the 
different Aβ isoforms. Figure 6.8 depicts a representative mass spectra that was typically 
observed. As indicated in Table 6.21, all cases from SAD, FAD and TREM2 variant AD 
cases had many more N-terminally truncated and pyroglutamate modified Aβ isoforms in the  
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Figure 6.7: Quantification of microglial immunohistochemistry in the presubiculum 
and entorhinal cortex. The density of microglial staining was calculated using the 
microglial antibodies Iba1 (a), CD68 (b) and CR3-43 (c). Iba1 density was similar in FAD 
and TREM2 but significantly less in the entorhinal cortex of SAD. Both CD68 and CR3-
43 densities showed significantly less microglia in the SAD and FAD groups. FAD; 
Familial Alzheimer’s disease: SAD; Sporadic Alzheimer’s disease: TREM2; TREM2 
variant AD cases. Significance was identified by Wilcoxon paired ranks test and is shown 
as * for p<0.05, ** for p<0.005, *** for p<0.0005, ****p<0.0001. Bars represent median 
with 95% confidence intervals. 
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entorhinal cortex than the presubiculum. The full length Aβ1-42 and the N-terminally 
truncated Aβ4-42 isoforms were the only isoforms detected in the presubiculum other than 
one SAD case which also detected pyroglutamate modified pGluAβ3-42.  
To identify whether this result was also observed pathologically, previously published N-
terminally truncated and pyroglutamate modified Aβ isoform antibodies were used for further 
pathological comparison between the two areas (Wittnam et al., 2012). However, all the 
antibodies followed the same morphological pattern as the previous Aβ 
immunohistochemistry (Figure 6.9). This is contradictory to the mass spectrometry results 
but may indicate that while these isoforms are present as indicated by 
immunohistochemistry, the levels vary dramatically and were undetectable using these 
MALDI-MS methods.  
6.4.5 Proteomic expression in the presubiculum 
Further exploration of the protein expression differences between the presubiculum and 
entorhinal cortex were performed using laser-capture microdissection and quantitative label 
free mass spectrometry analysis. Homogenised samples were split into a soluble and 
insoluble fraction during the extraction process and run separately on the mass 
spectrometer. A total of 561 proteins were detected in the soluble supernatant fraction and 
1824 proteins in the insoluble pellet fraction. Proteins were detected either in both fractions 
(303 proteins) or in just the soluble fraction (254 proteins) or the insoluble fraction (1488 
proteins). The fold change in expression was calculated for each protein for one region 
compared to the other (2.7.5).  
An average of all AD cases (SAD, FAD and TREM2 combined) was used to determine the 
main differences occurring between the two regions with a more detailed analysis of the 
different disease subgroups completed later. The complete list of proteins, their expression 
and fold change expression can be found in Supplementary CD Table 2.  
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Case type 5-42 7-42 8-42 9-42 10-42 4-42 1-40 2-42 2-43 1-42 p3-40 p3-42 p11-42
SAD Y Y






Case type 5-42 7-42 8-42 9-42 10-42 4-42 1-40 2-42 2-43 1-42 p3-40 p3-42 p11-42
SAD Y Y Y Y Y Y Y Y Y
SAD Y Y Y
FAD Y Y Y Y Y Y Y Y Y Y
FAD Y Y Y Y Y Y Y Y Y Y Y
TREM2 AD Y Y
TREM2 AD Y Y Y Y Y Y Y Y Y
Figure 6.8: Mass spectra of the Aβ peptide pattern from the presubiculum and 
entorhinal cortex. Representative mass spectra from case 9 highlights the differences 
between the full length Aβ species identified in the presubiculum (A) compared to the 
truncated and post-translationally modified Aβ species identified in the entorhinal cortex (B). 
* represent unidentified non-Aβ related peaks. A peak was considered as identified if the 
signal-to-noise was > 2.   
Table 6.1: Aβ isoforms present in the presubiculum and entorhinal cortex of SAD, FAD 
and TREM2 variant AD cases. Different lengths of isoform are shown in each column with p 
indicating pyroglutamate modified Aβ isoforms. SAD (cases 9 and 25); FAD (cases 27 and 
30); TREM2 variant AD (cases 1 and 5). 
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When averaging the results from all AD cases, a total of 107 proteins had a fold change of 
1.5 or greater increase in the presubiculum compared to the entorhinal cortex in the soluble 
fraction and 221 in the insoluble fraction. The most altered 30 proteins in each instance are 
shown in Table 6.2 and Table 6.3. The number of gene ontology terms that were over-
represented from these proteins were determined using Webgestalt, with the top biological 
processes all indicating biosynthetic and biogenetic processes (Table 6.7).  
Among the list of proteins found to be increased in the presubiculum were proteins that 
already have been shown to be associated with AD. DOCK2 (Dedicator of cytokinesis 
protein 2, Table 6.2, row 7), had an 11-fold average increase in the presubiuclum and is 
known to modulate microglial cytokine secretion, phagocytosis and paracrine neurotoxicity 
Figure 6.9: Comparison of different Aβ isoforms in the presubiculum and entorhinal 
cortex. Antibodies for 1-57, 2-48 and pE were tested. The presubiculum can be identified in 
each as shown in the first column of images by the black arrow (2x magnification). The 
second column shows the presubiculum with each antibody at 20x magnification and the third 
depicts the entorhinal cortex at 20x magnification.  
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(Cimino et al., 2009, 2013). HSPA9 (Heat shock 70kDa protein 9, Table 6.2, row 9), had a 9-
fold average increase in the presubiculum and it has been shown that this protein could 
regulate Aβ toxicity (Flachbartová and Kovacech, 2013). LDHA (L-lactate dehydrogenase A 
chain, Table 6.2, row 11) has a 5-fold increase in the presubiculum and its overexpression is 
linked to resisting the toxic effects of Aβ (Newington et al., 2012). NSG1 (Neuron-specific 
protein family member 1, Table 6.2, row 20), has an average increase of 3-fold in the 
presubiculum and has been shown to have a role in the proteolytic processing of APP 
(Muthusamy et al., 2015). AGPS (Alkyldihydroxyacetonephosphate synthase, Table 6.3, row 
4) has an average increase of 19-fold in the presubiculum and is a rate limiting enzyme that 
can alter APP levels (Grimm et al., 2011). Lastly, INPP5D (phosphatidylinositol 3_4_5-
trisphosphate 5-phosphatase 1, Table 6.3, row 25), is increased by an average of 4.5-fold in 
the presubiculum and is a negative regulator of the innate immune system (Efthymiou and 
Goate, 2017).  
Additionally, there were 2 proteins that were only detected in the presubiculum, Annexin A1 
in the soluble fraction and TUSC5 in the insoluble fraction (Table 6.6). Annexin A1 plays a 
role in the innate immune system and is involved in the resolution of inflammation and 
wound healing. It was detected with a count of 13.2 in SAD and 273 in the TREM2 variant 
AD cases. TUSC5 (tumour suppressor candidate 5) is thought to be involved in fat 
metabolism.  
109 proteins had a 1.5 or greater fold change increase in the entorhinal cortex compared to 
the presubiculum in the soluble fraction and 559 in the insoluble fraction. The most altered 
30 of these proteins in each instance are found in Table 6.4 and Table 6.5. The number of 
gene ontology terms that were over-represented from these proteins were determined using 
Webgestalt, with the top biological processes indicating that cell organisation and cell 
signalling are affected (Table 6.8). This was validated with Ingenuity Pathway analysis which 
also showed the top canonical pathways that were altered in the insoluble fraction were a 
number of cell signalling pathways (Figure 6.10). 
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  Gene ID Gene name Average SAD FAD TREM2 
DHCR7 7-dehydrocholesterol reductase  49.60 N/A N/A 124.71 
SATB1 DNA-binding protein SATB1  41.63 4.58 5.96 93.12 
SLC24A3 
Sodium/potassium/calcium 
exchanger 3  20.93 8.88 N/A 24.22 
SMARCA4 Transcription activator BRG1  17.94 N/A N/A 196.05 
CD2 T-cell surface antigen CD2  15.98 4.81 N/A 162.09 
PRKCSH Glucosidase 2 subunit beta  12.87 N/A N/A 19.21 
DOCK2 Dedicator of cytokinesis protein 2  11.68 7.65 N/A N/A 
RPL30 60S ribosomal protein L30  9.47 1.58 N/A 31.92 
HSPA9 Stress-70 protein_ mitochondrial  9.39 3.05 1.04 53.17 
SLC12A9 Solute carrier family 12 member 9  6.26 2.13 3.32 36.80 
LDHA L-lactate dehydrogenase A chain  5.10 19.10 1.25 1.24 
DLAT 
Acetyltransferase component of 
pyruvate dehydrogenase complex  4.70 2.21 2.71 14.91 
ANXA5 Annexin A5  4.52 1.12 1.34 15.53 
ABCA8 
ATP-binding cassette sub-family A 
member 8  4.20 1.50 3.84 N/A 
USP35 
Ubiquitin carboxyl-terminal hydrolase 
35 4.20 1.43 14.19 N/A 
CCDC88C Protein Daple 3.98 1.27 69.86 2.75 
R3HDM1 R3H domain-containing protein 1  3.79 1.45 9.49 14.37 
RERE 
Arginine-glutamic acid dipeptide 
repeats protein  3.76 1.64 1.38 12.44 
ATRIP ATR-interacting protein  3.44 1.50 2.80 12.78 
NSG1 
Neuron-specific protein family 
member 1  3.33 1.67 2.43 7.32 
VAT1 
Synaptic vesicle membrane protein 
VAT-1 homolog  3.13 1.59 1.01 6.40 
PTK2 Focal adhesion kinase 1  3.01 3.67 1.40 11.35 
TUBB1 Tubulin beta-1 chain  2.93 1.09 9.91 4.18 
TUBA3C Tubulin alpha-3C/D chain  2.84 10.65 3.45 2.31 
BCS1L Mitochondrial chaperone BCS1  2.80 1.81 5.38 1.12 
EHD2 EH domain-containing protein 2  2.77 1.04 1.83 7.26 
PFN1 Profilin-1  2.74 1.08 1.29 5.26 




oncogenes  2.73 1.82 10.39 2.00 
TBC1D1 TBC1 domain family member 1  2.61 1.27 2.73 10.89 
Table 6.2: Top 30 proteins with greatest average fold change increase in the 
presubiculum for the soluble fraction. Fold change for average of all cases (SAD, FAD 
and TREM2 combined) as well as the fold change for each disease group (SAD, FAD, 
TREM2) is shown. Yellow indicates a fold change where increase is in presubiculum 
whereas green indicates fold change where increase is in entorhinal cortex. N/A is shown 
where the protein was found in only one region, the region that was found is indicated by 
colour.  
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Gene ID Gene name Average SAD FAD TREM2 
CTDSPL CTD small phosphatase-like protein  217.36 29.26 N/A 431.19 
PRR12 Proline-rich protein 12  36.36 N/A 6.37 N/A 
ZFP30 Zinc finger protein 30 homolog  27.09 340.01 N/A N/A 
AGPS 
Alkyldihydroxyacetonephosphate 
synthase_ peroxisomal  
19.10 49.12 9.46 8.29 
SLC38A10 
Putative sodium-coupled neutral 
amino acid transporter 10  
18.78 23.76 5.04 29.46 
IFT122 
Intraflagellar transport protein 122 
homolog  
16.58 61.79 N/A N/A 
LRRC70 
Leucine-rich repeat-containing protein 
70  
12.64 57.57 4.21 N/A 
ZNF540 Zinc finger protein 540  11.61 29.52 3.44 15.96 
ZBTB48 
Zinc finger and BTB domain-
containing protein 48  
10.71 18.20 9.46 3.80 
S100A9 Protein S100-A9  9.96 38.49 N/A N/A 
CEP55 Centrosomal protein of 55 kDa  9.20 39.35 N/A 28.29 
PRSS2 Trypsin-2  8.49 131.53 10.58 2.45 
GNB3 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-3  
6.71 1.28 23.33 12.02 
KRT16 Keratin_ type I cytoskeletal 16  6.54 9.05 3.15 6.44 
CWC27 
Peptidyl-prolyl cis-trans isomerase 
CWC27 homolog  
6.29 50.39 1.44 2.14 
MTERF2 
Transcription termination factor 2_ 
mitochondrial  
5.99 1.03 8.23 N/A 
ADAMTS15 
A disintegrin and metalloproteinase 
with thrombospondin motifs 15  
5.77 N/A 4.68 N/A 
DDX56 
Probable ATP-dependent RNA 
helicase DDX56  
5.77 22.81 8.10 361.36 
DDX19A 
ATP-dependent RNA helicase 
DDX19A  
5.63 1.44 2.14 14.53 
ZNF267 Zinc finger protein 267  5.61 8.94 N/A 3.54 
VAT1 
Synaptic vesicle membrane protein 
VAT-1 homolog  
5.51 3.74 N/A 24.30 
KRT9 Keratin_ type I cytoskeletal 9  5.47 3.01 11.07 5.24 
FMO2 
Dimethylaniline monooxygenase [N-
oxide-forming] 2  
5.21 59.44 4.82 1.59 
TRPM1 
Transient receptor potential cation 
channel subfamily M member 1  
5.16 25.33 N/A 7.70 
INPP5D 
Phosphatidylinositol 3_4_5-
trisphosphate 5-phosphatase 1  
4.49 676.90 N/A N/A 
C2CD2 C2 domain-containing protein 2  4.40 20.38 1.81 3.48 
BTAF1 
TATA-binding protein-associated 
factor 172  
4.25 4.12 9.93 1.25 
ESRP2 Epithelial splicing regulatory protein 2  4.21 28.85 1.11 1.46 
ACTN2 Alpha-actinin-2  4.00 5.42 1.96 21.91 
KRT14 Keratin_ type I cytoskeletal 14  4.00 2.92 5.91 5.17 
 
Table 6.3: Top 30 proteins with greatest average fold change increase in the 
presubiculum for the insoluble fraction. Fold change for average of all cases (SAD, FAD 
and TREM2 combined) as well as the fold change for each disease group (SAD, FAD, 
TREM2) is shown. Yellow indicates a fold change where increase is in presubiculum 
whereas green indicates fold change where increase is in entorhinal cortex. N/A is shown 
where the protein was found in only one region, the region that was found is indicated by 
colour. White indicates it was not detected for either. 
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Of particular interest, PSAP (Prosaposin, Table 6.4, row 3), has a 21-fold average increase 
in the entorhinal cortex compared to the presubiculum. It has been indicated to be involved 
with progranuluin neuroprotection mechanisms that are activated in models of AD and 
degradation of glycosphingolipids in lysosomes (Nicholson et al., 2016). Upregulation of this 
protein in the entorhinal cortex may indicate a defect in lysosomal catabolism. S100A8 
(Table 6.4, row 4), has a 17.6 fold increase in the entorhinal cortex and this protein has links 
to Aβ production (Lodeiro et al., 2017). OTUB1 (ubiquitin thioesterase, Table 6.4, row 16), 
has a 5-fold increase in the entorhinal cortex and is a tau deubiquitinating enzyme (Wang et 
al., 2017). XPO1 (exportin-1, Table 6.5, row 10), has a 39-fold increase in the entorhinal 
cortex and is known to be an Aβ toxicity modifier (Rosenthal et al., 2012). AQP4 (aquaporin 
4, Table 6.5, row 19), has a 21-fold increase in the entorhinal cortex. AQP4 is an astrocytic 
water channel protein and it has been identified to be distributed in the proximity of Aβ 
plaques and may have a role in Aβ clearance (Hoshi et al., 2012; Xu et al., 2015). LRP1 
(Prolow-density lipoprotein receptor-related protein 1, Table 6.5, row 23), has a 15.5-fold 
increase in the entorhinal cortex and is involved in clearance of Aβ, as referred to in Chapter 
3 (Ismail et al., 2017; Storck and Pietrzik, 2017; Zandl-Lang et al., 2017). C3, a complement 
protein (Table 6.5, row 26), has a 13-fold increase in the entorhinal cortex and this has been 
shown to be elevated in AD and contributes to Aβ clearance (Shi et al., 2017). Lastly, despite 
not being one of the most altered 30 changing proteins, APOE (apolipoprotein E) still has an 
8.6-fold increase in the entorhinal cortex compared to the presubiculum. Having an ApoE4 
allele confers increased risk of having AD and APOE is thought to play roles in Aβ clearance 
and microglial recruitment as discussed in previous chapters.  
A greater number of proteins were only detected in the entorhinal cortex than in the 
presubiculum, with 48 being listed (Table 6.6). For example, CXCR3, was detected in the 
entorhinal cortex of all three AD subgroups, whereas SFTPC, PRMT5, PURA, SNX6 and 
RAB21 were only detected in the entorhinal cortex of SAD and FAD cases. CX3CR3 (C-X-C 
chemokine receptor type 3, Table 6.6, row 6), has a role in microglial activation and has an 
impact on Aβ plaque burden (Krauthausen et al., 2014, 2015). SFTPC (Pulmonary  
Chapter 6 – Could the presubiculum be protected from neurodegeneration observed in AD 
and TREM2 variant cases 
Page | 203  
 
Gene ID Gene name Average SAD FAD TREM2 
DNALI1 
Axonemal dynein light intermediate 
polypeptide 1  36.52 N/A 1.26 86.91 
SERPINB5 Serpin B5  29.92 N/A N/A N/A 
PSAP Prosaposin  21.16 N/A 17.47 N/A 
S100A8 Protein S100-A8  17.64 40.50 1.93 69.12 
GSDMD 
Gasdermin domain containing 1_ 
isoform CRA_d  15.15 5.44 N/A N/A 
CDK5RAP2 
CDK5 regulatory subunit-associated 
protein 2  9.59 4.95 2.05 26.67 
EPN3 EPN3 protein  9.45 2.14 9.48 62.64 
SMARCA2 
Probable global transcription 
activator SNF2L2  8.16 N/A N/A N/A 
CKAP5 Cytoskeleton-associated protein 5  7.52 1.26 1.02 30.87 
EIF2AK4 
Eukaryotic translation initiation 
factor 2-alpha kinase 4  7.01 5.18 8.11 21.02 
CKMT1A 
Creatine kinase U-type_ 
mitochondrial  6.52 4.87 N/A N/A 
LGALS7 Galectin-7  6.42 11.64 2.18 2.42 
PGAM1 Phosphoglycerate mutase 1  5.46 3.53 1.39 91.14 
ADGRE2 
Adhesion G protein-coupled 
receptor E2  5.26 28.93 N/A 3.80 
MXRA8 
Matrix-remodeling-associated 
protein 8  4.98 1.49 620.99 4.81 
OTUB1 Ubiquitin thioesterase OTUB1  4.75 N/A N/A N/A 
DPYSL2 
Dihydropyrimidinase-related protein 
2  4.73 1.43 3.02 33.45 
SNAP25 Synaptosomal-associated protein 25  4.47 1.29 6.20 37.93 
PCDHGA1 Protocadherin gamma-A1  4.41 6.20 7.76 109.56 
MMP8 Neutrophil collagenase  4.31 N/A N/A 45.29 
CLIP2 
CAP-Gly domain-containing linker 
protein 2  4.29 7.42 N/A N/A 
S100A9 Protein S100-A9  4.20 9.29 1.26 2.11 
GFAP Glial fibrillary acidic protein  3.93 1.35 9.27 6.33 
YARS Tyrosine--tRNA ligase  3.93 1.60 3.71 27.44 
SLC6A17 
Sodium-dependent neutral amino 
acid transporter SLC6A17  3.81 1.40 8.18 2.75 
CALM2 Calmodulin  3.58 1.73 4.15 9.97 
CALML3 Calmodulin-like protein 3  3.51 4.00 2.76 10.96 
FAM109A Sesquipedalian-1  3.41 8.25 4.00 1.16 
TRAP1 
Heat shock protein 75 kDa_ 
mitochondrial  3.22 1.24 4.32 17.84 
MTFR1 Mitochondrial fission regulator 1  3.19 N/A N/A N/A 
 
Table 6.4: Top 30 proteins with greatest average fold change increase in the 
entorhinal cortex for the soluble fraction. Fold change for average of all cases (SAD, 
FAD and TREM2 combined) as well as the fold change for each disease group (SAD, FAD, 
TREM2) is shown. Yellow indicates a fold change where increase is in presubiculum 
whereas green indicates fold change where increase is in entorhinal cortex. N/A is shown 
where the protein was found in only one region, the region that was found is indicated by 
colour. White indicates it was not detected for either. 
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Gene ID Gene name Average SAD FAD TREM2 
OR6M1 Olfactory receptor 6M1  
234.71 132.14 2270.51 235.48 
ANXA4 Annexin A4  151.09 1.59 N/A N/A 
SH3GL1 Endophilin-A2  141.46 106.03 N/A N/A 
ATP6V1D V-type proton ATPase subunit D  95.62 0.00 N/A 1.85 
C9orf172 Uncharacterized protein C9orf172  78.34 2.16 N/A N/A 
SQSTM1 Sequestosome-1  61.44 17.10 N/A N/A 
NAGLT1 Sodium-dependent glucose transporter 1  51.13 13.33 9.00 217.03 
TUBGCP6 Gamma-tubulin complex component 6  44.26 16.59 150.94 29.57 
PITPNA 
Phosphatidylinositol transfer protein 
alpha isoform  
40.75 31.17 96.02 25.87 




family member 6  
38.36 N/A N/A N/A 
SLC19A3 Thiamine transporter 2  30.85 377.55 25.65 1.03 
NDUFB9 
NADH dehydrogenase [ubiquinone] 1 
beta subcomplex subunit 9  
29.92 30.91 N/A N/A 
PSMD1 
26S proteasome non-ATPase regulatory 
subunit 1  
27.06 N/A N/A N/A 
ZSCAN18 
Zinc finger and SCAN domain-containing 
protein 18  
25.93 2.77 N/A N/A 
PCSK6 
Proprotein convertase subtilisin/kexin 
type 6  
24.92 N/A N/A N/A 
GNPTAB 
N-acetylglucosamine-1-
phosphotransferase subunits alpha/beta  
24.72 24.13 N/A 3.83 
SLC35E3 Solute carrier family 35 member E3  21.61 12.83 127.25 154.01 
AQP4 Aquaporin-4  20.81 18.44 164.78 1.48 
GFAP Glial fibrillary acidic protein  18.38 3.60 172.48 2.79 
UQCRB Cytochrome b-c1 complex subunit 7  16.14 28.44 N/A N/A 
C1QBP 
Complement component 1 Q 
subcomponent-binding protein_ 
mitochondrial  
16.01 N/A N/A N/A 
LRP1 
Prolow-density lipoprotein receptor-
related protein 1  
15.57 N/A N/A 1.24 
DAAM2 
Disheveled-associated activator of 
morphogenesis 2  
14.67 5.36 N/A 2.21 
HOMEZ 
Homeobox and leucine zipper protein 
Homez  
14.13 8.16 N/A 1.55 
C3 Complement C3  13.23 15.29 N/A N/A 
WDR7 WD repeat-containing protein 7  12.44 5.44 N/A N/A 
NADK2 NAD kinase 2_ mitochondrial  12.43 N/A N/A N/A 
THBS2 Thrombospondin-2  12.11 N/A 10.12 N/A 
TWF2 Twinfilin-2  12.05 1.56 N/A N/A 
Table 6.5: Top 30 proteins with greatest average fold change increase in the 
entorhinal cortex for the insoluble fraction. Fold change for average of all cases (SAD, 
FAD and TREM2 combined) as well as the fold change for each disease group (SAD, FAD, 
TREM2) is shown. Yellow indicates a fold change where increase is in presubiculum 
whereas green indicates fold change where increase is in entorhinal cortex. N/A is shown 
where the protein was found in only one region, the region that was found is indicated by 
colour. White indicates it was not detected for either. 
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surfactant-associated protein C, Table 6.6, row 10), is also able to fibrillise into the amyloid 
conformational state (Johansson et al., 2004).  PRMT5 (protein arginine N-methyltransferase 
5, Table 6.6, row 20), is known to have a role in Aβ toxicity (Quan et al., 2015). PURA 
(transcriptional activator protein Pur-alpha, Table 6.6, row 24), is known to regulate APP 
transcription (Darbinian et al., 2008). SNX6 (sorting nexin 6, Table 6.6, row 28), is involved in 
APP cleavage regulation (Okada et al., 2010). RAB21 (ras-related protein Rab-21, Table 6.6, 
row 46), is involved in γ- secretase activity (Sun et al., 2017).  
Interestingly, many of the proteins only detected in the entorhinal cortex were not detected at 
all in the TREM2 variant AD cases (Table 6.6). Furthermore, the gene ontology terms that 
are specifically being over-represented in each disease subgroup are markedly variable. The 
biological processes show very little overlap between disease groups in either soluble or 
insoluble conditions or where these proteins are higher in the presubiculum or higher in the 
entorhinal cortex (Figure 6.11). The same can be seen when looking at the heatmap of 
canonical pathways identified to be represented in these cases. The TREM2 group has an 
opposite level of activation or inhibition when compared to SAD and FAD (Figure 6.10).  
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Gene ID Gene name 
Presubiculum Entorhinal cortex 
SAD FAD TREM2 SAD FAD TREM2 
Soluble fraction 
ANXA1 Annexin A1  13.23 0 272.97 0 0 0 
Insoluble fraction 
REV1 DNA repair protein REV1  0 0 0 0 25.40 0 
IL18R1 Interleukin-18 receptor 1  0 0 0 146.97 41.69 20.44 
MATR3 Matrin-3  0 0 0 16.79 80.66 0 
MGAT5B Alpha-1_6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase B  0 0 0 0 47.84 0 
CXCR3 C-X-C chemokine receptor type 3  0 0 0 120.05 32.83 16.35 
KPNA4 Importin subunit alpha-3  0 0 0 29.88 154.19 0 
FES Tyrosine-protein kinase Fes/Fps  0 0 0 0 141.58 0 
ADAM23 Disintegrin and metalloproteinase domain-containing protein 23  0 0 0 261.58 313.14 0 
SFTPC Pulmonary surfactant-associated protein C  0 0 0 7.49 36.46 0 
HLA-C HLA class I histocompatibility antigen_ Cw-6 alpha chain  0 0 0 5.71 109.15 0 
IRS4 Insulin receptor substrate 4  0 0 0 31.66 103.96 0 
F10 Coagulation factor X  0 0 0 0 46.64 0 
UBE3C Ubiquitin-protein ligase E3C  0 0 0 4.76 154.69 0 
KPNA5 Importin subunit alpha-6  0 0 0 0 64.52 0 
SNX3 Sorting nexin-3  0 0 0 66.40 192.78 0 
FRYL Protein furry homolog-like  0 0 0 4.97 92.82 0 
PARVA Alpha-parvin  0 0 0 0 92.10 0 
SHB SH2 domain-containing adapter protein B 0 0 0 175.43 0 0 
PRMT5 Protein arginine N-methyltransferase 5  0 0 0 18.15 61.53 0 
KCNRG Potassium channel regulatory protein  0 0 0 0 30.91 0 
SFXN5 Sideroflexin-5  0 0 0 29.32 103.02 0 
LANCL2 LanC-like protein 2  0 0 0 54.68 168.97 0 
PURA Transcriptional activator protein Pur-alpha  0 0 0 214.74 475.79 0 
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PGLYRP2 N-acetylmuramoyl-L-alanine amidase  0 0 0 120.23 37.64 17.65 
RPS17 40S ribosomal protein S17  0 0 0 49.15 94.80 0 
DBNL Drebrin-like protein  0 0 0 0 86.94 0 
SNX6 Sorting nexin 6_ isoform CRA_b  0 0 0 0 58.57 0 
PTRF Polymerase I and transcript release factor 0 0 0 24.72 363.85 0 
ASPSCR1 Tether-containing UBX domain for GLUT4  0 0 0 0 100.34 0 
PLCD3 1-phosphatidylinositol 4_5-bisphosphate phosphodiesterase delta-3  0 0 0 0 91.18 0 
EIF2S1 Eukaryotic translation initiation factor 2 subunit 1  0 0 0 0.58 68.89 1.03 
AP1S1 AP-1 complex subunit sigma-1A  0 0 0 16.06 106.38 0 
HPCAL4 Hippocalcin-like protein 4  0 0 0 89.90 278.02 0 
NARS Asparagine--tRNA ligase_ cytoplasmic  0 0 0 56.47 342.24 0 
GALK1 Galactokinase  0 0 0 3.94 146.20 0 
MPP2 MAGUK p55 subfamily member 2  0 0 0 0 103.68 22.75 
DCLK2 Serine/threonine-protein kinase DCLK2  0 0 0 45.18 186.62 0 
MYBBP1A Myb-binding protein 1A  0 0 0 11.14 286.39 0 
ARHGEF2 Rho guanine nucleotide exchange factor 2  0 0 0 19.97 90.59 0 
CENPJ Centromere protein J  0 0 0 0 50.32 0 
RNPEP Aminopeptidase B  0 0 0 0 125.99 0 
MST1R Macrophage-stimulating protein receptor  0 0 0 0 146.84 0 
GIT1 ARF GTPase-activating protein GIT1 0 0 0 10.31 72.13 0 
CALU Calumenin  0 0 0 65.71 129.02 0.06 
RAB21 Ras-related protein Rab-21  0 0 0 18.83 80.71 0 
PDXP Pyridoxal phosphate phosphatase  0 0 0 0 223.36 0 
RCN2 Reticulocalbin-2  0 0 0 32.74 153.52 0 
POGZ Pogo transposable element with ZNF domain  0 0 0 0 56.31 0 
TUSC5 Tumor suppressor candidate 5  0 0 141.22 0 0 0 
Table 6.6: Proteins only detected in either the presubiculum or the entorhinal cortex. Raw counts for each disease group are shown for both the 
presubiculum and the entorhinal cortex. 
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GO ID GO term
GO:0004111 creatine kinase activity
GO:0004859 phospholipase inhibitor activity
GO:0016775 phosphotransferase activity, nitrogenous group as acceptor
GO:0055102 lipase inhibitor activity
GO:0004857 enzyme inhibitor activity
GO:0046915 transition metal ion transmembrane transporter activity
GO:0005546 phosphatidylinositol-4,5-bisphosphate binding
GO:0005544 calcium-dependent phospholipid binding
GO:0017016 Ras GTPase binding
GO:0031267 small GTPase binding
Insoluble fraction
Biological process Molecular function Cellular component
GO ID GO term GO ID GO term GO ID GO term
GO:0044281 small molecule metabolic process GO:0043168 anion binding GO:0005856 cytoskeleton
GO:0009152 purine ribonucleotide biosynthetic process GO:0005198 structural molecule activity GO:0044430 cytoskeletal part
GO:0022607 cellular component assembly GO:0036094 small molecule binding GO:0044444 cytoplasmic part
GO:0034329 cell junction assembly GO:0036094 small molecule binding GO:0005737 cytoplasm
GO:0043269 regulation of ion transport GO:0000166 nucleotide binding GO:0033267 axon part
GO:0010035 response to inorganic substance GO:1901265 nucleoside phosphate binding GO:0030424 axon
GO:0009260 ribonucleotide biosynthetic process GO:0032549 ribonucleoside binding GO:0005882 intermediate filament
GO:0046390 ribose phosphate biosynthetic process GO:0032550 purine ribonucleoside binding GO:0044463 cell projection part
GO:0044085 cellular component biogenesis GO:0016462 pyrophosphatase activity GO:0045111 intermediate filament cytoskeleton




Table 6.7: Top 10 over-represented gene ontology terms from proteins that had greater than 1.5 fold change increase in the presubiculum 
compared to entorhinal cortex in the categories Biological processes, Molecular function and cellular components. 
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Biological process Molecular function Cellular component
GO ID GO term GO ID GO term GO ID GO term
GO:0035637 multicellular organismal signaling GO:0005200 structural constituent of cytoskeleton GO:0033267 axon part
GO:0019226 transmission of nerve impulse GO:0005198 structural molecule activity GO:0043005 neuron projection
GO:0006836 neurotransmitter transport GO:0050786 RAGE receptor binding GO:0044463 cell projection part
GO:0007268 synaptic transmission GO:0005515 protein binding GO:0045202 synapse
GO:0007267 cell-cell signaling GO:0005509 calcium ion binding GO:0005829 cytosol
GO:0048812 neuron projection morphogenesis GO:0008022 protein C-terminus binding GO:0005882 intermediate filament
GO:0045103 intermediate filament-based process GO:0042287 MHC protein binding GO:0030424 axon
GO:0050877 neurological system process GO:0005504 fatty acid binding GO:0033269 internode region of axon
GO:0045104 intermediate filament cytoskeleton organization GO:0019829 cation-transporting ATPase activity GO:0045111 intermediate filament cytoskeleton
GO:0032990 cell part morphogenesis GO:0005856 cytoskeleton
Insoluble fraction
Biological process Molecular function Cellular component
GO ID GO term GO ID GO term GO ID GO term
GO:0048666 neuron development GO:0005515 protein binding GO:0005737 cytoplasm
GO:0071842 cellular component organization at cellular level GO:0043168 anion binding GO:0044444 cytoplasmic part
GO:0071841 cellular component organization or biogenesis at cellular levelGO:0000166 nucleotide binding GO:0005622 intracellular
GO:0071840 cellular component organization or biogenesis GO:1901265 nucleoside phosphate binding GO:0044424 intracellular part
GO:0016043 cellular component organization GO:0032553 ribonucleotide binding GO:0005829 cytosol
GO:0051649 establishment of localization in cell GO:0032555 purine ribonucleotide binding GO:0005856 cytoskeleton
GO:0030030 cell projection organization GO:0017076 purine nucleotide binding GO:0044430 cytoskeletal part
GO:0009056 catabolic process GO:0036094 small molecule binding GO:0032991 macromolecular complex
GO:0022008 neurogenesis GO:0001883 purine nucleoside binding GO:0043234 protein complex
GO:0051641 cellular localization GO:0032549 ribonucleoside binding GO:0044422 organelle part
Soluble fraction
 
Table 6.8: Top 10 over-represented gene ontology terms from proteins that had greater than 1.5 fold change increase in the entorhinal cortex 
compared to the presubiculum in the categories Biological processes, Molecular function and cellular components. 
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Figure 6.10: Canonical pathways represented in insoluble fraction of presubiculum 
proteomic data. Pathways found according to z-score given by IPA software. Orange 
represents a predicted activation of the pathway and blue represents a predicted inhibition of 
the pathway based on expression values found in the data. Intensity of colour relates to how 
activated or inhibited the pathway is predicted to be. 
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Figure 6.11: Comparison of overlapping over-represented gene ontology biological 
process terms between different disease groups. Venn diagram for each condition, both 
soluble and insoluble fractions and for the proteins that were increased in the presubiculum 
and those that were increased in the entorhinal cortex. Pink represents SAD, Blue 
represents FAD, Green represents TREM2 variant cases. Numbers indicate how many GO 
terms are in that category.  
 
6.5 Discussion 
In this chapter, the morphological differences in the presubiculum compared to the 
neighbouring entorhinal cortex in sporadic AD cases were confirmed and these results were 
built upon with the discovery that these morphological differences are also present in familial 
AD and TREM2 variant cases. Therefore indicating that these changes are not specific to 
one subtype of AD. Not only does the presubiculum have a large non-fibrillar Aβ deposit 
compared with the fibrillar dense-core Aβ plaques of the entorhinal cortex, there was also 
significantly reduced tau accumulation, significantly less microglial activation and less N- 
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Figure 6.12: Amyloid processing pathway proteins with presubiculum proteomic 
expression data overlaid. Green represents downregulation of that protein in the 
presubiculum compared to the entorhinal cortex. Pathway generated using Ingenuity 
Pathway Analysis software. 
 
terminally truncated and pyro-glutamate modified Aβ peptides present than in the entorhinal 
cortex. Furthermore, the proteomic expression profile of the presubiculum varies dramatically 
from the entorhinal cortex region. 
Through fluorescent immunohistochemistry and Thioflavin-S staining it was confirmed that 
the large deposit of the presubiculum is not of a fibrillar amyloid conformational state, in 
agreement with previous studies that also showed Thioflavin and congo red negative 
staining and no PiB ligand binding (Akiyama et al., 1990; Ji et al., 2015; Wisniewski et al., 
1998). Numerous studies predict that non-fibrillar Aβ will mature into fibrillar Aβ in time, 
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indicating that diffuse plaques mature into dense-core fibrillar plaques during disease 
progression (Cork et al., 1990; Iwatsubo et al., 1996; Mann et al., 1992; Pappolla et al., 
1991; Probst et al., 1991). However, the diffuse non-fibrillar Aβ deposits found in the 
presubiculum are present from an early disease stage (Thal phase 2 or 3) and do not mature 
into dense-core plaques with disease progression, with the diffuse deposits even seen at 
end- stage disease (Thal et al., 2000). Therefore, the presubiculum must have different 
properties that do not allow the diffuse Aβ to mature into dense-core Aβ plaques. There may 
be a factor or multiple factors that are stopping this process from occuring.  
To determine if the Aβ peptide species in each region differed and whether it could explain 
the differences in the conformational state of the amyloid present, both the presubiculum and 
Aβ plaques from the entorhinal cortex were laser-capture microdissected and analysed by 
mass spectrometry. Aβ peptides are formed from cleavage of the amyloid precursor protein, 
APP (Ghiso and Frangione, 2002; Hébert et al., 2004; Shirotani et al., 2004). It is cleaved at 
both the N-terminal and the C-terminal. However, in both instances the cleavage can occur 
at different points in the protein and by different secretases. A beta-secretase known as 
BACE1 is the secretase that cleaves APP at the N-terminus, whereas a γ-secretase 
complex, made up of presenilin-1, presenilin-2, nicastrin, APH-1 and PEN-2 is responsible 
for cleaving at the C-terminus (Niimura et al., 2005; Thinakaran and Koo, 2008). C-terminal 
cleavage results in cleavage either at residue 40 or 42. Both Aβ1-40 and Aβ1-42 are thought 
to have pathogenic roles and both exist in Aβ plaques (Alonzo et al., 1998; Iwatsubo et al., 
1994). However, the Aβ1-40 peptide is more commonly linked to amyloid deposition in CAA 
than AD (Alonzo et al., 1998). It is thought that the ratio between these two peptides is more 
indicative of disease status (Spies et al., 2010). Many N-terminally truncated Aβ peptides 
can be formed and a combination of these are reported to be found in dense-core Aβ 
plaques (Portelius et al., 2010). In addition, several Aβ peptides can be modified by 
pyroglutamate and this process is thought to mature the Aβ plaques (Wittnam et al., 2012). 
Only the Aβ1-42, Aβ4-42 and pGluAβ3-42 peptides were found in the presubiculum, and 
these were not all present in each case. On the other hand, a whole range of N-terminally 
truncated and pyroglutamate modified peptides were detected in the plaques from the 
entorhinal cortex. This finding suggests that a variety of N-terminally truncated or 
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pyroglutamate-modified Aβ peptides need to be present for fibrillisation to occur and that 
cleavage of APP in the presubiculum may differ and stop this occurring. 
However, when a range of antibodies for various N-terminally truncated and pyroglutamate 
modified Aβ peptides that were previously characterised were used immunohistochemically 
to identify Aβ1-57, Aβ2-48, pE-Aβ peptides, all were present in the presubiculum (Wittnam et 
al., 2012). This suggests that these peptides do exist in the presubiculum, so the reason 
fibrillisation does not occur may not only be down to the differing APP cleavage. Reasons for 
the discrepancies between the mass spectrometry analysis and immunohistochemistry 
analysis may be down to sensitivity in the different methods. Even though the various Aβ 
peptides exist in the presubiculum, they may not be present in the same quantities as they 
are in the entorhinal cortex and are therefore below a detectable level using MS due to the 
concentration of the full length Aβ peptides. The proteins could alter in their solubility or post-
translational modifications and these possible differences could also explain the variation 
observed here.  
In addition, some of the proteins that had markedly different levels of expression between 
the presubiculum and entorhinal cortex in the label-free proteomic data, were proteins 
involved in APP cleavage or Aβ deposition and fibrillisation (Figure 6.12). Both SNX6 and 
NSG1 are involved in BACE1 mechanisms. SNX6 negatively regulates BACE1 cleavage of 
APP and this protein was only detected in the entorhinal cortex of samples (Okada et al., 
2010). NSG1 is a neuronal vesicle trafficking protein and it affects the proteolytic processing 
of APP through BACE1 with its endocytic and recycling functions (Muthusamy et al., 2015). 
NSG1 expression was markedly increased in the presubiculum compared to entorhinal 
cortex. The lack of SNX6 and the increase of NSG1 in the presubiculum could indicate that 
greater amounts of BACE1 are internalised into endosomes, and that the BACE1 that is left 
is not regulated by SNX6, therefore producing less N-terminally truncated Aβ peptides.  
Conversely, RAB21 regulates γ-secretase activity via interaction with presenilin-1. 
Overexpression of RAB21 results in greater Aβ production, whereas silencing of this gene 
reduced Aβ levels (Sun et al., 2017). RAB21 was only detected in the entorhinal cortex, 
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suggesting that its absence in the presubiculum could lead to decreased Aβ production in 
this region.  
Aβ production levels in the presubiculum are also highlighted by the proteins PURA and 
S100A8. PURA is a transcription factor and it has multiple consensus binding sites within the 
APP promoter. It therefore regulates the transcription of APP and when PURA is bound, 
transcription of APP is downregulated (Darbinian et al., 2008). Although PURA is only found 
in the entorhinal cortex, indicative of APP transcription being downregulated in this area, it 
may in fact indicate that there is dysregulation of APP transcription in the presubiculum. 
S100A8 is thought to aggregate itself prior to Aβ plaque formation and treatment of a 
neuronal cell line with S100A8 leads to increased Aβ1-42 but decreased levels of Aβ1-40 
(Lodeiro et al., 2017). S100A8 was increased in the entorhinal cortex which may indicate that 
Aβ in the presubiculum is not able to mature into dense-core plaques as S100A8 is not 
present in the correct levels to stimulate aggregation, through its own aggregation.  
The results show that Aβ generation/processing is different in the presubiculum compared to 
the entorhinal cortex and this may go some way to explaining the reason that the Aβ 
deposits in the presubiculum do not go on to form mature plaques. However, this 
phenomenon is not unique to AD. A similar observation of a large diffuse amyloid deposit 
can be seen in the presubiculum of both Familial British Dementia (FBD) and Familial Danish 
Dementia (FDD) (Murray et al, in preparation). Both of these diseases have amyloid that 
fibrillises to form amyloid deposits, as in AD, but in these diseases it is formed from the ABri 
and ADan proteins, respectively, due to mutations in the BRI2 gene. This may suggest that 
mechanisms other than Aβ generation/processing may occur here and lead to a hypothesis 
that other factors in the tissue environment are causing these protein expression levels to 
change.   
Previous studies identified the presubiculum had decreased tau accumulation and lacked 
neurofibrillary degeneration, in contrast to the entorhinal cortex which displayed many NFT’s 
(Akiyama et al., 1990; Bobinski et al., 1995; Fukutani et al., 1997; Kalus et al., 1989). This 
study also confirmed these observations with significantly less phosphorylated tau and 
significantly less NFT’s in the presubiculum than in the entorhinal cortex. This would suggest 
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that the mechanisms affecting accumulation of either Aβ or tau are not present or are 
disrupted in the presubiculum. It has been argued that since Aβ plaques can promote tau 
aggregation, the relative lack of Aβ plaques observed in the presubiculum has a downstream 
effect by halting tau aggregation or provoking less hyperphosphorylation of tau (Bennett et 
al., 2017). The proteomic results revealed that OTUB1 (OTU Deubiquitinase, Ubiquitin 
Aldehyde Binding 1), a tau deubiquitinating enzyme is increased in the entorhinal cortex 
compared to the presubiculum. OTUB1 has been shown to increase AT8 positive tau 
accumulation and to increase tau-seeded tau aggregation (Wang et al., 2017). The fact that 
OTUB1 is not seen in high levels in the presubiculum, strengthens the possibility that tau is 
not able to form aggregates as well or as quickly in the presubiculum as it does in the 
entorhinal cortex.  
Inflammation also occurs in AD and is thought to be a part of the pathogenic mechanism. 
Microglia play a large role in this, with reports of microglia becoming activated, clustering 
around Aβ plaques and phagocytosing to clear Aβ (see chapter 4 for more detail) (Boche et 
al., 2013; Gahtan and Overmier, 1999; Gentleman, 2013; Giulian et al., 1996; Griffin et al., 
1989, 1995; Itagaki et al., 1989; Meda et al., 1995; Rogers and Lue, 2001; Rogers et al., 
1992a, 1992b; Sheng et al., 1998; Yin et al., 2017). Additionally, they are known to release a 
selection of toxic cytokines that have a pro-inflammatory effect and lead to further cell death 
(Blasko et al., 2004; Goldgaber et al., 1989). Previous reports have identified that the 
presubiculum contains no activated microglia compared to many activated microglia in the 
entorhinal cortex (Akiyama et al., 1990; Wisniewski et al., 1998). This was also confirmed in 
this study with significantly less microglia positive for activated microglial markers CD68 and 
CR3-43 in the presubiculum than in the entorhinal cortex. However, microglia were present 
in both areas, as shown by the Iba1 microglial marker that detects both activated and non-
activated microglia.  
Proteomic results also suggest that the microglia in the presubiculum act differently to the 
microglia in the entorhinal cortex. DOCK2 is part of the prostaglandin pathway and has been 
shown to modulate microglial cytokine secretion and phagocytosis (Cimino et al., 2009). 
DOCK2 deficient AD mice do not have morphologically different microglia but do have 
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reduced Aβ plaque size (Cimino et al., 2013). DOCK2 was found only to affect fibrillar Aβ 
with no change occurring in soluble Aβ levels (Cimino et al., 2013). As DOCK2 is increased 
in the presubiculum, where no mature Aβ plaques are forming, this increase in expression 
could be due to increased modulation of the microglia, rather than its effect on Aβ. INPP5D 
is a negative regulator of the innate immune system and has been linked to AD in GWAS 
studies (Efthymiou and Goate, 2017; Gjoneska et al., 2015; McKeever et al., 2017). INPP5D 
mRNA expression was shown to be increased in early stage AD but to decrease as cognitive 
decline worsens (Yoshino et al., 2017). The increase of INPP5D in the presubiculum 
suggests that negative regulation of the immune system is more likely to occur here than in 
the entorhinal cortex. This may explain why microglia do not become activated in this region. 
Additionally, CX3CR3 is a fractalkine receptor and is involved in neuroinflammatory 
modulation. APP/PS1 CX3CR3-/- mouse models have been reported to have reduced plaque 
burden with microglia being less associated with plaques (Krauthausen et al., 2015). 
Furthermore, this deficiency caused the attenuation of activated microglia and astrocytes 
with activated microglial markers CD45 and CD11b being absent and reduced levels of pro-
inflammatory cytokines being released (Krauthausen et al., 2014, 2015). As CX3CR3 was 
only found in the entorhinal cortex, the presubiculum could be modelling a CX3CR3 
deficiency, leading to reduced activation of the microglia and reduced association with the 
Aβ present. ANXA1 promotes resolution of inflammation by supressing microglial activation 
and inhibiting secretion of their pro-inflammatory cytokines (Ries et al., 2016). ANXA1 was 
only detected in the presubiculum suggesting that a protective role in attenuating the 
microglial response to Aβ.  
Whilst protein changes heavily influence the generation of Aβ/ tau inclusions, there are other 
cellular mechanisms that are likely to contribute to aberrant protein accumulation. For 
example, the difference in Aβ morphology could be due to altered clearance mechanisms of 
Aβ. The proteins C3, AQP4, LRP1 and APOE are all increased in the entorhinal cortex and 
have an effect on Aβ clearance. C3 is part of the complement cascade and has been shown 
to be elevated in AD (Shi et al., 2017). C3 deficient mice confer protection against 
hippocampal synapse loss and alter the microglial phenotype (Shi et al., 2017). Blockage of 
C3 resulted in Aβ- induced synapse loss rescue before Aβ plaques could accumulate (Shi et 
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al., 2017). AQP4 has been linked to lymphatic drainage as well as transcytosis mechanisms 
of clearance of Aβ (Yang et al., 2016). It is commonly found associated with Aβ plaques 
(Yang et al., 2017b). LRP1 is involved in the endocytosis and transcytosis of Aβ (Kanekiyo et 
al., 2012, 2013; Nazer et al., 2008; Shibata et al., 2000; Storck and Pietrzik, 2017; Zandl-
Lang et al., 2017). Overexpression of LRP1 has been shown to lead to increased Aβ 
production, however, deletion of LRP1 in multiple AD mouse models show an increase in 
soluble Aβ and a decrease in clearance (Cam et al., 2005; Pietrzik et al., 2002; Storck and 
Pietrzik, 2017; Zerbinatti et al., 2004). Interestingly, LRP1 binds to APOE and both are found 
to be upregulated in the entorhinal cortex (Bell et al., 2007). C3 also has been shown to bind 
to the ApoE4 allele (Bonham et al., 2016). Additionally, APOE has been reported to aid Aβ 
clearance by helping to transport Aβ to the blood vessels (Cirrito et al., 2005; Huynh et al., 
2017). Although these results are indicative of less clearance occurring in the presubiculum, 
this could be down to these proteins playing different roles or having their activity altered in 
some way. For example, LRP1 can only clear Aβ when it is membrane bound but cleavage 
by beta and gamma secretases, similar to APP, can cause the protein to be released 
extracellularly (Arnim et al., 2005; Shackleton et al., 2016; Storck and Pietrzik, 2017). 
Conversely, less Aβ clearance could be a consequence of the absence of fibrillar Aβ, with 
these mechanisms of clearance only occurring in the presence of mature Aβ plaques.  
Another downstream effect of the presubiculum only containing the non-fibrillar Aβ is less Aβ 
toxicity. Both HSPA9 and LDHA were upregulated in the presubiculum but are normally 
shown to be downregulated in AD (Newington et al., 2012; Silva et al., 2014). HSPA9 is a 
chaperone protein and an expression study identified the isoforms of this protein to be 
differentially expressed in the hippocampal region, and it is thought to regulate the Aβ toxicity 
pathway (Flachbartová and Kovacech, 2013). LDHA confers a resistance to Aβ toxicity by 
decreasing ROS production and mitochondrial respiration (Newington et al., 2012). 
Reduction in Aβ toxicity may not be the cause of the different deposits in the presubiculum 
but could add to the neuroprotective nature of the region, allowing it stay in this conformation 
even as disease progresses.  
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There are limitations to this study that also need to be considered. Firstly, the number of 
cases analysed by mass spectrometry is low and these results could not be confirmed until 
the same methods were applied to a larger cohort. Secondly, the absence of a protein in one 
of the regions does not necessarily indicate that it is absent from this region. It could be due 
to technical variability of the mass spectrometer. Therefore, further validation of proteins of 
interest would be needed to be certain of this.  
Although the results discussed were seen in all three AD subgroups, TREM2 variant cases 
do appear to have an altered proteomic expression compared to SAD and FAD cases. The 
result is similar but fewer proteins appear to be causing this effect. As TREM2 is expressed 
on microglia and mediates its effects through microglia, this could point to the microglial 
changes observed here being the key to the neuroprotection that the presubiculum appears 
to have.  
6.5.1 Conclusions 
In summary, the presubiculum is morphologically and proteomically diverse from its 
neighbouring region, the entorhinal cortex. The anatomically driven, targeted proteomic 
screen has highlighted that many changes occur in this region and these associate with less 
aggregation of Aβ/tau and reduced microglial activation. The presubiculum has deep 
connections with both the entorhinal cortex, the hippocampus and other areas of the brain. It 
would therefore be expected that AD pathology would deposit in the same manner in the 
presubiculum. It remains unclear why this is the case but further biochemical analysis of this 
area and the proteins mentioned here is needed to elucidate what the cause of this 
phenomenon is and what is occurring as an effect. Understanding what factor is the key to 
this neuroprotective mechanism, could lead to therapeutic neuroprotection that can be 
applied to the whole brain and help halt the disease in its tracks.  
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7 General discussion 
7.1 Summary 
1. TREM2 variant cases that had a diagnosis of AD had similar levels of amyloid 
plaques and neurofibrillary tangle pathology to sporadic cases and TREM2 variant 
cases that were diagnosed as controls had no AD pathology, with no pathological 
aging present. 
2. Five out of six TREM2 variant cases had CAA pathology, including one case that 
had no AD pathology present. 
3. All TREM2 variant SAD cases were identified to have an ApoE4 allele present 
whereas TREM2 variant control cases did not. 
4. Amyloid plaque load was significantly different between FAD cases and TREM2 
variant cases and SAD cases. However there were no differences in type of plaque 
between disease groups. 
5. Tau load did not significantly differ between TREM2 variant cases and other disease 
groups.  
6. TREM2 variant cases had more CD68+ve, circular microglia than other disease 
groups, indicative of a phenotype of a phagocytic state. 
7. TREM2 variant AD cases showed upregulation of many neuroinflammatory genes 
compared to other disease groups, whereas TREM2 variant control cases showed 
downregulation in these genes. 
8. Proteins known to be increased in AD were found to be further increased in TREM2 
variant AD cases and decreased in TREM2 variant controls. 
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9. The presubiculum was identified to be pathologically and biochemically altered 
compared to its neighbouring region, the entorhinal cortex. The presubiculum 
contains diffuse amyloid deposits, significantly less neurofibrillary tangles, 
significantly less activated microglia and an altered proteomic profile.  
 
TREM2 was discovered as a genetic risk factor for late onset AD with a similar odds ratio to 
ApoE4. Several variants were found to be pathogenic and having confirmed that TREM2 is 
expressed on microglia, it was speculated that inflammation may play a greater role in AD 
pathogenesis than was first thought. Various studies have been undertaken to determine 
what effect a TREM2 variant may have on the brain, and its role in AD pathogenesis. 
However, those have predominantly been on animal or cell models, causing a deficiency or 
overexpression of TREM2. The aim of this thesis was to elucidate further the role TREM2 
variants may have on the brain compared to other sporadic and familial forms of AD and 
healthy controls. Using multiple techniques and methods the role of TREM2 has been 
investigated to understand how TREM2 may confer a risk.  
The TREM2 variant cases that had a pathologically confirmed diagnosis of AD had similar 
macroscopic abnormalities to those seen in sporadic and familial forms of AD. The TREM2 
variant cases that were confirmed to be normal controls showed no marked differences to 
normal healthy controls at the macroscopic level. At the microscopic level, the pathology was 
indicative of AD with amyloid plaque deposition and neurofibrillary tangles present in TREM2 
variant AD cases and indicative of controls with no AD pathology in the TREM2 variant 
control cases.  
7.2 The effect of TREM2 variants on amyloid deposition 
Mouse models (APPPS1) overexpressing TREM2 showed decreases in amyloid plaque 
deposition whereas models of TREM2 deficiency showed conflicting results on the amount of 
amyloid load between cortical and hippocampal regions (Jay et al., 2015, 2017; Jiang et al., 
2014, 2016b; Wang et al., 2015, 2016). On the other hand, amyloid plaques that were found 
in TREM2 deficient mice and post-mortem TREM2 R47H variants were reported to be more 
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diffuse and less compact than those of wildtype mice (Yuan et al., 2016). Here, this was 
investigated by assessing the numbers of diffuse and dense core plaques between Thal 
phase regions and the different AD subgroups (SAD, FAD, TREM2 SAD). Whilst there were 
significantly more diffuse plaques than dense-core plaques in all regions and in each disease 
group, there was no difference when comparing each disease group to each other. 
Therefore, this data conflicted with the experiment Yuan et al., (2016) performed previously. 
Yuan et. al, classified the plaques into a greater number of categories and only assessed the 
frontal gyrus so the conflicting data could be due to these results not having the same 
specificity and variation seen across regions. 
The type of amyloid plaque deposition did not differ between the disease groups. However, 
the type of plaque is important in the process of AD pathogenesis. This was demonstrated 
by the presubiculum region showing a level of neuroprotection against neurodegeneration 
and the amyloid deposited in this region was shown to be Thioflavin-S negative and 
therefore in a non-amyloid conformational state. Further to this, the presence of N-terminally 
truncated and pyroglutamate modified Aβ peptides were observed to be decreased in the 
presubiculum, although still present when compared to the entorhinal cortex. These N-
terminally truncated and pyro-glutamate modified forms of Aβ have been shown to be 
located in dense-core amyloid plaques and mature the plaques (Portelius et al., 2010; 
Wittnam et al., 2012). Additionally, the decreased expression of the S100A8 protein in the 
presubiculum compared to the entorhinal cortex, highlighted that the Aβ in the presubiculum 
may be stopped from maturing into dense core plaques (Lodeiro et al., 2017). These dense 
core plaques are also known to be more toxic than diffuse plaques (Serrano-Pozo et al., 
2011) and proteins involved with the mechanisms of Aβ toxicity are differentially expressed 
in the presubiculum compared to the entorhinal cortex, showing reduced Aβ toxicity 
mediated effects in this region.  
From these observations, it can be hypothesised that fibrillar dense cored plaques 
encourage the toxic effects and neurodegeneration that ensue in the AD brain. As the 
TREM2 variant AD cases do not show differences in the levels of diffuse and dense cored 
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plaques when compared to SAD and FAD, it might be suggested that TREM2 variants do not 
confer risk through the fibrillisation of Aβ plaques.  
When the total Aβ load was determined, there were differences between regions and a 
difference in the amount of Aβ load in the FAD cases. FAD cases had significantly more Aβ 
load in the later Thal phases than SAD and TREM2 variant SAD cases. Proteins involved 
with APP cleavage and Aβ production were also found in the top proteins changing in 
expression of the FAD cases when comparing levels to controls. As FAD cases have 
pathogenic mutations in the genes that produce Aβ, this is logical. However, the larger levels 
of Aβ and the pathways involved with it may be the main mechanism in this group, meaning 
other mechanisms found in SAD may not work in the same way. This would be important to 
remember if any treatments come to light.  
Although FAD cases had the highest Aβ load and the largest variation of amyloid processing 
genes changing in expression compared to controls, the amyloid processing pathway in the 
proteomic data was predicted to be activated in all groups other than the TREM2 variant 
control group in which it was predicted to be inhibited. TREM2 variant AD cases had the 
highest levels of upregulation of APP protein and TREM2 variant controls were the only 
group to show downregulation of APP compared to controls. Proteins involved in this 
pathway also changed in expression in the presubiculum when compared to the entorhinal 
cortex. The amyloid processing pathway is therefore clearly important in AD pathogenesis 
and differences in this pathway between TREM2 variant SAD cases to SAD cases indicate 
that changes in Aβ production may increase risk, even if how the Aβ is then fibrillised doesn’t 
show a difference.  
7.3 The effect of TREM2 variants on tau deposition 
In the same way to Aβ, hyperphosphorylated tau only increased in load in FAD cases in the 
frontal cortex and putamen compared to other disease groups, otherwise no differences in 
tau load were observed. This gives further indication that the TREM2 variant SAD cases act 
similarly to SAD cases along the mechanisms forming the pathological hallmarks of AD. 
However, TREM2 deficient mouse models showed that tau was increased compared to 
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wildtypes, suggesting that a difference in tau accumulation is only partially observed in 
heterozygous variants (Jiang et al., 2015, 2016a). On the other hand, TREM2 variant SAD 
cases had the highest increase of MAPT protein expression compared to controls whereas 
TREM2 variant controls were the only group to show downregulation. A pattern that was also 
seen with APP. This data allows us to hypothesise that although there may be increased 
production of amyloid and tau, the mechanisms that are involved with causing their 
aggregation are no different in the TREM2 variant SAD cases to SAD cases but play a larger 
role in FAD cases.  
As TREM2 variant controls have a downregulation of tau at the protein level compared to 
controls without a TREM2 variant, they may lack the ability to produce tau as well as the 
mechanisms involved with TREM2 aggregation being no different. Therefore, resulting in no 
build-up of neurofibrillary tangles. The proteins NEDD8 and MAP1B were two of the top 
upregulated proteins in the TREM2 variant controls and they have both been reported to be 
located with neurofibrillary tangles (Iqbal et al., 2005; Mori et al., 2005). This suggests that 
there is the propensity for neurofibrillary tangles to occur, however another factor is stopping 
this, potentially less tau being produced.  
TREM2 variant controls may have similar mechanisms to the neuroprotection observed in 
the presubiuclum of AD cases. Significantly less hyperphosphorylated tau and neurofibrillary 
tangles are present in this area compared to the neighbouring entorhinal cortex. Additionally, 
a protein OTUB1 known to increase tau accumulation and aggregation was shown to be 
decreased in the presubiculum compared to the entorhinal cortex (Wang et al., 2017). Less 
production and aggregation of tau in both the presubiculum and the TREM2 variant controls 
may be one way in which these cases or region is protected from the effects/risk of AD.  
7.4 Inflammatory response in TREM2 variant cases 
Microglia are known as surveillant cells that detect any foreign substances or cell debris and 
initiate an inflammatory reaction to reduce it. One way that they do this is by being activated 
into a phagocytic phenotype. Microglia in AD are thought to be responsible for clearing Aβ 
plaques via phagocytic mechanisms and TREM2 is thought to have a role in these 
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mechanisms (Boche et al., 2013; Gahtan and Overmier, 1999; Guerreiro et al., 2013a; 
Jonsson et al., 2012b; Shaffer et al., 1995; Weldon et al., 1998; Wu et al., 2014).  
TREM2 deficiency models observed a decreased level of phagocytosis, whereas TREM2 
overexpression models observed an increased level of phagocytosis (Jay et al., 2015; Jones 
et al., 2014; Kleinberger et al., 2014; Satoh et al., 2013; Ulrich and Holtzman, 2016; Wang et 
al., 2015; Zhao and Lukiw, 2013). It was therefore hypothesised that TREM2 variants would 
have a loss of function that would result in less clearance of Aβ and hence a higher risk of 
AD. When in the phagocytic phenotype, the microglia display an amoeboid morphology, 
which are CD68 positive. When assessing the microglial morphology of the microglia in 
these cases, it was observed that the TREM2 variant SAD cases had more of an amoeboid 
morphology as they had increased CD68 microglial load, increased circularity across 
microglial markers and a reduced perimeter, indicative of the smaller rounder amoeboid 
microglia. This would suggest that the microglia in the TREM2 variant SAD cases are more 
capable of phagocytosis. This either would conflict with the data from the TREM2 deficiency 
models or suggest that even though the microglia are in the phagocytic amoeboid 
morphology, the process of phagocytosis is not as efficient or reduced. Mazaheri et al., 
(2017) show that TREM2 deficient microglia have reduced chemotaxis and response to 
neuronal injury. Alterations in the phagocytic mechanisms in these TREM2 variant microglia 
may play a part in their reduced response to neuronal injury. 
Although TREM2 is thought to initiate a cascade in which phagocytosis occurs, an 
alternative mechanism of phagocytosis also exists via toll-like receptors (Blander and 
Medzhitov, 2004; Frank et al., 2008; Guerreiro et al., 2013a; Jonsson et al., 2012b; Piccio et 
al., 2007; Takahashi et al., 2005). This alternative mechanism also promotes release of pro-
inflammatory cytokines that go on to cause further neuronal damage and exacerbate the 
inflammatory reaction (Blander and Medzhitov, 2004; Frank et al., 2008; Guerreiro et al., 
2013a; Jonsson et al., 2012b; Takahashi et al., 2005). This pathway was shown to be 
activated in the TREM2 deficient models and this could therefore lead to the increased risk 
seen in these TREM2 variant cases (Takahashi et al., 2005). Further evidence of this 
alternative mechanism being used was found in the genetic expression data, using 
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nanostring technology. This pathway was shown to be upregulated in all AD cases. 
However, the TREM2 variant SAD cases had higher levels of upregulation than SAD cases, 
especially of TLR2 and TLR4. As this pathway is activated at higher levels in TREM2 variant 
SAD cases, this could lead to increased phagocytosis using this mechanism. Thus, 
explaining the more amoeboid phagocytic morphology that is seen in these cases. These 
cases with a TREM2 variant would then be at increased risk of AD, as higher levels of pro-
inflammatory cytokines would be released, leading to increased neuronal loss. 
The TLR pathway is not the only neuroinflammatory pathway to be affected in AD. The 
importance of inflammation in AD was observed when the presubiculum, the region not 
affected by AD pathology, showed significantly less activated microglia than the entorhinal 
cortex and protein expression levels showed altered modulation, regulation, activation of 
microglia and a reduced association of microglia with Aβ plaques. Suggestive that in an area 
with little neurodegeneration, the inflammatory profile is changed markedly.  
Further to this, the whole neuroinflammatory pathway was predicted to be activated in all of 
the AD groups, with inhibition only predicted in the TREM2 variant control group. However, 
as observed in the TLR pathway, the TREM2 variant SAD cases have an increased amount 
of activation as more genes in this overall pathway are upregulated.  
The TREM2 variant control group observed large levels of downregulation of genes involved 
in the overall neuroinflammatory pathway, showing a striking difference from the healthy 
controls, which also have no AD pathology. They also show downregulation across the 
whole TLR pathway. The microglia in these cases had a different pattern of morphology to 
that seen in the TREM2 variant SAD cases; exhibiting an opposite pattern of Iba1 load, 
microglia lacking antigen presenting cells in a more surveillant phenotype, and increased 
P2RY12 homeostatic microglia. These cases have the same variant of TREM2 as the 
TREM2 variant SAD cases but have opposing microglial and inflammatory phenotypes and 
little AD pathology present. Therefore, another factor other than the TREM2 variant must 
have an effect in order to determine the effects the variant has on the brain and how much 
risk of AD is present.  
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7.5 APOE genotype effect on TREM2 variant cases 
APOE is the major known risk factor for late onset AD and confers different levels of risk 
dependent on its genotype (Allen D. Roses, 1996). The presence of two ApoE4 alleles 
confer the greatest risk with ApoE2 allele’s having more of a protective role (Yu et al., 2015). 
ApoE4 additionally causes risk of CAA (Alonzo et al., 1998; Pfeifer et al., 2002). However, 
for CAA, ApoE2 has been shown to cause vascular changes so not be protective of CAA (Yu 
et al., 2015). This is evident within these TREM2 variant cases. The APOE genotype was 
determined for each case and it was found that the TREM2 variant cases that had a SAD 
diagnosis all had at least one ApoE4 allele, whereas the TREM2 variants that were 
diagnosed as controls, having no AD pathology, had no ApoE4 allele. Five out of six of these 
cases all had CAA, indicating that the ApoE genotype may determine the presence of CAA, 
regardless of TREM2 variant. As a case that no AD pathology had CAA, it may suggest a 
link between TREM2 and the failure of intramural periarterial drainage (IPAD) and CAA. As 
these cases have an altered extracelleular matrix composition as shown in the proteomic 
study, the basement membrane could be impaired leading to CAA.  
The finding that all TREM2 variant SAD cases had an ApoE4 allele could also be seen 
throughout the cases identified with TREM2 variants in the literature (Korvatska O et al., 
2015; Krasemann et al., 2017; Yuan et al., 2016). Therefore, the hypothesis that both an 
ApoE4 genotype and a TREM2 R47H variant are needed to cause AD was introduced 
(Murray et al, in press). APOE has been shown to be a ligand for TREM2 and it has been 
reported that APOE binding to TREM2 initiates the TREM2 signalling pathway, via its 
signalling adaptor protein, TYROBP/DAP12 (Atagi et al., 2015; Bailey et al., 2015; 
Jendresen et al., 2017; Krasemann et al., 2017). To date there has been no confirmation that 
different ApoE alleles bind to TREM2 at different affinities. However, as TREM2 variants, 
R47H in particular, have been shown to have reduced ligand binding, including lipoproteins, 
the binding to APOE in these variants may be reduced or changed (Abduljaleel et al., 2014; 
Wang et al., 2015).  
Where possible, a separate analysis based on APOE genotype rather than disease group 
was completed, to determine if the effect we are seeing between disease groups was 
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independent of APOE genotype or not. ApoE4 is reported to increase Aβ deposition and 
decrease its clearance (Castellano et al., 2011). However, in this data, no difference was 
found between genotypes for Aβ load, leading to the conclusion that APOE may have an 
effect on the way the Aβ is deposited rather than how much is deposited.  
Within the microglia, in which TREM2 binding to the APOE associated with plaques is 
reported to trigger phagocytic mechanisms, the ApoE2/2 microglia appeared to have an 
inactivated phenotype with decreased microglial load, a more ramified, surveillant shape and 
a smaller perimeter. In particular, they had an increased P2RY12 load that is indicative of 
larger amounts of homeostatic microglia. On the other hand, the ApoE4/4 microglia had a 
similar phenotype to that found in TREM2 variant SAD cases with increased CD68 load and 
a more amoeboid morphology. These results therefore indicate that APOE genotype has a 
larger effect on microglial phenotype than the deposition of AD pathology and hence may be 
an important link to inflammation.  
Furthermore, APOE is upregulated at the protein level of the insoluble fraction across all 
groups. This upregulation is highest in the TREM2 variant SAD group and markedly higher 
fold changes were observed in all groups compared to the TREM2 variant controls, in which 
the neuroinflammatory pathway is downregulated instead of upregulated. Similarly, APOE is 
increased in the entorhinal cortex compared to the presubiculum. As APOE is upregulated in 
areas or cases in which neuroinflammation is not activated, its role in inflammation is more 
convincing. 
ApoE4 genotypes have been shown to have increased neuroinflammation in P301S tau 
transgenic mouse models (Shi et al., 2017). The link between TREM2 and APOE may be 
modulated through the neuroinflammatory route. The TLR pathway had higher levels of 
upregulation in TREM2 variant SAD cases compared to other SAD cases. TLR activators 
have been shown to reduce microglial expression of TREM2 with further reduction observed 
in ApoE4/4 carriers compared to other genotypes. APOE itself is an upstream regulator of 
TLR2, which is one of the genes increased in TREM2 variant SAD cases. APOE and its 
individual phenotypes, may be causing decreased expression of TREM2, leading to reduced 
inhibition of the TLR response pathway and an increase in pro-inflammatory cytokines being 
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released. As TREM2 variant controls have no ApoE4 allele present, this effect would be 
reduced, leading to further inhibition of the TLR pathway, shown by downregulation of these 
genes, and the conventional phagocytosis triggered by TREM2 occurs with less 
inflammatory cascades. If this hypothesis is true, it would show that the effect of APOE 
genotype and TREM2 variants are linked, adding notion to the hypothesis that the TREM2 
variant cannot cause AD unless an ApoE4 allele is present.  
7.6 General conclusions 
Overall, this thesis has shown that TREM2 variant cases have differences in microglial 
phenotype, genetic and proteomic expression compared to either sporadic or familial AD 
cases but do not show changes in amyloid plaque or neurofibrillary tangle deposition 
analysed through semi-quantiative assessments or through diagnostic criteria. 
Previous literature suggested that TREM2 variants have a loss of function and they have 
reduced function in clearing amyloid plaques via phagocytic mechanisms. This study did not 
find a change in the amyloid load in TREM2 variants compared to AD and the TREM2 
variant cases did not show a difference in the number of diffuse and dense core plaques, this 
may not be the case. Instead, the microglial actions and inflammatory cascades that ensue 
may be having the effect in order to cause risk of AD. The most distinct changes in TREM2 
variant SAD cases here is in the changes seen in the neuroinflammatory pathway.  
The observation that TREM2 variant cases that do not have any AD pathology at time of 
death, have a different profile not only to other TREM2 variants and AD cases but also to 
normal controls, suggests that another factor is needed to promote a different route of 
pathogenesis to AD cases. TREM2’s link to APOE and the fact that the APOE genotype 
lacks an ApoE4 allele in these cases, indicates that APOE may be exerting this change 
between TREM2 variants, leading us to question whether the TREM2 R47H variant is acting 
independently.  
Limitations to this study include the small number of cases due to the rarity of the TREM2 
mutations that come to brain donation and the fact only late stage AD post-mortem brains 
have been investigated. This makes it harder to determine whether the changes we observe 
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are cause or consequence of the disease and the results need to be repeated in larger 
cohorts. Putting these limitations aside, I would propose the hypothesis that TREM2 and 
APOE work closely together, having an impact on the pro-inflammatory cascades that lead 
to further neuronal damage and death and lead to exacerbation of disease. Further 
investigations into these pathways and the differences between TREM2 variants that 
develop disease and those that don’t may lead us to the mechanisms that can be targeted 
for treatments.  
7.7 Future directions 
Human studies Experimental work 
Repeat these experiments on a larger set of 
cases. Although there wasn’t wide variation 
between the TREM2 variants, whilst split into 
their AD/control groups, this could be by 
chance. Therefore, studying these effects 
observed in a greater number of cases 
would allow us to be certain these 
differences are true. 
Assess the pathology in the same way in 
different TREM2 mouse models to determine 
if the methods are producing different results 
or whether the pathology differs greatly 
between rodents and humans. 
To further establish what changes may occur 
with Aβ plaques in the TREM2 variants, the 
size of the plaques could be determined and 
additionally the microglia that are seen to 
surround the dense core plaques could be 
counted, with the physical interactions 
between the two verified using a range of 
markers.  
iPSC models from patients with a TREM2 
variant could be used to determine when the 
Aβ plaques appear and when they do, what 
size they are and a microglial cell dish could 
be used to determine how they react when 
Aβ is introduced to the culture. 
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Further validation of new commercial TREM2 
antibodies would help elucidate this 
connection between amyloid plaques and 
microglia. These studies would help to 
determine why TREM2 models do see 
differences in amyloid plaque deposition and 
in this study, we do not.  
If failure to find a reproducible commercial 
antibody in human tissue, the TREM2 
distribution between different regions could 
be determined using pathology found in 
TREM2 haplosufficient mouse models.  
Validating the proteomic data with western 
blots to determine the increased protein level 
of APP, MAPT, APOE and GFAP in the 
TREM2 variant SAD cases would also be 
beneficial. 
Proteomics on TREM2 mouse models could 
be performed to determine if the same 
differences in protein expression can be 
observerd. This would help elucidate how 
reliable these mouse models are.  
As the genes within astrocytes in the 
neuroinflammation signalling pathway were 
shown to be altered and the protein levels of 
reactive astrocytes appear to be increased in 
TREM2 variant SAD cases, the astrocyte 
phenotype and morphology could be 
determined in a similar way to the microglial 
phenotype in this study. Results from this 
experiment could help elucidate the role of 
TREM2 further and how it interacts with all 
cell types, not just microglia. 
iPSC models from patients with a TREM2 
variant could be made into astrocytic cultures 
and the way that the astrocytes behave 
could be studied. Their reaction to Aβ being 
introduced could be measured.  
It would be interesting to see if the same 
differences found at the genetic and 
proteomic levels in the frontal cortex of these 
Mouse models that are TREM2 deficient 
could also have other inflammatory genes 
knocked out/inhibited and the accumulative 
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cases were also found in other regions 
affected by AD pathology and also in the 
regions that do not contain AD pathology. 
The results from the study on the 
presubiculum, an area protected from 
neurodegeneration, suggest that changes in 
the inflammatory proteins are key to 
neuroprotection so investigating these 
proteins in multiple other regions may help to 
reveal proteins that could be targeted to stop 
AD progression. 
effect could be observed. Assays to detect 
inflammatory proteins in these models could 
also be performed to determine if the same 
effects are seen in the mouse models.  
The differences between different AD 
subgroups in these datasets could also be 
further investigated to isolate which 
mechanisms are particular to each disease 
group and what the common mechanisms 
are. These findings should also be validated 
with immunohistochemistry, RT-PCR or 
western blotting techniques.  
Once uncommon/common pathways and 
mechanisms have been discovered between 
the different disease groups, inhibitors to 
molecules within the pathways could be 
used on mouse models and the effects 
observed.  
If the proteomics could be repeated on AD 
cases without a TREM2 variant but with a 
range of APOE genotypes it would allow us 
to better determine whether the APOE 
genotype is the main cause of the changes 
we observe in this study and whether these 
changes are independent or dependent on 
TREM2. Assessing the APOE load with 
immunohistochemistry and determining what 
The APOE genotype found in the different 
TREM2 mouse models in which they have 
measured pathology should be investigated 
to determine if the same links can be seen in 
these models.  
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cells it is located with would also help to 
further understand this link between APOE 
and TREM2. However, as APOE has 
multiple functions this could be a difficult 
task. 
APOE also has a role in the transport of Aβ 
to the blood vessels and is also known to 
confer risk to CAA. Five out of six of the 
TREM2 variant cases also have CAA 
pathology, so further investigation into 
whether the prevalence of CAA is higher in 
TREM2 variants compared with other AD 
cases would help us to also understand the 
full role that APOE is playing in these brains. 
Investigating the difference clearance 
mechanisms in TREM2 mouse models would 
help establish whether microglial clearance 
is the only clearance mechanism impaired. In 
particular, the IPAD mechanisms could be 
investigated in these mouse models to 
investigate the high prevalence of CAA in 
these TREM2 variant cases and to 
determine if APOE is linked to TREM2 
mechanisms via this pathway.  
As always, studying post-mortem brain tissue predominantly means studying late stage 
disease when changes have already occurred and picking out what is causing disease and 
what is occurring as a result of the disease can be confusing. The main alternative to this is 
using different models to look at these investigations. The caveat with this is that most 
models can only model one aspect of the disease so it is difficult to determine if the whole 
effect is seen. Ideally, these experiments could be repeated on post-mortem brains in a set 
of cases that have early stage disease.  
This thesis has highlighted that further investigation towards inflammation in AD needs 
pursuing and that there is still more to be discovered about the TREM2 signalling pathway 
and the link it has to APOE. Through some of these mentioned future directions, we could 
find answers to some of these questions, making us closer to understanding AD 
pathogenesis and finding targets for treatments.  
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Appendix Table 1: Bland-altman plots to determine number of random squares to be 
analysed. (a) Plot for ten squares, (b) plot for twenty squares, (c) Statistics for both sets of 
results. A lower R square value and greater p value for regression signifies a more reliable 
method. Ten squares is a reliable method in this instance.  
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Case Disease type Code 
Concentration 
(ng/μl) A260/A280 A260/A230 
1 TREM2 SAD B11 102.4 1.99 2.10 
2 TREM2 SAD B7 36.3 2.00 1.93 
3 TREM2 Control B8 70.3 2.01 2.07 
4 TREM2 Control B10 65.0 2.02 2.07 
5 TREM2 SAD B9 87.0 2.28 2.10 
6 TREM2 FAD B12 89.3 1.97 1.60 
7 SAD C4 197.0 2.11 2.53 
9 SAD C5 91.8 1.99 1.91 
10 SAD C7 16.4 2.14 1.87 
11 SAD C9 114.5 1.98 1.85 
12 SAD C1 77.0 1.99 2.06 
13 SAD C6 91.0 2.01 2.17 
14 SAD C2 55.5 2.00 2.08 
15 SAD C8 46.9 2.07 2.17 
17 SAD C10 43.7 1.99 1.79 
18 SAD C3 48.5 2.00 1.92 
26 FAD D6 80.0 2.01 2.08 
29 FAD C11 173.0 2.13 2.67 
30 FAD D2 38.5 1.94 1.69 
31 FAD D1 15.1 2.15 1.89 
32 FAD C12 40.3 2.05 1.65 
33 FAD D5 66.0 2.00 1.68 
34 FAD D3 54.9 2.03 1.98 
35 FAD D4 46.5 1.97 1.60 
37 Control D7 85.0 2.03 2.26 
38 Control D9 74.0 2.01 1.85 
39 Control D8 71.9 2.03 2.23 
40 Control D12 52.3 2.04 0.57 
41 Control D10 51.5 1.99 2.17 
42 Control D11 75.6 1.99 1.37 
Appendix Table 2: RNA concentration and spectrophotometer readings for Nanostring 
samples. Case number refers to the case in Table 2.3. Code refers to the well the sample 
was run on the Nanostring chip. 
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Official Symbol Accession Official Full Name 
Human inflammation panel genes 
AGER NM_001136.3 advanced glycosylation end product-specific receptor 
ALOX12 NM_000697.1 arachidonate 12-lipoxygenase 
ALOX15 NM_001140.3 arachidonate 15-lipoxygenase 
ALOX5 NM_000698.2 arachidonate 5-lipoxygenase 
AREG NM_001657.2 amphiregulin 
ARG1 NM_000045.2 arginase, liver 
ATF2 NM_001880.2 activating transcription factor 2 
BCL2L1 NM_138578.1 BCL2-like 1 
BCL6 NM_001706.2 B-cell CLL/lymphoma 6 
BIRC2 NM_001166.3 baculoviral IAP repeat containing 2 
C1QA NM_015991.2 complement component 1, q subcomponent, A chain 
C1QB NM_000491.3 complement component 1, q subcomponent, B chain 
C1R NM_001733.4 complement component 1, r subcomponent 
C1S NM_001734.2 complement component 1, s subcomponent 
C2 NM_000063.3 complement component 2 
C3 NM_000064.2 complement component 3 
C3AR1 NM_004054.2 complement component 3a receptor 1 
C4A NM_007293.2 complement component 4A (Rodgers blood group) 
C5 NM_001735.2 complement component 5 
C6 NM_000065.2 complement component 6 
C7 NM_000587.2 complement component 7 
C8A NM_000562.2 complement component 8, alpha polypeptide 
C8B NM_000066.2 complement component 8, beta polypeptide 
C9 NM_001737.3 complement component 9 
CCL11 NM_002986.2 chemokine (C-C motif) ligand 11 
CCL13 NM_005408.2 chemokine (C-C motif) ligand 13 
CCL16 NM_004590.2 chemokine (C-C motif) ligand 16 
CCL17 NM_002987.2 chemokine (C-C motif) ligand 17 
CCL19 NM_006274.2 chemokine (C-C motif) ligand 19 
CCL2 NM_002982.3 chemokine (C-C motif) ligand 2 
CCL20 NM_004591.1 chemokine (C-C motif) ligand 20 
CCL21 NM_002989.2 chemokine (C-C motif) ligand 21 
CCL22 NM_002990.3 chemokine (C-C motif) ligand 22 
CCL23 NM_145898.1 chemokine (C-C motif) ligand 23 
CCL24 NM_002991.2 chemokine (C-C motif) ligand 24 
CCL3 NM_002983.2 chemokine (C-C motif) ligand 3 
CCL4 NM_002984.2 chemokine (C-C motif) ligand 4 
CCL5 NM_002985.2 chemokine (C-C motif) ligand 5 
CCL7 NM_006273.2 chemokine (C-C motif) ligand 7 
CCL8 NM_005623.2 chemokine (C-C motif) ligand 8 
CCR1 NM_001295.2 chemokine (C-C motif) receptor 1 
CCR2 NM_001123041.2 chemokine (C-C motif) receptor 2 
CCR3 NM_001837.2 chemokine (C-C motif) receptor 3 
CCR4 NM_005508.4 chemokine (C-C motif) receptor 4 
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CCR7 NM_001838.2 chemokine (C-C motif) receptor 7 
CD163 NM_004244.4 CD163 molecule 
CD4 NM_000616.3 CD4 molecule 
CD40 NM_001250.4 CD40 molecule, TNF receptor superfamily member 5 
CD40LG NM_000074.2 CD40 ligand 
CD55 NM_000574.3 
CD55 molecule, decay accelerating factor for 
complement (Cromer blood group) 
CD86 NM_175862.3 CD86 molecule 
CDC42 NM_001039802.1 cell division cycle 42 (GTP binding protein, 25kDa) 
CEBPB NM_005194.2 CCAAT/enhancer binding protein (C/EBP), beta 
CFB NM_001710.5 complement factor B 
CFD NM_001928.2 complement factor D (adipsin) 
CFL1 NM_005507.2 cofilin 1 (non-muscle) 
CREB1 NM_134442.2 cAMP responsive element binding protein 1 
CRP NM_000567.2 C-reactive protein, pentraxin-related 
CSF1 NM_000757.4 colony stimulating factor 1 (macrophage) 
CSF2 NM_000758.2 colony stimulating factor 2 (granulocyte-macrophage) 
CSF3 NM_000759.2 colony stimulating factor 3 (granulocyte) 
CXCL1 NM_001511.1 
chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha) 
CXCL10 NM_001565.1 chemokine (C-X-C motif) ligand 10 
CXCL2 NM_002089.3 chemokine (C-X-C motif) ligand 2 
CXCL3 NM_002090.2 chemokine (C-X-C motif) ligand 3 
CXCL5 NM_002994.3 chemokine (C-X-C motif) ligand 5 
CXCL6 NM_002993.3 
chemokine (C-X-C motif) ligand 6 (granulocyte 
chemotactic protein 2) 
CXCL9 NM_002416.1 chemokine (C-X-C motif) ligand 9 
CXCR1 NM_000634.2 chemokine (C-X-C motif) receptor 1 
CXCR2 NM_001557.2 chemokine (C-X-C motif) receptor 2 
CXCR4 NM_003467.2 chemokine (C-X-C motif) receptor 4 
CYSLTR1 NM_006639.2 cysteinyl leukotriene receptor 1 
CYSLTR2 NM_020377.2 cysteinyl leukotriene receptor 2 
DAXX NM_001350.3 death-domain associated protein 
DDIT3 NM_004083.4 DNA-damage-inducible transcript 3 
DEFA1 NM_004084.2 defensin, alpha 1 
ELK1 NM_005229.3 ELK1, member of ETS oncogene family 
FASLG NM_000639.1 Fas ligand (TNF superfamily, member 6) 
FLT1 NM_002019.4 
fms-related tyrosine kinase 1 (vascular endothelial 
growth factor/vascular permeability factor receptor) 
FOS NM_005252.2 FBJ murine osteosarcoma viral oncogene homolog 
FXYD2 NM_021603.3 FXYD domain containing ion transport regulator 2 
GNAQ NM_002072.2 
guanine nucleotide binding protein (G protein), q 
polypeptide 
GNAS NM_080425.1 GNAS complex locus 
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GNB1 NM_002074.3 
guanine nucleotide binding protein (G protein), beta 
polypeptide 1 
GNGT1 NM_021955.3 
guanine nucleotide binding protein (G protein), gamma 
transducing activity polypeptide 1 
GRB2 NM_203506.2 growth factor receptor-bound protein 2 
HDAC4 NM_006037.3 histone deacetylase 4 
HIF1A NM_001530.2 
hypoxia inducible factor 1, alpha subunit (basic helix-
loop-helix transcription factor) 
HLA-DRA NM_019111.3 major histocompatibility complex, class II, DR alpha 
HLA-DRB1 NM_002124.1 major histocompatibility complex, class II, DR beta 1 
HMGB1 NM_002128.4 high mobility group box 1 
HMGB2 NM_001130688.1 high mobility group box 2 
HMGN1 NM_004965.6 high mobility group nucleosome binding domain 1 
HRAS NM_005343.2 v-Ha-ras Harvey rat sarcoma viral oncogene homolog 
HSH2D NM_032855.2 hematopoietic SH2 domain containing 
HSPB1 NM_001540.3 heat shock 27kDa protein 1 
HSPB2 NM_001541.3 heat shock 27kDa protein 2 
IFI44 NM_006417.4 interferon-induced protein 44 
IFIT1 NM_001548.3 
interferon-induced protein with tetratricopeptide 
repeats 1 
IFIT2 NM_001547.4 
interferon-induced protein with tetratricopeptide 
repeats 2 
IFIT3 NM_001031683.2 
interferon-induced protein with tetratricopeptide 
repeats 3 
IFNA1 NM_024013.1 interferon, alpha 1 
IFNB1 NM_002176.2 interferon, beta 1, fibroblast 
IFNG NM_000619.2 interferon, gamma 
IL10 NM_000572.2 interleukin 10 
IL10RB NM_000628.3 interleukin 10 receptor, beta 
IL11 NM_000641.2 interleukin 11 
IL12A NM_000882.2 
interleukin 12A (natural killer cell stimulatory factor 1, 
cytotoxic lymphocyte maturation factor 1, p35) 
IL12B NM_002187.2 
interleukin 12B (natural killer cell stimulatory factor 2, 
cytotoxic lymphocyte maturation factor 2, p40) 
IL13 NM_002188.2 interleukin 13 
IL15 NM_000585.3 interleukin 15 
IL17A NM_002190.2 interleukin 17A 
IL18 NM_001562.2 interleukin 18 (interferon-gamma-inducing factor) 
IL18RAP NM_003853.2 interleukin 18 receptor accessory protein 
IL1A NM_000575.3 interleukin 1, alpha 
IL1B NM_000576.2 interleukin 1, beta 
IL1R1 NM_000877.2 interleukin 1 receptor, type I 
IL1RAP NM_002182.2 interleukin 1 receptor accessory protein 
IL1RN NM_173842.1 interleukin 1 receptor antagonist 
Appendix 
Page | 273  
 
Official Symbol Accession Official Full Name 
IL2 NM_000586.2 interleukin 2 
IL21 NM_021803.2 interleukin 21 
IL22 NM_020525.4 interleukin 22 
IL22RA2 NM_181309.1 interleukin 22 receptor, alpha 2 
IL23A NM_016584.2 interleukin 23, alpha subunit p19 
IL23R NM_144701.2 interleukin 23 receptor 
IL3 NM_000588.3 interleukin 3 (colony-stimulating factor, multiple) 
IL4 NM_000589.2 interleukin 4 
IL5 NM_000879.2 interleukin 5 (colony-stimulating factor, eosinophil) 
IL6 NM_000600.1 interleukin 6 (interferon, beta 2) 
IL6R NM_000565.2 interleukin 6 receptor 
IL7 NM_000880.2 interleukin 7 
IL8 NM_000584.2 interleukin 8 
IL9 NM_000590.1 interleukin 9 
IRF1 NM_002198.1 interferon regulatory factor 1 
IRF3 NM_001571.5 interferon regulatory factor 3 
IRF5 NM_002200.3 interferon regulatory factor 5 
IRF7 NM_001572.3 interferon regulatory factor 7 
ITGB2 NM_000211.2 
integrin, beta 2 (complement component 3 receptor 3 
and 4 subunit) 
JUN NM_002228.3 jun proto-oncogene 
KEAP1 NM_012289.3 kelch-like ECH-associated protein 1 
KNG1 NM_000893.2 kininogen 1 
LIMK1 NM_002314.3 LIM domain kinase 1 
LTA NM_000595.2 lymphotoxin alpha (TNF superfamily, member 1) 
LTB NM_002341.1 lymphotoxin beta (TNF superfamily, member 3) 
LTB4R NM_181657.3 leukotriene B4 receptor 
LTB4R2 NM_019839.4 leukotriene B4 receptor 2 
LY96 NM_015364.2 lymphocyte antigen 96 
MAFF NM_001161572.1 
v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog F (avian) 
MAFG NM_002359.2 
v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog G (avian) 
MAFK NM_002360.3 
v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog K (avian) 
MAP2K1 NM_002755.2 mitogen-activated protein kinase kinase 1 
MAP2K4 NM_003010.2 mitogen-activated protein kinase kinase 4 
MAP2K6 NM_002758.3 mitogen-activated protein kinase kinase 6 
MAP3K1 NM_005921.1 
mitogen-activated protein kinase kinase kinase 1, E3 
ubiquitin protein ligase 
MAP3K5 NM_005923.3 mitogen-activated protein kinase kinase kinase 5 
MAP3K7 NM_145333.1 mitogen-activated protein kinase kinase kinase 7 
MAP3K9 NM_033141.2 mitogen-activated protein kinase kinase kinase 9 
MAPK1 NM_138957.2 mitogen-activated protein kinase 1 
MAPK14 NM_001315.1 mitogen-activated protein kinase 14 
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MAPK3 NM_001040056.1 mitogen-activated protein kinase 3 
MAPK8 NM_002750.2 mitogen-activated protein kinase 8 
MAPKAPK2 NM_004759.3 
mitogen-activated protein kinase-activated protein 
kinase 2 
MAPKAPK5 NM_003668.2 
mitogen-activated protein kinase-activated protein 
kinase 5 
MASP1 NM_139125.3 
mannan-binding lectin serine peptidase 1 (C4/C2 
activating component of Ra-reactive factor) 
MASP2 NM_139208.1 mannan-binding lectin serine peptidase 2 
MAX NM_002382.3 MYC associated factor X 
MBL2 NM_000242.2 mannose-binding lectin (protein C) 2, soluble 
MEF2A NM_005587.2 myocyte enhancer factor 2A 
MEF2BNB-
MEF2B 
NM_005919.2 MEF2BNB-MEF2B readthrough 
MEF2C NM_002397.3 myocyte enhancer factor 2C 
MEF2D NM_005920.2 myocyte enhancer factor 2D 
MKNK1 NM_003684.3 MAP kinase interacting serine/threonine kinase 1 
MMP3 NM_002422.3 
matrix metallopeptidase 3 (stromelysin 1, 
progelatinase) 
MMP9 NM_004994.2 
matrix metallopeptidase 9 (gelatinase B, 92kDa 
gelatinase, 92kDa type IV collagenase) 
MRC1 NM_002438.2 mannose receptor, C type 1 
MX1 NM_002462.2 
myxovirus (influenza virus) resistance 1, interferon-
inducible protein p78 (mouse) 
MX2 NM_002463.1 myxovirus (influenza virus) resistance 2 (mouse) 
MYC NM_002467.3 
v-myc myelocytomatosis viral oncogene homolog 
(avian) 
MYD88 NM_002468.3 myeloid differentiation primary response gene (88) 
MYL2 NM_000432.3 myosin, light chain 2, regulatory, cardiac, slow 
NFATC3 NM_004555.2 
nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 3 
NFE2L2 NM_006164.3 nuclear factor (erythroid-derived 2)-like 2 
NFKB1 NM_003998.2 
nuclear factor of kappa light polypeptide gene enhancer 
in B-cells 1 
NLRP3 NM_001079821.2 NLR family, pyrin domain containing 3 
NOD1 NM_006092.1 nucleotide-binding oligomerization domain containing 1 
NOD2 NM_022162.1 nucleotide-binding oligomerization domain containing 2 
NOS2 NM_000625.4 nitric oxide synthase 2, inducible 
NOX1 NM_007052.4 NADPH oxidase 1 
NR3C1 NM_001018074.1 
nuclear receptor subfamily 3, group C, member 1 
(glucocorticoid receptor) 
OAS2 NM_016817.2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 
OASL NM_198213.1 2'-5'-oligoadenylate synthetase-like 
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OXER1 NM_148962.3 oxoeicosanoid (OXE) receptor 1 
PDGFA NM_002607.5 platelet-derived growth factor alpha polypeptide 
PIK3C2G NM_004570.4 
phosphatidylinositol-4-phosphate 3-kinase, catalytic 
subunit type 2 gamma 
PLA2G4A NM_024420.2 
phospholipase A2, group IVA (cytosolic, calcium-
dependent) 
PLCB1 NM_182734.1 phospholipase C, beta 1 (phosphoinositide-specific) 
PPP1R12B NM_002481.3 protein phosphatase 1, regulatory subunit 12B 
PRKCA NM_002737.2 protein kinase C, alpha 
PRKCB NM_212535.1 protein kinase C, beta 
PTGDR2 NM_004778.1 prostaglandin D2 receptor 2 
PTGER1 NM_000955.2 prostaglandin E receptor 1 (subtype EP1), 42kDa 
PTGER2 NM_000956.2 prostaglandin E receptor 2 (subtype EP2), 53kDa 
PTGER3 NM_000957.2 prostaglandin E receptor 3 (subtype EP3) 
PTGER4 NM_000958.2 prostaglandin E receptor 4 (subtype EP4) 
PTGFR NM_000959.3 prostaglandin F receptor (FP) 
PTGIR NM_000960.3 prostaglandin I2 (prostacyclin) receptor (IP) 
PTGS1 NM_000962.2 
prostaglandin-endoperoxide synthase 1 (prostaglandin 
G/H synthase and cyclooxygenase) 
PTGS2 NM_000963.1 
prostaglandin-endoperoxide synthase 2 (prostaglandin 
G/H synthase and cyclooxygenase) 
PTK2 NM_005607.3 PTK2 protein tyrosine kinase 2 
RAC1 NM_198829.1 
ras-related C3 botulinum toxin substrate 1 (rho family, 
small GTP binding protein Rac1) 
RAF1 NM_002880.2 v-raf-1 murine leukemia viral oncogene homolog 1 
RAPGEF2 NM_014247.2 Rap guanine nucleotide exchange factor (GEF) 2 
RELA NM_021975.2 
v-rel reticuloendotheliosis viral oncogene homolog A 
(avian) 
RELB NM_006509.2 v-rel reticuloendotheliosis viral oncogene homolog B 
RHOA NM_001664.2 ras homolog family member A 
RIPK1 NM_003804.3 receptor (TNFRSF)-interacting serine-threonine kinase 1 
RIPK2 NM_003821.5 receptor-interacting serine-threonine kinase 2 
ROCK2 NM_004850.3 Rho-associated, coiled-coil containing protein kinase 2 
RPS6KA5 NM_004755.2 ribosomal protein S6 kinase, 90kDa, polypeptide 5 
SHC1 NM_001130040.1 
SHC (Src homology 2 domain containing) transforming 
protein 1 
SMAD7 NM_005904.2 SMAD family member 7 
STAT1 NM_007315.2 signal transducer and activator of transcription 1, 91kDa 
STAT2 NM_005419.2 
signal transducer and activator of transcription 2, 
113kDa 
STAT3 NM_139276.2 
signal transducer and activator of transcription 3 (acute-
phase response factor) 
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TBXA2R NM_001060.3 thromboxane A2 receptor 
TCF4 NM_003199.1 transcription factor 4 
TGFB1 NM_000660.3 transforming growth factor, beta 1 
TGFB2 NM_003238.2 transforming growth factor, beta 2 
TGFB3 NM_003239.2 transforming growth factor, beta 3 
TGFBR1 NM_004612.2 transforming growth factor, beta receptor 1 
TLR1 NM_003263.3 toll-like receptor 1 
TLR2 NM_003264.3 toll-like receptor 2 
TLR3 NM_003265.2 toll-like receptor 3 
TLR4 NM_138554.2 toll-like receptor 4 
TLR5 NM_003268.3 toll-like receptor 5 
TLR6 NM_006068.2 toll-like receptor 6 
TLR7 NM_016562.3 toll-like receptor 7 
TLR8 NM_016610.2 toll-like receptor 8 
TLR9 NM_017442.2 toll-like receptor 9 
TNF NM_000594.2 tumor necrosis factor 
TNFAIP3 NM_006290.2 tumor necrosis factor, alpha-induced protein 3 
TNFSF14 NM_003807.2 tumor necrosis factor (ligand) superfamily, member 14 
TOLLIP NM_019009.2 toll interacting protein 
TRADD NM_003789.2 TNFRSF1A-associated via death domain 
TRAF2 NM_021138.3 TNF receptor-associated factor 2 
TREM2 NM_018965.3 triggering receptor expressed on myeloid cells 2 
TSLP NM_033035.4 thymic stromal lymphopoietin 
TWIST2 NM_057179.2 twist homolog 2 (Drosophila) 
TYROBP NM_003332.3 TYRO protein tyrosine kinase binding protein 
Genes added to panel - neurodegeneration related 
ABCA7 NM_033308.1 ATP-binding cassette sub-family A member 7 
ADAM10 NM_001110.2 
Disintegrin and metalloprotease domain-containing 
protein 10 
AIF1 (Iba1) NM_032955.1 Allograft inflammatory factor 1 
APH1A NM_001077628.1 Gamma-secretase subunit APH1A 
APH1B NM_001145646.1 Gamma-secretase subunit APH1B 
APOE NM_000041.2 apolipoprotein e 
APP NM_000484.3 Amyloid beta A4 protein 
BACE1 NM_012104.3 Beta-secretase 1 
CD33 NM_001177608.1 Myeloid cell surface antigen CD33 
CD68 NM_001251.2 Macrosialin 
CLU NM_203339.2 Clusterin 
CoQ10A NM_001099337.1 





CR1 XM_006711166.2 Complement receptor type 1 
CTSD NM_001909.3 Cathepsin D 
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FCGR1A (CD64) NM_000566.3 High affinity immunoglobulin gamma Fc receptor 1 
GFAP NM_002055.4 Glial fibrillary acidic protein 
IL4RA NM_000418.3 Interleukin-4 receptor subunit alpha 
KLK6 NM_002774.3 Kallikrein 6  
MAPT NM_016834.3 Microtubule-associated protein tau 
MRC1 NM_002438.2 Macrophage mannose receptor 1 
NeuN NM_001082575.1 Neuronal nuclei 
P2RX7 NR_033948.1 P2X purinoreceptor 7 
PEN2 NM_172341.1 Gamma-secretase subunit PEN2 
PSEN1 NM_000021.2 Presenilin 1 
PSEN2 NM_000447.2 Presenilin 2 
SNCA NM_000345.2 Alpha-synuclein 
SOCS3 NM_003955.3 Suppressor of cytokine signalling 3 
TREM1 NM_001242589.1 Triggering receptor expressed on myeloid cells 1 
TSPO NM_000714.4 Translocator protein 
Housekeeping genes 
CLTC NM_004859.2 clathrin, heavy chain (Hc) 
GAPDH NM_002046.3 glyceraldehyde-3-phosphate dehydrogenase 
GUSB NM_000181.1 glucuronidase, beta 
HPRT1 NM_000194.1 hypoxanthine phosphoribosyltransferase 1 
PGK1 NM_000291.2 phosphoglycerate kinase 1 
TUBB NM_178014.2 tubulin, beta class I 
Appendix Table 3: List of genes used for nanostring analysis. Genes included those 
from the Human Inflammation Panel designed by Nanostring, thirty custom added genes 
related to neurodegeneration and housekeeping genes. 
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ABCA7 189.93 339 295.49 514.01 544.82 185.53 1.78 0.0192 1.56 0.1027 2.13 0.0025 2.26 0.0445 1.3 0.1294 
ADAM10 542.12 771.98 716.58 1202.38 1024.62 868.18 1.42 0.0005 1.32 0.0056 1.75 0.1099 1.49 0.1435 1.26 0.6066 
AGER 32.33 55.04 48.03 59.43 61.85 36.98 1.7 0.0069 1.49 0.1083 1.45 0.5129 1.51 0.0921 1.11 0.5086 
AIF1 348.37 348.14 336.66 626.95 346.67 227.97 1 0.998 1.03 0.9263 1.42 0.6199 1.27 0.5759 1.94 0.2813 
ALOX12 1.92 1.87 2.23 5.12 2.17 1.02 1.03 0.9416 1.16 0.7664 2.32 0.1278 1.02 0.9661 2.16 0.0736 
ALOX15 10.95 18.72 12.58 14.28 60.18 11.46 1.71 0.1023 1.15 0.8244 1.03 0.9732 4.33 0.0164 1.21 0.3934 
ALOX5 236.47 276.99 318.59 600.57 415.34 181.05 1.17 0.5549 1.35 0.5011 2 0.3104 1.39 0.4007 1.66 0.1127 
APH1A 596.43 835.95 799.1 1413.32 1025.48 920.34 1.4 0.01 1.34 0.066 1.87 0.1142 1.36 0.2915 1.22 0.4322 
APH1B 266.5 305.36 246.13 433.39 345.91 425.32 1.15 0.1935 1.08 0.5177 1.28 0.2774 1.02 0.7793 1.26 0.3929 
APOE 4204.16 7235.88 6240.44 13205.84 8258.37 3936.9 1.72 0.005 1.48 0.0782 2.48 0.1485 1.55 0.4009 1.35 0.474 
APP 19720.44 21666.61 19213.21 24370.35 28842.07 30319.48 1.1 0.3207 1.03 0.8085 1.03 0.7956 1.15 0.2358 1.21 0.0902 
AREG 4.1 2.35 7.88 4.63 2.71 2.36 1.75 0.4678 1.92 0.5373 1.04 0.9646 1.78 0.6559 2.05 0.5572 
ARG1 9.65 4.4 13.82 6.58 34.44 8.62 2.19 0.1824 1.43 0.6891 1.86 0.4512 2.82 0.1183 1.42 0.4718 
ATF2 1116.59 1153.73 1099.9 1125.54 1520.18 1614.9 1.03 0.7718 1.02 0.8978 1.26 0.4113 1.07 0.7192 1.14 0.2828 
BACE1 1099.77 1174.42 983.79 1331.6 1455.45 2598.8 1.07 0.6464 1.12 0.4465 1.05 0.7287 1.04 0.721 1.86 0.3069 
BCL2L1 1658.7 2676.48 2296.48 5015.73 4073.34 1783.33 1.61 0.0056 1.38 0.1581 2.38 0.0571 1.94 0.241 1.18 0.1249 
BCL6 1353.36 2509.78 3416.49 5203.26 4839.84 1383.9 1.85 0.0226 2.52 0.0096 3.03 0.0586 2.82 0.1636 1.24 0.2306 
BIRC2 789.2 945.78 1005.13 1425.74 1351.84 1168.33 1.2 0.0201 1.27 0.0046 1.42 0.0893 1.35 0.0893 1.17 0.4984 
C1QA 105.59 106.43 145.68 310.15 167.96 50.2 1.01 0.983 1.38 0.4419 2.32 0.3636 1.25 0.7495 2.67 0.0205 
C1QB 748.58 789.38 1172.66 2062.52 1034.21 371.18 1.05 0.906 1.57 0.3376 2.17 0.4104 1.09 0.9041 2.56 0.0512 
C1R 406.1 511.04 1138.83 1023.44 1190 293.19 1.26 0.5056 2.8 0.0562 1.99 0.5245 2.31 0.1562 1.76 0.14 
C1S 413.57 444.09 794.42 760.66 839.81 367.84 1.07 0.7885 1.92 0.1592 1.45 0.5981 1.6 0.271 1.43 0.1552 
C2 63.45 77.28 125.6 77.62 130.36 50.82 1.22 0.3381 1.98 0.1153 1.04 0.9682 1.62 0.1317 1.58 0.4989 
C3 716.86 972.89 1014.54 1799 1070.01 558.18 1.36 0.3783 1.42 0.2854 1.98 0.3013 1.18 0.7915 1.63 0.5514 
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C3AR1 153.39 266.66 259.66 607.88 343.02 116.95 1.74 0.0472 1.69 0.1762 3.13 0.1546 1.76 0.5333 1.66 0.2103 
C4A 712.84 1757.19 1654.96 2412.3 2113.42 1166.48 2.47 0.0358 2.32 0.0477 2.67 0.3483 2.34 0.0427 1.29 0.7702 
C5 54.58 90.38 86.29 86.63 96.43 134.17 1.66 0.0127 1.58 0.0185 1.25 0.2648 1.39 0.0381 1.94 0.2034 
C6 1.05 1.45 1.89 2.87 2.17 2.3 1.38 0.0172 1.81 0.0275 2.46 0.1134 1.86 0.1589 1.97 0.5642 
C7 52.27 39.96 116.81 97.51 182.51 41.45 1.31 0.6253 2.23 0.3264 1.47 0.6 2.75 0.0579 1.6 0.382 
C8A 1.05 1.68 1.45 2.87 2.17 1.03 1.6 0.0008 1.38 0.1317 2.46 0.1134 1.86 0.1589 1.13 0.1838 
C8B 1.05 1.84 1.67 2.87 2.17 1.05 1.76 0.0042 1.6 0.0508 2.46 0.1134 1.86 0.1589 1.11 0.2419 
C9 1.28 1.63 1.61 2.87 2.17 1.03 1.28 0.2987 1.26 0.4321 1.98 0.1751 1.5 0.2516 1.4 0.1975 
CCL11 1.05 1.49 1.67 2.87 2.17 1.03 1.42 0.0128 1.6 0.0508 2.46 0.1134 1.86 0.1589 1.13 0.1838 
CCL13 1.05 1.58 1.67 2.87 2.17 1.03 1.51 0.0046 1.6 0.0508 2.46 0.1134 1.86 0.1589 1.13 0.1838 
CCL16 1.34 1.97 2.43 2.87 2.17 1.05 1.48 0.2153 1.82 0.1812 1.97 0.1905 1.49 0.2991 1.39 0.2997 
CCL17 1.05 1.58 1.4 2.87 2.17 1.03 1.51 0.0033 1.34 0.0802 2.46 0.1134 1.86 0.1589 1.13 0.1838 
CCL19 15.74 19.71 41.72 6.81 38.07 14.26 1.25 0.7079 2.65 0.1484 2.93 0.0915 1.91 0.3792 1.4 0.5034 
CCL2 58.82 207.92 283.3 551.32 495.88 73.22 3.53 0.0478 4.82 0.0288 7.39 0.139 6.65 0.294 1.02 0.9866 
CCL20 1.05 1.87 3.98 2.87 2.17 1.42 1.79 0.004 3.81 0.0556 2.46 0.1134 1.86 0.1589 1.21 0.6188 
CCL21 1.05 1.48 1.9 2.87 2.17 1.03 1.42 0.0166 1.82 0.0373 2.46 0.1134 1.86 0.1589 1.13 0.1838 
CCL22 1.05 1.97 1.88 2.02 2.17 2.72 1.89 0.0121 1.8 0.069 1.74 0.3767 1.87 0.1557 2.35 0.5505 
CCL23 1.05 1.69 1.99 2.87 2.17 1 1.61 0.0008 1.9 0.0399 2.52 0.1077 1.91 0.1486 1.14 0.1764 
CCL24 2.96 2.69 1.86 5.48 2.32 3.4 1.1 0.8118 1.59 0.3212 1.52 0.696 1.56 0.6581 1.06 0.8974 
CCL3 7.68 12.17 23.39 9.02 7.95 12.5 1.59 0.5134 3.05 0.1404 1.08 0.9547 1.22 0.9161 1.28 0.8978 
CCL4 35.08 26.76 42.25 18.42 27.29 34.92 1.31 0.4945 1.2 0.6867 2.41 0.2782 1.63 0.2279 1.27 0.8676 
CCL5 4.09 13.38 15.13 15.58 13.15 3.7 3.27 0.0839 3.7 0.1087 3.12 0.3542 2.64 0.1405 1.35 0.8535 
CCL7 1.05 1.68 1.15 2.87 2.17 1.03 1.6 0.0008 1.1 0.2407 2.52 0.1077 1.91 0.1486 1.1 0.3044 
CCL8 1.05 1.48 2.19 2.87 2.17 1.02 1.41 0.0133 2.09 0.0474 2.46 0.1134 1.86 0.1589 1.14 0.158 
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CCR1 43.13 46.37 48.69 51.65 57.27 32.65 1.08 0.8657 1.13 0.7964 1.06 0.9722 1.05 0.9028 1.68 0.2035 
CCR2 1.76 3.44 7.1 9.32 3.36 1.05 1.95 0.1848 4.03 0.0775 4.7 0.334 1.7 0.7181 1.89 0.1783 
CCR3 1.04 1.78 1.67 2.87 2.17 1.03 1.7 0.0006 1.6 0.0495 2.57 0.1042 1.94 0.1462 1.09 0.3632 
CCR4 1.8 2.44 2.19 3.04 1.41 1.49 1.35 0.3743 1.22 0.6009 1.39 0.4833 1.56 0.2657 1.47 0.4586 
CCR7 1.1 1.87 2.08 2.87 2.17 1.03 1.7 0.0075 1.89 0.0495 2.34 0.1214 1.77 0.157 1.19 0.1568 
CD163 74.64 78.36 218.76 439.06 223.43 37.01 1.05 0.9361 2.93 0.2305 4.64 0.2064 2.36 0.1774 2.56 0.1935 
CD33 11.76 8.82 14.44 36.69 23.76 9.52 1.33 0.5264 1.23 0.7445 2.46 0.2659 1.59 0.2405 1.57 0.4956 
CD4 33.49 39.95 56.24 91.07 73.61 35.11 1.19 0.4322 1.68 0.0815 2.14 0.3103 1.73 0.2748 1.21 0.354 
CD40 49.57 76.48 100.55 117.85 139.93 61.01 1.54 0.0874 2.03 0.0194 1.87 0.0967 2.23 0.1185 1.03 0.9039 
CD40LG 1.05 1.86 1.67 2.87 2.17 1.03 1.78 0.0015 1.6 0.0508 2.46 0.1134 1.86 0.1589 1.13 0.1838 
CD55 126.25 202.5 160.57 312.41 246.62 216.33 1.6 0.0069 1.27 0.0797 1.95 0.0425 1.54 0.3662 1.35 0.5244 
CD68 136.77 186.57 260.15 359.63 235.09 141.99 1.36 0.1972 1.9 0.0182 2.07 0.2528 1.36 0.4495 1.22 0.6176 
CD86 13.58 17.67 17.77 40.19 15.33 16.14 1.3 0.5631 1.31 0.6308 2.33 0.2501 1.12 0.7903 1.07 0.9038 
CDC42 4203.45 4127.74 3787.4 5975.39 5251.03 5143.92 1.02 0.6867 1.11 0.1824 1.12 0.4594 1.02 0.8875 1.04 0.8088 
CEBPB 854.34 1030.38 1938.02 2382.35 2426.32 787.34 1.21 0.4064 2.27 0.0122 2.2 0.063 2.24 0.2165 1.38 0.1329 
CFB 87.38 102.3 246.31 244.4 224.68 57.25 1.17 0.577 2.82 0.0593 2.21 0.425 2.03 0.2867 1.94 0.1524 
CFD 28.41 34.63 26.94 53.79 37.03 12.44 1.22 0.5726 1.05 0.9237 1.49 0.2623 1.03 0.9384 2.9 0.2759 
CFL1 13002.54 13345.57 11922.26 16790.01 17202.29 15854.6 1.03 0.6196 1.09 0.1983 1.02 0.801 1.04 0.4943 1.04 0.3303 
CLU 53696.47 75322.2 93128.3 92165.85 115303.41 62745.54 1.4 0.005 1.73 0.0108 1.35 0.4592 1.69 0.0773 1.09 0.481 
CR1 48.96 59.96 59.56 41.53 75.77 72.72 1.22 0.5747 1.22 0.7626 1.49 0.6892 1.22 0.7176 1.17 0.9214 
CREB1 704.62 975.75 973.98 1400.21 1407.96 925.92 1.38 0.0072 1.38 0.0236 1.57 0.0283 1.58 0.1129 1.04 0.8296 
CRP 1.1 1.72 1.67 2.87 4.38 1.03 1.57 0.0298 1.53 0.0732 2.31 0.1244 3.53 0.5261 1.21 0.1382 
CSF1 113.66 267.15 326.38 532.54 538.01 182.88 2.35 0.0053 2.87 0.0123 3.69 0.0986 3.73 0.2682 1.27 0.7553 
CSF2 3.29 3.42 2.86 10.21 5.05 2.1 1.04 0.9059 1.15 0.7467 2.45 0.3212 1.21 0.8841 1.98 0.5016 
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CSF3 8.89 3.98 6.12 5.63 6.7 2.87 2.24 0.3354 1.45 0.6834 1.86 0.5241 1.56 0.6643 3.64 0.3984 
CTSD 3343.76 5158.64 4878.47 9326.44 7262.01 4896.18 1.54 0.0005 1.46 0.0662 2.2 0.1044 1.71 0.2071 1.15 0.4393 
CXCL1 81.55 68.15 128.66 339.35 286.72 42.59 1.2 0.7542 1.58 0.4398 3.28 0.1991 2.77 0.4375 2.43 0.6162 
CXCL10 6.05 8.32 6.8 25.32 2.17 3.81 1.37 0.5767 1.12 0.8779 3.43 0.6633 3.4 0.0564 1.94 0.3056 
CXCL2 107.7 94.39 214.46 188.37 217.71 112.9 1.14 0.7287 1.99 0.2412 1.38 0.6195 1.59 0.5189 1.21 0.5589 
CXCL3 16.16 13.1 39.01 22.86 29.46 16.07 1.23 0.5468 2.41 0.1751 1.12 0.8746 1.44 0.3303 1.28 0.6118 
CXCL5 29.06 32.03 36.33 29.94 42.23 46.45 1.1 0.6561 1.25 0.4118 1.23 0.7725 1.15 0.5214 1.26 0.3159 
CXCL6 3.27 8.75 13.81 4.08 22.8 10.52 2.68 0.0957 4.23 0.0607 1.06 0.9469 5.92 0.1435 2.73 0.0863 
CXCL9 1.64 2.65 1.87 8.84 1.84 1.03 1.61 0.1819 1.14 0.6906 4.59 0.3236 1.05 0.9277 1.87 0.0618 
CXCR1 18.63 35.58 44.28 35.58 31.05 27.24 1.91 0.0839 2.38 0.0714 1.51 0.5845 1.31 0.4756 1.15 0.8192 
CXCR2 5.62 26.4 51.8 42.82 62.79 9.77 4.7 0.0692 9.22 0.015 6.11 0.0345 8.96 0.0178 1.39 0.6469 
CXCR4 164.43 376.94 431.2 614.82 609.55 253.33 2.29 0.0307 2.62 0.0442 2.95 0.1929 2.92 0.1021 1.21 0.6167 
CYSLTR1 24.2 21.6 31.26 32.06 24.8 20.74 1.12 0.6836 1.29 0.4895 1.04 0.8895 1.24 0.821 1.48 0.3277 
CYSLTR2 85.33 137.58 140.73 168.81 194.41 102.66 1.61 0.0021 1.65 0.0269 1.56 0.1683 1.8 0.0252 1.05 0.4956 
CoQ10A 315.26 443.62 405.09 571.8 554.24 419.13 1.41 0.0001 1.28 0.1518 1.43 0.2045 1.39 0.0945 1.05 0.6106 
CoQ2 69.25 89.13 95.22 151.99 113.75 92.27 1.29 0.0434 1.37 0.0078 1.73 0.1125 1.3 0.0103 1.05 0.7976 
DAXX 487.43 789.39 784.93 1313.04 1162.47 643.93 1.62 0.0008 1.61 0.0205 2.12 0.0659 1.88 0.1113 1.04 0.6765 
DDIT3 624.74 827.21 1286.11 1400.05 1340.22 925.31 1.32 0.017 2.06 0.0085 1.77 0.1445 1.69 0.1984 1.17 0.4491 
DEFA1 31 20.16 25.64 19.22 31.02 4.76 1.54 0.7245 1.21 0.8982 2.05 0.58 1.27 0.8928 8.25 0.3619 
ELK1 520.65 1030.47 924.02 1437.08 1931.48 401.3 1.98 0.0128 1.77 0.11 2.18 0.1581 2.93 0.046 1.65 0.1541 
FASLG 1.05 1.78 2.11 2.87 2.17 1.03 1.7 0.0012 2.01 0.0582 2.46 0.1134 1.86 0.1589 1.13 0.1838 
FCGR1A 181.16 142.44 168.42 185.96 163.49 100.07 1.27 0.5295 1.08 0.8407 1.24 0.8533 1.41 0.539 2.3 0.0282 
FLT1 1108.17 1523.2 2276.55 3217.89 4069.62 698.84 1.37 0.3004 2.05 0.0555 2.29 0.3306 2.9 0.0276 2.01 0.3637 
FOS 657.25 800.52 2080.39 1721.16 1568.64 1134.3 1.22 0.4949 3.17 0.0536 2.07 0.4656 1.88 0.1112 1.36 0.6754 
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FXYD2 38.62 63.43 54.88 78.88 97.84 43.87 1.64 0.0056 1.42 0.3406 1.61 0.0235 2 0.127 1.12 0.7472 
GFAP 30455.98 60563.46 71161.77 90586.38 76572.51 50251.64 1.99 0.0132 2.34 0.0119 2.35 0.278 1.98 0.0137 1.3 0.7109 
GNAQ 3078.45 3992.3 3835.19 5342.89 5985.81 3545.13 1.3 0.0008 1.25 0.1858 1.37 0.3304 1.53 0.0824 1.1 0.2984 
GNAS 3912.56 4359.78 4583.61 5864.88 6337.23 6329.91 1.11 0.3164 1.17 0.2251 1.18 0.5337 1.28 0.0391 1.28 0.3393 
GNB1 8717.4 9280.99 9169.2 12328.92 12906.74 11887.72 1.06 0.4605 1.05 0.6722 1.12 0.6436 1.17 0.0777 1.08 0.4608 
GNGT1 1.05 1.69 1.68 2.87 2.17 1.03 1.61 0.0008 1.6 0.0509 2.46 0.1134 1.86 0.1589 1.13 0.1838 
GRB2 40.53 39.53 37.37 74.26 65.37 66.03 1.03 0.8939 1.08 0.6831 1.44 0.0104 1.27 0.0667 1.28 0.048 
HDAC4 673.22 1050.65 1080.62 1721.3 1929.93 807.77 1.56 0.0095 1.61 0.0541 2.02 0.0904 2.26 0.0009 1.06 0.6122 
HIF1A 2411.9 3204.34 3168.81 4454.22 5439.5 2875.07 1.33 0.0421 1.31 0.0927 1.46 0.2662 1.78 0.294 1.06 0.5323 
HLA-DRA 1195.25 1360.24 1520 3029.41 1087.53 967.91 1.14 0.6709 1.27 0.4921 2 0.4402 1.39 0.6306 1.57 0.5227 
HLA-DRB1 795.06 879.45 1124.32 2034.53 1315.1 689.59 1.11 0.8442 1.41 0.5341 2.02 0.5471 1.3 0.767 1.46 0.6674 
HMGB1 1630.3 1972.64 1884.15 2981.86 2244.16 2659.49 1.21 0.0131 1.16 0.0429 1.44 0.0755 1.09 0.6604 1.29 0.2377 
HMGB2 252.9 303.95 366.11 497.3 454.36 235.6 1.2 0.2272 1.45 0.1448 1.55 0.1808 1.42 0.3751 1.36 0.1357 
HMGN1 1287.33 1785.18 1817.02 2875.47 2036.18 1538.52 1.39 0.0165 1.41 0.0558 1.76 0.1071 1.25 0.4149 1.06 0.8835 
HRAS 342.09 357.9 391.14 456.44 552.07 354.54 1.05 0.6525 1.14 0.4441 1.05 0.8465 1.27 0.5016 1.22 0.1562 
HSH2D 2.1 1.88 1.39 4.97 2.17 1.03 1.12 0.8698 1.51 0.5606 2.02 0.476 1.13 0.8628 2.39 0.2431 
HSPB1 505.19 1351.6 2898.42 2748.11 3749.8 429.84 2.68 0.0044 5.74 0.0041 4.29 0.0657 5.85 0.1633 1.49 0.323 
HSPB2 279.12 700.42 751.62 1208.11 1322.87 396.28 2.51 0.0008 2.69 0.009 3.41 0.0618 3.74 0.211 1.12 0.5513 
IFI44 83.11 125.73 144.56 315.65 170.15 127.24 1.51 0.0365 1.74 0.0537 3 0.3398 1.61 0.5148 1.21 0.6913 
IFIT1 779.35 1000.62 793.78 2492.58 1465.2 1210.94 1.28 0.1135 1.02 0.9052 2.52 0.2199 1.48 0.0159 1.23 0.4101 
IFIT2 162.14 217.21 153.53 632.42 378.38 172.06 1.34 0.1888 1.06 0.8226 3.08 0.3362 1.84 0.1835 1.2 0.8237 
IFIT3 84.22 114.83 77.56 388.03 131.45 125.82 1.36 0.022 1.09 0.6058 3.63 0.3115 1.23 0.0197 1.18 0.567 
IFNA1 2.2 2.57 2.36 2.87 1.84 11.32 1.16 0.7217 1.07 0.8923 1.08 0.879 1.44 0.5127 4.26 0.0243 
IFNB1 1.05 1.68 1.67 2.87 2.17 1.03 1.6 0.0008 1.6 0.0508 2.46 0.1134 1.86 0.1589 1.13 0.1838 
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IFNG 1.05 1.68 1.8 2.87 2.17 1.03 1.6 0.0008 1.72 0.0289 2.46 0.1134 1.86 0.1589 1.13 0.1838 
IL10 1.29 2.36 3.93 3.41 2.17 1.03 1.83 0.0225 3.05 0.0387 2.26 0.0355 1.44 0.2666 1.47 0.0393 
IL10RB 218.44 262.08 296.53 463.5 334.33 249.32 1.2 0.3631 1.36 0.1931 1.67 0.088 1.21 0.4788 1.11 0.7903 
IL11 4.83 4.81 3.69 2.87 8.8 3.4 1 0.9926 1.31 0.6342 2.13 0.1487 1.44 0.4195 1.8 0.159 
IL12A 10.78 12.72 29.3 10.37 18.6 32.13 1.18 0.6408 2.72 0.0176 1.32 0.803 1.36 0.3856 2.35 0.1911 
IL12B 1.04 1.61 1.61 2.02 2.17 2.16 1.55 0.0065 1.54 0.0784 1.81 0.3515 1.94 0.1462 1.94 0.5242 
IL13 1.05 1.58 1.67 2.87 2.17 1.03 1.51 0.0046 1.6 0.0508 2.46 0.1134 1.86 0.1589 1.13 0.1838 
IL15 10.64 17.97 17.82 44.08 27.43 14.56 1.69 0.0373 1.67 0.0892 3.27 0.2802 2.03 0.3459 1.08 0.6808 
IL17A 1.1 1.77 1.67 2.87 2.17 3.03 1.61 0.0007 1.52 0.0748 2.4 0.1147 1.81 0.1448 2.53 0.5389 
IL18 133.78 225.98 293.5 535.67 354.49 146.54 1.69 0.1121 2.19 0.0629 3.16 0.039 2.09 0.2779 1.16 0.6789 
IL18RAP 2.17 2.91 4.17 2.02 5.19 1.03 1.34 0.6421 1.92 0.4715 1.24 0.7837 2.07 0.4799 2.44 0.1876 
IL1A 2.07 3.28 2.02 3.04 1.41 7.5 1.58 0.2547 1.03 0.9469 1.18 0.7351 1.84 0.1698 2.9 0.2444 
IL1B 22.66 16.95 15.68 6.42 20.69 31.7 1.34 0.5566 1.44 0.4554 4.48 0.2215 1.39 0.5004 1.1 0.7847 
IL1R1 34.89 49.5 106.88 94.12 117.38 17.92 1.42 0.2877 3.06 0.026 2.13 0.2334 2.65 0.0282 2.47 0.4853 
IL1RAP 401.69 406.61 467.6 633.91 530.26 415.11 1.01 0.8963 1.16 0.1881 1.24 0.0019 1.04 0.3726 1.23 0.2658 
IL1RN 7.21 6.19 26.87 14.45 8.72 2.76 1.16 0.7181 3.73 0.1074 1.58 0.7729 1.05 0.8743 3.32 0.0398 
IL2 1.53 2.28 1.33 7.14 2.19 1.05 1.49 0.3128 1.15 0.7095 3.9 0.0165 1.2 0.8057 1.74 0.1621 
IL21 1.05 1.68 1.68 2.87 2.17 1.03 1.6 0.0008 1.6 0.0509 2.46 0.1134 1.86 0.1589 1.13 0.1838 
IL22 1.05 1.68 1.67 2.87 2.17 1.03 1.6 0.0008 1.6 0.0508 2.46 0.1134 1.86 0.1589 1.13 0.1838 
IL22RA2 1.05 1.68 1.67 2.87 2.17 1.03 1.6 0.0008 1.6 0.0508 2.46 0.1134 1.86 0.1589 1.13 0.1838 
IL23A 1.29 1.8 1.63 2.87 2.17 2.76 1.4 0.2424 1.26 0.4641 1.92 0.1917 1.45 0.2845 1.84 0.1836 
IL23R 1.47 2.88 2.11 2.4 1.84 4.33 1.96 0.0395 1.43 0.3524 1.4 0.5723 1.08 0.8795 2.54 0.0135 
IL3 1.05 1.68 1.67 2.87 2.17 1.03 1.6 0.0008 1.6 0.0508 2.46 0.1134 1.86 0.1589 1.13 0.1838 
IL4 1.23 1.95 1.68 2.87 2.17 1.7 1.59 0.0747 1.36 0.2405 2.02 0.1627 1.53 0.2155 1.2 0.7704 
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IL4RA 90.55 102.74 188.26 301.58 208.42 74.06 1.13 0.642 2.08 0.1042 2.63 0.2252 1.82 0.2934 1.55 0.5873 
IL5 2.07 4 3.11 6.12 3.4 10.36 1.94 0.1127 1.51 0.4124 2.43 0.2062 1.35 0.8111 4.12 0.031 
IL6 11.23 6.61 17.68 24.5 18.72 9.69 1.7 0.422 1.57 0.5794 1.79 0.5771 1.37 0.649 1.41 0.7653 
IL6R 88.87 122.14 157.68 293.92 224.03 81.68 1.37 0.1229 1.77 0.0465 2.61 0.1933 1.99 0.1976 1.38 0.0833 
IL7 1.25 1.7 1.61 2.52 2.17 1.03 1.36 0.2324 1.29 0.3921 1.79 0.3419 1.54 0.2263 1.37 0.2312 
IL8 46.2 61.65 132 173.14 185.43 12.22 1.33 0.5011 2.86 0.1111 2.96 0.1596 3.17 0.4433 4.79 0.5333 
IL9 1.04 1.36 2.05 2.87 2.17 1.03 1.3 0.0474 1.96 0.063 2.57 0.1042 1.94 0.1462 1.09 0.3632 
IRF1 21.33 59.21 73.2 259.86 96.59 28.85 2.78 0.0292 3.43 0.018 9.61 0.209 3.57 0.1174 1.07 0.8511 
IRF3 64.07 100.43 117.78 168.1 142.09 98.95 1.57 0.0093 1.84 0.0092 2.07 0.1548 1.75 0.0025 1.22 0.1139 
IRF5 54.65 88.96 75.38 191.72 110.1 54.19 1.63 0.04 1.38 0.3572 2.77 0.1079 1.59 0.4953 1.28 0.5877 
IRF7 11.05 36.03 33.7 44.77 52.83 10.76 3.26 0.0141 3.05 0.0578 3.2 0.5291 3.77 0.2046 1.3 0.5962 
ITGB2 186.35 328.5 416.07 766.34 418.55 129.32 1.76 0.1145 2.23 0.0675 3.24 0.1727 1.77 0.207 1.83 0.3024 
JUN 604.6 524.71 1103.28 713.6 964.05 710.97 1.15 0.1362 1.82 0.0389 1.07 0.6978 1.26 0.0337 1.08 0.8008 
KEAP1 213.51 372.72 301.8 648.47 609.01 276.7 1.75 0.0003 1.41 0.1537 2.4 0.079 2.25 0.1122 1.02 0.8663 
KLK6 96.4 203.82 87.95 332.28 260.01 799.55 2.11 0.1216 1.1 0.8257 2.72 0.3143 2.13 0.2344 6.54 0.2703 
KNG1 4.16 3.2 3.91 6.86 9.91 6.19 1.3 0.602 1.06 0.9088 1.3 0.7239 1.88 0.1446 1.17 0.8545 
LIMK1 1861.21 1838.25 1658.52 2263.42 2983.26 2251.27 1.01 0.894 1.12 0.5991 1.04 0.9068 1.26 0.019 1.05 0.8333 
LTA 5.03 9.39 13.8 12.96 39.55 8.81 1.87 0.2842 2.75 0.1544 2.03 0.3701 6.21 0.0044 1.38 0.5714 
LTB 9.25 17.18 13.01 7.87 6.22 9.73 1.86 0.0925 1.41 0.4702 1.49 0.3392 1.89 0.7575 1.2 0.5264 
LTB4R 45.05 57.85 61.61 109.19 96.76 29.24 1.28 0.3582 1.37 0.3696 1.91 0.274 1.69 0.1485 1.95 0.0301 
LTB4R2 42.46 55.94 50.22 90.59 64.12 48.68 1.32 0.0912 1.18 0.3878 1.68 0.1416 1.19 0.2197 1.11 0.6293 
LY96 168.69 161.36 262.55 307.12 286.15 111.23 1.05 0.8141 1.56 0.1447 1.44 0.4066 1.34 0.4521 1.92 0.0117 
MAFF 41.27 110.06 180.8 405.38 303.67 33.55 2.67 0.0611 4.38 0.0059 7.75 0.1274 5.8 0.2198 1.56 0.5395 
MAFG 618.75 777.93 776.6 1194.04 1254.25 594.87 1.26 0.0248 1.26 0.3563 1.52 0.2685 1.6 0.3239 1.32 0.1576 
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MAFK 763.61 1239.47 1119.04 2383.66 1738.43 972.32 1.62 0.0095 1.47 0.071 2.46 0.1281 1.8 0.4009 1 0.979 
MAP2K1 3524.14 3296.22 3058.5 3289.39 4919.48 4328.11 1.07 0.6035 1.15 0.3406 1.36 0.2167 1.1 0.6543 1.03 0.8593 
MAP2K4 1768.6 1757.89 1818.74 2199.13 3076.82 2318.78 1.01 0.9677 1.03 0.8844 1.02 0.9469 1.37 0.0657 1.03 0.8746 
MAP2K6 187.11 231.73 239.47 211.67 298.94 281.53 1.24 0.0086 1.28 0.2141 1.12 0.7833 1.26 0.2861 1.19 0.0244 
MAP3K1 217.55 303.89 370.52 536.83 460.2 277.51 1.4 0.0025 1.7 0.0162 1.95 0.0899 1.67 0.3082 1.01 0.9746 
MAP3K5 624.92 835.55 898.03 978.26 1214.79 693.6 1.34 0.0041 1.44 0.0096 1.23 0.4505 1.53 0.0653 1.14 0.1516 
MAP3K7 968.19 1151.03 1172.16 1589.16 1624.3 1371.33 1.19 0.0033 1.21 0.026 1.29 0 1.32 0.166 1.12 0.0239 
MAP3K9 590.1 611.49 599.91 639.17 1026.45 717.29 1.04 0.808 1.02 0.9519 1.17 0.7863 1.37 0.0432 1.04 0.8868 
MAPK1 5144.49 5389.07 5030.87 6418.12 6834.98 6064.7 1.05 0.521 1.02 0.7622 1.02 0.7849 1.05 0.7025 1.08 0.1941 
MAPK14 1138.48 1377.92 1535.53 1846.48 2003.1 1308.73 1.21 0.0078 1.35 0.0054 1.28 0.1718 1.39 0.0004 1.1 0.1597 
MAPK3 5693.47 6831.73 5784.22 8405.47 8393.47 5478.84 1.2 0.0396 1.02 0.8937 1.16 0.5968 1.16 0.23 1.32 0.0237 
MAPK8 1074.68 1091.52 995.38 1249.32 1578.62 1302.22 1.02 0.8465 1.08 0.6143 1.09 0.7089 1.16 0.0501 1.05 0.6443 
MAPKAPK2 266.06 520 646.99 1190.52 952.12 355.96 1.95 0.0019 2.43 0.0054 3.53 0.0728 2.82 0.2272 1.06 0.8784 
MAPKAPK5 951.85 1427.34 1328.04 2212.9 1804.52 1194.29 1.5 0.0006 1.4 0.0375 1.83 0.0614 1.5 0.3241 1.01 0.8816 
MAPT 4349.65 4748.61 3870.27 6423.27 6737.65 4140.08 1.09 0.2477 1.12 0.5238 1.16 0.5937 1.22 0.0434 1.33 0.0326 
MASP1 11.98 17.49 33.71 19.25 25.17 43.87 1.46 0.2704 2.81 0.0363 1.27 0.7572 1.66 0.4734 2.89 0.3412 
MASP2 1.63 2.46 3.9 6.31 7.53 5.09 1.5 0.3558 2.38 0.1803 3.22 0.2784 3.84 0.1438 2.6 0.0274 
MAX 1318.72 1850.31 1971.45 3273.27 2950.67 1613.99 1.4 0.0035 1.49 0.0172 1.96 0.0591 1.76 0.2707 1.04 0.582 
MBL2 1.05 1.68 1.67 2.87 2.17 1.03 1.6 0.0008 1.6 0.0508 2.46 0.1134 1.86 0.1589 1.13 0.1838 
MEF2A 3115.33 4145.18 4102.06 5673.51 5710.97 3789.33 1.33 0.0002 1.32 0.0105 1.44 0.0151 1.45 0.0732 1.04 0.7125 
MEF2BNB-
MEF2B 5.05 10.61 7.44 7.51 8.75 9.57 2.1 0.0563 1.47 0.4815 1.17 0.8362 1.37 0.513 1.49 0.2315 
MEF2C 4806.42 4283.04 4700.78 4633.48 6496.44 6739.17 1.12 0.4352 1.02 0.9201 1.32 0.5604 1.07 0.7406 1.11 0.7429 
MEF2D 1552.91 1543.79 1375.72 1589.94 2003.64 1758.31 1.01 0.9055 1.13 0.4411 1.24 0.6071 1.02 0.931 1.12 0.4738 
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MKNK1 787.58 1055.1 1095.52 1431.5 1311.21 816.59 1.34 0.007 1.39 0.044 1.43 0.0878 1.31 0.0627 1.22 0.3353 
MMP3 1.34 2.52 3.62 4.22 5.05 2.3 1.89 0.0704 2.71 0.088 2.83 0.1681 3.39 0.442 1.54 0.6947 
MMP9 9.69 14.12 63.87 24.11 31.94 1.37 1.46 0.7282 6.59 0.1341 2.12 0.5462 2.81 0.4033 8.26 0.0808 
MRC1 44.22 14.38 33.4 55 64.19 26.26 3.08 0.0197 1.32 0.7575 1.02 0.9782 1.14 0.6579 2.14 0.479 
MX1 984.84 1214.08 1084.74 3448.56 1440.19 1252.41 1.23 0.0473 1.1 0.2968 2.76 0.3109 1.15 0.2522 1 0.9754 
MX2 43.66 60.09 50.57 190.92 63.1 53.5 1.38 0.1851 1.16 0.5993 3.45 0.2764 1.14 0.6656 1.03 0.9199 
MYC 151.64 201.75 303.86 394.65 342.74 134.93 1.33 0.2718 2 0.0414 2.05 0.0773 1.78 0.2395 1.43 0.4619 
MYD88 99.86 138.67 228.9 303.03 235.6 101.52 1.39 0.2199 2.29 0.021 2.39 0.2351 1.86 0.082 1.25 0.3724 
MYL2 1.23 3.54 1.98 2.87 2.17 1 2.88 0.0051 1.61 0.2339 2.02 0.1627 1.53 0.2155 1.42 0.1204 
NFATC3 214.09 346.66 394.29 487.74 512.8 280.49 1.62 0.0005 1.84 0.0018 1.8 0.0572 1.89 0.0855 1.03 0.8838 
NFE2L2 725.19 1045.34 1470.84 1849.19 1726.46 1096.19 1.44 0.0257 2.03 0.0014 2.01 0.0495 1.88 0.1731 1.19 0.656 
NFKB1 66.11 110.24 121.61 203.05 176.81 124.01 1.67 0.006 1.84 0.0004 2.42 0.1855 2.11 0.3065 1.48 0.2775 
NLRP3 61.42 83.38 53.46 83.32 58.97 86.26 1.36 0.081 1.15 0.7758 1.07 0.8908 1.32 0.7117 1.11 0.4271 
NOD1 47 58.62 77.22 122.13 90.16 52.6 1.25 0.2595 1.64 0.1298 2.05 0.1417 1.51 0.2926 1.13 0.5176 
NOD2 8.03 9.56 13.03 44.79 15.33 6.77 1.19 0.7578 1.62 0.5314 4.4 0.3766 1.51 0.4869 1.5 0.4872 
NOS2 106.13 151.76 85.13 154.17 157.5 93.05 1.43 0.0656 1.25 0.2841 1.15 0.6782 1.17 0.2985 1.45 0.4424 
NOX1 6.42 11.41 4.54 10.18 15.06 12.41 1.78 0.1702 1.41 0.4966 1.25 0.8097 1.85 0.3307 1.52 0.296 
NOX4 2.11 5.45 7.28 7.27 4.19 5.48 2.58 0.0223 3.44 0.0269 2.82 0.1511 1.63 0.4674 2.13 0.6056 
NR3C1 1670.21 2303.49 2200.37 3005.22 2944.63 2785.3 1.38 0.0351 1.32 0.059 1.42 0.0244 1.39 0.1101 1.32 0.0949 
NeuN 1029.8 1165.51 901.21 986.44 1543.22 1208.03 1.13 0.3194 1.14 0.5039 1.32 0.5856 1.18 0.4494 1.08 0.8088 
OAS2 61.1 119.55 100.96 363.77 162.63 103.72 1.96 0.0079 1.65 0.0907 4.7 0.2756 2.1 0.3077 1.34 0.4696 
OASL 2.99 4.46 3.03 13.01 4.19 5.1 1.49 0.2637 1.01 0.9736 3.58 0.4991 1.15 0.8212 1.4 0.7929 
OXER1 10.22 11.61 14.66 21.01 18.51 16.35 1.14 0.7456 1.43 0.2552 1.62 0.5454 1.43 0.4236 1.26 0.5884 
P2RX7 343.62 517.46 416.56 773.37 709.23 646.32 1.51 0.0095 1.21 0.2117 1.77 0.0023 1.63 0.0261 1.48 0.5611 
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PDGFA 178.71 247.67 288.05 356.17 405.32 266.78 1.39 0.0103 1.61 0.0057 1.57 0.1407 1.79 0.0009 1.18 0.585 
PEN2 545.94 709.58 654.52 1166.65 934.76 595.37 1.3 0.0537 1.2 0.2949 1.69 0.1216 1.35 0.3458 1.16 0.6036 
PIK3C2G 14.87 17.61 8.45 15.91 3.38 13.79 1.18 0.394 1.76 0.0371 1.19 0.5893 5.58 0.2126 1.37 0.426 
PLA2G4A 67.66 68.91 93.87 147.55 105.22 62.71 1.02 0.9072 1.39 0.0803 1.72 0.1993 1.23 0.3332 1.37 0.5007 
PLCB1 2767.57 3145.69 2949.28 2924.32 4644.68 3207.87 1.14 0.3093 1.07 0.7692 1.2 0.7392 1.32 0.1887 1.09 0.7169 
PPP1R12B 475.45 593.58 559.94 600.58 807.54 939.52 1.25 0.0582 1.18 0.2153 1 0.9719 1.34 0.1832 1.56 0.1438 
PRKCA 1535.17 2141.49 2566.38 2907.12 3235.97 1707.37 1.39 0.0066 1.67 0.01 1.49 0.3866 1.66 0.1763 1.14 0.0304 
PRKCB 4450.21 5335.96 4535.07 5998.35 8347.35 4433.44 1.2 0.0929 1.02 0.9305 1.06 0.8919 1.48 0.0158 1.27 0.2788 
PSEN1 633.19 802.73 721.42 1331.95 1034.26 1458.24 1.27 0.0348 1.14 0.1032 1.66 0.233 1.29 0.0995 1.82 0.389 
PSEN2 291.48 310.86 314.98 428.85 389.75 317.71 1.07 0.414 1.08 0.4306 1.16 0.4171 1.05 0.4682 1.16 0.0937 
PTGDR2 42.67 87.02 47.19 102.36 96.74 46.05 2.04 0.053 1.11 0.853 1.89 0.4081 1.79 0.1607 1.18 0.7457 
PTGER1 1.05 1.8 1.67 2.87 2.17 1.03 1.72 0.0023 1.6 0.0508 2.46 0.1134 1.86 0.1589 1.13 0.1838 
PTGER2 6.06 15.87 12.87 8.3 5.65 4.14 2.62 0.0588 2.12 0.2874 1.08 0.9528 1.36 0.871 1.86 0.7387 
PTGER3 87.58 78.28 86.39 81.33 85.78 67.54 1.12 0.6848 1.01 0.9723 1.37 0.2293 1.29 0.3621 1.64 0.1545 
PTGER4 8.15 10.08 26.29 14.39 10.39 10.78 1.24 0.5609 3.23 0.0313 1.39 0.7147 1.01 0.9956 1.04 0.9138 
PTGFR 10.95 13.55 23.29 8.5 60.05 15.21 1.24 0.7063 2.13 0.3728 1.63 0.5605 4.32 0.0145 1.1 0.8309 
PTGIR 1.16 1.8 1.69 2.87 2.17 1.03 1.55 0.0493 1.45 0.1705 2.21 0.1287 1.68 0.1532 1.26 0.2573 
PTGS1 23.64 37.55 41.14 58.53 41.38 29.79 1.59 0.0411 1.74 0.107 1.95 0.0493 1.38 0.2448 1.01 0.9872 
PTGS2 109.3 88.13 151.96 120.94 161.93 89.86 1.24 0.2234 1.39 0.1348 1.15 0.6402 1.17 0.1688 1.54 0.6075 
PTK2 5485.04 7227.5 6038.03 10211.49 9340.37 5792.11 1.32 0.0027 1.1 0.3948 1.47 0.1449 1.34 0.0048 1.2 0.0068 
RAC1 3264 3815.16 4029.66 5612.78 5216.37 5202.95 1.17 0.0239 1.23 0.0235 1.36 0.1421 1.26 0.0741 1.26 0.0713 
RAF1 616.39 877.49 985.99 1455.53 1447.13 922.48 1.42 0.0046 1.6 0.0027 1.86 0.041 1.85 0.1404 1.18 0.2078 
RAPGEF2 1417.18 1705.76 1604.4 2089.04 2586.04 1657.88 1.2 0.06 1.13 0.3334 1.16 0.5537 1.44 0.0853 1.08 0.7356 
RELA 89.43 174.77 189.17 354.36 327.93 149.42 1.95 0.0024 2.12 0.0023 3.12 0.052 2.89 0.2144 1.32 0.4289 
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RELB 35.36 36.94 49.65 79.29 62.03 37.09 1.04 0.7872 1.4 0.0984 1.77 0.3526 1.38 0.5501 1.21 0.158 
RHOA 682.94 871 1221.45 1770.81 1393.76 1371.86 1.28 0.0695 1.79 0.0076 2.04 0.0971 1.61 0.087 1.58 0.3039 
RIPK1 316.13 462.85 482.31 802.69 650.3 419.43 1.46 0.0164 1.53 0.0402 2 0.1023 1.62 0.1745 1.05 0.6818 
RIPK2 298.89 327.23 414.56 535.54 464.96 409.74 1.09 0.3313 1.39 0.0242 1.41 0.0683 1.23 0.0581 1.08 0.821 
ROCK2 2980.88 3737.17 3908.35 5127.17 5515.33 3706.11 1.25 0.0328 1.31 0.0231 1.36 0.2764 1.46 0.1428 1.02 0.9084 
RPS6KA5 921.95 1470.97 1109.71 2129.67 1731.11 1480.62 1.6 0.0004 1.2 0.0902 1.82 0.0004 1.48 0.0823 1.27 0.0218 
SHC1 310.21 408.86 689.41 655.62 782.79 307.53 1.32 0.1059 2.22 0.0073 1.67 0.1911 1.99 0.1052 1.28 0.0984 
SMAD7 412.81 655.94 829.49 977.51 962.58 654.23 1.59 0.002 2.01 0.0036 1.87 0.2092 1.84 0.1962 1.25 0.3281 
SNCA 5496.88 4673.89 3376.47 4549.4 5305.78 4902.24 1.18 0.0309 1.63 0.0262 1.53 0.1314 1.31 0.3044 1.42 0.0249 
SOCS3 118.59 143.54 357.6 508.6 358.51 78.49 1.21 0.7387 3.02 0.1143 3.38 0.2894 2.38 0.2372 1.92 0.5071 
STAT1 406.49 392.47 435.79 1068.55 477.7 854.76 1.04 0.8183 1.07 0.6908 2.07 0.4565 1.08 0.5882 1.66 0.0109 
STAT2 1431.87 2154.76 1910.69 3903.2 2496.73 2037.23 1.5 0.001 1.33 0.0234 2.15 0.219 1.38 0.1421 1.12 0.7225 
STAT3 1748.55 2697.34 3527.85 5383.82 4578.06 2182.83 1.54 0.0289 2.02 0.0177 2.43 0.1289 2.06 0.2296 1.02 0.9333 
TBXA2R 4.19 5.78 6.93 10.91 23.85 3.79 1.38 0.4802 1.65 0.3727 2.05 0.5553 4.49 0.0386 1.4 0.8375 
TCF4 3251.19 4394.53 4352.03 6233.65 6514.26 3651.28 1.35 0.0053 1.34 0.0996 1.51 0.1566 1.58 0.1256 1.13 0.1678 
TGFB1 141.96 348.55 409.2 850.22 607.02 160.76 2.46 0.0024 2.88 0.0141 4.72 0.0813 3.37 0.2421 1.12 0.6498 
TGFB2 577.63 867.97 1269.86 1125.8 1866.28 706.91 1.5 0.0237 2.2 0.0004 1.54 0.2055 2.55 0.0004 1.04 0.824 
TGFB3 213.7 591.89 403.18 741.42 661.33 346.68 2.77 0.0014 1.89 0.0411 2.74 0.1421 2.44 0.316 1.28 0.5244 
TGFBR1 318.98 515.85 510.06 900.67 696.33 365.14 1.62 0.0144 1.6 0.0792 2.23 0.2114 1.72 0.3647 1.11 0.7636 
TLR1 180.57 224.38 216.35 421.45 267.65 161.88 1.24 0.2423 1.2 0.5811 1.84 0.2721 1.17 0.7303 1.41 0.3891 
TLR2 112.24 177.47 230.95 508.01 280.96 96.07 1.58 0.2538 2.06 0.1571 3.57 0.0819 1.97 0.2955 1.48 0.2984 
TLR3 48.11 60.76 52.04 111.52 68.42 52.55 1.26 0.3514 1.08 0.7507 1.83 0.3413 1.12 0.7522 1.16 0.6794 
TLR4 388.04 651.59 768.6 945.32 1015.86 440.29 1.68 0.0011 1.98 0.0461 1.92 0.2088 2.06 0.2442 1.12 0.6997 
TLR5 67.64 87.9 93.17 164.18 124.42 51.18 1.3 0.223 1.38 0.4383 1.91 0.0886 1.45 0.4786 1.68 0.2248 
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TLR6 60.78 69.29 84.84 111.72 101.47 61.55 1.14 0.5537 1.4 0.2698 1.45 0.4245 1.32 0.6047 1.25 0.513 
TLR7 24.99 28.25 30.23 62.07 28.56 15.1 1.13 0.7386 1.21 0.5353 1.96 0.2127 1.11 0.9108 2.1 0.0505 
TLR8 7.78 12.23 33.62 39.55 40.63 3.6 1.57 0.4334 4.32 0.0403 4.17 0.1076 4.29 0.0402 2.63 0.2783 
TLR9 14.16 20.89 35.33 40.47 73.38 9.96 1.48 0.3396 2.5 0.0879 2.25 0.1828 4.09 0.1548 1.8 0.1736 
TNF 1.11 2.85 1.45 6.01 1.41 1.03 2.57 0.004 1.3 0.212 4.7 0.1966 1.1 0.7612 1.24 0.0905 
TNFAIP3 84.63 107.64 223.49 254.26 251.36 59.62 1.27 0.3881 2.64 0.0951 2.37 0.2897 2.34 0.276 1.8 0.0348 
TNFSF14 1.23 2.8 2.14 2.87 4.56 6.25 2.27 0.0117 1.74 0.1658 2.02 0.1627 3.22 0.4264 4.41 0.0051 
TOLLIP 5696.49 6637.88 6004.14 8432.85 10346.95 4408.31 1.17 0.1946 1.05 0.8009 1.17 0.6838 1.43 0.0054 1.64 0.0874 
TRADD 27.82 50.2 49.11 71.06 78.95 41.25 1.8 0.0376 1.77 0.0582 2.01 0.0359 2.24 0.1609 1.17 0.5017 
TRAF2 160.32 232 304.51 351.57 396.38 213.84 1.45 0.0146 1.9 0.0197 1.73 0.1486 1.95 0.2322 1.05 0.7534 
TREM1 2.86 3.71 5.8 2.52 4.99 9.57 1.3 0.482 2.03 0.2394 1.39 0.5975 1.43 0.4573 2.75 0.0292 
TREM2 70.04 142.45 151.39 215.35 193.66 81.45 2.03 0.0139 2.16 0.0081 2.42 0.0405 2.18 0.2702 1.09 0.9114 
TSLP 4.47 6.86 12.62 5.17 14.14 9.17 1.53 0.3136 2.82 0.0579 1.1 0.817 2.49 0.1404 1.62 0.4262 
TSPO 23.19 50.9 54.86 113.9 79.53 31.63 -2.2 0.0465 2.37 0.0929 3.87 0.0361 2.71 0.2279 1.08 0.8496 
TWIST2 16.51 12.24 21.2 9.14 27.97 8.78 1.35 0.3181 1.28 0.5193 2.29 0.1676 1.34 0.3975 2.38 0.3198 
TYROBP 448.45 630.26 839.27 1473.77 850.64 351.05 1.41 0.2067 1.87 0.0371 2.59 0.1688 1.5 0.4505 1.62 0.3504 
CLTC 3948.01 3612.09 3719.84 4345.29 5183.08 5046.3 1.09 0.3433 1.06 0.5814 1.15 0.2288 1.04 0.6801 1.01 0.9435 
GAPDH 28768.73 28176.37 29936.19 30678.52 41197.88 36030.03 1.02 0.7624 1.04 0.563 1.19 0.4511 1.13 0.0571 1.01 0.8077 
GUSB 128.53 160.81 120.85 242.18 134.04 173.21 1.25 0.3442 1.06 0.7933 1.49 0.3632 1.22 0.2657 1.06 0.838 
HPRT1 2916.06 2317.79 2080.72 2234.1 2513.32 4395.75 1.26 0.214 1.4 0.1128 1.66 0.2059 1.47 0.1668 1.19 0.5074 
PGK1 7778.7 7925.97 8587.72 9220.33 11858.94 9205.08 1.02 0.8252 1.1 0.1863 1.07 0.6389 1.2 0.0219 1.07 0.7234 
TUBB 1611.36 1410.59 1583.3 2015.67 1767.74 2069.75 1.14 0.1122 1.02 0.83 1.01 0.8793 1.16 0.0659 1.01 0.8393 
Appendix Table 4: Nanostring results. Average counts for each disease group are listed followed by the fold change of each group compared to 
control with the significance of this fold change. Red highlights upregulation and green highlights downregulation compared to controls.  
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Appendix Table 5: Gene heatmap for TREM1 signalling pathway. All genes shown are 
associated with the pathway. Red shows upregulated genes and green shows 
downregulated genes compared to controls. 
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Appendix Table 6: Gene heatmap for NF-κB signalling pathway. All genes shown are 
associated with the pathway. Red shows upregulated genes and green shows 
downregulated genes compared to controls. 
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Appendix Table 7: Gene heatmap for p38 MAPK signalling pathway. All genes shown 
are associated with the pathway. Red shows upregulated genes and green shows 
downregulated genes compared to controls. 
Appendix 
Page | 293  
 

























ACE ABCD3 SEPT8 ABCA7 SEPT2 ABI2 SEPT2 SEPT3 SEPT6 ABCA7 MARC2 A2M 
ACSS1 ABCG8 ACAA1 ACAP2 SEPT3 ACACB AAK1 ABI2 SEPT7 ACBD6 SEPT2 A2M 
ACSS3 ACAA1 ACAA2 ACAP2 SEPT6 ACAT2 ABI2 ACACB ABAT ACOT7 A1BG AAK1 
ADPRHL2 ACOT8 ACAN ACSF3 SEPT7 ACBD6 ABI3BP ACBD6 ACAA1 ACOT8 ABCF2 ABR 
AKR1A1 ADAM11 ACTR3B ACSL6 SEPT8 ACE ABLIM2 ACBD7 ACAA2 ACSBG1 ACOT13 ACSL3 
ALDH4A1 AFG3L2 ACVR1B ADAMTS2 SEPT9 ACSM2B ACADVL ADAM11 ACAT2 ADAM11 ACTB ACSS1 
ALDH6A1 ALDH3A2 ADAR ADGRB2 ABLIM2 ACTL6B ACLY ADGRB2 ACO2 ADSS ACTN1 ACSS3 
ALDH9A1 ALYREF ADRM1 AGAP2 ACAA2 AFG3L2 ACOT2 ADNP ACSS1 AFG3L2 ACTN2 ADGRB2 
ALMS1 AP2S1 AHCY AIP ACLY AGAP2 ACSL3 AGAP2 ACSS3 AK5 ACTN3 ADSS 
ANXA2 APOO AHCYL1 AK5 ACOT1 AGL ACSL6 AGFG1 ADAR AKAP5 ADAM22 AFG3L2 
APBA1 ARFGEF1 AKR1A1 ANKMY2 ACOT9 AHCYL1 ACSS1 AGK ADCY3 ANK1 
ADAMTS2
0 AGFG1 
APOE ARFGEF3 AKR1B1 ANKRD18B ACSS1 AHSG ACSS3 AGK ADD2 AP3B2 ADD2 AGL 
APP ASAP3 ALDH2 ANKS1B ACSS3 ALB ACTN2 AGL ADGB AP3D1 AHCYL1 AHSA1 
ARF6 ASNS AMPD2 APBA1 ACTBL2 ALDOA ACTN2 AK5 ADGRL1 ARFGEF3 AHNAK AK4 
ARFGEF1 ATG7 ANXA11 APC2 ACTBL2 ANKRD12 ACTR10 AK9 ADH5 ARHGAP26 AIP AK5 
ARFIP2 AZI2 ANXA2 APCS ACTN4 APBA1 ACY1 ANKFY1 ADPRHL1 ARHGAP26 AK9 AKAP10 
ARHGEF4 B2M ANXA4 ARF6 ACTR1A ARFGEF2 ADAM10 ANKRD36 AGFG1 ARHGEF12 AK9 AKAP12 
ASAH1 C2CD2L ANXA5 ARFGAP1 ADH5 ARFGEF3 ADAM22 AP2A1 AGL ARMC10 AKAP6 AKAP5 
ASAP2 CA1 AP2S1 ARFGEF3 AGAP3 ASAP1 ADAM23 AP2A2 AGRN ASAP3 AKAP9 ALB 
BAIAP3 CA1 AP3D1 ARFGEF3 AGRN ASAP1 ADD2 AP2M1 AHCYL1 ASNS ALDH3A2 ALYREF 
BBS1 CA2 APBA2 ARHGAP21 AHSA1 ASAP3 ADD3 AP2S1 AHCYL1 ATG2A ALDH9A1 ANKFY1 
C14orf159 CADM2 APBB1IP ARHGAP26 AK1 ASNS ADSS AP3D1 AHNAK ATP2A3 ALDOC ANKIB1 
C4A CADM3 APOB ARHGAP35 AK3 ATP1A4 AFG3L2 AP3S1 AHSG ATPAF1 ALMS1 ANXA2 
CABP1 CAMK4 APOE ARHGEF9 AKR1A1 ATP1B1 AHCYL1 APBA1 AKAP12 ATXN10 ANK3 AP1B1 
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CALD1 CAMSAP2 APOL2 ARID4A AKR1B1 ATP2C1 AHSA1 APOA1 AKR1A1 BCR ANKRD36 AP1B1 
CCDC88A CAPZA2 APP ARMC9 ALDH1L1 ATP6V0D1 AHSG ARFGEF3 AKR1C2 C2CD3 ANXA1 APOH 
CCNB3 CARF APPL1 ASNS ALDH6A1 ATP6V1F AK5 ARFGEF3 AKR1C2 CA1 AP2B1 ARFGAP1 
CCT2 CAST AQP4 ASPM ALDH9A1 ATP6V1G2 AKAP12 ARHGAP44 ALB CA1 AP2M1 ARFGEF2 
CKB CCAR2 ARFGEF2 ATAT1 ALS2CR12 AVPR1B AKAP12 ARHGEF12 ALDH3A2 CA2 APEX1 ARHGAP26 
CLASP2 CD44 
ARHGAP2
3 ATG7 ANKRD28 BASP1 AKAP5 ARHGEF6 ALDH6A1 CADM2 AQP4 ARHGEF11 
CLIC4 CDC42 ASPH ATP6V0D1 ANLN C16orf70 AKR1B1 ASAP1 ALDH9A1 CAMK2A ARF3 ARID3B 
CNN3 CDON ATAD3C ATP8B4 ANXA11 C1orf95 AKR1C1 ASAP3 ALMS1 CAMK2D 
ARHGAP3
5 ARID4A 
CNOT1 CDR2 ATP6V1D BAG6 ANXA5 C9orf172 ALB ASMTL ANKRD36 CAMK4 ARMC9 ARL3 
CNP CEND1 AZGP1 BAI1 ANXA6 CA1 ALB ASNS ANXA1 CAMKK1 ARPC3 ARMC10 
COL25A1 CFH BAG3 BCKDK APC CA4 ALDH1L1 ATAD1 ANXA2 CAMKK1 ASAH1 ARMC9 
COL6A2 CNOT1 BAG6 BGN APOE CABP1 ALDH3A2 ATIC ANXA5 CAMSAP1 ASAH1 ASAP3 
COL7A1 CORO1A BCAS1 BRK1 APP CADM2 ALDH3A2 ATP5C1 AP3D1 CAND1 ASAP1 ASS1 
COL9A2 COX5A BCL2L13 BRSK1 ARHGDIA CADM3 ALDH4A1 
ATP5J2-
PTCD1 APBB1 CBWD2 ASH2L ATG2A 
COMMD3 CPNE4 BICD1 C1orf95 ARHGEF6 CADM4 ALDH4A1 ATP6V0D1 APEX1 CCAR2 ASRGL1 ATIC 
CORO1C CRIP2 BRAF C9orf172 ARL3 CAMK2A ALDH6A1 ATP6V1B1 APOB CCBL2 ASXL2 ATP2A3 
CRAT CTNND2 BROX CACNG3 ARRB1 CAMK2A ALDH7A1 ATP8A2 APOE CCDC183 ATG7 ATP2B2 
CROCC2 CXXC1 BSN CADPS2 ASAH1 CAMKK1 ALDOC BANF1 APOL2 CCDC43 ATM BAG3 
CRTC1 DDX3X BZRAP1 CALM1 ATAD1 CAMSAP1 ALDOC BASP1 APP CCDC51 ATP1A1 BBS1 
DBNL DEPDC5 BZW2 CAMK2A ATP2A2 CAPN8 ALMS1 BCL2L13 ARFGEF3 CCNG1 ATP1A3 BCAS3 
DCLK2 DHTKD1 C4A CAMK2B ATP2A3 CASK ANK3 BCLAF1 ARFIP2 CDC42BPA ATP5F1 BGN 
DCTN2 DMTN CALB2 CAMK4 ATP2B1 CD59 ANKIB1 BPHL ARMC9 CDH6 ATP5H BPHL 
DDX23 DMWD CALML4 CAMKK1 ATP8A1 CD81 ANKRD35 BSDC1 ASAH1 CDH8 ATP5J BZW2 
DES DNAAF5 CALR CAMKK2 ATRNL1 CD9 ANKS1B BSN ASCL4 CEP170 BAG5 C14orf159 
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DGKI DYNLRB1 CALU CAMKV BCKDHA CDH13 ANLN C1orf94 ATG4B CFAP69 BANF1 C2CD3 
DLAT EIF4A3 CAST CAMSAP1 BCLAF1 CDH23 ANXA1 C1RL ATP1A3 CFH BASP1 C3 
DLG1 EIF4G2 CCDC6 CAND1 BIN1 CDH8 ANXA2 C2CD3 ATP2A2 CHD5 BGN C4A 
DNM3 EMC8 CCHCR1 CAP2 BLVRB CDK18 ANXA2 C5orf42 BCLAF1 CIAPIN1 BSN CA1 
DRC3 EPB42 CD81 CAPN1 C1orf123 CDON ANXA3 CADM2 BPHL CIRBP C2CD3 CALCOCO1 





2 CENPE ANXA5 CADPS C1orf229 CNN1 CALM1 CAMK4 
EIF3E ERP29 CDH23 CCDC88A CAPNS1 CEP290 ANXA5 CAMK1 C1QB COASY CAMK2A CAMSAP2 
EPPK1 FARSA CENPK CCDC88C CCDC171 CFAP57 ANXA6 CAMK2A C2CD5 COBL CAMK2G CASP5 
ERCC6L2 GAP43 CEP350 CCT8 CCDC22 CHD5 APC CAMK2A C3 COL4A1 CAPZB CCBL2 
EZR GAP43 CFAP45 CDC42BPA CCDC87 CIRBP APOA1 CAMK2B C4A CTTNBP2NL CASK CCBL2 
FBN1 GNA11 CHGB CDH15 CCDC93 CKAP5 APOA2 CAMK2B CABP1 CUBN CASK CCDC136 
FBXO2 GNL1 CLIC4 CDK5 CCNG1 CLCC1 APOB CAMK2D CACYBP CUX2 CC2D1A CCDC43 
FGA GPR158 CLSTN1 CELSR1 CDC37 CMAS APOE CAMK2D CADM3 CYP20A1 
CCDC144
A CCDC43 
FGB H2AFY2 CLU CEP152 CEP152 COASY APOE CAMK2G CALD1 DCTN4 CCDC30 CCDC6 
FGFR2 HBA1 CNDP2 CEP170B CEP192 COL22A1 APP CAMKK1 CAMK2A DENND4A CCT5 CCDC73 
FGG HECTD4 CNNM4 CGN CFL2 COL6A5 APP CAMKK1 CAMK2B DGKZ CD9 CCDC88A 
FGG HIST1H1E CNTNAP1 CHL1 CGNL1 COPS3 APPL1 CAMKK2 CAPG DHTKD1 CEP152 CCHCR1 
FLNB HMGB1P1 COL18A1 CIRBP CHCHD2 CORO1A ARFGEF1 CAMKV CAPS DHX34 CEP170 CDH8 
FSCN1 HPCAL1 COMMD6 CKM CHCHD3 CPLX2 ARFIP1 CAMSAP2 CAPS DHX9 CEP170B CHGB 
GALK1 IFT172 CORO2B CLASP2 CHST2 CPNE7 ARFIP2 CAPS CASC5 DLAT CHCHD6 CHGB 
GCLC IRF2BP2 CPLX2 CLIP1 CLASP1 CPNE8 ARHGAP32 CASKIN1 CBR1 DLGAP4 CHMP4B CIAPIN1 
GFAP ITSN2 CPNE2 CLPB CLIC4 CPSF7 ARHGAP35 CCDC51 CBR3 DMWD CIAPIN1 CKB 
GFAP KAT6A CPOX CMAS CLTCL1 CRYM ARHGDIA CCHCR1 CBX1 DNAAF3 CKMT1A CKM 
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GLRX3 KCNH1 CPSF7 CNKSR2 CNDP2 CRYZ ARRB1 CD59 CCDC144B DNAAF5 CKMT2 CLIC5 
GOLGA4 KPNA6 CPT1A CNN1 COL25A1 CSTB ASRGL1 CDC42BPA CCDC88A DNAJB11 CLIP1 CLIP2 
GRPEL1 KSR1 CSRP1 CNTNAP2 COPB2 CTNND2 ATP1B3 CDH13 CCT8 DNM1L CLTCL1 CNNM4 
GSTK1 KTN1 CTGF COASY COPE CUL1 ATP5D CDK18 CD44 DOC2A CMAS CNTN2 
GSTM3 LMO7 CUL3 CPNE4 COPS2 CXXC1 ATP6V1A CDS2 CDH23 EHHADH CNP COG1 
H3F3A MARCKS DCDC2 CPNE5 COPS4 CYC1 ATP6V1C1 CEND1 CGNL1 EIF3B CNTN1 COL6A1 
HADHA MBP DCT CRIP2 CORO1B DDX19A ATP6V1G1 CETN2 CKB EMC8 COL1A2 COPB1 
HADHB MKRN1 DDX18 CSNK2B CORO1C DDX59 ATPAF2 CFB CLIC1 EML1 COL6A1 COPS7A 
HAPLN4 MTCH2 DDX46 CTBP1 CPT1A DECR1 ATRNL1 CHGA CLIC1 EPB42 COL6A2 CORO1A 
HIST1H2B
K MTMR2 DDX53 CTTNBP2 CRABP1 DENND4A ATXN2 CHGB CLIC4 EPC2 CORO1C COX6A1 
HNRNPA2
B1 MUT DGAT1 CUL1 CRK DEPDC4 BAG3 CHL1 CLIP1 EPPK1 COX5B CPLX2 
HOMER2 MYH11 DICER1 DCLK1 CROCC DIAPH1 BCAM CHMP4B CLTCL1 ERVK-24 CPNE4 CRIP2 
HSP90AA
1 NASP DKK3 DDB1 CST3 
DKFZp566H1
924 BCAS1 CIRBP CMPK1 ESYT2 CST3 CRKL 
HSP90AB
1 NBPF15 DMWD DDN CTNND1 
DKFZp686J1
372 BDP1 CIRBP CMPK2 ETFA CTPS1 CROCC 
HSPB1 NCAM1 DNAJB6 DGKZ CYFIP1 DLG3 BGN CKB CNTNAP1 FAAP100 CTSB CRYL1 
IDH3B NCKAP5 DNM3 DHX57 CYLD DNPH1 BGN CNKSR2 COL1A2 FAHD2A CTSD CTNNA1 
IMPDH2 NDUFA9 DNPEP DHX9 DBN1 DPP6 BLVRB CNRIP1 COL6A3 FAM179B CUL2 CTNNB1 
IRF2BP1 NUCKS1 DOCK10 DNAH2 DCLK2 ECT2 BLVRB COA6 COL6A5 FBF1 CUL3 CTPS2 
KIF15 OPCML DPP7 DNAJA3 DCTN1 EHBP1 C14orf159 COASY COPS4 FDXR CYFIP2 CTTN 
KMT2C PAICS DRG1 DNAJB2 DCTN2 
Em:AP00035
1.3 C1orf167 COL5A1 CORO1B FSD1 DCTN2 CTTNBP2NL 
KRT1 PALM DYNC1I2 DNAJB4 DDX23 ENAH C1QTNF6 COPS4 CORO1C FTCD DDN CUTA 
KRT14 PALM DYNC1LI1 DNAJC5 DDX4 EPB42 C21orf62 CORO1A CORO2B FUBP1 DDX49 CUX2 
KRT16 PCP4 ECHDC1 DNAJC6 DGKZ EPC2 C4A CORO1B CPSF7 FXYD6 DFFA CXXC1 
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KRT17 PDAP1 EFHD2 DNM3 DLAT EPHA5 C4A CORO1C CRABP1 GAD2 DGKZ DCAF11 
KRT38 PDIA4 EHBP1 DOCK6 DLGAP3 EPHB3 CA1 COX6A1 CRABP1 GLS DHRS7C DCDC1 
KRT5 PDK2 EHBP1 DTX3 DMXL2 EPN3 CA1 COX6B1 CRAT GNB2L1 DIAPH1 DDAH2 
KRT6A PDZRN4 EHD2 EBF1 DNAH10 ETFDH CA2 COX7A2 CSDE1 GNL1 DLG3 DDX19A 
KRT6B PEBP1 ELAVL1 EFR3A DSCR3 EVI5L CA2 COX7C CTNND1 GOLGB1 DLG4 DENND2D 
KRT6C PITPNM3 ENDOD1 EIF2AK2 DUT F3 CACNA1A CPNE3 CTR9 GPATCH2 DLGAP1 DES 
KRT9 PJA2 ENPP6 EIF3G DVL1 FAM131B CADM4 CPNE7 CUL5 GPR98 DLGAP2 DGKI 
LETM1 PPFIA1 ENPP6 EIF3G DYNC1LI1 FAM71D CALB2 CRIP2 CYP11B1 GPR98 DLGAP3 DHX9 
LONP1 PRIM1 EPHX1 ENO1 ECHS1 FAM71F1 CALCOCO1 CRKL CYP2C8 GPRIN1 DMD DIP2B 
LRPAP1 PRNP EPS8 EPB41L1 EEF1D FARSA CALD1 CRMP1 DBI GRIA2 DNAJA3 DIRAS2 
LTF PRODH ERMN ERC1 EEF1G FDXR CAMK4 CRYM DBN1 GTPBP1 DNAJC11 DLAT 
LZTS3 PRRT2 ERO1A ESYT1 EHD1 FER1L5 CAND1 CRYZ DCAF11 HBS1L DOCK6 DLG4 
MAPT PSMD1 ERP44 ETFDH EHD2 FGG CAPN2 CSE1L DCDC2 HECW1 DSP DLG5 
MCCC1 PTK2B EXOC8 EVI5L EIF2AK2 FLRT2 CARS CSNK2B DCTN1 HIST1H1E DYNC1I1 DLST 
MRPL47 PTPRF FAF2 FAAP100 EIF3D FN1 CARS2 CTH DCTN2 HIVEP3 DYNC1LI2 DMTN 
MUT RAB3GAP1 FAM114A2 FAM131B ENOPH1 GAP43 CAT CTIF DHX9 HMGB1 EIF2S3 DMXL2 
MYEF2 RAB4B FAM118B FAM81A EPN3 GAPDH CBR1 CTTN 
DKFZp434B2
017 HNRNPA0 ELAVL4 DMXL2 
MYH6 RAB5A FAM149B1 FAM83F ERCC5 GFAP CBR3 CUL1 DLAT HNRNPL EMC1 DNAAF5 
MYH9 RAPGEF4 FAM169A FAM98C ERP44 GFM1 CC2D1A CXXC1 DLD HNRNPUL1 ENO1 DNAJA1 
MYO9A RHOBTB1 FARP1 FARSA EVL GJA1 CCAR2 CYC1 DLG1 HSPA4L ENO2 DNAJC9-AS1 
NACA SCG2 FARP2 FAT1 FABP7 GNA11 CCBL2 CYCS DLG3 IFT81 ENO3 DNMT1 
NAE1 SDR39U1 FBLN1 FBXO44 FABP7 GNAL CCDC136 DBN1 DNPH1 IMPDH2 ERC2 DOCK2 
NANS SDSL FGG FBXO8 FAM131B GNB2L1 CCDC6 DBNL DOCK3 INA ESYT1 DST 
NCK1 SENP6 FHAD1 FGD6 FAM20C GNG3 CCDC87 DCAF11 DSCAML1 IQSEC1 FABP3 EEA1 
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NFS1 SIRPA FMNL1 FKBP15 FBN1 GOLGA4 CCT4 DCDC1 DSG2 ITPR1 FBLN1 EFR3B 
NISCH SLC12A7 FMNL1 FLNA FGA GOT1 CD44 DCLK1 ECT2 KDM5A FBXO44 EHD3 
NLRP4 SLC4A1 FSCN1 FLNB FGA GOT2 CD9 DCTN1 EEF1E1 KRT15 FBXO8 EIF3B 
NRCAM SNAP91 FTH1 FN1 FGB GPR98 CDKN1B DDN EMC1 KSR1 FGA EIF3K 
OBSCN SON FTH1 FTCD FGB GRID2IP CDS2 DDX1 EMC2 KYNU FGB EIF3L 
OGDHL SPTA1 FTL FXR1 FGD4 GRM2 CELSR1 DDX17 ENAH LARP1 FGG EIF4G2 
OLFML1 SRR FTSJ3 GAD2 FILIP1 GRSF1 CFAP54 DGKB ENO1 LIX1L FNDC1 EMC2 
OLFML2B STRAP FYCO1 GAK FKBP4 GSR CFH DGKI ENTPD2 LMO7 FOCAD EPB41 
OSBPL8 SV2B GANAB GART FMNL1 GTPBP1 CHORDC1 DIAPH1 EPHX1 LYNX1 FSCN1 EPN1 
PAFAH1B
3 SYNPO GARS GAS7 FMNL2 GYS1 CLASP1 DLG4 EWSR1 LZTS3 FTO EPRS 
PARD3 TAGLN GFAP GDA FTL HADHA CLCC1 DLG4 EXOC2 MAP2K4 FXR1 EPS8 
PC TAGLN3 GFAP GFM2 GALK1 HBA1 CLIC4 DLGAP2 EZR MAP4 GAN ERO1A 
PCDH17 TAX1BP1 GIMAP1 GNA15 GAS7 HEPACAM CLIP2 DLGAP3 FABP5 MDN1 GAP43 ERO1A 
PCYT2 TBC1D10B GLUD1 GOLGA4 GAS7 HIST1H1E CLTCL1 DLGAP3 FABP7 MIPOL1 GAPDH ERVK-24 
PDE4B TBC1D8B GLUD2 GOLGB1 GDI1 HIST1H2BK CLU DLST FAM98B MKRN1 GCC2 EZR 
PDHX TCEAL3 GMPR GRIA2 GFAP HNRNPDL CLU DNAJA2 FBN1 MYH1 GFAP F13A1 
PDP1 TECPR1 GMPR2 GRIA3 GIGYF2 HNRNPL CMAS DNAJC5 FGG MYH11 GJA1 FAAP100 
PGAM1 THOP1 GNA14 GRIA3 GJA1 HP CNDP1 DNM1L FH MYL9 GLIPR2 FAM171B 
PHB THY1 GNB2L1 GRID2IP GNAI2 HP1BP3 CNN1 DOCK4 FHAD1 MYRIP GLIPR2 FAM171B 
PHB2 TIAM1 GNB5 GRIN2B GNAL HSP90AB2P CNTN2 DPYSL4 FHL1 MYT1L GLRX3 FARP1 
PI4KA TLN2 GPATCH8 GRSF1 GNB1 HSP90AB3P CNTNAP2 DRG1 FHL1 NBPF8 GLS FARSA 
PLCB1 TMEM44 GRIA2 GUCY1B3 GOLGA2 HSPA1L CNTRL DSTN FKBP5 NCL GNA13 FARSB 
PLCD3 TNKS1BP1 GRIK1 H2AFY GPI HSPB1 COBLL1 DYNC1I1 FLOT1 NCOR2 GNAO1 FASN 
PLCG1 TNRC18 GRM3 HBS1L GPR158 IFFO2 COG1 DYNLRB1 FTH1 NEDD4 GNAS FASN 
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PNN TPM2 GSS HECW1 GPSM2 IGHG1 COL12A1 EHHADH FTH1 NIT2 GNB1 FBF1 
PNPLA6 TPM2 GSTP1 HERC3 GRIA2 IGKC COL4A1 EIF3B FTL NOC3L GNG7 FDFT1 
PPIA TRIP11 HAPLN1 HINT2 GRM3 IGLL5 COL6A1 EIF3K FTL NSF GOLGA3 FDXR 
PPIF TRPV4 HAPLN2 HK2 GSTM2 ITGAV COL6A1 EIF4A1 GALNT7 NUCKS1 GOLGB1 FGFR1 
PPT1 TSPAN32 HAPLN2 HLA-A GSTM3 KHSRP COL6A2 EIF4B GAPDH OGDHL GPD1 FHAD1 
PRDX5 UBE2K HAPLN4 
HNRNPUL2-
BSCL2 GSTP1 KIAA1468 COL9A2 EIF4G2 GC OGT GPM6A FLNB 
PRPF6 UNC13B HAPLN4 HSD17B4 HADHB KSR1 COMT EIF5 GFAP OSBPL7 GRID2IP FLNC 
PRPF8 UQCRC1 HIBADH HSP90AA5P HAPLN4 KYNU COPS2 ELAVL2 GFAP PAICS GRIPAP1 FLNC 
PSMB2 UQCRFS1 HIP1 HSPA12A HARS LARP1 COTL1 EML1 GLUD1 PARP1 GRM7 FRYL 
PSMC4 USP11 HIST1H1E HSPG2 HDAC5 LRRC42 CP EPB41L1 GMCL1 PARP14 GSK3B FSD1 
PTPRN USP34 HOOK3 IARS HDLBP LRRC53 CPNE7 EPHA4 GMPR2 PCDHGA3 GSN GABBR1 
PYGM USP4 HSD17B10 IDH2 HERC5 LSAMP CPSF7 EPS15L1 GNA13 PCLO GSTK1 GAD1 
QARS VCPIP1 HSPB1 IGHG2 HRG MDH1 CPT1A ERC1 GNB1 PDIA6 GTPBP1 GAD2 
RAB3C VGF HSPB1 IGSF9B HSD17B10 MEIOB CRABP1 ERC2 GNG12 PFKL H1F0 GAK 
RIC8A VPS51 HUWE1 INTS3 
HSP90AA
1 MGST3 CRABP1 ERVK-24 GOLGA3 PGM5 H2AFV GBAS 
RPL22 WDFY1 HYOU1 IQSEC1 
HSP90AB
1 MICU2 CRYAB FAF2 GOLGA8R PHLDB3 H2AFY GC 
RPS3 WDR64 HYOU1 IQUB 
HSP90AB
3P MLLT4 CRYZL1 FAM169A GPI PIP5K1C H3F3A GLMN 
RTCB ZBED4 HYPK ITGB1 HSPA1A MMS19 CSNK2B FAM171A2 GPNMB PITPNM2 HADHB GLS 
S100A13 ZC3H14 ILF2 ITPKA HSPA6 MORN1 CSRP1 FAM171B GRIA2 PITPNM3 HAPLN4 GNL1 
SAMD9L   ISOC2 JUP HSPA8 MPDZ CSRP1 FAM81A GSTM3 PLCL1 HAUS3 GPD1L 
SARAF   ITPR1 KIF3B HSPA9 MTOR CTAGE4 FARSB GSTM3 PPM1E HDGF GPR98 
SCG2   JAKMIP3 KRT1 HSPB1 MYH10 CTBP1 FBL GSTT1 PPP1R11 HEPACAM GRIA2 
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SH3KBP1   KIAA1468 KRT7 HTT MYH7B CTNNB1 FECH H2AFZ PRPF40A 
HIST1H2A
H GSTM1 
SHANK1   KIAA2026 KRT9 IARS MYO9A CTNND1 FGD6 HADHA PRUNE2 
HIST1H2B
C GUCY1B3 
SLC25A22   KIF27 LARP1 IDH3A NAE1 CTNND2 FKBP8 HADHB PSG5 HIST1H4A H2AFY 
SLC9A3R2   KLC3 LARS IDH3B NCL CUL3 FLNB HAPLN4 PSMD4 HIST1H4A H3F3A 
SNCA   KPNA1 LONRF3 IDH3G NEB CUL3 FLOT1 HGH1 PTPRC HK1 HBA1 
SNRNP20
0   KREMEN2 LPP ISOC2 NGEF CUL5 FNBP1 HINT2 PTPRK HNRNPD HBB 
SNRPE   KRT2 LRRC53 ITGB8 NIPSNAP3A CUL9 FREM1 HIST1H2BH PTPRN HNRNPDL HBD 
SQSTM1   KRT4 LSM14B ITSN2 NKTR CUX1 FSD1 HIST1H2BH PXN HNRNPU HEBP1 
SSBP1   LETM1 MAP1B KDM5A NLGN2 CUX2 FTO HIST1H4A RAB17 
HNRNPUL
1 HEBP2 
STK10   LIMCH1 MAPK8IP3 KIF5B NNT DAAM2 GABBR1 HIST1H4A RAB2B 
HNRNPUL
2 HECTD1 
SUB1   LMAN1 MARK1 KIRREL NRCAM DAB2 GABBR1 HNRNPA2B1 RAB4B HOMER1 HERC2 
SUCLA2   LMBRD2 MBOAT7 KTN1 NTM DARS GABRB1 HNRNPK RANBP3L HOMER2 HGS 
SUCLG2   LMX1B MBP LAMC1 NUCB2 DBI GAD2 HNRNPR RAPGEF4 HP1BP3 HIST1H1E 
SYNM   LPIN1 MPO LNP NUCKS1 DBI GAP43 HP RASSF2 HSPA8 HMOX2 
THNSL1   LRPPRC MPP1 LPP OMG DCTN1 GAP43 HSD17B10 RB1CC1 HSPD1 HNRNPA1 
TIMM44   LTF MPP2 LTA4H OPCML DCTN2 GDAP1 HSP90AA1 RBM4 HSPH1 HNRNPUL1 
TJP2   LTN1 MPRIP LTF PAICS DDAH2 GDAP1L1 HSPA1A RECQL5 IFT122 HSD11B1 
TLDC1   MAG MRPL11 LTN1 PARK7 DDX21 GIT1 HSPB1 RFTN1 IGHA2 HSPA12B 
TNKS1BP
1   MAP3K3 MST1R LYN PCDHGA8 DDX3Y GLDC HSPB1 RGPD8 IGHG1 HSPA4L 
TRA2B   MAPT MTIF2 LYNX1 PCLO DDX59 GLS HSPG2 ROCK1 IGKC HSPA6 
TSC2   MAPT MTMR7 MAN2A2 PCP4 DEF6 GNAZ HTRA1 RPL10A IL1B HUWE1 
TXNRD2   MCU MYH13 MAPRE1 PEBP1 DES GNB5 IARS2 RUNDC3A IMMT IDH2 
UBA2   MFN2 MYH2 MAPT PFKL DHRS7 GNG10 IDH3A SAMD11 INF2 IFI16 
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UBC   MGAM MYH6 MCU PFKP DHX9 GNPDA2 IDH3B SCRIB IQSEC2 IGBP1 
UBL4A   MGLL MYL9 MPI PHF24 DISC1 GPI IDH3G SEC16A IRAK1 IGLON5 
UBN1   MPI MYL9 MSN PHYHIPL DLAT GRID2IP IFIT1 SEMA4D ITGB8 ILVBL 
USP7   MPP5 NBAS MTCH1 PI4KA DLC1 GRM5 IFIT3 SENP6 JUP IMPA2 
VPS26B   MPRIP NCOA7 MTCL1 PIK3C2A DMXL2 GRM8 IGHG4 SFXN3 KALRN INADL 
VPS33A   MRPL46 NCOR1 MYO1D PJA2 DNAJA2 GRSF1 IQGAP1 SGSM1 KANK3 INPP4A 
VPS35   MYOM2 NDC80 MYO5C PLCD3 DNAJC2 GSK3A ITGB1 SI KDM2B INTS3 
ZNF618   MYRIP NDUFA2 NAGK PLXNC1 DOC2A GSTM3 ITGB4 SIRT2 KIAA0513 IQSEC3 
    NDUFB6   POTEKP   GYS1   SLC12A5   ISCA1 KIF27 
    NDUFS2   PPP1R9A   H1F0   SLC27A6   ITPR1 KRT1 
    NEDD4L   PPP2R5E   H2AFJ   SMG1   KCNIP4 KRT10 
    NGEF   PPP3R1   H2AFV   SON   KDM5D KRT10 
    NSF   PPP5C   H2AFY   SOWAHC   KHSRP KRT2 
    NUAK1   PRDX6   H3F3B   SPG11   KIAA1467 KRT4 
    NUBPL   PRNP   HBS1L   SPOCK2   KIF13A KRT9 
    OAS1   PRPF40A   HDGFRP3   SPTBN2   KIF3A LAMA2 
    OGDHL   PRPH   HGS   SQRDL   KIF3B LAMA5 
    OGT   PRR14L   HIST1H1E   SRP14   KLC3 LARS 
    PA2G4   PRRT2   HIST1H2AA   SRRM2   KNG1 LDHB 
    PACS1   PSMD10   HIST1H4A   SYN3   KPNA6 LIMCH1 
    PACSIN1   R3HDM1   HIVEP3   SYNE1   KRT9 LLGL1 
    PALM3   RAPGEF4   HMGB1P1   TAGLN   KSR1 LMNB2 
    PARP14   RBM4   HMOX2   TAGLN   KTN1 LPP 
    PCCA   RDX   HNRNPA2B1   TAX1BP1   KTN1 LRRC59 
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    PDAP1   REEP5   HNRNPAB   TBC1D8B   LAP3 LRRFIP2 
    PDK2   RHOB   HNRNPDL   TBL3   LATS1 LSAMP 
    PDZRN3   RHOT1   HNRNPH1   TECPR1   LINGO1 LTN1 
    PEX5   RPL10A   HNRNPH2   TERF2   LMO7 LVRN 
    PFKL   RPL14   HNRNPLL   THOP1   LNP LYRM4 
    PFKP   RPL21   HNRNPM   TM9SF4   LONP1 MACF1 
    PHACTR1   RPL7A   HNRNPM   TNS3   LRP1 MALT1 
    PIK3C2A   RPLP2   HOMER1   TPM2   LRRC32 MAP1A 
    PIKFYVE   RPS3A   HP1BP3   TPM4   LRRC45 MAP1B 
    PIN1   RPS8   HPCA   TRAPPC10   LRSAM1 MAP2K1 
    PIP5K1C   RPSA   HPCAL1   TRPV4   LSM2 MAP4 
    PITPNM3   RTN4RL2   HPCAL4   TSC1   LSP1 MCF2L 
    PKHD1L1   SAFB2   HSDL2   UBE2D2   MADD MCM5 
    PKP4   SCML2   HSPA4L   UBE2N   MAGED1 MCU 
    PLCB1   SEC16A   HTRA1   UBL4A   MAP2K4 MECP2 
    PLCL2   SEC23A   ICAM5   UTP15   MAP2K6 MMRN1 
    PLEKHA1   SEMA3D   IDH2   VCL   MAP2K6 MPDZ 
    POTEE   SENP6   IDH2   VGF   MAP3K11 MPP7 
    POTEF   SFXN1   IDH3A   VTI1B   MAP6 MRAS 
    PPID   SFXN3   IGLC2   WDR19   MAPK3 MRPS22 
    PPM1E   SFXN3   IGSF9B   WNK2   MEIOB MSN 
    
PPP1R12
B   SGSM1   IQSEC1   ZC3H14   MEST MUC16 
    PPP1R21   SIRPA   ITPKA   ZEB2   METAP2 MYH10 
    PPP1R9A   SLC12A5   ITSN2   ZMYM1   MKRN1 MYH16 
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    PRKAA2   SLC17A7   JAK2   ZMYND8   MRVI1 MYH9 
    PRKCA   SLC17A7   KALRN   ZNF287   MSRA MYL12A 
    PRKCB   SLC25A22   KCTD12   ZNF852   MST1R MYL6 
    PRKCG   SMARCC2   KIAA0513       MTFR1L MYL6B 
    PRKRA   SNAP91   KIAA1211L       MTMR2 MYO1C 
    PRPF8   SNCA   KIF20B       MTURN NACA 
    PSAP   SNCG   KIF3B       MUT NCAPD3 
    PTGES3   SOD1   KIF5C       MYH1 NCL 
    PTPN23   SOD2   KLC3       MYH4 NCOR2 
    PTPRF   SON   KNG1       MYO18B NDRG1 
    PTPRN   SPOCK2   KRT15       MYO1D NDUFA6 
    PTPRN2   SQSTM1   KSR1       MYO6 NDUFS4 
    PTRF   SRL   LARP1       
NAALADL
2 NDUFS4 
    PVRL1   SRRM2   LASP1       NCEH1 NEB 
    QSOX1   SRSF5   LCP1       NCK2 NECAB1 
    RAB3B   STARD9   LGALSL       NDUFS2 NEDD8 
    RAB3C   STMN1   LMNB1       NEDD4L NEFH 
    
RAB3GAP
1   STXBP4   LMO7       NES NEFL 
    RAB4B   SYNPO   LOC102724023       NF1 NEFM 
    RAD54L   SYP   LONP1       NFASC NFASC 
    RALBP1   SYT1   LRRC32       NFS1 NIT2 
    RAN   TAOK1   LRRC47       NIN NME2 
    RANBP3L   
TBC1D10
B   LRRC7       NNT NUAK1 
    RAPGEF4   TBC1D8B   LRRC8A       NPTX1 NUCKS1 
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    RASA3   TBL3   LZTS3       NRXN1 NUDC 
    RASGRP1   TCEAL3   MADD       NUMA1 OSBPL2 
    RB1CC1   TF   MAP1S       OGDHL PACSIN1 
    RECQL5   THAP4   MAP2       OGDHL PAK3 
    REPS2   THUMPD3   MAP3K11       OGN PARK7 
    RPH3A   THY1   MAPK10       OTUB1 PARP1 
    RPL10A   TNR   MAPK8IP3       OXCT2 PC 
    RPL13AP3   TRIM24   MAPRE3       
PAFAH1B
3 PCSK1N 
    RPL17   TRIM32   MARCKS       PAICS PCYT2 
    RPL27   TSFM   MATR3       PALMD PDCD5 
    RPL36   TSNAXIP1   MBOAT7       PANK4 PDZRN3 
    RPL4   TTC23   MBP       PAPOLA PEBP1 
    RPS13   TTR   MECP2       PCCA PEX19 
    RPS8   TUBB1   MECR       PCK2 PGBD5 
    RPS9   TXN   MFN2       PDE1B PGK2 
    RPTOR   TXN2   MGEA5       PDE4B PGM1 
    SAFB   TXNRD2   MGST3       PDIA4 PHB2 
    SAFB2   UBL4A   MGST3       PDIA6 PHGDH 
    SAMM50   UBR1   MKRN1       PDK2 PHYHIPL 
    SARS2   UBXN6   MOB2       PDPK1 PLCD1 
    SBF2   UQCRC1   MORC3       PDXK PLEC 
    SCFD1   UQCRFS1   MRI1       PDZRN4 PLEKHB1 
    SCN2A   USP34   MRTO4       PEPD PLP1 
    SCP2   VARS   MTCH1       PFKL PLPP3 
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    SDK2   VCAN   MT-CO2       PFKP PNN 
    SDR39U1   VCL   MTFR1L       PGM2 PPP1R12B 
    SEC63   VDAC2   MTIF2       PGRMC1 PPP1R3A 
    SEL1L   VPS13A   MTMR2       PHPT1 PPP3CA 
    SHANK3   VPS26B   MTMR7       PIK3R1 PPP3R1 
    SIRT5   VPS45   MTOR       PIP4K2A PPT1 
    SLC12A7   WASF1   MTX2       PIP4K2C PRDX1 
    SLC39A12   ZNF365   MYLK       PLAA PRDX2 
    SLC6A12       MYRIP       PLCB1 PRDX6 
    SLFN11       NAPG       PLCL2 PSAP 
    SLIRP       NCALD       PLXNA1 PSD 
    SNRPE       NCAM1       PLXNA1 PSIP1 
    SNW1       NCAPD3       PMFBP1 PSMB2 
    SNX3       NCEH1       POLR1C PSMD2 
    SPATA1       NCKAP1       PPM1E PTCH1 
    SPG20       NCKIPSD       PPME1 PTEN 
    SPIRE1       NCL       PPP1CA PTK2B 
    SPOCK2       NDUFA12       PPP1R21 PTPRT 
    SRC       NDUFA2       PPP2R4 RAB11FIP1 
    SRSF1       NDUFA7       PRELP RAB39B 
    SRSF10       NDUFAB1       PREP RAB7A 
    SRSF6       NDUFB4       PRKDC RABGAP1 
    SSB       NDUFB4       PRPF8 RASGRF2 
    STK38L       NDUFS3       PRUNE RBM41 
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    STOX2       NECAB1       PSD3 RHPN2P1 
    SYNCRIP       NECAB2       PSMA1 RNF141 
    SYNPO       NEDD4       PSMC3 RNH1 
    SYP       NEDD4L       PSMC4 ROCK2 
    TAGLN       NFS1       PSMD10 ROGDI 
    TAGLN       NID2       PSMD13 RPL10 
    TANC2       NOC3L       PTPN23 RPL11 
    TFRC       NOP56       PTPRE RPL12 
    THNSL1       NOP58       PTPRN RPL13 
    THRAP3       NOVA2       PTPRN2 RPL17 
    TLN1       NPM1       PTRF RPL18 
    TMEM44       NPTN       PTRF RPL21 
    TNIK       NPTN       PUDP RPL22 
    
TNKS1BP
1       NPTX1       PUF60 RPL24 
    TNRC18       NRN1       PXN RPL27 
    TNXB       NRXN1       PYGM RPL27A 
    TOP2B       NUBPL       RAB24 RPL3 
    TPM2       NUCB2       RAB3B RPL4 
    TSC1       NUCKS1       RANBP6 RPL5 
    TSFM       NUMA1       RANGAP1 RPL6 
    TTC21B       NUMBL       RASSF2 RPL7 
    TTC25       NUMBL       RBSN RPL7A 
    TTYH2       NUP214       RDH13 RPL8 
    TUBB4A       OLA1       RFXANK RPLP0 
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    TUFM       OLR1       RGS3 RPS10 
    TXNRD1       OPA1       RILPL1 RPS13 
    UACA       OPCML       RMDN3 RPS14 
    UBXN6       OPHN1       RMND1 RPS23 
    UFL1       OPTN       RNF20 RPS24 
    UGT1A6       OSBPL2       RNF40 RPS3 
    UROS       OXCT1       RPL7A RPS4X 
    USP11       PACSIN1       RPN2 RPS8 
    USP5       PAK1       RPSA RPS9 
    UTY       PALM2       RRP1B RSF1 
    VAT1       PAM       RTN4 RTN1 
    VCL       PARD3       RUVBL1 S100A13 
    VCPIP1       PCBP1       SAMM50 SARS 
    VGF       PCLO       SAMM50 SART3 
    VPS41       PCSK1N       SBF1 SASH1 
    WDR1       PDE1B       SCAI SBF1 
    WDR37       PDE2A       SEC16A SCFD1 
    WDR7       PHB       SEC22B SCN8A 
    WNK2       PHF24       SEC23A SCYL1 
    XIRP2       PHF24       SERPINB6 SEC23A 
    XRCC6       PHYHIP       SH3KBP1 SET 
    ZNF470       PHYHIPL       SIX6OS1 SETX 
            PIN1       SLC12A7 SHTN1 
            PIP4K2C       SLC17A7 SI 
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            PIR       SLC35A2 SKP1 
            PITPNM2       SLC4A1 SLC14A1 
            PITPNM3       SLC4A1 SLC1A2 
            PJA2       SLC6A17 SLC25A5 
            PLCL1       SLC8A2 SLC25A6 
            POLDIP2       SNPH SLC44A1 
            PPFIA4       SNX2 SLC4A10 
            PPIL1       SOGA3 SLK 
            PPP1R1B       SPARCL1 SLMAP 
            PPP1R9A       SPTA1 SLU7 
            PPP2R5E       SPTB SMARCA5 
            PRKCE       SQSTM1 SMS 
            PRKCG       SRGAP1 SNCA 
            PRKRA       SRR SNRNP200 
            PRNP       SRRM2 SNRPD3 
            PRPS2       STK38L SNRPE 
            PRUNE2       STOM SOD1 
            PSAP       STRAP SPAG9 
            PSAP       STXBP1 SPG11 
            PSD3       STXBP5 SRI 
            PSMD4       SUCLG1 SRSF1 
            PTEN       SYNJ2BP SRSF10 
            PTGES2       TAGLN SRSF2 
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            PVRL1       TBC1D23 SRSF5 
            RAB11FIP5       TBCB SRSF6 
            RAB15       TBCC ST3GAL1 
            RAB1A       TCF25 STAT1 
            RAB3B       TECPR1 STXBP1 
            RAB5A       TGM2 SUCLG1 
            RABGAP1L       TIAM1 SYNE2 
            RABGGTB       TIGD4 SYNGAP1 
            RALGAPB       TJP2 SYNJ1 
            RALY       TJP3 SYNM 
            RANBP3L       TLN2 SYNPO 
            RANBP6       TMPO SYP 
            RAP1GAP       
TNKS1BP
1 TCP1 
            RAP1GAP2       TNPO2 TECPR1 
            RAPGEF2       TNS3 TFAM 
            RAPGEF4       TOM1 TIGAR 
            RASGRF2       TPM2 TJP1 
            RB1CC1       TRIM28 TKT 
            RBM14       TRIM32 TLDC1 
            RBSN       TRPV4 TLN2 
            RCN2       TSC1 TNC 
            REPS2       TSC2 TOP1 
            REXO2       TSR2 TOP2B 
            RGS7       TTC25 TPPP3 
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            RHOT1       TTC25 TRANK1 
            RMDN3       TTR TRAP1 
            ROCK1       TTYH2 TRIP11 
            RPA3       TUBB2A TUBA4A 
            RPGRIP1L       TWF2 TUFM 
            RPH3A       UBA1 TXNRD2 
            RPL10       UBA2 UACA 
            RPL10A       UCHL3 UBC 
            RPL12       
UHRF1BP
1L UBE2N 
            RPL14       UNC13B UBR5 
            RPL17       UNK UCHL1 
            RPL17       USO1 UGP2 
            RPL18       USP11 UQCRC1 
            RPL22       USP4 UQCRQ 
            RPL35A       USP47 USO1 
            RPL4       USP7 USP44 
            RPL7A       VARS USP9X 
            RPLP2       VCL UTY 
            RPS16       VIM VDAC1 
            RPS17       VPS35 VDAC2 
            RPS5       VPS35 VIM 
            RPS6KC1       VPS50 VPS13D 
            RPS7       WDFY1 VPS51 
            RPS7       WDFY4 VSNL1 
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            RPS8       WDR1 WASL 
            RTN4RL2       WDR61 WDR19 
            RUFY3       WIPI2 WDR47 
            SAFB       XPNPEP1 WNK2 
            SAMD9       ZADH2 XRCC5 
            SAMM50       ZBED8 XRCC6 
            SARS2       ZMYM1 ZCCHC17 
            SCFD1       ZMYND8 ZNF518B 
            SCG2       ZNF638   
            SCN3A           
            SDE2           
            SDR39U1           
            SDSL           
            SEC63           
            SEL1L           
            SEMA4D           
            SENP6           
            SET           
            SGSM1           
            SGTA           
            SH3GL2           
            SH3GL3           
            SH3KBP1           
            SHC1           
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            SHTN1           
            SIRPA           
            SIRPA           
            SLC12A5           
            SLC12A7           
            SLC17A7           
            SLC25A22           
            SLC25A22           
            SLC25A27           
            SLC27A6           
            SLC2A3           
            SLC4A10           
            SLC6A17           
            SLC6A7           
            SLK           
            SMARCA5           
            SNAP25           
            SNAP91           
            SNAP91           
            SNCA           
            SNCAIP           
            SNRNP70           
            SNW1           
            SNX3           
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            SON           
            SPAG7           
            SPAG9           
            SPATA2           
            
SPECC1L-
ADORA2A           
            SPG11           
            SPG20           
            SPIRE1           
            SRSF1           
            SRSF10           
            SRSF2           
            SRSF5           
            SRSF7           
            STIL           
            STK39           
            STRN3           
            STX1A           
            STX1B           
            STX6           
            STXBP1           
            SUCLA2           
            SULT4A1           
            SV2A           
            SV2B           
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            SVIP           
            SYN1           
            SYNGAP1           
            SYNGR3           
            SYNPO           
            SYNPO           
            SYP           
            SYT1           
            SYT5           
            TAX1BP1           
            TBC1D10B           
            TBC1D15           
            TBC1D8B           
            TBCA           
            TBCB           
            TBL3           
            TBRG4           
            TCF20           
            TERF2           
            TFRC           
            TGFBI           
            THY1           
            TIGAR           
            TJP1           
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            TMEM43           
            TMEM94           
            TMX4           
            TNKS1BP1           
            TOMM70A           
            TP53BP1           
            TPPP           
            TRIB2           
            TRIM24           
            TRIM67           
            TRIO           
            TSC1           
            TSC22D2           
            TSFM           
            TSPAN7           
            TTC21B           
            TUBA4A           
            TUBA8           
            TUBB           
            TUBB2A           
            TUBB4A           
            TXN2           
            TYRO3           
            UACA           
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            UBA2           
            UBAP2L           
            UBE2D2           
            UBE2N           
            UBE3C           
            UBXN6           
            UCHL1           
            USP11           
            USP47           
            UTP15           
            VAMP2           
            VAPB           
            VAT1L           
            VCAN           
            VDAC3           
            VGF           
            VPS29           
            WASF1           
            WDFY1           
            WDFY4           
            WIPI2           
            WNK2           
            XRCC5           
            XRCC5           
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            XRCC6           
            YWHAB           
            YWHAE           
            YWHAG           
            YWHAH           
            ZBTB22           
            ZNF511           
            ZNF852           
Appendix Table 4: Proteins greater than 1.5 fold change compared to control in each disease group 
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